,ticker,content
0,MYL,mylan myl see positive improvement relative strength rs rating monday rise look best stock buy watch be sure pay attention relative price strength unique rating track market leadership show stock price action last week measure other stock database history show market biggest winner tend have rs rating least early stage move see mylan continue show renew price strength clear threshold see ibd help make more money stocksmylan be work consolidation buy point see stock break heavy volume earning sale growth come respectively latest report marked acceleration top bottom line mylan earn rank peer medical generic drug industry group ani pharmaceutical anip be top rank stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
1,MYL,mylan myl share plunge late wednesday food drug administration identify minor deficiency application advair generic copy glaxosmithkline gsk blockbuster asthma inhaler generic drugmaker now expect fda issue formal complete response letter delay approval advair generic mylan say determine receive letter be impact outlook hour trading stock market today mylan topple stock end regular trading session glaxo stock jump wrapping regular session generic pharmaceutical stock rise close bell advair seretide drug name outside north america bring sale get newsletter deliver inbox more info product service privacy policy term userelated link chart read basic buy point mark time real tame volatile swing trade half positionlook best stock buy watch start here
2,MYL,welcome move mylan myl see relative strength rating improve tuesday re research best stock buy watch be sure pay attention relative price strength proprietary rating identify market leadership used worst best score show stock price action last week match other stock decade market research show best perform stock tend have rs rating north early stage move see mylan continue show renew price strength hit benchmark look best stock buy watch start heremylan be build consolidation entry see stock clear price heavy trading earning sale growth come respectively latest report marked acceleration earning share sale company earn rank peer medical generic drug industry group ani pharmaceutical anip be rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
3,MYL,valeant pharmaceutical vrx surge month high tuesday analyst acknowledge turnaround upgrade stock boost price target pharmaceutical company stock market today valeant pop close valeant stock be form cup buy point broadly share pharmaceutical company rise mizuho analyst irina koffler upgrade valeant buy rating neutral raise price target note acknowledge turnaround drug drug review conclude valeant be grow key brand have stabilize loss older product say report client be even potential pipeline upside get newsletter deliver inbox more info product service privacy policy term usetoday valeant profile look more mylan myl koffler say sale consist stable product be consumer focuse be older drug have already go generic further be actual growth potential pipeline contain multiple catalyst say stock work next year think valeant simply need execute quarters push new product launch so far happen first quarter valeant stock jump pharmaceutical company top sale view raise guidance firm soon change name bausch health company bausch lomb segment valeant pledge double dermatology revenue next year koffler doubt promise come fruition do see sale valeant significant drug possible significant valeant list psoriasis treatment call siliq jemdel duobrii also have treatment glaucoma eye redness opioid related constipation firm expect sale grow compound annual growth rate adjust earning interest taxe depreciation amortization grow koffler see guidance challenge other pharmaceutical company have set similarly high seemingly unattainable growth target say minimal clinical downside valeant be minimal pipeline expectation so anything work be upside stock upcoming food drug administration consider approval drug psoriasis treatment drug treat acne also possible valeant unveil datum study medicine treat acne related chart read basic buy point mark time real trade stock most penny stock fail make investor richstill rule stock investor always cut loss short
4,MYL,investor didn cut mylan myl slack thursday company announce regulator likely delay generic version blockbuster asthma inhaler advair stock market today mylan tumble close meanwhile share generic pharmaceutical company dip glaxosmithkline gsk develop asthma inhaler advair advanced food drug administration find minor deficiency mylan application generic advair likely issue complete response letter reject application news isn entirely surprising mizuho analyst irina koffler say koffler argue announcement be cosmetic setback mylan gain approval biosimilar amgen amgn neulasta drug be bone marrow stimulant generate north sale get newsletter deliver inbox more info product service privacy policy term use corporate strategy be trailblaze complex generic high value biosimilar only natural have more difficult pathway say report say cut slack koffler keep buy rating price target mylan still model sale generic advair see generic advair sale hit peak mylan keep outlook total sale mylan application generic advair receive priority designation fda mean grab approval prior standard day time period mylan respond minor deficiency don currently know long take company gather information compile response entail believe risk associate lengthy delay be modest point koffler say glaxo full year guidance assume competitor bring generic advair market mid scenario model sale advair year adjust earning share be expect be flat constant currency basis advair bring global sale come related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
5,MYL,stock open narrowly higher then turn mixed tuesday major index struggle extend early june rally mylan myl twitter twtr apple aapl iii apparel group giii post significant early move downsw global oil price drag early action economic datum show sharp upturn service sector activity dow jone industrial average quickly shed open gain slip slight decline wrestle breakeven point nasdaq comsposite add mylan communication disca post strongest early move nasdaq dow be jockey add third day rally begin june nasdaq peg new close high monday friday move level benchmark open tuesday less march record high monday moved short term resistance be interim high set march still january peak dow be set take run level briefly clear late remain high mark late january record get newsletter deliver inbox more info product service privacy policy term usebrent crude lead early slip oil price just barrel government request increase barrel day oil supply saudi arabia other opec producer accord bloomberg request follow twitter message president trump regard opec policy rise oil price oil price rise follow reinstatement economic sanction iran additional upward pressure have come dwindle production venezuela price increase reversed organization petroleum export country begin discuss end year production cap agreement russia benchmark west texas intermediate trade early tuesday well barrel wti price have fall past session be high apple set early pace dow stock company bask attention annual worldwide developer conference stock peg new high monday company unveil other thing next generation mobile operate system share be late april low past year apple stock have rise average month lead wwdc month wwdc apple stock have fall average last year mylan easily lead company announce late monday food drug administration have approve fulphila biosimilar amgen amgn neulasta drug treat chemotherapy patient suffering reduce white blood cell count mylan share have be decline january amgen share fall nearly tuesday early trade twitter pop early action standard poor announce late monday stock replace list start trade thursday netflix nflx replace list germany bayer bayry agree pay acquire st loui base twitter share be extend nearly clear cup handle base late health equity hqy open flat report better expect earning revenue late monday custodian health saving account end monday session breaking flat base iii apparel manufacturer levi guess kenneth cole brand spiked early action new york base company score big first quarter sale earning beat lift second quarter guidance view stock be extend buy range clear cup base hd supply holding hds advanced first quarter earning growth outpaced analyst expectation revenue fall less forecast move lift share buy range past buy point saucer base datum researcher markit show sharp upturn service sector activity lift ihs markit service pmi month be april index largest increase april backlog increase highest rate more year prompt strongest job creation september input cost selling price inflation also continue however capacity issue intensified raw material procurement become more difficult institute supply management et also labor department release april job opening labor turnover survey et also ibd stock be buy range big picture bull market gain tractionhot chinese stock software firm buy range action planamazon resistant retailer expect growth near buy zone
6,MYL,stock open brisk gain thursday follow european central bank outline potentially wind decade long stimulus program end year stock receive add boost positive unemployment retail sale number stock future overseas market have trade lower early fallout wednesday fed announcement work way global market drugmaker mylan myl software giant oracle orcl drag early trade ibd leaderboard name etsy etsy bolt sharply higher ipos huya huya pivotal software pvtl post strong early advance nasdaq composite power ahead aid premarket gain comcast cmcsa dish network dish mylan post largest decline nasdaq stock dow jone industrial average jump nike nke walt disney jump top dow royal caribbean rcl comcast top mylan drop fall regulatory filing reveal food drug administration have reject application mylan generic asthma drug base glaxosmithkline gsk blockbuster advair filing say fda have find minor deficiency drug mylan share close wednesday low key level support climb right side month consolidation get newsletter deliver inbox more info product service privacy policy term useoracle also drag early action jpmorgan downgrade stock neutral overweight pare price target note cite jpmorgan survey point sharp decrease oracle product spending oracle share have be consolidate march meanwhile recent ipos look ready add recent run up etsy spiked early trade brooklyn company raise full year revenue outlook base increase transaction fee charge seller used art craft marketplace etsy say transaction fee rise also say charge month access fee be prepare roll premium service aim larger better establish vendor etsy share be extend mid rebound support week move average stock end wednesday record high set just ipo april china base huya swung more early trade stream online gaming entertainment platform have gain week wednesday be extend breaking ipo base end wednesday ipo price pivotal software san francisco base developer vault early action stock spiked wednesday analyst ratchete price target follow strong first quarter report late tuesday gain put share ipo base buy point april ipo price other etsy early indicator be not good retailer tailor brand tlrd michael company mik take steep dife heel first quarter report tailor brand owner jos bank chain strip premarket decline company report narrow beat first quarter sale earning line range second quarter earning guidance be low relative consensus view share close wednesday april extend rebound week support craft retailer michael also dive irve texas base chain report earning expectation revenue line estimate first quarter same store sale miss analyst target stock have be struggle recover deep month correction global market shift lower follow wednesday loss trade person central bank china disappoint market leave key interest rate unchanged china long standing strategy have be track increase decrease rate maintain spread country rate hong kong hang seng index drop japan tokyo nikkei tumble market europe reversed early loss surge higher afternoon trade ecb announce wind bond purchase december cac paris lead frankfurt dax post gain london ftse add first time unemployment claim continue decline slip week end june accord labor department be prior week application run counter consensus projection uptick claim retail sale jump commerce department datum show sale growth accelerate vs april gain forecast call increase sale also rise auto gasoline vs consensus projection gain benchmark oil price leane higher global mood turn positive west texas intermediate moved trade barrel oil price steady barrel week welter supply related news oil price gain higher wednesday follow official datum show larger expect barrel draw inventory week end june tuesday energy information administration estimate average oil production barrel day prior year minister organization petroleum export country plan meet partner include russia june discuss production strategy also big picture hawkish fed cut market rally short watch top rate fund own rank chinese leader recent require patience disciplineibd stock day ferrari break buy top dividend stock break yield
7,MYL,mylan myl surge nearly week high tuesday food drug administration approve knockoff amgen amgn bone marrow stimulant neulasta stock market today mylan pop close earlier stock rocket much touch high last see mid april meanwhile share amgen dip share be form buy point cup base be first neulasta biosimilar approve likely win be last leerink analyst geoffrey porge say report client coherus bioscience chrs novartis nvs be also work biologic copy neulasta coherus share jump novartis be expect approval challenge amgen top line first approval biosimilar neupogen short act version neulasta amgen product revenue fall annually due volume price erosion say get newsletter deliver inbox more info product service privacy policy term use similar erosion pattern such important product unlikely be offset company growth product portfolio new launch migraine drug aimovig amgen top line revenue be risk potential decline say amgen neulasta sale be represent total revenue porge say mylan neulasta biosimilar drug call fulphila be codevelop privately hold biocon shouldn hurt amgen revenue outlook further amgen work push neulasta onpro medical device automatically inject drug patient body rbc analyst kennen mackay say report first quarter neulasta sale come onpro mackay cut price target amgen keep sector perform rating call weakness share trim sale expectation neulasta street expect next coherus neulasta biosimilar go fda november later novartis partner apotex have update second approve biosimilar neulasta create increase competition potential price headwind mackay say mizuho analyst irina koffler see mylan generate revenue neulasta biosimilar climb peak year estimate report client realistically sale outperform expectation neulasta profile syringe currently generate sale year mylan be thus far only approve biosimilar therefore fill channel ahead competition say leerink porge note amgen mylan be fight patent battle amgen claim mylan neulasta biosimilar infringe patent method purify protein used biological product trial likely begin mid view manufacturing patent weak protection amgen be not surprised see mylan launch risk say mylan expect launch fulphila few week related do spot major market top easy look heavy trade stock most penny stock fail make investor richsell take profit hold here be several guideline follow
8,MYL,biotech giant celgene celg big patent official shut challenge face novartis nvs multiple sclerosis drug gilenya analyst say thursday wednesday appeal board patent trademark office upheld patent protect novartis gilenya december extend gilenya exclusivity well past prior august expiration date rbc capital market analyst brian abraham say undoubtedly novartis decision also have implication fellow multiple sclerosis drugmaker celgene biogen biib say report celgene recently suffer delay multiple sclerosis drug ozanimod give celgene more time get approval ozanimod be currently hamstrung question food drug administration generic gilenya come begin take share say get newsletter deliver inbox more info product service privacy policy term use celgene provide better ozanimod launch runway especially new drug application filing delay give biogen less medium term price share compression risk ms franchise particularly drug call tecfidera say stock market today celgene jump close novartis advanced end session biogen rise generic competition multiple sclerosis be already underway october mylan myl gain approval generic version teva pharmaceutical teva multiple sclerosis drug copaxone first quarter teva say sale copaxone decline year year same happen novartis gilenya generic arrive patent appeal board decision generic rival likely appeal evercore analyst umer raffat say gilenya still lose patent protection point depend appeal summary ozanimod longer be launch vs generic gilenya say report client give ozanimod least year window launch brand market establish presence ms rbc abraham note celgene benefit tune upside depend length delay generic gilenya ozanimod be meant be safer version gilenya class drug call sphingosine phosphate receptor modulator modulator gilenya be tie heart rate liver issue patient be monitored first dose attribute neurologist care most next generation therapy be absence first dose monitoring piper jaffray analyst christopher raymond say also rank advantage liver enzyme impact pretty far list comparative advantage re look vs gilenya not clear ozanimod have similar requirement celgene management indicate go assumption be ozanimod win avoid raymond say note client see ozanimod avoid first dose monitoring celgene face battle effort differentiate molecule say related chart read basic buy point mark time real much volume look stock trade stock most penny stock fail make investor rich
9,MYL,amgen amgn allergan agn be sideline friday food drug administration delay herceptin biosimilar give roche rhhby blockbuster breast cancer drug herceptin breathe room biotech company didn identify issue herceptin biosimilar work closely fda bring important medicine patient amgen say prepared statement do not expect impact launch plan duo isn first get snag seek approval herceptin biosimilar mylan myl partner biocon grab approval december follow similar delay fda pfizer pfe teva pharmaceutical teva celltrion copy have also be delay get newsletter deliver inbox more info product service privacy policy term useapproval seem be move more smoothly europe european medicine agency committee have recommend approve amgen allergan biosimilar pfizer herceptin biosimilar samsung biogen teva celltrion already have copy market europe herceptin be major cash cow roche bring sale just fellow cancer drug rituxan mabthera generate herceptin sale stem europe roche be work feverishly push back competition herceptin last year roche sue dow jone component pfizer block selling herceptin biosimilar roche genentech unit say pfizer herceptin biosimilar infringe patent patent herceptin begin expire bloomberg report stock market today roche stock rally close hit year close low thursday herceptin biosimilar setback amgen stock advanced share partner allergan climb meanwhile share pharmaceutical company lift biotech stock rise related intuitive surgical break record fda approve new robotibd stock day chinese internet giant power buy zone composite rating stock skyrocket huge earning growth chart basic buy point mark time real invest stock free new apps term retirement investing strategy etfs
10,MYL,mylan myl have relative strength rs rating upgrade tuesday welcome improvement still better score prefer see ibd proprietary rating track market leadership worst best score score show stock price behavior trail week stack other stock database year market history show stock go make biggest gain tend have rs rating north early stage move see mylan continue show renew price strength clear threshold look best stock buy watch start heremylan be not currently potential buy area see stock go build base ignite new run company report negative growth top bottom line last quarter company be expect release next quarterly number mar mylan hold rank peer medical generic drug industry group ani pharmaceutical anip be rank stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
11,MYL,mylan myl share pop midday wednesday generic drugmaker reiterate sale guidance stoke investor confidence lag first quarter revenue epipen shortage stock market today mylan fly higher close still share have largely trade day move average early february other generic drug stock rise fraction mizuho analyst irina koffler keep buy rating mylan stock note topline miss expectation bottom line come penny ahead mylan sale adjust earning outlook beat consensus attribute sale miss year year decrease north america segment say note client european sale easily beat expectation rest world segment be line get newsletter deliver inbox more info product service privacy policy term quarter mylan report sale vs last year consensus have call mizuho koffler say north america sale lag view european sale grow top consensus rest world sale be line grow decline north america be primarily due combine impact loss exclusivity olmesartan blood pressure product lower sale brand product include epipen auto injector divestiture certain contract manufacturing asset impact adoption new accounting standard mylan say news release adjust earning cent share climb year year beat consensus penny metric come line mylan own expectation shortfall first quarter mylan reiterate guidance sale beating consensus midpoint adjust profit be expect be share also top analyst view midpoint investor also be likely look ahead potential copycat version amgen amgn bone marrow stimulant neulasta glaxosmithkline gsk asthma inhaler advair mylan have application copycat pending food drug administration meanwhile mylan acknowledge epipen shortage epipen be emergency injection treat severe allergic reaction fda acknowledge be intermittent supply constraint due manufacturing issue mylan too note supply issue statement mylan manufacturing partner pfizer pfe inform fda supply issue few month mylan say however product be available mylan be currently receive continual supply manufacturing partner meridian medical technology pfizer company mylan say mylan be expedite shipment wholesaler receipt supply level vary wholesaler pharmacy related much money do need start investing long term retirement investing strategy buy stock ahead earning report
12,MYL,teva pharmaceutical teva jump monday rival perrigo prgo say expect food drug administration delay generic version teva asthma inhaler call proair afternoon trading stock market today teva pop close near month high teva stock be consolidate buy point perrigo other hand dip delay canaccord analyst dewey steadman keep buy rating price target perrigo steadman now expect perrigo launch generic proair delay perrigo generic proair be clearly disappointing re impressed quick disclosure expect complete response letter company effort frame impact product result say note client get newsletter deliver inbox more info product service privacy policy term useon friday perrigo say fda likely delay generic proair firm didn say previously perrigo have expect launch copycat fourth quarter have expect generic proair be worth cent full year earning share have guide share overall profit quarterly earning conference call steadman note difficulty develop asthma product glaxosmithkline gsk advair also face mount competition teva launch generic mylan myl be expect launch year see delay generic proair relatively minor evidence generic advair development now proair be extremely difficult develop generic inhaled product re not certain timeline potential proair launch say teva perrigo delay mean be other potential maker generic proair credit suisse analyst vamil divan say note proair generate sale still teva be face number other issue attempt restructure new chief executive kare schultz plan unveil february cut workforce close several plant terminate slew specialty program effort save delay generic competition be benefit teva top line be obviously rather minor positive relative other challenge company be currently face divan say see proair add quarterly mid divan have outperform rating price target teva related do spot major market top easy look heavy best stock buy watch start herenew option strategy limit risk earning
13,MYL,nasdaq easily outran dow tuesday morning oil price continue slide economic datum show sharp upturn service sector activity mylan myl twitter twtr apple aapl iii apparel group giii be strong early leader netflix nflx punch new high ahead addition index dow jone industrial average struggle red slight gain edge nasdaq comsposite extend lead mylan dish network dish post strongest move get newsletter deliver inbox more info product service privacy policy term usebrent crude lead early dive oil price just barrel government request increase barrel day oil supply saudi arabia other opec producer accord bloomberg request follow twitter message president trump regard opec policy rise oil price oil price rise follow reinstatement economic sanction iran additional upward pressure have come dwindle production venezuela price increase reversed organization petroleum export country begin discuss end year production cap agreement russia benchmark west texas intermediate trade tuesday barrel wti price have fall past session be high apple be early leader dow stock company bask attention annual worldwide developer conference ibd leaderboard stock peg new high monday company unveil other thing next generation mobile operate system share be late april low past year apple stock have rise average month lead wwdc month wwdc apple stock have fall average last year mylan easily lead company announce late monday food drug administration have approve fulphila biosimilar amgen amgn neulasta drug treat chemotherapy patient suffering reduce white blood cell count mylan share have be decline january amgen share fall nearly tuesday early trade twitter pop early action standard poor announce late monday stock replace list start trade thursday also announce netflix replace list germany bayer bayry agree pay acquire st loui base twitter share be extend nearly clear cup handle base late netflix jump tuesday morning ibd leaderboard stock be extend flat base health equity hqy leap report better expect earning revenue late monday custodian health saving account end monday session breaking flat base iii apparel manufacturer levi guess kenneth cole brand spiked early action new york base company score big first quarter sale earning beat lift second quarter guidance view stock be extend buy range clear cup base hd supply holding hds advanced first quarter earning growth outpaced analyst expectation revenue fall less forecast move lift share buy range past buy point saucer base datum researcher markit show sharp upturn service sector activity lift ihs markit service pmi month be april index largest increase april backlog increase highest rate more year prompt strongest job creation september input cost selling price inflation also continue however capacity issue intensified raw material procurement become more difficult read be second service sector gauge manufacturing ism index institute supply management index rise april consensus forecast increase also fashion apparel maker stun profit stock soarsthese ibd stock be buy range big picture bull market gain tractionhd supply earning top stock jumpshot chinese stock software firm buy range action planamazon resistant retailer expect growth near buy zone
14,MYL,wall street be split wednesday celgene celg sell side analyst downgrade stock say have tilt greater risk upgrade share beleaguered biotech company stock market today celgene share gain close share crumble year low monday report head business development exit april share biotech company rise fraction wednesday argus analyst david toung downgrade celgene hold rating buy same time analyst sanford bernstein upgrade stock outperform rating market perform reportedly say valuation be too cheap ignore toung be concern longevity cancer drug revlimid generic pharmaceutical company mylan myl dr reddy laboratory rdy be vie make copycat revlimid revlimid patent extend europe get newsletter deliver inbox more info product service privacy policy term use more revlimid patent be invalidate broad generic competition begin say report client be devastate celgene bring revlimid sale contend celgene acquire juno therapeutic juno lead drug candidate cancer treatment bring peak year sale toung doesn expect commercial launch month celgene also put acquire impact biomedicine have experimental cancer drug firm plan file approval key drug mid also work bluebird bio blue multiple myeloma treatment pipeline asset be promising combine potential revenue be not enough completely replace revlimid view toung say toung assessment follow food drug administration list attempt shame several pharmaceutical company block generic competition big drug large biotech company fda also list gilead science gild biogen biib celgene have also have number misstep recent history last october scrap study drug call ged crohn disease treatment february fda say wouldn review drug call ozanimod multiple sclerosis drug be now delay least year related do spot major market top easy look heavy basic sell stocksell take profit hold here be several guideline follow
15,MYL,mylan myl see positive improvement relative strength rs rating friday rise ibd proprietary rating measure price movement worst best score score show stock price behavior last week compare other stock database history show market biggest winner tend have rs rating north early stage move see mylan continue rebound clear threshold look winning stock try simple routinewhile mylan be not ideal buy zone right now see be able form break proper chart pattern mylan post negative growth sale earning last quarter company be expect report next quarterly number mar mylan hold rank peer medical generic drug industry group ani pharmaceutical anip be rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
16,MYL,mylan myl deny report friday interested buy merck kgaa consumer health care business email investor business daily mylan spokesperson say rumor be untrue mylan policy not comment rumor speculation give egregious inaccuracy report issue morning company be compel confirm reuter article be untrue spokesperson say mylan share dip rumor first report early friday fall close stock market today get newsletter deliver inbox more info product service privacy policy term report suggest merck kgaa sell unit cite person familiar matter previously nestle reckitt benckiser have interest buy unit source say germany merck say last year be aim sell consumer health care business help foot bill prescription drug research segment bring annual sale merck kgaa couldn be reach merck co mrk be initially establish subsidiary merck kgaa germany later nationalized own independent company consumer health business have be merger wringer recently industry include counter drug vitamin other offering march glaxosmithkline gsk agree buy novartis nvs share consumer health business deal allow novartis divest stake unit glaxo expect transaction be accretive earning meanwhile dow jone component pfizer pfe have long struggle offload consumer health business last month glaxo reckitt benckiser dump bid buy business pfizer announce plan sell spinoff unit october sale rise year year sell advil centrum few other big moneymaker related invest stock free new apps aim trade stock most penny stock fail make investor richlong term retirement investing strategy etfs
17,MYL,mylan myl share rebound thursday follow worry first quarter sale lag base tough year year comparison allergy drug epipen concern stem commentary mylan investor day mizuho analyst irina koffler say wednesday mylan reiterate guidance call tough comparison first quarter adjust profit sale epipen management indicated first half contain nontrivial amount brand epipen sale result slightly tougher comp first half koffler write note client koffler now expect adjust income first quarter account full year profit year earlier period get newsletter deliver inbox more info product service privacy policy term use therefore push sale earning further second half say mylan cane get least larger approval expect summer think investor get more constructive execution guidance urge investor buy wednesday dip share close investor listen stock market today mylan climb close mylan still expect report sale adjust profit share sale guide be slightly consensus midpoint adjust profit view be just north analyst mylan expect first quarter adjust profit share full year earning be base point lower last year firm also expect higher interest expense follow recent debt financing koffler say koffler have buy rating price target mylan think stock be undervalue say firm recently launch generic copycat teva pharmaceutical teva multiple sclerosis drug copaxone view gradual ramp time koffler say firm also have key approval come year include generic version amgen amgn bone marrow stimulant neulasta glaxosmithkline gsk inhaler advair allergan agn eye disease drug restasis management note fda ask additional clarification advair application even formal information request have be complete lead investor concern approval delay koffler say management note advair be not story mylan be also work theravance biopharma tbph treatment chronic obstructive pulmonary disease condition lung food drug administration be likely make decision drug november related much money do need start investing long term retirement investing strategy etfslook next nvidia start simple routine
18,MYL,mylan myl have relative strength rs rating upgrade friday ibd unique rs rating measure technical performance used worst best score show stock price action last week match other stock decade market research reveal best perform stock often have rs rating north early stage move see ibd help make more money stocksmylan be not currently potential buy zone see stock go form base kick new price move mylan report negative growth sale earning last quarter company hold rank peer medical generic drug industry group ani pharmaceutical anip be top rank stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
19,MYL,mylan myl see welcome improvement relative strength rs rating friday rise unique rating measure technical performance show stock price action last week measure other stock database decade market research reveal market biggest winner typically have rs rating begin largest climb see mylan continue rebound clear threshold look best stock buy watch start herewhile not currently ideal time invest see stock be able offer clear proper buy point company report negative growth sale earning last quarter mylan hold rank peer medical generic drug industry group ani pharmaceutical anip be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
20,MYL,putt together watch list look stock higher rs rating teva pharmaceutical teva now meet criterium jump wednesday look best stock buy watch factor watch closely be relative price strength unique rating measure technical performance show stock price action last week compare other stock database decade market research show market biggest winner typically have rs rating north early stage move look best stock buy watch start hereteva pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average earning sale growth come respectively latest report show improvement ep revenue company earn rank peer medical generic drug industry group ani pharmaceutical anip collegium pharmaceutical coll mylan myl be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
21,MYL,allergan agn tank year low thursday mylan myl revance therapeutic rvnc announce plan bring botox copycat market just regulator impose delay allergan drug early trading stock market today allergan topple close fall much share touch lowest point october meanwhile mylan stock weather soft quarter guidance rise botox announcement mizuho analyst irina koffler say note client mylan revance be likely several year market botox copy still downside effect allergan be undeniable say botox account nearly allergan sale allergan sell botox cosmetic drug treat age line forehead eye mouth botox therapeutic also treat number condition include excess sweat chronic migraine create immediate overhang allergan reimburse therapeutic franchise future outlook koffler write be less concern cosmetic pressure aren expect mylan invest dedicate sale force still expect fear weigh stock mylan be pay revance upfront revance be also eligible clinical regulatory milestone sale base milestone piper jaffray analyst david amsellem say note client deal help revance monetize expertise botulinum toxin active ingredient botox amsellem say call deal mylan form downside protection drug know rt injectable neuromodulator botox put way be way revance participate wider chunk botulinum toxin market context decline pricing environment due other brand botulinum toxin product botox biosimilar say revance have say first goal be have rt approve cosmetic treatment frown line eventually expect go therapeutic indication mizuho koffler say allergan also say late wednesday food drug administration push back review application drug call ulipristal acetate august provide full review file ulipristal acetate be be consider treat bleed woman uterine fibroid drug already sell europe canada esmya fibristal related chart read basic buy point mark time real do spot major market top easy look heavy much money do need start investing
22,MYL,look best stock buy watch focus rise relative price strength stock fit bill be eagle pharmaceutical egrx have relative strength rs rating upgrade monday look best stock buy watch factor watch closely be relative price strength unique rating identify market leadership used worst best score indicate stock price action last week match other publicly trade company history reveal top perform stock often have rs rating least early stage move see ibd help make more money stockseagle pharmaceutical have climb more past entry first stage cup handle meaning now proper buy zone look stock offer new chance pick share week tight pullback day week line earning growth drop last quarter top line rise company earn rank peer medical generic drug industry group ani pharmaceutical anip collegium pharmaceutical coll mylan myl be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
23,MYL,mylan myl jump late wednesday generic drugmaker report mixed fourth quarter revenue lag street continue volatility adjust profit top penny guidance also be mixed mylan sale outlook miss consensus midpoint firm view adjust earning beat expectation midpoint chief executive heather bresch note health care market remain volatile deliver increase total revenue year year strong performance europe rest world segment more offset volatility health care industry marketplace say prepared statement fourth quarter total revenue be year year narrowly miss consensus adjust profit share decline top average view analyst poll zack investment research share north america segment third party net sale decline sale epipen treat emergency allergic reaction decrease launch authorize generic higher governmental rebate follow deal department justice europe segment sale climb revenue rest world grow mylan guide adjust profit share total revenue consensus have expect adjust earning share sale mylan also announce sign license agreement revance therapeutic rvnc bring biosimilar botox market botox be brand allergan agn hour trading stock market today mylan lift close regular session related celgene gamble ozanimod didn pay offcelgene tank fda refuse review multiple sclerosis drugthese biotechs diverge biggest moneymaker lag expectation
24,MYL,tech heavy nasdaq surge early tuesday dow post more modest gain market value report north korea be willing discuss abandon nuclear weapon program xmicron technology mu mylan myl jump head nasdaq general electric ge easily lead dow china base internet play baozun bzun surge past buy point early trade nasdaq composite snap early lead apple aapl swung netflix nflx seize early lead fang stock tech leader dow jone industrial average gain future add north korean leader kim jong tell south korean envoy country be willing negotiate exit nuclear weapon program place moratorium related testing negotiation accord new york time north south korea also agree summit meeting kim south korea moon jae late april trump administration have previously say consider talk north korea country concede accord washington post asian market book healthy gain tuesday global news agency cite rise pushback lawmaker broad brush trade tariff propose last week president trump factor rebound tokyo nikkei surge snap day sell hong kong hang seng index jump report north korea be willing discuss normalize relation circulate close asia market use ibd marketsmith free march
25,MYL,see stock buy point get chart pattern recognition run custom screen start nowin europe stock continue ease early high afternoon trade frankfurt dax trim back gain london ftse advanced nasdaq be look add third day dow industrial second day rebound last week pullback nasdaq turnabout show index day move average positive sign market remain pressure dow remain day level institutional back week old uptrend uncertain dow general electric jump intel intc advanced open dow peer home depot hd drop more netflix quickly trim early gain still lead way fang stock stock hammer new high open trade follow gain monday be work fourth straight weekly advance chip bellwether micron technology surge almost extend monday past buy point goldman sachs boost price target buy rate stock report cite improve trend pricing dram memory chip computer datum storage leader netapp ntap jump follow report stock be work fourth straight weekly advance climb right side week consolidation current pattern netapp not form base offer valid buy point end friday session china base online retailer baozun spiked report powerful fourth quarter earning beat sale miss still company guide first quarter revenue well analyst expectation say anticipate increase service revenue quarter move marked past buy point month base pattern china name live stream service provider yy dive open company report strong fourth quarter performance late monday loss send share back week move average drugmaker mylan sprint more morgan stanley place first overweight rating stock year stance equal weight cite growth prospect strong new product pipeline mylan share be attempt start right side month consolidation retailer be early pressure ann taylor lane bryant dressbarn chain owner retail group asna slump report soft fiscal second quarter result late monday targettgt dump open dump nearly earlier trade chain fourth quarter earning fall short expectation report stronger expect same store sale fourth quarter full year earning guidance be also expectation midpoint first quarter earning guidance be consensus target be interested big picture stock extend rebound long tech leader have break more be buy point stock buy point be show strong relative strengththese tech stock be set find key top chip play poise break re risky
26,MYL,tuesday teva pharmaceutical teva earn positive adjustment relative strength rs rating re research best stock buy watch keep close eye relative price strength ibd proprietary rs rating measure technical performance used worst best score show stock price performance trail week stack other stock database history show best stock typically have better rs rating early stage move see teva pharmaceutical continue show renew price strength clear threshold look best stock buy watch start hereteva pharmaceutical be work cup handle buy point see stock clear price volume least higher normal earning sale growth come respectively latest report show improvement earning share sale teva pharmaceutical earn rank peer medical generic drug industry group ani pharmaceutical anip collegium pharmaceutical coll mylan myl be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
27,MYL,amgen amgn future biotech company be trouble analyst say tuesday company sector trade premium biotech company celgene celg biogen biib pipeline contain fewer blockbuster opportunity meanwhile generic biosimilar competition be hacking away chunk revenue leerink analyst geoffrey porge say investor have be reward amgen share repurchase program steady cash flow lack long term stability generally investor look biotech company unpriced optionality pipeline amgen doesn have amgen case inability identify program offer upside particularly company size reinforce belief amgen commit significant business development activity expand portfolio pipeline porge say report client get newsletter deliver inbox more info product service privacy policy term useporge estimate amgen portfolio be likely steadily decline biggest moneymaker epogen aranesp neupogen neulasta enbrel be face rivalry growth potential new acquire product isn enough offset decline franchise epogen aranesp treat anemia dow jone component pfizer pfe just gain approval make copy epogen procrit novartis nvs also have copycat neupogen bone marrow stimulant blockbuster neulasta enbrel be also risk neulasta also stimulate bone marrow enbrel treat chronic disease include form arthritis psoriasis novartis already have copycat enbrel novartis mylan myl coherus bioscience chrs be work copy neulasta response amgen have restructure expense base initiate dividend lever company balance sheet porge say compare peer regard amgen more defensive stock also lack explosive upside potentially typically associate breakthrough rapidly grow bio therapeutic stock say porge see amgen worth share be most recent close price have market perform rating price target amgen stock stock market today share rise close share biotech company lift fraction most concern conclusion analysis be lack opportunity amgen pipeline outside element sum part say celgene biogen other hand have greater pipeline optionality growth prospect eventually firm have engage smart merger acquisition porge say best merger acquisition pivot away amgen challenged legacy product mid late stage pipeline opportunity build revenue projection possible biotech be interested merger equal stand company current pipeline be very early have share economic thus be unlikely meaningfully outlook company current revenue year say related chart read basic buy point mark time real trade stock most penny stock fail make investor richnew option strategy limit risk earning
28,MYL,amgen amgn stock take double hit tuesday dow jone component pfizer pfe grab approval knockoff amgen anemia treatment eli lilly lly report strong result compete headache drug stock market today amgen stock topple close pfizer dip finish lilly slip share stock be consolidate respective buy point share biotech company pharmaceutical company fall fraction food drug administration approve pfizer drug call retacrit midday tuesday retacrit be biosimilar almost identical biologic copy amgen drug epogen procrit epogen procrit be anemia treatment get newsletter deliver inbox more info product service privacy policy term usepfizer approval isn major hit amgen revenue see just first quarter sale epogen epogen be amgen seventh biggest drug first quarter sale decline vs year earlier period other be attempt copy amgen biggest drug neulasta enbrel neulasta increase bone marrow stimulation enbrel treat chronic disease include form arthritis psoriasis be blockbuster novartis nvs have enbrel biosimilar call erelzi drug be approve novartis unit sandoz launch erelzi patent dispute amgen be complete novartis sandoz mylan myl coherus bioscience chrs also be work biosimilar neulasta amgen be also rivale lilly teva pharmaceutical teva aldr migraine drug class call cgrps short calcitonin gene related peptide firm be work treatment prevent chronic migraine tuesday lilly say medicine call galcanezumab meet key goal late stage study patient episodic cluster headach reduce weekly cluster headach compare placebo week month treatment period statistically significantly greater percentage patient treat lilly medicine also see least reduction weekly attack compare placebo week drug prove safe tolerable lilly drug be also be study migraine amgen novartis partner develop aimovig likely be first class get approval prevent chronic migraine food drug administration be expect make decision aimovig later week related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
29,MYL,top hedge fund manager have bet warren buffett take large position unitedhealth unh anthem antm other health insurer xmeanwhile buffett berkshire hathaway brkb have more double stake generic drugmaker teva pharmaceutical teva also confirm have become second largest shareholder apple aapl sec filing detail list stock holding march company say own teva american depositary receipt worth be adrs worth previous quarter health insurer share slump buffett amazon amzn chief jeff bezos jpmorgan chase jpm ceo jamie dimon announce january joint venture aim be cut health care cost want employee get better medical service lower cost buffett say berkshire annual shareholder meeting earlier month resistance be unbelievable fail least try however rival be bet plan power player jana partner reveal tuesday new position anthem cigna ci omega advisor billionaire investor julian robertson tiger management have take new position unitedhealth accord regulatory filing teva have be pressure mylan myl generic version multiple sclerosis drug copaxone be approve october challenge face generic medicine industry contend teva announce restructure plan trim spending close plant cut drug program february teva say be well way realize half saving year end buffett decision hedge fund manager seem agree be increase apple hold barry rosenstein jana partner have new position tech giant have sell share facebook fb highlight rough recent performance homebuilder jana also reveal have cut stake horton share other new position include adobe system adbe adt adt boston scientific bsx dr pepper snapple dps contrast tiger management up position facebook also take more stock google parent alphabet googl david einhorn greenlight capital add interactivecorp iac exit chemour cc activist investor carl icahn sell stake american international group aig increase position herbalife nutrition hlf hedge fund superstar bill ackman famously lose bet herbalife back march take claim company be pyramid scheme third point raise stake facebook take share wynn resort wynn share microsoft msft also be interested cvs re go deliver amazon jpmorgan berkshire seek doamazon berkshire hathaway jpmorgan chase team health care cvs unitedhealth facebook esport medium boom legalize sport bet company be now outperform stock invest stock market start simple routine
30,MYL,teva pharmaceutical teva rocket late wednesday news berkshire hathaway brkb take stake israeli drugmaker accord cnbc hour trading stock market today teva launch close same time generic drug stock lift collective regular session teva have be pressure mylan myl generic version multiple sclerosis drug copaxone be approve october challenge face generic medicine industry sign free ibd newsletter market prep tech reportto contend teva announce restructure plan trim spending close plant cut drug program last week teva say be well way realize half saving year end related dow merck fail alzheimer drug shouldn hurt biotech stock rocket immuno oncology tie bristolwhy payer win balk price tag vertex new drug
31,MYL,teva pharmaceutical teva pop early thursday israeli drugmaker top wall street first quarter estimate raise outlook say expect key migraine drug get approval year stock market today teva share lift much wildly reverse course stock end regular trading session share be consolidate buy point meanwhile generic drug group dip fraction mizuho analyst irina koffler reiterate buy rating price target teva note commentary regard teva preventative chronic migraine drug call fremanezumab help stock teva indicated expect pre approval inspection celltrion facility come month launch fremanezumab end say report news remove prior concern weigh stock last quarter get newsletter deliver inbox more info product service privacy policy term usefremanezumab belong class drug design block calcitonin gene related peptide cgrp receptor believe be intricately tie migraine amgen amgn eli lilly lly aldr be also work preventative treatment teva report smaller expect decline first quarter adjust profit cent share fall crushed view cent sale come dip still beat consensus analyst poll zack investment research generic drug teva biggest unit decline north america teva cite price erosion slide europe teva generic drug climb growth counter volume be partially offset price reduction sale multiple sclerosis drug copaxone tumble third globally still beat koffler view revenue decline copaxone now face generic copycat mylan myl novartis nvs partner momenta pharmaceutical mnta austedo bring crush koffler estimate drug be first approve april treat cholera associate huntington disease august get approval treat involuntary body movement tie long term use drug teva also boost guidance now see adjust profit share midpoint beat analyst view also expect sale slightly midpoint top estimate related build long term profit stock take many gain sell take profit hold here be several guideline basic analyze stock cup handle
32,MYL,mylan myl have relative strength rs rating upgrade monday welcome improvement still short better score look ibd unique rating measure share price performance worst best score score show stock price movement last week compare other stock database year market history show stock go make biggest gain often have rs rating early stage move see mylan continue rebound hit benchmark look winning stock try simple routinemylan be not currently potential buy zone see stock go form sound pattern ignite new run company report negative growth top bottom line last quarter mylan hold rank peer medical generic drug industry group ani pharmaceutical anip be rank stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
33,MYL,glaxosmithkline gsk expect adjust profit slide grow competition key asthma hiv unit base drugmaker say early wednesday guidance follow better expect quarter glaxo post adjust profit cent share sale analyst have see earning cent share sale respectively accord reuter adjust profit grow constant currency basis year generic copy asthma inhaler advair chip away earning mylan myl be expect launch generic teva pharmaceutical teva launch authorize generic early generic emerge midyear glaxo expect adjust earning be flat constant currency basis generic emerge adjust profit grow regardless exchange rate look ahead see potential generic version advair guidance reflect chief executive emma walmsley say written statement ibd take bull market be great time review stock selling smart first establish sell rule strongest stock way bottom fall re prepared more head investor corner glaxo tick cent close stock market today glaxo hiv unit be also face mount competition gilead science gild say tuesday combine hiv hepatitis drug sale grow fourth quarter gilead be also work new regimen used drug call bictegravir still walmsley say glaxo deliver mid high single digit growth adjust earning share constant currency basis focuse new launch include inhaler call trelegy ellipta hiv drug juluca shingle medication shingrix related allergan pop consensus top quarter strong migraine trialgilead beat quarterly view topple soft guidancethese biotechs spring back market correction analyst
34,MYL,stock stage positive turnabout late wednesday rise close boee ba walt disney exxon mobil xom lead rebound dow jone industrial land gain first advance session boee top index ride strong first quarter result disney kick late aid upgrade market perform underperform bmo capital exxon surge raise quarterly dividend more hold gain edward lifescience ew drop hard miner freeport mcmoran fcx tumble fourth straight day head list railroad norfolk southern nsc tax man block hrb jump respectively heavy loss tripadvisor trip checkpoint software chkp generic drugmaker mylan myl prevent nasdaq composite shedding fractional loss texas instrument txn hop biogen biib gain first quarter result report late tuesday biogen also receive upgrade outperform neutral robert baird wednesday crude oil price gain benchmark crude settle barrel bond edge lower send year yield basis point telecom fiber optic gear maker mortgage service group post session heaviest loss industry group track ibd get free access ibd digital april
35,MYL,get premium stock list pass fail stock rating more start herein fiber optic group name include oclaro ocrl lumentum lite finisar fnsr take hard hit rate sensitive mortgage service stock lendingtree tree hff hf drop respectively apple aapl pare gain close investor await detail meeting chief executive tim cook president trump cook reportedly also meet trump economic advisor larry kudlow well trade representative robert lighthizer well president wednesday morning trump tweet meeting cover many topic include have be treat unfairly many year many country trade apple share be fight regain day move average fang stock tech leader finished session lower alphabet googl lead group fraction stifel nicolaus upgrade stock buy hold follow company result tuesday netflix nflx slump pricing offer high yield bond share be week rebound back day move average facebook fb end flat investor look social medium giant report close consensus view project rise ep revenue accord zack investment research be facebook first quarterly report cambridge analytica datum privacy scandal break last month facebook share have be recover march low be now week meeting resistance day move average boee throttle report first quarter revenue earning significantly expectation management also raise full year earning guidance well consensus target stock be attempt retake week move average be form cup type base buy point other top defense name also post result early wednesday northrop grumman noc trim early loss report result general dynamic gd slump chip stock return volatile trade late day texas instrument stretched gain teradyne ter collapse robert baird cut stock neutral outperform chip equipment maker tuesday warn second quarter result miss consensus target due weaken demand mobile testing device advanced micro device amd tank report earning close comcast maintain gain follow first quarter result company also formally offer long run battle walt disney st century fox fox take base broadcaster sky disney share close fox also advanced ibd stock align technology algn gain ahead quarterly result due today close maker clear orthodontic brace be week line month base pattern bottom list edward lifescience pare loss finish medical product leader deliver strong first quarter sale earning beat second quarter guidance be softer expect sale come short company closely watch tavr segment management raise full year earning outlook analyst forecast share be shallow consolidation march high related big picture be bull market finally facebook twitter boee paypal visa earning action planboee lift earning cash flow view crush estimate twitter stock jump beating earning revenue forecast northrop grumman general dynamic top earning view
36,MYL,rapid turnaround allergan agn say late thursday doesn intend bid shire shpg leave thrice rebuff takeda pharmaceutical alone race rare disease drugmaker entire saga erupt early thursday report emerge allergan be interested buy shire same time shire confirm have reject bid takeda worth north allergan first say be early stage potential bid shire hour stock plunge later allergan say definitively win make offer take shire meanwhile still evaluate full range potential strategic option allergan say news release share allergan close be flat hour trading stock market today shire sank close bell get newsletter deliver inbox more info product service privacy policy term usespeculation shire takeda merger have be swirl late march then takeda have make bid shire case shire board determine bid significantly undervalue firm growth prospect pipeline takeda confirm put forth buyout bid shire worth share comprise cash stock firm say be willing continue negotiating still takeda be confident remain well position even negotiation fall build takeda exist momentum acquisition shire accelerate transformation result global value base drive leader headquarter japan takeda say prepared statement short live interest allergan come surprise leerink analyst etzer say note firm have say become acquisitive be look strategic option combination shire introduce growth challenge year be reflect negative stock reaction say shire be likely face erosion attention deficit hyperactivity medicine vyvanse begin significant erosion hemophilia business compete rival roche rhhby allergan have have justify bid shareholder say shire interest come flurry biotech acquisition kick earlier year celgene celg announce plan buy juno therapeutic sanofi sny unveil plan acquire bioverativ bivv ablynx ablx novartis nvs sell share glaxosmithkline gsk consumer health unit used part proceed fund plan acquire avexis avxs merck kgaa agree sell counter unit proctor gamble pg day be rumore mylan myl buy earlier week shire say sell cancer unit france servier analyst have speculate celgene also be lookout more acquisition agio pharmaceutical agio jounce therapeutic jnce potential target amgen amgn also have huge war chest be face competition older medicine related chart read basic buy point mark time real opportunitylong term retirement investing strategy etfssell take profit hold here be several guideline follow
37,MYL,teva pharmaceutical teva mylan myl be group generic drug maker hit thursday consortium hospital say make medicine circumvent rise drug price estimate hospital group be involved effort create nonprofit company provide generic medicine hospital accord new york time goal be avoid rise drug price medicine shortage stock market today generic stock collectively dip fall earlier trade share teva fall close mylan lose other tumble include lannett lci close aclaris therapeutic acrs dip ani pharmaceutical anip dove nearly hospital have struggle shortage drug morphine sodium bicarbonate saline last april department justice serve subpoena number firm include pfizer pfe baxter bax relate saline shortage drugmaker have be political hook rise price particularly older patent drug martin shkreli former head turing pharmaceutical draw ire buy drug used aids patient spiking price tablet ibd take ani pharma lead company generic drug industry group ibd composite rating best possible mean outperform most stock term key growth metric head ibd stock checkup look other strongly rate drug stock valeant pharmaceutical vrx become wall street superstar crash burn early buy older drug then raise price valeant stock be nearly hit bottom april share dip thursday number generic drug maker become subject antitrust investigation price antibiotic diabetes medicine related beware price war big pharma biotech company horizongeneric drug maker face pricing issue other pharmas don twill trump break republican push major drug price reform
38,MYL,teva pharmaceutical teva jump monday grab upgrade price target boost restructure plan look more reasonable analyst say credit suisse analyst vamil divan upgrade teva outperform rating neutral raise price target last week teva update investor plan include new organizational structure cut workforce firm be also close plant plan announce closure end also examine portfolio cut specialty program year end teva expect achieve least half spending cut have plan now have more detail plan include outlook believe be achievable be see sign early execution plan be take additional step upgrading teva share divan say note client close bell stock market today teva pop finish guidance sale year include potential impact generic version teva multiple sclerosis drug copaxone milligram teva say earning conference call first quarter be strongest ibd take teva be trading line day move average do line mean be risk head investor corner closer look used day move average pinpoint opportunity risk mylan myl already have approval copaxone copycat dr reddy laboratory rdy be delay generic momenta pharmaceutical mnta novartis nvs sandoz unit have generic market year analyst say copaxone be bright spot fourth quarter divan say revenue decline hold better expect assume second generic enter market first half see rapid sale erosion delay teva migraine drug be new negative be expect divan say class drug call cgrp inhibitor teva be rivale amgen amgn eli lilly lly aldr believe migraine market be large enough multiple blockbuster even teva be third fourth market say generic be likely continue face challenge pricing pressure acceleration food drug administration approval compete generic difficulty acquire share drug originator say divan expect generic sale decline then face single digit decline however here well believe expectation enter be more reasonable have be past provide opportunity company meet beat expectation move forward say related regeneron benefit lackluster datum present rivalscan crispr small biotechs cure diseasesthese biotechs spring back market correction analyst
39,MYL,relative strength rs rating teva pharmaceutical teva jump new percentile wednesday rise unique rating measure technical performance used worst best score show stock price action trail week match other stock history show best stock typically have rs rating north begin biggest run see ibd help make more money stock be not proper buy zone right now see go form break proper chart pattern teva pharmaceutical show earning growth latest quarterly report sale growth come next quarterly number be expect feb company earn rank peer medical generic drug industry group ani pharmaceutical anip collegium pharmaceutical coll mylan myl be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
40,MYL,plunge share teva pharmaceutical teva weigh generic drug stock thursday sale profit continue drop offer weak guidance top word potential delay key migraine drug fourth quarter teva bring adjust profit cent share sale decline respectively sale multiple sclerosis drug copaxone decline grow generic competition year teva see adjust profit share sale lag consensus respectively teva outlook reflect likelihood increase challenge management note roughly half decline reflect impact loss exclusivity copaxone milligram piper jaffray analyst david amsellem say note client significant chunk decline also not surprisingly reflect continue pressure generic business close bell stock market today teva plunge close earlier fall much generic drug stock collectively dip analyst say rival mylan myl new copaxone generic be price discount teva brand drug dr reddy laboratory rdy be delay momenta pharmaceutical mnta novartis nvs unit sandoz have milligram generic market year pfizer pfe manufacturing facility pass re inspection generic drug sale fall year year teva record goodwill impairment related generic business pricing pressure government regulation accelerate generic approval delay launch continue be challenge sale be teva profit revenue top consensus analyst poll zack investment research adjust profit cent share sale copaxone sale also beat consensus view mizuho analyst irina koffler say note client still expect generic entrant mid ibd take teva relative strength rating have be rise month now have rs rating best possible see go rating visit ibd datum story further teva say manufacturer active pharmaceutical ingredient used migraine drug fremanezumab receive warning letter food drug administration regard fill finish part facility mean fremanezumab be delay fremanezumab be currently set go fda june drug belong class know cgrps aim prevent migraine aldr amgen amgn eli lilly lly be work drug class be source anxiety surround business simply afford have additional misstep particularly context highly competitive cgrp migraine space amsellem say related sanofi regeneron dip eczema drug dupixent lag crispr small biotechs cure disease biotechs spring back market correction analyst
41,MYL,tuesday ani pharmaceutical anip get upgrade ibd smartselect composite rating new rating be sign stock be outpace stock come most important stock pick criterium history show top market performer tend have higher score launch major climb ani pharmaceutical be currently form cup handle buy point look stock break heavy trade least average look winning stock try simple stock have ep rating meaning recent quarterly annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week company post earning growth top line growth come prior quarter ani pharmaceutical hold rank peer medical generic drug industry group collegium pharmaceutical coll mylan myl be also group highest rate stock related company be now outperform stock
42,MYL,tech giant amazon amzn be preliminary talk generic drugmaker mylan myl novartis nvs unit sandoz ahead potential entry pharmaceutical space accord report cnbc hour trading stock market today mylan climb close nearly novartis be flat share end day amazon lift close bell accord person familiar matter conversation have be high level unclear amazon enter space amazon become drug wholesaler sell generic medication retailer amazon decline comment representative mylan sandoz novartis unit didn immediately return request investor business daily comment related amgen have edge rival prevent migrainesdoe gilead kite acquisition offer new buy opportunity teva restructure plan case be here do
43,MYL,mylan myl pop week high friday gain approval generic blood thinner rumor talk amazon amzn ahead online giant potential entry pharmaceutical close bell stock market today mylan surge close share novartis nvs unit sandoz be also reportedly talk amazon tick close food drug administration approve mylan application generic version heparin sodium inject anticoagulant approval be different dose be package vial accord mylan sale heparin sodium injectable dose be month end oct currently mylan have pending application generic drug represent annual brand sale mylan president rajiv malik note drugmaker have approximately product injectable portfolio available patient mylan expect make heparin available hospital come week ibd take lead medical stock file initial public offer be testing support new flat basis keep peer just break get deep dive ibd stock analysis be very proud today fda approval heparin sodium injection approval add yet highly complex difficult maufacture product portfolio malik say prepared statement news follow report late thursday amazon be talk mylan sandoz ahead potential entry pharmaceutical amazon role be unclear possible tech giant be drug wholesaler sell generic medicine retailer amazon decline comment investor business daily representative mylan sandoz didn return request comment related do gilead kite acquisition offer new buy opportunity amgen have edge rival prevent migrainesepipen rivalry slug mylan result outlook beat view
44,MYL,perrigo prgo see positive improvement relative strength rs rating thursday upgrade ibd proprietary rating track price action worst best score grade show stock price behavior trail week compare other stock database year market history reveal top perform stock often have rs rating least early stage move see perrigo continue rebound clear threshold look winning stock try simple routineperrigo break earlier have fall back prior entry flat base case stock break then fall more entry price consider fail happen best new base take shape also keep mind latest pattern be later stage base make riskier establish new position add share exist perrigo see earning sale growth rise last quarter earning share increase revenue rise company earn rank peer medical generic drug industry group ani pharmaceutical anip mylan myl collegium pharmaceutical coll be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
45,MYL,stock open narrowly lower friday head first trading session december delay senate tax reform effort appear make progress dow fought hold level dow jone industrial average ease open fraction red nasdaq composite open decline apple aapl shed fang stock open lower stock future european market pull back congressional committee review late thursday find financial impact bill fall short expectation news report early friday note least gop senate holdout be prepared support measure minor modification senate aim submit measure vote friday dow general electric ge visa drop more chevron cvx lead upside gain amazon com amzn dip price target hike oppenheimer news report late thursday say amazon be preliminary talk generic drugmaker mylan myl novartis nvs regard potential entry pharmaceutical market mylan rise early action novartis slip chipmaker qualcomm qcom drop micron technology mu nvidia nvda also fall more ambarella amba power third quarter earning revenue decrease less forecast analyst gap gain put chip developer buy range buy point cup handle base vmware vmw rise ibd name slip more earning report be extend press new high vmware be buy range rebound support week move average china base name be feel early pressure jd com jd baidu bidu alibaba group holding baba trading loss bitcoin jump early trade spiking briefly wednesday crytpocurrency related play riot blockchain riot premarket action marathon patent group mara spiked bitcoin investment trust gbtc vault higher manufacturing growth slow november accord researcher markit report november manufacturing index october consensus view institute supply management manufacturing purchasing manager index be due et commerce department october construction spending estimate be also slate release weekly oil gas rig count report baker hughe bhge fill et release slot november sale result automaker be expect day fed official be force friday st loui federal reserve bank president james bullard set speak just et dalla fed president report kaplan be next speaking be et mcallen texas president patrick harker philadelphia federal reserve bat cleanup et speech related amazon reportedly talk mylan novartisblue chip stock power head bullish news adobe fly cloud remain airborne
46,MYL,putt together watch list look stock higher rs rating insys therapeutic insy now meet criterium jump thursday ibd proprietary rating identify share price action worst best score score show stock price movement last week compare other stock database history show stock go make biggest gain often have rs rating north early stage move look winning stock try simple routineinsys therapeutic be not currently potential buy area see stock go build sound pattern launch new move company post negative growth top bottom line last quarter insys therapeutic hold rank peer medical generic drug industry group ani pharmaceutical anip collegium pharmaceutical coll mylan myl be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
47,MYL,wednesday perrigo prgo receive positive adjustment relative strength rs rating exclusive rating investor business daily measure market leadership worst best score rating show stock price behavior last week hold other stock database history show top perform stock typically have rs rating north early stage move see perrigo continue rebound clear threshold look best stock buy watch start hereperrigo be try complete flat base entry see clear price heavy trading earning grow last quarter prior report revenue also increase company hold rank peer medical generic drug industry group ani pharmaceutical anip mylan myl collegium pharmaceutical coll be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
48,MYL,ani pharmaceutical anip see improvement ibd smartselect composite rating wednesday new rating be sign stock be outpace stock come most important stock pick criterium top perform stock tend have better grade launch significant move ani pharmaceutical break earlier have fall back prior entry cup handle stock re watch climb buy point then retreat more original entry price consider fail base best stock form new pattern see ibd help make more money stock earn ep rating mean recent quarterly annual earning growth top stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company report earning share gain sale growth come previous quarter ani pharmaceutical earn rank peer medical generic drug industry group mylan myl collegium pharmaceutical coll be also group highest rate stock related company be now outperform stock
49,MYL,mylan myl see dip epipen sale third quarter lead total revenue adjust income lag share stay black early monday better expect outlook company third quarter mylan report adjust income share sale respective vs year earlier period metric miss analyst view adjust profit share sale mylan also raise lower end sale earning guidance year now see sale midpoint be just ahead analyst view year year basis sale rise midpoint adjust income be expect come share midpoint slightly lag analyst view decline vs prior year sale epipen injection treat emergency allergic reaction decline quarter add competition mylan own generic brand drug rival mylan also face higher governmental rebate result settlement drug be classify medicaid drug rebate program epipen have previously be labele generic drug allow mylan pay lower rebate drug close bell stock market today mylan surge close ibd take biotech stock have struggle third quarter earning season be now rank sixth group track third last week biotech result have be classify alarm head ibd industry theme deeper dive group north america sale decline consensus mizuho analyst irina koffler say note client european sale top view rest world sale lag vs model segment be therefore relatively stable vs competitor view koffler say guidance suggest least positive revenue benefit net income benefit recent launch generic version copaxone single quarter koffler say copaxone multiple sclerosis drug be make teva pharmaceutical teva mylan conservatively maintain earning target least spite positive trend see third quarter say related teva dife earning miss weak guidance zoetis top viewsmylan topple president name mind blow antitrust allergan public relation backlash deepen weekgeneric drug maker face pricing issue other pharmas don
50,MYL,british billionaire reportedly be consider buy stake teva pharmaceutical teva prod share israeli drugmaker pop monday price target cut follow lackluster quarter xby close bell stock market today teva jump close allergan agn also sustain price target cut follow mixed report last week share dip close len blavatnik be look acquire stake teva accord reuter cite report israeli outlet weekend teva have market cap share hit year low last week third quarter earning miss teva cut guidance blavatnik acquire stake teva private stock list scoop allergan stake allergan receive teva part deal last year sell generic business teva last week allergan say be look sell stake credit suisse analyst vamil divan trim price target teva keep underperform rating expect stock continue languish investor await update strategic plan new chief executive kare schultz teva left lot question unanswered conference call divan say note client be understandable new ceo just joined company day lack insight be still frustrate ibd take least biotech have alarm result earning be mixed most head ibd industry theme breakdown industry group thus far third quarter earning season teva maker generic drug now find flip side coin mylan myl just launch generic version copaxone multiple sclerosis drug teva now divan see teva pull copaxone sale next year year year mylan come market immediately price be lower teva expect say question also remain allergan divan say separate report cut price target allergan keep outperform rating teva allergan be soon face generic competition restasis eye drug see competition january july base case now assume restasis generic entry start instead mid say base ep be previous large part change assume be relatively rapid erosion sale generic also pressure namenda ex extend release estrace delzicol aczone drug treat dementia menopausal side effect ulcerative colitis type acne respectively divan also lower estimate kybella drug reduce fat chin give limit commercial progress product have make now see peak sale related epipen rivalry slug mylan result sale outlook beat viewsallergan soft revenue earning top nordisk mixedteva dife long road ahead earning miss guidance cut
51,MYL,invest disruptor advice wall street giant biotech company incumbent big pharma be brace get crushed more innovative cheaper new drug start continue analyst say generic drug approval be rise interesting new medicine be start take market share legacy maker medication consumer use frequently include big pharma biotech company blockbuster drug represent estimate annual sale be set lose patent protection next decade analyst say disruption come generic drug innovative new biologic alternative come market be brutal jmp security analyst mike king tell investor business daily be knife fight market cholesterol lower drug king expect amgen amgn regeneron pharmaceutical regn sanofi sny feel heat like esperion therapeutic espr medicine co mdco alnylam pharmaceutical alny meanwhile inflammatory treatment celgene celg otezla gain blockbuster status miss sale forecast wide cut third quarter analyst say newly approve drug treat same condition eli lilly lly novartis nvs be take market share gilead science gild be still feel pain mature hepatitis drug unit europe rapid pace gilead hepatitis sale decline be expect slow somewhat newer medicine abbvie abbv mavyret be likely swipe sale big pharma isn get help regulator food drug administration head scott gottlieb continue increase approval copycat drug stoke competition brand generic drug face new rival firm try undercut price big pharma company pfizer pfe be forefront feel sting generic take sale earlier month teva pharmaceutical teva be allow launch generic copy blockbuster erectile dysfunction drug viagra generic drug tend be cheaper brand counterpart viagra be pricey drug tablet accord accessrx pfizer lose exclusivity viagra canada europe worldwide sale fall today generic europe have slash price drug contain same active ingredient viagra generic version viagra cost third price canada viagra price also fall trend repeat generic market teva meanwhile be struggle debt end third quarter thursday teva announce plan cut workforce more quarter close several manufacturing facility suspend dividend ordinary share firm be also plan review generic drug portfolio most specifically change price discontinue product ibd take see giant biotechs fared vs smaller player third quarter visit industry snapshot hint quarter be classify alarm large cap biotech be trouble see more competition traditional moneymaker board spending prescription drug increase just person accord report express script esrx rise represent drop growth rate trend be likely continue fbb capital partner analyst mike bailey tell ibd credit gottlieb decline generic price gottlieb be run fda business allow cycle more approval more competition lower price center medicare medicaid service use tool influence pricing unlikely president trump use executive power enact sweeping drug pricing reform such allow medicare negotiate price enact pricing control bailey say wouldn expect major change trump administration pricing say think mechanically politically difficult get pricing law system politically more acceptable just get more generic drug approval jmp king count drug treat rheumatoid arthritis psoriatic arthritis crowd area drug class cost average prescription benefit increase utilization unit cost accord express script third quarter thing begin look dour like celgene miss expectation inflammation drug otezla lag be even sharper analyst suggest celgene be force take price concession celgene also cut guidance terminate trial drug treat crohn disease condition result chronic inflammation digestive tract now see inflammation immunology drug bring combine outlook issue biotech company big pharma need get realistic pricing competitive arena king say same be say company make treatment hepatitis multiple sclerosis high cholesterol be highly saturate market latter point expect price drug know pcsk inhibitor repatha amgen praluent regeneron sanofi be microscope drug lower bad ldl cholesterol blood evidence show also have benefit cardiovascular outcome repatha be list year praluent cost rival be close medicine co alnylam be work cholesterol drug know inclisiran meanwhile analyst expect bempedoic acid esperion be cheaper big pharma biotech company be probably go get arm twisted lot king say pricing umbrella have create opportunity new company come scale market share be careful own incumbent invest disruptor other area be seemingly immune pricing pressure analyst say price multiple sclerosis drug rise average continue trend fbb bailey say price increase have be so egregious house democrat launch investigation august note many drug carry price tag north year investigation be launch rep elijah cumming peter welch center bayer bayry biogen biib emd sereno novartis roche rhhby sanofi teva pharmaceutical biotech company teva milligram dose copaxone have increase most rise approval annual price today accord national multiple sclerosis society novartis gilenya approve be highest price investigation be year too late say more difficult push price control specialty market multiple sclerosis be massive market now stakeholder view specialty market rare disease innovative cancer therapy also seem immune pricing control analyst say example earlier year novartis gilead acquisition kite pharma gain approval car drug know kymriah yescarta respectively car drug be develop used patient own immune system cell be trained seek destroy cancer cell kymriah go year yescarta be list ark invest analyst manisha samy write recent post gene therapy be begin cure cancer come price cause sticker stock say say compare traditional therapy suppress do not cure cancer cost benefit analysis gene therapy be compelling pricing shock tend tamp excitement really compelling drug bailey say prime example be biogen ionis pharmaceutical ion spinraza first spinal muscular atrophy drug approve cost first year subsequent year sentiment biotech company share be already say so drug pricing concern shouldn be big stock killer past biotech stock go quickly get new drug person be excited lot time someone throw grenade drug pricing bailey say sentiment be already even concern drug pricing see little less downside ibd company biotech industry group be now rank group track have fall first just month share collectively near year high october have shucked almost point same time amgen celgene biggest biotechs have see share price dive respectively regeneron have take hit gilead have tumble meanwhile alnylam esperion look likely rival psck inhibitor drugmaker amgen regeneron have lift respectively abbvie recently launch rival gilead hepatitis franchise be novartis lilly be compete celgene treat inflammatory condition have see share retreat smaller degree respectively share price be match dip ibd company ethical drug industry group generic drug stock rank group have actually broadly rise mid october respective dip teva mylan myl biggest name related teva restructure plan case be here do generic drug maker face pricing issue other pharmas don ttop biotech company innovation earn recognition new award
52,MYL,wake weak earning report teva pharmaceutical teva have long road ahead rival mylan myl prepare launch copycat teva copaxone drug generic environment worsen analyst say thursday xby close bell stock market today teva dove year low share collapse finish earlier crash much stock hit lowest point decade touch low last see quarter teva report sale line consensus adjust earning share lag average view analyst poll zack investment research topple year year biggest source pain come teva generic unit plunge generic drug sale fall european sale increase sale remainder world decline counter sale decrease president donald trump have say install competitive system bring drug price end food drug administration commissioner scott gottlieb have pledge speed generic approval lower drug cost ibd take teva isn only drugmaker struggle third quarter dow pfizer fall week low several drug legacy medicine unit lose market exclusivity head income investor more befall pfizer quarter teva acknowledge decline be mainly due challenge market dynamic include pricing decline result customer consolidation larger buy group accelerate fda approval generic version compete patent medicine specialty medicine also decline sale fall partially offset increase europe rest world respectively unit bring total sale quarter teva say news release biggest decline teva be azilect parkinson disease drug copaxone multiple sclerosis medication azilect topple copaxone teva largest moneymaker plunge fda approve generic version drug respiratory drug climb collective sale oncology drug inched teva cut forecast cite earlier generic competition multiple sclerosis drug copaxone teva now see adjust profit share vs prior guidance full year revenue be compare previous guidance analyst have previously call adjust income sale fourth quarter new guidance imply sale cent adjust earning share metric lag consensus expectation revenue adjust income share evercore analyst umer raffat sum teva quarterly report guidance cut sentence be long road ahead teva animal health specialist zoetis climb close top analyst view sale adjust income third quarter zoetis wrapped period adjust profit cent share revenue expectation cent respectively sale grow adjust profit rise vs year earlier quarter firm also raise full year target see adjust earning share sale analyst have modeled adjust profit share revenue related blood disease datum send biotech stock exelixis juno stock rocket crush viewsmylan topple president name mind blow antitrust scheme
53,MYL,mylan myl company president rajiv malik be name sweeping lawsuit tuesday state attorney general expand complaint charge drugmaker prosecutor call mind blow scheme fix generic drug price newly expand complaint allege drugmaker collude fix price pharmaceutical communicate trade show conference other event well email phone text message together company work together falsely inflate price drug treat glaucoma arthritis high blood pressure diabetes anxiety asthma well several other condition attorney general allege allege complaint defendant company collusion be so pervasive essentially eliminate competition market drug entirety connecticut attorney general george jepsen say prepared statement jepsen be lead charge describe conspiracy allege mind blow mylan say stand malik have find evidence price fix part mylan employee mylan say still wait attorney general share information intend substantiate new allegation mylan have deep faith integrity president rajiv malik stand fully firm say prepared statement mylan rajiv malik intend defend case vigorously look forward opportunity present full defense ibd take biotech stock have largely have mixed report quarter celgene sale miss lower expect sale otezla cause stock slide hard head ibd industry theme closer look earning season thus far generic drug sale be estimate today generic drug industry account prescription written mylan lawsuit also include generic giant teva pharmaceutical teva new complaint add actavis pharma acquire teva allergan agn dr reddy laboratory rdy novartis nvs sandoz unit close bell stock market today mylan topple broad generic drug group plunge collective generic firm name complaint lannett lci lead downward slide fall close mylan malik satish mehta chief executive manage director privately hold emcure pharmaceutical parent company heritage pharmaceutical be other individual name complaint earlier year former heritage executive admit price fix scheme april december involve generic antibiotic diabetes drug heritage be drugmaker name initial lawsuit late evercore analyst umer raffat expect series settlement have originally expect teva pay damage ultimately settle mylan pay related generic drugmaker crash perrigo search antitrust probecelgene ceo drug pricing debate hinge incentive innovationdoj charge pharma exec price fix teva mylan stock fall
54,MYL,commerce leader amazon amzn receive price target hike friday follow day conference cloud compute demonstrated grow strength artificial intelligence well fargo security analyst ken sena raise price target amazon premium stock currently trade sena raise estimate amazon web service company fast grow cloud compute unit expect aw revenue reach fourth quarter year period amazon announce slew new product service annual cloud compute conference la vegas week call re invent attendee share drop close stock market today event amazon announce new machine learn service collectively amazon be deliver tool developer help build deploy manage own machine learn system machine learn be application artificial intelligence provide system ability learn improve experience be explicitly programme amazon also announce expansion database service aw sena raise aw estimate also oppenheimer analyst jason helfstein raise price target amazon follow price target hike davidson analyst tom forte thursday pace innovation be strong oppenheimer write research note client add aw be pace bring more new service feature market year ibd take amazon be ibd leaderboard stock composite rating possible amazon com sit extend buy point buy range be capped amazon also announce new aw customer show include disney expedia expe addition report surface late thursday amazon be preliminary talk generic drugmaker mylan myl novartis nvs unit sandoz ahead potential entry pharmaceutical space related retail commerce news stock watchamazon stock quote company news chart analysis
55,MYL,major market average sell late morning trade abc news report michael flynn briefly trump national security adviser testify president part plea deal special counsel robert mueller tech heavy nasdaq tumble dow jone industrial average lose flynn plead guilty friday morning lie fbi conversation russian ambassador trump take office abc news cite source say flynn be willing testify trump order make contact also tap today be possible senate vote gop tax bill republican leader claim have vote pass legislation economic front ism manufacturing index november come compare econoday consensus figure dow jone industrial component chevron cvx pace advancer rise gain price crude oil stock be approach flat base buy point downside apple aapl fall look close week more weekly decline share be back top buy range cup handle entry elsewhere dow visa drop more remain day line well flat base buy point fang stock amazon com amzn fall report cnbc commerce giant be talk generic drugmaker mylan myl novartis nvs unit sandoz potential entry pharmacy market stock be extend buy point tech leader facebook fb drop back day line flat base buy point company report earning ibd sector leader handily beat top bottom line estimate late thursday share moved remain well extend buy point discount retailer big lot big drop early fall back buy range cup handle entry early friday company report better expect earning raise current quarter full year guidance beauty store ulta beauty ulta fall report slow same store sale growth mixed outlook share have be stick downtrend mid be currently more week high ibd only handful name be trading positive territory morning trade lead chip stock be pressure stock market today apply material amat decline nearly fall further day line meanwhile graphic chip maker nvidia nvda continue battle support day line share fall nearly downside alibaba baba be pace extend day lose streak fall share be track close week line first time feb cup handle entry share have rise much buy point related ibd crush earning view see strong holiday salesdow jone industrial average dow stock news stock news quote facebook amazon netflix googleu auto manufacturing sector focus investing action plan
56,MYL,allergan agn stock tank monday federal judge invalidate patent cover eye drug restasis dispute pit allergan group generic drugmaker lead teva pharmaceutical teva mylan myl xby close bell stock market today allergan topple finish teva fall close mylan lift fraction end regular trading session judge william bryson say idea cover restasis patent be too obvious protect evercore analyst umer raffat write note client bryson tend agree allergan be case infringement patent be hold be valid allergan pledge news release appeal decision ruling invalidate patent restasis date none propose generic version restasis have receive approval none be able launch market firm note allergan remain commit vigorously defend intellectual property product allow continue invest develop bring forward new medicine million patient chief legal officer robert bailey say statement ibd take allergan have ibd composite rating meaning outperform just half stock track term key growth metric head ibd stock checkup list better perform drugmaker follow allergan move last month transfer right patent st regis mohawk tribe legal play be call creative controversial take advantage native american tribe sovereign status bryson have serious concern legitimacy tactic raffat say allergan purport have sell patent tribe reality have paid tribe allow allergan purchase perhaps more precisely rent tribe sovereign immunity say successful method give patent defendant new method defeat challenge raffat expect final decision base allergan appeal late suggest allergan seek injunction rival generic related allergan hepatitis drug likely win get fda approvalgeneric drug maker face pricing issue other pharmas don tteva mylan pressure rivalry loom key drug
57,MYL,perrigo prgo have relative strength rs rating upgrade wednesday welcome improvement still higher score prefer see exclusive rating investor business daily identify market leadership worst best score score show stock price performance last week hold other stock database history show market biggest winner tend have higher rs rating begin largest price move see perrigo continue rebound clear threshold see ibd help make more stocksperrigo be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week line earning sale growth come respectively latest report mean earning have have show improvement straight quarters sale have increase company be expect report next quarterly number nov company hold rank peer medical generic drug industry group ani pharmaceutical anip mylan myl akorn akrx be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
58,MYL,allergan agn be already face public relation backlash transfer patent right restasis eye medication native american tribe judge monday then invalidate patent xnow allergan face battle regain credibility wall street credit suisse analyst vamil divan write note client cut price target allergan keep outperform rating generally have be fan allergan management team find challenge defend step be take patent agreement write note client believe take time management team regain credibility have lose process process involved transfer right restasis patent st regis mohawk tribe september avoid patent challenge native american tribe st regis mohawk have sovereign immunity play have be call creative well controversial monday judge invalidate patent cover restasis judge william bryson say idea cover patent be too obvious protect also expressed serious concern regard legitimacy transfer st regis mohawk ibd take allergan have ibd composite rating best possible lag top player abbvie cr meaning perform top stock term key growth metric head ibd stock checkup look other high ranking drug stock even monday allergan stock have lose value follow agreement divan write loss district court also do nothing erase public relation backlash company have suffer go agreement first place combine push food drug administration approve generic drug faster clip divan assume generic launch restasis drug mid earlier view mylan myl teva pharmaceutical teva be work generic version drug longer term investor divan see attractive entry point stock short term catalyst include third quarter earning nov potential guidance update generic restasis competition guidance be not provide nov call least high level investor likely have january time frame company guidance divan say datum readout include late stage trial treat acute migraine midstage trial drug prevent migraine first half class drug call cgrps teva amgen amgn eli lilly lly aldr be also work arena close bell stock market today allergan slip close end monday trade related allergan tank judge invalidate restasis patentswhy allergan hepatitis drug likely win get fda approvalgeneric drug maker face pricing issue other pharmas don
59,MYL,stock rolled narrowly mixed start wednesday weak monthly job datum share apple aapl amazon com amzn feel pressure european regulatory action dow jone industrial average waver positive negative trade take fractional loss nasdaq composite dip major index not be due pullback dow sit week run up have consecutively score new high investor also have eye speech federal reserve chair janet yellen schedule today close well friday payroll report ahead market often see subdue trade apple drop deepest early loss dow industrial stock stock continue lag week move average well buy point have be struggle clear early august amazon com fade european union regulator order luxembourg government recoup taxe commerce giant taxe have be waive part financial incentive program eu also say be pursue ireland assess similar charge apple amazon stock have be meeting resistance week move average unable start right side month flat base netflix nflx lead fang stock second day surge buy point month cup handle base china base name show strongest early move ibd stock boost strong session hong kong hong kong hang seng index rise wednesday putt ahead so far week less year high hong kong market close thursday china market shanghai shenzhen number other asian market remain close week holiday athm lead index early trade stock be climb monday low sharp week pullback cut week move average heavy trade sell signal ibd name tal education tal add open stock be work advance past week leave extend flat base july pharma stock be also heavy premarket motion mylan myl spiked open trade drugmaker announce late tuesday food drug administration have approve company generic version copaxone treatment relapse form multiple sclerosis mylan end tuesday april high cytomx therapeutic ctmx soar announce immuno oncology partnership biotech giant amgen amgn deal include upfront payment cytomx amgen buy cytomx share potential milestone payment amgen share be unchanged early wednesday teva pharmceutical teva have previously manufacture copaxone patent protection fall start bell economic news number new hire employer fall september accord national employment report adp consensus economist have project slowdown add job layoff trade transportation technology service skewer number lower datum point put negative slant expectation labor department payroll report due friday researcher markit release september service index et follow service index institute supply management et st loui federal reserve bank president james bullard be schedule speak et federal reserve chair janet yellen speak community banking st century conference st loui related stock again hit record high defensive stance be good option chip equipment maker buy range touch new high shale stock form basis investing action plan get start ibdfollow market stock market today
60,MYL,never count mylan myl analyst say wednesday food drug administration approve generic version teva pharmaceutical teva copaxone multiple sclerosis drug set share company vastly divergent path xby close trading stock market today mylan have spiked teva meanwhile plunge analyst largely hadn expect fda approve generic copaxone approval be milligram daily dose milligram shot time week milligram approval be first generic dose novartis nvs sandoz momenta pharmaceutical mnta get approval milligram daily copaxone generic glatopa mylan also announce patient support service dub mylan ms advocate help ease patient brand copaxone generic interactive mobile app home injection training call center copay assistance eligible patient support nurse experience treat ms analyst be widely surprised approval come heel fresh comment fda commissioner scott gottlieb bloomberg regard need speed generic drug approval spur competition reduce drug price bottom line be incrementally positive mylan teva negative surprise cash flow hit rbc analyst randall stanicky write note client reiterate underperform rating teva stock teva call impending launch mylan risk meaning rival generic drugmaker be subject damage other remedy pending outcome appeal decision other patent litigation case teva be argue december decision patent trial appeal board find claim copaxone patent be invalid teva also be argue january decision district court invalidate claim patent cover copaxone firm also be sue company include mylan claim infringe patent cover manufacturing process copaxone company be work bring generic copy ms drug market ibd take teva have poor ibd composite rating best possible meaning perform bottom stock term key growth metric see better rate drug stock ibd stock checkup teva expect mylan generic launch eat cent earning share fourth quarter end dec rbc stanicky note teva have previously predict generic lead annual revenue downside hit share earning teva previously guide slow copaxone deterioration due stickiness patient support program play initially write however mylan patient support program drive more switch time consensus number project erosion teva copaxone fourth quarter decline evercore analyst umer raffat write note client expect teva have dig deeper additional cost cut offset btig analyst timothy chiang model mylan bring generic copaxone sale first month follow launch assume generic pricing be discount brand drug mylan grab market share believe company gain approval strength copaxone not only validate mylan core competency premier generic company also provide important signal investor simply never count mylan especially area complex generic product say chiang keep buy rating mylan stock boost price target mylan news release say other first filer be eligible day generic drug exclusivity note fda hadn yet make formal determination month end july strength copaxone bring sale firm say approval be negative other entrant momenta novartis sandoz be work get approval milligram version copaxone february duo get warning letter fda detailed issue manufacturer pfizer pfe fill finish plant momenta stock plunge response mylan approval payer be likely also put pressure biogen biib lower price ms drug rbc analyst brian abraham write research report drug suite bring just shy sale believe highlight need biogen concede price share multiple new generic brand therapy enter market come year especially space do not have high intrinsic growth write abraham estimate biogen report ms drug sale decline note decline be higher payer get more aggressive biogen stock dip response related generic drug maker face pricing issue other pharmas don tbiotechs find strength number treat multiple roche game changer drug chip away biogen novartis
61,MYL,index other major average rise modestly record high apple aapl report strong earning guidance iphone launch facebook fb crushed view warn soar operate cost tesla tsla miss badly temper model goal production hell continue alibaba baba deliver huge growth symantec symc several security stock tumble oclaro oclr spur big fiber optic retreat president trump nominated new federal reserve chairman house gop finally unveil big tax cut plan job growth do not rebound much expect last month index dow industrial nasdaq extend weekly streak modest gain new high new wave earning president trump fed pick gop tax plan megacap apple give nice friday lift follow strong result facebook crushed view warn ll hike security spending russia tie political content reach nearly half american tesla report big loss burn cash push back model production path cut model model output alibaba have stellar result fiber optic several cybersecurity stock be hammer home depot hd homebuilder sell thursday house republican include measure slash mortgage interest deduction tax plan related stock buy watch top ipos big small cap growth stocksapple sell more iphone ipad mac computer expect fiscal fourth quarter apple earn share sale analyst expect china sale rise first time quarters december quarter typically conservative apple guide revenue slightly consensus ceo tim cook say be bullish apple prospect expect best holiday season yet thank iphone iphone handset iphone go sale friday share jump record high friday close related apple beat earning sale target guide sale higherapple give rare bullish outlook iphone hit storesfacebook report blowout earning snap quarter string decelerate revenue growth social medium giant say see faster growth expense facebook commit step spending improve security platform follow day congressional hearing role facebook google googl twitter twtr play russia misinformation campaign presidential campaign facebook share fall thursday close week fractional gain still buy zone related analyst hail blowout earning be facebook be downchina commerce leader alibaba report better expect fiscal second quarter result annual active consumer alibaba retail marketplace reach year end quarter mobile monthly active user previous quarter share have run several day record high head earning dip follow report alibaba earning revenue beat estimate strong third quarter adjust loss cash burn be much expect tesla reveal continue model rollout wo tesla now expect hit production rate model vehicle week late first quarter push back plan month tesla share fall thursday hit month low related tesla third quarter result show big miss model wo economy add job october less expect be notable upward revision prior month affected hurricane unemployment rate dip new cycle low average hourly wage be flat vs september meanwhile ism manufacturing index pull back longtime high still show factory activity be expand rapidly related jobless rate sink wage slip october payroll president trump tap federal reserve gov jerome jay powell succeed janet yellen chair central bank term expire february wall street breathe bit easier become clear powell get nod be expect follow yellen low interest rate path powell republican former investment banker serve george bush treasury department be somewhat more amenable yellen ease post crisis bank regulation trump priority yellen lead fed keep rate steady wednesday sign point december hike related federal reserve hold rate steady december hike bioscience nbix exelixis exel juno therapeutic juno rise demolish view clovis oncology clvs dove widely miss incyte incy report better expect metric expand cancer deal astrazeneca azn dow pfizer pfe allergan agn be soft revenue narrow full year sale outlook teva pharmaceutical teva earning miss drugmaker cut full year forecast cite challenge face copaxone generic drug add industry concern pricing tuesday sweeping antitrust lawsuit vs generic drugmaker be expand include total company president mylan myl meanwhile bluebird bio blue juno pop preliminary datum respectively sickle cell disease aggressive lymphoma related teva dife long road ahead earning miss guidance blood disease datum send biotech stock flyingdow pfizer fall legacy medicine exelixis juno stock rocket crush viewsshale operator generally show spending discipline third quarter investor shift focus production growth cash growth spending cash flow pioneer natural resource pxd boost capital spending outlook concho resource cxo devon energy dvn beat bottom line anadarko petroleum apc miss eog resource eog beat quarterly estimate announce new oil play together hold barrel oil equivalent crude future trade year high related eog resource beat view announce new premium oil playspioneer natural resource crush earning view laredo mixedshale earning concho resource devon energy beat anadarko blizzard atvi post better expect third quarter sale profit raise full year guidance thank game destiny call duty wwii guidance not have be strong enough activision reversed lower record high friday nintendo ntdoy nearly double profit outlook current fiscal year thank switch console exclusive game super mario odyssey nintendo now expect ship switch console financial year end march previous prediction ea ea stock fall publisher forecast lower expect sale holiday quarter prospect star war battlefront game remain big question mark december quarter related nintendo nearly double profit outlook switch hit home runbroadcom avgo deliver positive surprise thursday announce revenue fiscal fourth quarter end oct be higher end guidance range friday broadcom rise apple earning report be close deal buy fellow iphone chipmaker qualcomm qcom spiked meanwhile other chip company get mixed reaction third quarter result qorvo qrvo drop disappointing december quarter sale earning guidance cavium cavm beat wall street forecast sale earning september quarter share still fall cirrus logic crus also report better expect result quarter stock rise department justice sue block buy time warner twx say report analyst say leak reflect doj try increase leverage negotiating condition set deal condition involve access time warner content base analysis emerge internet video service pay tv market sprint owner softbank reportedly walk away merger talk involve mobile tmus parent deutsche telekom sprint valuation management control seem be stumbling block late week talk be say be back ford motor grow new car sale october consumer demand utility vehicle truck continue intensify series truck be especially brisk seller general motor gm see sale slide do better expect fiat chrysler fcau sale drop estimate slash low margin fleet sale annualize pace auto sale last month be accord autodata be september see strong post hurricane demand replacement vehicle ferrari race top earning view raise full year guidance share drop buy point related ford gm top october sale view fiat chrysler tumbleferrari raise earning revenue view tesla big flopoclaro oclr plunge december quarter guidance send share other optical device supplier include finisar fnsr lumentum hold lite neophotonic nptn weak demand china telecom gear maker have pressured fiber optic stock new worry involve datum center market internet company be shift purchase new type optical device inventory build slower part lumentum fall expectation apple aapl order more sensor iphone acacia acia also give december quarter guidance well estimate earning computer security software maker be mixed share qualys qlys cyberark software cybr jump report september quarter result investor hammer check point software technology chkp symantec symc fireeye feye analyst say shift cloud compute service be roil security market startup be take share incumbent casino operator la vegas sand lvs melco resort entertainment mlco wynn resort wynn mgm resort international mgm get lift month gross gaming revenue increase macau well positive datum nevada news gamble expansion pennsylvania share melco plunge thursday top earning sale forecast aetna aet object acquisition talk cvs health cvs grab center stage easily beat earning expectation soft top line result wellcare health plan wcg steal show leap buy zone earn rank ibd medical manage care industry group base earning revenue margin stock performance trend wellcare earning surge help strength medicaid medicare focuse acquisition aetna highlighted medicare primary growth driver report increase ep revenue fall molina health moh medicaid obamacare exchange insurer report better expect earning send share soar friday aetna add recent cvs tie gain mostly friday wellcare rocket record high cvs aetna finalize deal december reportaetna top earning view mum cvs wellcare health soarsshopify shop report first ever adjust profit beating view share commerce software maker fall high volume trading analyst call shopify battleground stock criticism short seller citron research paycom software payc report earning top expectation light revenue guidance send share maker human resource payroll process software constellation brand stz beer wine spirit producer say take stake canadian medical cannabis provider canopy growth move intend keep apace early stage consumer trend concern legalization impact booze sale molson coor tap say keep eye marijuana market cme group cme massive derivative marketplace say plan launch bitcoin future mark big step financial world acceptance still volatile cryptocurrency bitcoin soar new high mastercard beat third quarter earning revenue expectation raise year operate expense forecast largely due spending related investment masterpass digital wallet armour uaa cut full year target cent ep well view cent turn mixed result quarter share crumble tuesday multiyear lows
62,MYL,everyone know high prescription drug price be problem pharma stockholder few person realize price cut be ripple generic side industry take look recent event tumble generic drug price wipe billion dollar market value august like teva pharmaceutical teva mylan myl dr reddy laboratory rdy compound industry wo brutal second quarter earning season relatively small contingent pharma company produce cheaper version brand name drug be get broadside player distribution chain lead wholesaler be squeeze drugmaker lower price undercut battle pharmacy contract meanwhile group purchasing organization be consolidate grab more negotiating power represent hurdle generic comprise large chunk purchase analyst say be month price stabilize ever recover mean lower price patient drugmaker be take brunt battle price have clearly deteriorate aftermath contract negotiation evercore analyst umer raffat say aug audio report question really be do mean go forward say look way mylan teva stock have behaved look way estimate have be revise clearly suggest material worsening business teva stock lose august have re-cover month drugmaker market cap be close lose status july teva market value have fall nearly half comparatively mylan trail cap teva isn only feel pain selling pressure shave mylan market capitalization august share have topple begin august particularly disheartening quarterly report whole investor business daily generic drug industry group be year date near year low august rank group track ibd underlie cause price erosion stem back drugmaker spiked price base shortage monopoly other opportunity credit suisse analyst vamil divan tell ibd something be day see day re only make be competition say else produce have more flexibility price drug now card be go say ibd take teva have ibd composite rating best possible meaning perform bottom stock term key growth metric top rank generic drugmaker be ani pharmaceutical have middling cr visit ibd stock checkup look stock not only competition be more fierce also generic face adversary heavy scrutiny medium washington january then president elect donald trump accuse drugmaker get away murder pricing now aim use competition undercut price complicate matter drugmaker teva mylan perrigo prgo include be investigation department justice allege generic drug price fix last month member congress send letter maker multiple sclerosis drug probe rise drug price yet wrench generic story divan say investor be look cleaner story say too much unknown here teva mylan second quarter earning call project price erosion high single digit rest mylan specify erosion take place north american generic unit follow lackluster quarterly report mylan north american sale decline teva number be help acquisition actavis generic teva mylan cut forecast call executive company acknowledge increase generic approval food drug administration be champ sale new fda commissioner scott gottlieb be look speed generic approval even more help ease drug price be line trump vision quarter see increase competition result fda focus accelerate approval third fourth fifth generic mylan president rajiv malik say unfortunately have not see same first generic more complex niche product result mylan say delay launch generic version glaxosmithkline gsk asthma drug advair teva multiple sclerosis drug copaxone uncertain regulatory environment teva former interim chief executive yitzhak peterburg cite customer consolidation increase fda generic drug approval product be delay subject more competition accelerate price erosion decrease volume second quarter fda approval complication be cite second quarter report mizuho analyst irina koffler say aug report client generic approval be catch wind fda new goal complex generic molecular copy also have complex active ingredient formulation route device combination have be subject administrative delay koffler see mylan best position rebound tie challenged generic sector firm have pipeline complex generic biosimilar guidance be now more realistic less lever peer meaning pursue acquisition company stock have drop risk be pricing pressure not abate overall profitability company be decline expand lower margin international market now comprise greater percentage revenue say few drugmaker seemingly escap second quarter malaise report be somewhat mislead cfra analyst jeffrey loo tell ibd perrigo issue beat raise help stock fly day perrigo generic drug sale topple year year separate consumer health segment have smaller decline internationally respectively valeant pharmaceutical vrx crushed second quarter profit view sale come hair light firm also cut revenue target keep earning interest taxe depreciation amortization forecast lot person consider valeant generic play bulk business be now bausch lomb eye care product loo say quarter revenue bausch lomb well salix drug division represent total sale smaller generic unit other hand fall exclude valeant generic space perrigo none generic drugmaker really buck trend second quarter loo say think pressure group likely continue go forward next quarters teva lead generic drug sector also most pressure steven schoenfeld chief information officer bluestar index tell ibd bluestar index track israeli equity cybersecurity play check point software technology chkp be now bigger teva term market cap former teva chief executive erez vigodman step february bribery investigation then management have be shaky firm strategy have be kilter schoenfeld say follow loss several key patent protect ms drug copaxone january september teva name former lundbeck nordisk nvo veteran kare schultz new chief executive officer still teva be splitting focus generic brand drug schoenfeld say need strategy say need see want expand continue invest blockbuster drug ve now get early stage alzheimer asset other drug have decide re go be percentage generic so do profit go innovation meanwhile debt have rocket investor be longer sure teva paid acquire actavis generic allergan agn be good price say june teva have debt rise end march schultz teva recently avoid covenant violation debt teva say amend several term loan revolve credit facility provide teva greater flexibility financial leverage ratio covenant question forefront now be generic drug sector have hit bottom recent history mylan have come scrutiny pricing emergency allergy injection epipen turing pharmaceutical former chief executive martin shkreli draw criticism spiking price decade old hiv drug teva be be look ms drug price popular culture have turn bluestar schoenfeld say secular trend aren go go away market see pricing pressure have stock price worst teva be trading have major support time frame wouldn recommend anyone plunge teva most firm be now trading time earning cfra loo say continue price erosion see stock trading sideway next month note aren many drug go patent future cause somewhat roadblock new generic hope ve hit bottom say be not many catalyst go forward see buyer step buy share company time earning be awfully attractive valuation related biogen teva slip democrat launch ms drug pricing topple generic drugmaker be poise rebound fall generic drugmaker get analyst upgradegeneric drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
63,MYL,major market index advanced early friday apple aapl boee ba cisco csco give dow jone industrial average boost xpowershare qqq trust qqq spdr dow jone industrial average dium rise stock market today spdr spy add small cap outperformed ishare core small cap ijr ishare russell iwm respectively sector play bank retail homebuilder rally biotech oil service gold miner lag chip advanced vaneck vector semiconductor smh ishare phlx semiconductor soxx gain nearly soxx be record high smh be trading close time high june be extend buy point oil fund be mixed west texas intermediate crude price slip barrel gold etfs dip drop gold future ounce plenty stock etfs be extend recent buy area few large cap value fund remain striking distance be first trust large cap value alphadex fta continue hover just buy point flat base first clear oct base start form advance prior flat base fund track nasdaq alphadex large cap value index launch index start stock nasdaq large cap index meet price appreciation sale growth factor well value factor such book value price cash flow price ratio return asset etf top sector oct be financial consumer discretionary utility health care information technology top holding include mylan myl general motor gm unite continental ual delta air line dal gm have enjoy nice run rise past cup handle buy point share have outpaced broader market gain vs return automaker begin testing self drive car lower manhattan early next year speed commercialize autonomous technology ibd take lookout etf idea be worth closer look check ibd weekly etf leader column featured fund list highly rate etfs fta have return year date oct vs gain accord morningstar direct fta average annual return have lag past year fta be ahead past year return vs expense ratio be thursday pick ishare latin america ilf global msci argentina argt edge lower remain respective potential buy area related stock sell apple lose support equity play watchdow hit new record ibm surge check potential buysthese stock lift dow high big dividend payer buy zone
64,MYL,teva pharmaceutical teva rocket monday announce former nordisk nvo executive take helm teva just month last full time chief executive resign bribery scandal hour later teva say selling paragard implantable contraceptive coopersurgical cash paragard bring trail month period end june teva say news release deal include teva manufacturing site buffalo xby close bell stock market today teva catapult touch high last see early august teva lead ibd company generic drug industry group rise highest point july kare schultz become teva president ceo teva say press release schultz take interim ceo yitzhak peterburg peterburg assume control february former head erez vigodman resign bribery probe regulator schultz come danish drugmaker lundbeck work president chief executive year spend nearly decade nordisk slew role include chief operate officer lundbeck schultz be credit lead restructure effort turnaround put firm track achieve record sale profit teva say also previously work mckinsey anderson consult addition sale paragard teva say actively work sell remain piece woman health business well oncology pain business europe teva expect generate least total proceed sale business well other asset sale be wrapped year end ibd take teva have low ibd composite rating best possible meaning lag most stock term key growth metric head ibd stock checkup closer look drugmaker better rating teva share have be slump past year teva be generic drugmaker market cap biggest concern be brand drug name copaxone treat multiple sclerosis judge tossed key patent copaxone earlier year meaning generic competition be likely february vigodman left teva wake controversy then analyst say teva have lack direction july look possible astrazeneca azn chief executive pascal soriot jump ship take top job teva rumor quickly die last month teva crash day deliver consensus lag sale profit second quarter generic drug stock broadly trade course day lackluster report teva generic drugmaker mylan myl related teva mylan pressure rivalry loom key drugsbiogen teva slip democrat launch ms drug pricing probegeneric drug be rebound teva mylan free fall
65,MYL,abbvie abbv launch record high thursday settle patent dispute amgen amgn require biotech pay abbvie royalty sale humira copycat xby close bell stock market today abbvie pop earlier trade share be much record high amgen stock lift fractionally close settlement amgen drug know amgevita launch europe october version amjevita launch january drug be biosimilar abbvie drug humira inflammatory med biosimilar be biologic copy drug amgen pay royalty abbvie specific term be confidential abbvie say news release litigation pending be dismiss abbvie grant patent license amgen country country basis humira be abbvie most important drug bring total sale second quarter end june other drug firm be work humira biosimilar include biogen biib novartis nvs dow pfizer pfe mylan myl evercore analyst umer raffat say note client ibd take abbvie galapago be also work together cystic fibrosis drug vertex pharmaceutical say have strong lead analyst don disagree head new america breakdown market vertex be lead pack consensus be call amgen humira biosimilar first approve bring worldwide sale just set launch europe still be patent remain abbvie use extend litigation raffat say rbc analyst kennen mackay boost view success amgevita amjevita expect amgen drug penetrate peak humira biosimilar market europe respectively mackay model peak global sale amgevita amjevita hit sale share basis expect amgen have humira biosimilar market depend royalty rate keep sector perform rating price target amgen related biotechs beating market be buy range company gain trump foreign profit relief plan passeswhy amgen lilly be interested small biotechsabbvie new hepatitis drug chip away gilead share
66,MYL,teva pharmaceutical teva mylan myl stock rise tuesday sustain price target cut downgrade respectively follow lackluster second quarter report result haircut guidance xby close bell stock market today teva inched mylan gain still stock have trade well day move average month generic drug maker face pressure mizuho analyst irina koffler slash price target teva nearly half keep neutral rating see teva struggle bring gross debt year end face upcoming competition multiple sclerosis drug copaxone teva end second quarter debt likely struggle patch together combination asset sale operate cash flow allergan agn work capital settlement full dividend cut bring gross debt year initial debt hurdle be clear teva indicated be able push maturity bank debt refinancing koffler write note client help share wouldn solve teva problem generic version copaxone be likely come market erode already weak earning interest taxe amortization depreciation write longer term expect decline remain business don see anything brand pipeline change trajectory write teva eventually lose investment grade rating result further share deterioration be possibility longer term argus analyst jasper hellweg downgrade mylan hold rating buy cite weak outlook mylan guidance adjust income share imply decline midpoint firm also lower sale view ibd take top generic drug maker be poise rebound analyst say last week head ibd technology page deep dive drugmaker look stronger still mylan stock have be pressure year due controversy surround epipen pricing hellweg write note client earlier month mylan finalize settlement justice department epipen pricing medicaid justice department allege company have overcharge medicaid classify epipen generic rather brand product write drugmaker be able pay lower rebate government generic drug brand drug recently justice department reveal source information be sanofi sny separate antitrust suit sanofi allege mylan offer discount insurer pharmacy benefit manager make more difficult sanofi rival drug get medicaid reimbursement new york attorney general also be investigate mylan practice selling epipen school discount price exchange exclusive contract hellweg say mylan have eliminate exclusivity provision deal adamis pharmaceutical admp also be likely take share mylan epipen gain approval drug symjepi be market low cost alternative epipen hellweg write also prepare junior dose symjepi compete low dose epipen symjepi be smaller epipen potential advantage product be often carry time person life threaten allergy write look epipen benefit establish reputation many consumer be likely prefer epipen auto injector vs symjepi be self administer injection hellweg write related fall generic drugmaker get analyst upgradegeneric drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
67,MYL,mylan myl share rise thursday announce settlement justice department epipen classification medicaid analyst suggestion rebound generic downtrend afternoon trading stock market today mylan lift third consecutive day black earlier month mylan follow footstep teva pharmaceutical teva disappointing quarterly result guidance cut day july august ibd company generic drug industry group lose value number lackluster second quarter sale earning report then rise almost earlier hit lowest point nearly year thursday mylan pop announce justice department settlement underlie question case be epipen product be properly classify center medicare medicaid service settlement allocate money medicaid program state establish framework resolve potential state medicaid rebate liability claim day mylan say news release ibd take generic drug group have struggle disappointing report teva mylan break trend head ibd technology page closer look impact stock settlement mylan reclassify epipen epinephrine auto injector medicaid drug rebate program pay rebate applicable innovator product effective april previously drug be classify innovator product generic drugmaker struggle second quarter pricing erosion administrative delay food drug administration approval complex generic drug mizuho analyst irina koffler say note client mylan remain most attractive pick group say drugmaker be best poise rebound base pipeline complex generic biosimilar piece be less certain be take longer expect play risk be pricing pressure not abate overall profitability company be decline expand lower margin international market now comprise greater percentage revenue write second quarter earning conference call mylan say defer major launch guidance include generic advair generic copaxone advair be asthma drug glaxosmithkline gsk copaxone be teva multiple sclerosis treatment top epipen longer present source potential upside view next quarter have difficult comparison vs last year back school season koffler write still keep buy rating cut price target stock be trading target so still be upside approval generic advair lead pop koffler say update model mylan outlook sale adjust income share related fall generic drugmaker get analyst upgradegeneric drug be rebound teva mylan free fallperrigo beat rise lift generic drug buck teva mylan trend
68,MYL,mylan myl teva pharmaceutical teva stock diverged wednesday analyst reportedly upgrade mylan differentiate durable generic drug portfolio issue teva downgrade morning trade stock market today mylan pop much settle back gain close teva topple finish accord various news account citigroup analyst liav abraham see mylan have more favorable balance sheet relative peer teva endo international endp upgrade mylan buy rating neutral boost price target accord fly company be best position outperform challenge market generic drugmaker abraham reportedly say note client citigroup didn immediately return request copy report investor business daily abraham also downgrade teva neutral rating buy cut price target have neutral rating endo ibd take mylan have ibd composite rating meaning outperform third stock term key growth metric best possible head ibd stock checkup look better rate drug stock teva biggest obstacle be debt june be need finance acquisition actavis generic teva debt be nearly double market cap mylan teva cut guidance second half issue quarterly result lag consensus perrigo prgo beat trend soon report wall street top metric boost guidance related generic drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trendcan generic drug stock catch break mylan crash
69,MYL,stock open advance wednesday weak early housing datum nasdaq look revive rebound stall tuesday nasdaq composite perked start bell dow jone industrial average add fair value housing start build permit fall sharply july commerce department report start slip annualize rate normally busy summer season rate june disappointing forecast increase build permit activity slow annualize rate vs june projection more mild slowdown oil price also get attention morning energy information administration prepare deliver weekly inventory datum et investor keep close eye bank other interest rate sensitive issue see react minute federal open market committee july meeting set release et home depot hd lead dow bounce follow dive tuesday raymond james upgrade stock outperform market perform wal mart wmt rise ahead quarterly report due early thursday stock be work gain altitude clear cup base buy point target tgt jump report earning revenue be better expect second quarter same store sale rise vs expectation rise traffic store online advanced stock have be attempt muster rebound mid june remain deep multus year correction urban outfitter urbn rocket higher second quarter sale earning decrease less forecast overall comparable retail segment sale decline company say retail sale lag direct consumer online sale continue expand stock have be fight hold early june low attempt form bottom deep month correction agilent technology swung late tuesday report show revenue earning comfortably expectation fiscal third quarter maker research diagnostic tool drug genetic developer also lift fourth quarter earning revenue guidance consensus target move lift share back week support well buy point flat base china base internet heavyweight tencent holding tcehy rumble ahead second quarter earning revenue easily clear analyst hurdle stock be extend july rebound week support mylan myl advanced top nasdaq citigroup upgrade stock have take steep week dive buy hold biogen biib climb more open send share buy point cup handle base goldman sachs place stock conviction buy list today close cisco system csco netapp ntap vipshop holding vip be company schedule deliver quarterly result related techs be buy point classic bullish big picture small cap slam sector sell hardbullish chart pattern do know basic cup handle bullish chart pattern ii find exact buy pointstock buy watch top ipos big small cap growth stock
70,MYL,perrigo prgo shot month high thursday buck weakness generic drug business industry overall top second quarter expectation raise guidance xin morning trading stock market today perrigo pop earlier spiking much touch high last see late february meanwhile generic drug stock collectively rebound generic drug stock have be pressure month teva pharmaceutical teva mylan myl lead group report lackluster quarterly result cut guidance entire group trade straight day begin recover wednesday early thursday perrigo report sale adjust earning share top consensus cent respectively canaccord analyst dewey steadman write note client generic unit be become less important steadman say perrigo beat arrived back consumer business generic decline year year part lower sale crohn disease drug entocort ibd take biotechs be better rate generic drug stock perrigo have ibd composite rating best possible meaning underperform most stock term key growth metric celgene celg lead biotech group cr head ibd stock checkup look top rate stock year year basis consumer sale americas internationally decline respective perrigo sell unprofitable business last year exclude impact sale revenue grow respectively be stark contrast perrigo current large generic peer set face significant pricing challenge existential growth issue recent quarterly announcement steadman say consumer unit behave materially different generic steadman note expect perrigo shift further consumer drive business time significant opportunity keep buy rating price target perrigo perrigo also raise guidance adjust income share vs earlier view top consensus view steadman say related generic drug stock catch break mylan crash teva crash day be hurt generic drugmakersteva crash year low very tough quarter
71,MYL,teva pharmaceutical teva crash third straight day monday last week report wall street lag second quarter metric lead guidance dividend cut xshare topple stock market today close friday thursday day earning report cumulatively teva have lose value aug teva have trade july least analyst have downgrade teva last week include credit suisse analyst vamil divan write note client title strike re thursday downgrade teva neutral rating cut price target have take more constructive view teva share late feel remain challenge still ahead company valuation stock appear compelling write clearly misjudge scope challenge teva topple ibd company generic drug industry group have tank aug group have trade red july monday impax laboratory ipxl mylan myl plunge respectively impax topple be likely related settlement endo endp opioid impax be require pay endo higher expect royalty drug generic endo opana extend release formula ibd take teva have poor ibd composite rating best possible head ibd stock checkup list better rate generic drug stock be very few sign stabilization teva full time chief executive chief financial officer difficult see mid long term upside company argue future pricing volume deterioration generic further hurt teva also possible teva see generic competitor multiple sclerosis drug copaxone lose several key patent protect earlier year delay migraine drug know fremanezumab also provide challenge say ub analyst marc goodman call report bad day teva note thursday follow teva announcement reference goodwill impairment charge teva paid related generic report unit second quarter give significant guidance cut dividend cut impairment charge second quarter miss understandable stock trade significantly say note related teva crash year low very tough quarter biotech be jump today rival cannabis tie drugastrazeneca pop report ceo win jump ship teva pharma
72,MYL,generic drug maker mylan myl continue free fall friday rival teva pharmaceutical teva manage briefly arrest slide broader generic lead eagle pharmaceutical egrx defy trend spiked higher third straight day xin afternoon trading stock market today ibd company generic drug industry group pop highest point aug day teva report second quarter earning sale miss cut guidance generic drug stock broadly trade consecutive day begin recover earlier week eagle aclaris therapeutic acrs lead group midday friday rise respective perrigo prgo offer quarterly beat raise week pop analyst expect perrigo generic drug business topple quarter follow disappointment teva mylan generic business do decline strength consumer drive business be enough help perrigo top expectation perrigo shot thursday second quarter report amazing good quarter do ub analyst marc goodman write research report have buy rating price target perrigo goodman note perrigo do unexpected increase net sale guidance generic drug unit perrigo bump expect generic sale earlier view due earlier expect launch new product significant move stock be also due solid upside consumer business combination cost cut execution be drive margin improvement appear be sustainable goodman say ibd take inflation have have part play earning miss head ibd economy page see teva other have be impact perrigo boost generic guide call year year erosion generic drug price second half year separate report goodman nearly halved price target teva keep neutral rating expect teva see generic competition multiple sclerosis drug copaxone first quarter lose several key patent earlier year more importantly have significantly lower generic number topline margin base management see new generic landscape write analysis suggest be not buy opportunity hence remain neutral stock goodman assume teva generic business likely decline average decrease be drive base erosion be partially offset new product launch say teva expect generic revenue decline look save money close manufacturing facility well synergy allergan agn generic deal teva acquire allergan generic business last august related perrigo beat raise lift generic drug buck teva mylan trendhow teva crash day be hurt generic pop report ceo win jump ship teva pharma
73,MYL,stock pare loss afternoon trading wednesday threat attack north korea earning report influenced movement market dow jone industrial average be boee ba have be largely responsible dow outperformance past week fall be curious divergence rest defense aerospace stock be rise tension north korea country regime threaten strike installation guam president trump warn north korea not threaten boee share have be cool week soar much follow strong earning report july russia impose import duty boee airbus jetliner boost russian build rival sukhoi superjet irkut  forbe report nasdaq composite be lose russell tumble small cap lag significantly more other asset class volume be run higher exchange compare same time tuesday more so nasdaq telecom energy consumer industry group be worst perform wednesday market many health care stock particular be sharply pharmaceutical company mylan myl be highest comparative volume stock today stock sank year low sale profit miss expectation company also cut guidance next year sale epipen injection allergic reaction fall higher competition pra health science prah be buy point aggressive entry volume be intense loss reach limit cut loss short company soar tuesday strong earning fall today pra announce large share offer late tuesday jazz pharmaceutical jazz slide heavy trading undercut flat base have be form drugmaker miss quarterly sale earning target dentsply sirona xray gap touch lowest level january dental product maker also miss estimate adjust earning wasn misery medical sector myriad genetic mygn clear buy pint cup handle nordisk nvo gap top entry flat base myriad report adjust earning cent share view sale also top expectation nordisk also beat estimate raise profit revenue forecast full year other sector envestnet env break base provider tool financial advisor top earning expectation rise ep stock top buy point big volume eldorado resort eri break cup handle buy point casino resort operator rise post sale miss view loss related missile defense stock boost trump nuclear offense claim debunkedcan generic drug stock catch break mylan crash trump get boneyard boee new air force
74,MYL,mylan myl hit year low take generic drug stock report second quarter metric lag wall street cut guidance next year then re-cover post slight gain wednesday xon stock market today mylan end trading day earlier fall much hit low last see june be sixth consecutive day mylan have spend red follow disappointing report fellow generic drugmaker teva pharmaceutical teva crash initially send ibd company generic drug industry group much sector re-cover recent trade rise nearly close still taro pharmaceutical taro collegium pharmaceutical coll perrigo prgo remain respectively second quarter end june mylan report sale year year miss consensus adjust earning share lag cent fall revenue north america be hit hardest sale europe rest world grow respectively vs year earlier period sale epipen injection allergic reaction decline due increase competition ibd take mylan have ibd composite rating meaning perform bottom half stock term key growth metric get look better rate stock ibd stock checkup mylan also cut guidance sale adjust profit share now see adjust earning least earlier view new target be expectation midpoint give region ongoing challenge uncertain regulatory environment have elect defer major launch full year financial guidance include generic advair copaxone mylan say news release advair be used prevent asthma attack flare up chronic obstructive pulmonary disease brand glaxosmithkline gsk mylan other be work generic version food drug administration delay mylan application drug mylan other be also work generic version teva multiple sclerosis drug copaxone lose key patent earlier year medicine company mdco pop lag second quarter revenue loss beat expectation promising clinical update include ldl cholesterol lower drug rival amgen amgn regeneron pharmaceutical regn sanofi sny medicine co note second quarter come agreement regulator europe drug inclisiran cholesterol buster total expect enroll patient phase trial design support submission application approval inclisiran be know pcsk synthesis inhibitor have slightly different mechanism psck inhibitor amgen regeneron sanofi medicine co be also work study patient determine cardiovascular benefit inclisiran second quarter end june medicine co report sale miss consensus analyst poll zack investment research revenue adjust loss share widen cent loss year earlier period top consensus view adjust loss share medicine co lift close related tesaro beat sale view loss nektar miss teva crash day be hurt generic drugmakersmylan fda limbo generic multiple sclerosis drug
75,MYL,nasdaq composite lead major average lower undercut day move average president trump fiery rhetoric north korea negative reaction earning other corporate news xwalt disney announce split netflix nflx priceline pcln give weak guidance macy other department store crash snap snap miss everything send share lower nvidia nvda have blowout number price perfection share fall top rate china internet generally retreat slew earning government crackdown social medium nasdaq composite tumble sank move day move average dow industrial dip set record high tuesday number lead stock undercut recent buy point key support level cboe volatility index market fear gauge near month high sink time low late july trump threat wreck fire fury north korea continue make nuclear missile advance unnerved investor earning corporate news have have bigger effect related nasdaq break support step take nowbig picture market uptrend be pressurewalt disney end movie distribution deal netflix nflx say ll create own video demand subscription service disney win pull tv show netflix ongoing marvel netflix collaboration continue still move force netflix spend more own content notably big ticket film netflix fall nearly return july buy point friday bounce meanwhile disney report mixed result say plan espn stream service start early not end disney sank hit month low related netflix fall continue end disney movie deal key fact disney rogue move mean netflix nvda earn cent share year year sale quarter end july analyst expect cent current quarter graphic chip maker expect sale rise vs consensus nvidia cite strong chip sale video game device datum center artificial intelligence application analyst say datum center revenue be little light share fall friday sink thursday ahead result related nvidia earning crush view guidance bullish stock snapchat operator report wider expect adjust share loss revenue user growth average revenue user be weaker forecast snap snap crash friday hit record lows snap add just user facebook fb successfully clone snapchat offering notably instagram story snap fall short just metric stock crashesmacy kohl kss jwn report stronger expect earning sale tumble thursday regular session longer term concern midtier mall base big box retailer face amazon amzn discounter macy crash worst level september dd report surprise loss send stock plunge just edge higher friday solid late thursday result jcpenney jcp already fall sharply thursday crash friday record lows report wider expect loss weaker expect same store sale related beat rival chain plunge sale keep fallingj penney stock sink second quarter loss missespriceline pcln earning beat view revenue match online travel book site see ep vs wall street estimate booking growth estimate be also light tripadvisor trip earning also beat analyst expectation revenue be line hotel revenue climb airline traffic growth continue outpace gdp hotel revenue fall room rental company airbnb gain ground priceline fall tumble buy point day line tripadvisor rise related priceline share drop earning outlook fall shortsina sina weibo wb netease nte yy yy athm report better expect earning june quarter netease crash day line yy dip thursday wild session be nicely so far week auto info site soar result sina own control stake weibo reversed lower undercut monday weibo also retreat hold own entry china crack social medium hit twitter service well sina tencent tcehy baidu bidu trade desk ttd say second quarter adjust earning be cent share year revenue rise analyst expect trade desk report earning cent sale provider automate advertising technology compete facebook fb alphabet googl guide full year revenue estimate higher trade desk ipo september see first day pop peaked late july trade desk soar friday tumble day line thursday related trade desk earning blow past estimate sale outlook hikedlumentum holding lite fall september quarter guidance miss view ramp sensor device new customer assume analyst be apple aapl optical device maker report line profit revenue be light weakness company north america business well china lumentum management say have order device calendar manufacturing yield have be solid question be much apple business lumentum potentially share germany am finisar fnsr ii vi iivi lumentum say china inventory correction last december quarter drug biotech earning be mixed bag perrigo prgo horizon pharma hznp kite pharma kite valeant pharmaceutical vrx top view mylan myl jazz pharmaceutical jazz nektar therapeutic nktr alnylam pharmaceutical alny lag second quarter expectation valeant mylan cut guidance perrigo horizon ionis ion boost piece full year outlook meanwhile tesaro tsro beat top line report wider expect loss other news esperion therapeutic espr hit year high bump timeline file application cholesterol lower treatment wendy wen second quarter result top street estimate stephen analyst attribute strong show value meal marketing fresh never frozen beef hamburger jack box jack same store sale come better expect analyst hope chain reclaim customer bigger push cheap combo offering other deal company also continue weigh sell do something else qdoba chain red robin gourmet burger rrgb beat top bottom line mcdonald mcd set sight china form partnership aim expand number location norwegian cruise line nclh report second quarter ep growth revenue better expect cruise line operator stock pop record intraday tuesday fall week plan stock offer behalf exist shareholder tesla tsla say develop self drive semi truck platooning ability long haul trip tesla say prior week issue new debt fund model rollout say sell debt tesla share rise blue apron aprn lose cent share expect first quarterly report go public revenue rise beating view show slow growth meal kit provider customer base fall quarter quarter competitor expand amazon amzn loom blue apron be cut market spending be not great sign attract customer share crash week hit record low planet fitness plnt report ep rise cent beating cent revenue gain view systemwide same store sale grow gym operator also raise guidance full year earning revenue comp sale planet fitness break past buy point thursday pull back modestly friday share zillow group fall online real estate portal swung adjust profit traffic slow company forecast september quarter sale expectation
76,MYL,tech name lead stock lower wednesday open walt disney drag dow several china base leader mixed early trade nasdaq composite dive open netflix nflx priceline group pcln tripadvisor trip provide early drag dow jone industrial average shed marked decline earning news drive fossil group fosl office depot odp lower zillow zg early slide nordisk nvo jump sanchez energy sn pop report second quarter result more third dow jone industrial name open lower disney fall furthest follow mixed fiscal third quarter report late tuesday decline send share week move average very heavy trade sell signal big tech fang stock open sharply lower hardest hit be netflix drop disney announce late tuesday end movie distribution arrangement stream entertainment provider order launch online service own netflix be third week pullback july high wednesday loss reduce share less flat base buy point give gain priceline group topple report strong beat second quarter result lower third quarter earning guidance consensus number move drive priceline sharesbelow week move average very heavy trade trigger sell signal tripadvisor tumble premarket action dove beating second quarter earning revenue expectation give third quarter guidance consensus forecast stock have be battle year decline mylan myl reversed drop second quarter result netherlands base drugmaker miss view ibd list china base athm whip open gain earning revenue increase easily top analyst second quarter target management boost third quarter revenue guidance consensus view stock be extend clear cup base china base peer sina sina also ibd stock fall stronger expect second result share appear have be dent quarterly result micro blog site weibo wb fall top earning revenue target report gain user marketing cost show larger forecast increase nearly double year level sina own majority share weibo sina loss send share buy point flat base weibo be still buy point cup handle base productivity increase second quarter accord preliminary estimate labor department consensus expectation gain department also revise first quarter estimate flat gain unit labor cost increase period jump forecast economist department also revise first quarter unit cost number upward surge vs initial estimate increase june wholesale inventory datum be due commerce department et oil price be focus ahead energy information administration weekly inventory report et price benchmark oil be ahead open hold barrel charle evan president chicago federal reserve bank be schedule speak related netflix stock tumble disney announce compete beat earn outlook short share tumbledisney snub netflix debut stream service sina weibo earning top stock earning cruise past view share jump highermonster beverage earning miss production shortage share sink
77,MYL,life be simple rachel martin day work accounting firm way become cpa night run start notice foot feel strangely stiff xthat lead bit news day soon be good yet odd still stack day get notice multiple sclerosis get notice sell condo get notice receive cpa license tell investor business daily number haven go martin way ever be diagnosed half lifetime hasn work year have spend hour life work cpa take least medication treat ms exactly none have fully contain ailment barrage new drug be take aim ms however offer hope martin other debilitating illness medication be offer lower cost expect market heat offer prospect fewer side effect most critically greater effectiveness several heavy hitter industry be get involved biopharma battle roche rhhby have new drug swipe share market leader biogen biib meanwhile celgene celg number generic drug manufacturer be expect pile pressure mainstay field novartis nvs roche share be fractionally monday close biogen tick finish celgene be marginally novartis be slightly ms sector have be dominate biogen bring just shy sale medication arsenal include inventory be ms drug martin recently stop used avonex well other top seller tysabri tecfidera now paradigm shift especially roche ms drug ocrevus be concern accord michael analyst evercore ocrevus be approve earlier year treatment relapse remit primary progressive form ms offer medication primary progressive be breakthrough form ms comprise just market have not be target treatment past ocrevus twice year infusion look attractive patient martin discontinue used certain drug due ms related tremor martin first medication be interferon be medicine month shake hand become so severe couldn administer injection analyst say roche drug put biogen tysabri tecfidera greatest risk market share loss wall street estimate see ocrevus take away tysabri sale tecfidera revenue year ocrevus market have threat share be steal tell ibd also have possibility look generic version novartis gilenya teva pharmaceutical teva copaxone so lot move part ibd take ibd company biotech industry group be now rank fourth group track share have rise year ride high june rally still see upside accord estimate benefit spike head ibd industry theme closer look novartis case celgene be heap pressure company potential blockbuster ms drug now have test phase name ozanimod celgene biotech market cap be bill ozanimod safer version gilenya be target latter half file application approval food drug administration ozanimod gilenya class drug call receptor modulator work prevent specific white blood cell move central nervous system do so have be show improve outcome reduce ms relapse ms be disease central nervous system disrupt flow information brain brain body patient fatigue easily have difficulty walking go run walking walker then wheelchair say martin wasn muscular ability add be balance be able exercise hold something say medication have bring martin moderate success point generally walk cane belong ms group call let play los angele disease be steady say doctor take time physical therapy experimentation medicine medicine cause debilitating headach be chemotherapy today doctor know cause heart damage martin manage avoid martin current medication be make bayer bayry sell novartis require self injection other day begin used medicine april quit used biogen avonex year due headach biogen have most lose battle sale tysabri tecfidera avonex line second quarter be expect be biogen first real test mizuho analyst salim sy tell ibd result be due be report tuesday biogen drug tysabri roche ocrevus be consider highly efficient ms treatment tysabri label contain black box warning deadly virus attack brain ocrevus label doesn case virus progressive multifocal also call pml have be record single ocrevus user patient have just come tysabri year have only be treat once ocrevus most analyst don consider case be related ocrevus risk pml be likely enough prod number tysabri patient switch ocrevus sy say further biogen have estimate third patient tysabri test positive ailment know john cunningham virus patient have weak immune system be more susceptible pml analyst say erosion tysabri use be slow biogen isn particularly worry ms franchise franchise grow expand include zinbryta launch partner abbvie abbv first quarter end march biogen ms drug sale grow just sale tysabri zinbryta fall chief executive michel vounatsos doesn see biogen ms drug decline franchise evercore analyst umer raffat write june note client meeting vounatsos believe biogen lose market share roche ocrevus believe be plenty opportunity grow top line raffat say vounatsos do not believe generic copaxone teva drug generic gilenya novartis drug impact biogen ms franchise copaxone gilenya face own battle celgene other celgene ozanimod successfully reduce relapse rate vs traditional interferon treatment phase trial company present milligram milligram oral dose be safe tolerable year period novartis gilenya also have own safety issue mizuho sy say label patient undergo monitoring hour immediately follow first dose ensure heart rate don slow dangerous level gilenya have also be show have toxic effect liver enzyme so gilenya be not perfect drug say celgene say be safer gilenya just see top line datum ozanimod go come market get approve so ozanimod successful gouge gilenya sale analyst say second quarter gilenya sale grow constant currency basis follow major growth exclude impact foreign exchange rate celgene be optimistic chance multiple sclerosis market report leerink analyst geoffrey porge note management hasn commit first dose monitoring say unique dose schedule minimize need requirement safety celgene management expect show multiple point safety differentiation gilenya safety profile have label be consistent phase result say then potential generic competition novartis face slew generic have be approve pending patent litigation like teva mylan myl analyst consensus model see gilenya sale drop generic approve tentatively gilenya price point wait break evercore raffat say video raffat say unlikely gilenya go generic patent litigation likely push generic entry even then gilenya have patent set expire hasn really be vet say patent cover dose schedule only currently face challenge earlier stand challenge apotex novartis be also study low dose version gilenya milligram gilenya be now approve milligram dose trial work likely very patentable raffat say fda review fda say not clear milligram dose work alone be reason know milligram dose do work novartis trial be patentable not obvious new patent gilenya be obstacle generic competition evercore say note nullify gilenya go generic help broader ms industry stave cheaper generic tug drug pricing market ultimately competition be godsend patient martin be hopeful better ms medicine fewer side effect multiple sclerosis be something difficult describe person most look re do well martin say bubble look fine outside don feel fine related biogen takeover prospect soured mere novartis ms drug stomp celgene even hit market roche game changer drug chip away biogen novartis
78,MYL,stock stick very close home thursday mixed economic datum earning report frayed attempt build momentum better expect weekly jobless claim june consumer confidence number be positive sharp drop manufacturing growth report philadelphia fed open help stoke investor concern investor response earning report cut sharply direction mostly soft trade session result give nasdaq technical new high straight gain increase be less weak trade mean feat check point software chkp tripadvisor trip qualcomm qcom turn broad loss apple aapl netflix nflx google parent alphabet googl end minor loss day drugmaker mylan myl regeneron pharmaceutical regn lead nasdaq mylan jump positive phase trial result report late wednesday ibd stock regeneron also swung weak trade work new consolidation slip fraction back away new high notch intraday drugmaker be key leader also perrigo prgo mallinckrodt mnk post gain trade be weak dow jone industrial average close valiant effort nike nke buck more day stock have fall buy point entry remain play home depot hd fall ratchete drag dow catalyst appear be agreement sear holding shld sell respect kenmore brand home appliance amazon com amzn news send sear share nearly gain amazon sketch advance macom technology solution mtsi lead ibd more average trade be sufficient take new high share be already extend early july rebound week move average chipmaker plan report fiscal third quarter result aug side floor decor fnd tumble fast trade fall back week move average company price share follow offer just wednesday close price stock remain april ipo price related financial be buy range earning tonightamazon team sear new retail group tumblespaypal stock record high jpmorgan deal online payment sizzle
79,MYL,mylan myl stock dip week low thursday indicate late wednesday food drug administration be look more information generic version teva pharmaceutical teva copaxone midday trading stock market today mylan stock be earlier fall much touch low last see early teva stock other hand be accord evercore analyst umer raffat mylan say receive information request fda milligram version multiple sclerosis drug mylan didn offer update regard milligram version wall street have be expect update week raffat say note client mylan have previously guide target action date june target action date be internal goal fda take action application many investor have debate target action date be early part week raffat write lack update have be reason recent mylan weakness request more information doesn necessarily require meeting agency mylan say raffat doesn expect generic version copaxone hit market novartis nvs sandoz momenta pharmaceutical mnta be also work copaxone copy first quarter conference call mylan be confident fda take action milligram milligram copaxone application june ibd take mylan stock have middling ibd composite rating meaning outperform nearly stock term key growth metric head ibd stock checkup list best rate drugmaker see reason date be meet president rajiv malik say call believe scientific question have be resolve fda satisfaction also believe be facility issue be barrier approval momenta sandoz partner generic copaxone be less bullish first quarter call sandoz contract pfizer fill finish generic copaxone call glatopa pfizer receive warning letter fda february manufacturing process base work pfizer have already do resolve observation warning letter effort sandoz be putt forth resolve warning letter still believe be potential approval launch glatopa milligram time frame chief executive craig wheeler say call related small biotech ruffle market migraine drugsteva pharma run migraine trial lilly amgen benefitedteva pharma eagle pharma depome slew get price haircut
80,MYL,coherus bioscience chrs stock plunge year low monday regulator ask reanalysis datum more information regard copy amgen amgn chemotherapy drug neulasta close bell stock market today coherus share fall share amgen lift news mylan myl stock fall mylan be also work copy neulasta neulasta be bone marrow stimulant design reduce side effect chemotherapy radiation treatment coherus mylan be work copy amgen drug call biosimilar biosimilar be biological medical product be nearly identical copy original drug food drug administration request more datum monday be speed bump coherus fda be ask coherus reanalyze datum show copycat drug provoke immune response well more manufacturing information coherus note news release fda be not ask additional trial cancer patient biosimilar know ch additional trial prompt much bigger delay drug approval be disappoint delay additional request have cause remain confident ability address fda request purpose obtain approval ch chief executive denny lanfear say statement ibd take amgen isn just face neulasta competition regeneron pharmaceutical regn sanofi sny be rivale biotech cholesterol lower drug head ibd breakdown litigation surround company lanfear expect coherus be able respond fda definite path move forward come month approve expect ch generate health saving cost biosimilar be typically less expensive counterpart next mylan have guide late early copy neulasta indian partner biocon evercore analyst umer raffat write note client analyst broadly project neulasta sale topple come year biosimilar chip away consensus model drop wall street see just neulasta sale related teva pharma run migraine trial lilly amgen watch top fund buy biotech ipo small biotech ruffle market migraine drug
81,MYL,spark therapeutic once flexion therapeutic flxn alnylam pharmaceutical alny be lead biotech pop wednesday generalist become more comfortable president donald trump potential effect sector stock market today spark stock soar close share flexion jump finish regular trading session alnylam stock get boost meanwhile ibd company biotech industry group run trend see biotechs outperform major index include dow jone industrial average be less apiece ishare nasdaq biotechnology etf ibb pop spdr biotech etf xbi get lift brad loncar chief executive loncar investment say spike be continue june pop generalist begin return space share biotech sector have broadly rise begin june loncar cancer immunotherapy etf cncr jump wednesday last year be almost outflow biotech fund tell investor business daily be report week june be inflow biotech fund huge outlier number ibd take be biotech drug player buy range head investing action plan closer look come thursday uptrend follow report trump be work draft executive order ease drug price reduce regulation speedier food drug administration approval process recently bio century report order come end june trouble politic loncar say be tend be fluid same time rumor potential order emerge be senate hearing drug pricing loncar call totally unproductive very political meeting not much be accomplish drug pricing be bipartisan issue congress be go have something say well say executive order white house be very meaningful not go be wave magic wand issue make go away consumer be understandably angry say last several year valeant pharmaceutical vrx mylan myl privately hold turing pharmaceutical have come fire drug pricing practice same time new gop regime be work repeal replace affordable care act still president doesn look likely take hard line drug price loncar say lot leak detail rumore executive order be actually very positive sector say increase innovation speeding fda approval have better trade negotiation term other country way lower drug price add very constructive way think be point company agree related biotech rally get second wind small cap near breakoutwhy biotech rally still tack upsidebiotechs hit pause day rally regeneron bluebird topple
82,MYL,relative strength rs rating impax laboratory ipxl enter new percentile friday get lift ibd unique rating track share price performance worst best score score show stock price movement last week stack other stock database year market history show market biggest winner tend have rs rating north early stage move see impax laboratory continue show renew price strength clear threshold stock be not proper buy range right now see fundamental improve go form break proper chart pattern developer specialty generic brand pharmaceutical have post negative earning growth consecutive quarters have show negative revenue growth last report impax laboratory hold rank peer medical generic drug industry group akorn akrx eagle pharmaceutical egrx mylan myl be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
83,MYL,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
84,MYL,mylan myl stock topple midday tuesday receive warning letter fda describe significant violation manufacturing process india facility mylan correct violation fda say withhold approval new application supplement list mylan drug manufacturer letter be date april be post early tuesday accord fda mylan fail thoroughly investigate unexplained discrepancy failure batch drug didn meet specification firm also fail establish adequate quality control unit review production record first month mylan invalidate initial specification assay result sufficient investigation determine root cause failure fda write letter mylan be work fda address issue raise letter comprehensively expeditiously possible company tell investor business daily email ibd take mylan have middling ibd composite rating meaning outperform just north half stock term key growth metric head ibd stock checkup full rundown fda standard industry continue evolve be dedicate continually enhance system process deliberate thorough approach assure sustainable quality entire network facility mylan say statement nashik india facility be just mylan manufacturing site globe focuse oral solid dose production be ongoing mylan doesn expect supply issue related product be manufacture india site mylan say fda inspection medicine healthcare product regulatory agency inspect india facility say mylan meet good manufacturing practice minimum standard mylan stock fall close related biotech survive activist investor get take mylan topple big med player divest sharesmylan stock dip recall epipen outside
85,MYL,mylan myl embattled epipen see increase competition first quarter include own cheaper alternative wednesday generic drugmaker report first quarter sale lag wall street view profit top penny first quarter end march mylan report adjust income cent share beating consensus view cent sale advanced vs last year miss analyst model epipen sale drag net sale meda topical business acquire last year mylan say epipen sale decline due increase competition launch own cheaper generic version mylan didn specify sale figure mylan draw widespread scrutiny last year price tag epipen pack fivefold increase decade december mylan release generic version cost half price original ibd take generic drugmaker crash earlier month federal official search perrigo office related large price fix investigation also look teva pharmaceutical teva mylan get full story ibd industry theme epipen have long dominate allergy market private drugmaker kaleo be look take chunk february reintroduce compete drug auvi market sanofi sny buy auvi kaleo pull shelve cite dose issue stock market today mylan rise fall intraday related mylan say supply issue related fda warning india plant
86,MYL,teva pharmaceutical teva say thursday increase price multiple sclerosis drug copaxone partially offset dip global first quarter sale share fall total revenue miss wall street view stock market today teva stock rise earlier fall much share be year antitrust probe generic include teva mylan myl perrigo prgo first quarter end march teva report adjust income share sale profit top cent decline year year sale miss view grow vs last year generic medicine sale grow comprise total sale chunk represent year earlier period teva note acquisition actavis help boost segment quarter revenue teva specialty drug unit decline teva blame lower sale central nervous system respiratory drug decrease specialty medicine help offset teva receive payment takeda subsidiary buy royalty right multiple myeloma drug ninlaro copaxone see fewer sale quarter revenue multiple sclerosis drug fall partially offset price increase copaxone product january teva say teva sell milligram milligram dose copaxone ibd take generic drug stock topple last week federal official search perrigo office part widespread price fix investigation head ibd industry theme deeper look company face department justice scrutiny outside copaxone revenue grow teva face loom copaxone competition february delaware court rule invalid key patent protect drug siding mylan pfizer pfe momenta pharmaceutical mnta be work copaxone copy respiratory product also topple first quarter bring revenue sale asthma inhaler proair qvar decline respectively teva note wholesaler retailer inventory reduction well net pricing effect play dip teva also say michael mcclellan serve interim chief financial officer effective july follow plan departure eyal desheh join teva mcclellan have year career sanofi sny related mylan revenue fall short view epipen sale declineteva downgrade lose ms drug patent doj probe
87,MYL,generic drug stock crash wednesday news department justice have conduct search perrigo prgo office related widespread price fix investigation be also look teva pharmaceutical teva mylan myl early trading stock market today ibd company medical generic drug industry group fall collective week low lannett company lci perrigo stock lose most respectively lannett miss third quarter earning estimate late tuesday perrigo decline comment press release confirm authority execute search warrant perrigo corporate office have be previously disclose number company justice department antitrust division have be look industrywide pricing practice perrigo release say company be take investigation seriously be cooperate appropriate authority investigation center potential price collusion dozen company illegal company agree set price corporate discount perrigo case justice department be look price skin drug bloomberg report other drugmaker investigation be allergan agn impax laboratory impx covis pharma sun pharmaceutical mayne pharma taro pharmaceutical taro endo international endp subsidiary par pharmaceutical ibd take keep pharma news visit ibd biotech pharma industry stock news page mylan tell investor business daily last year receive subpoena regard doxycycline antibiotic hadn be ask information pricing tactic digoxin blood pressure drug be also search january jeffrey glazer jason malek former executive generic drug maker heritage pharmaceutical plead guilty price fix agreement other drugmaker related teva ceo step patent loss bribery settlement stock ionis outplay med sector perrigo tenet valeant diveperrigo share plunge plan sell ms drug royalty stream
88,MYL,eagle pharmaceutical egrx depome depo stock plunge thursday mizuho analyst slash price target slew drugmaker include generic drugmaker teva pharmaceutical teva mizuho analyst irina koffler cite risky guidance price target cut teva depome stock be more bullish dermira derm skin care firm trim price target prescription trend dermatology eagle stock meanwhile be too expensive say stock market today depome stock fall eagle teva stock lose dermira stock rise koffler see dermira takeout candidate koffler cut price target teva stock keep underperform rating cite expectation contraction further asset sale general pricing pressure copaxone issue minimal pipeline contribution remove sale laquinimod model laquinimod be be develop treat relapse remit multiple sclerosis fail recent trial force teva focus instead laquinimod primary progressive ms huntington disease ibd take keep drugmake industry bookmarking ibd biotech pharma industry stock news page meanwhile teva be likely experience more pressure blockbuster ms drug copaxone january district court judge tossed patent protect drug open teva competition mylan myl pfizer pfe momenta pharmaceutical mnta koffler keep neutral rating depome stock cut price target note weak long term outlook opioid market depome make pain management drug include nucynta first quarter sale profit miss expectation koffler like pragmatism new ceo arthur higgin make rapid decision stabilize product decline lower operate expense lower guidance now feel more achievable say eagle stock other hand be just too expensive koffler write note client unlikely be takeout candidate so koffler cut price target share teva eagle stock also have underperform rating first quarter eagle report consensus top revenue profit meet koffler lower expectation takeout note uncertainty associate chemotherapy bendeka likely slow ramp ryanodex exertional heat stroke dermira grab bullish view prescription trend dermatology be currently soft so koffler cut price target dermira stock be buy rate share note view company attractive takeout candidate dermira stock sell recently unexpected convertible debt financing koffler expect stock rebound innovative pipeline potential takeout stock now look derisked additional financing next year say note related do neurocrine just leave door open teva tourette teva hold own bring migraine drug marketteva pharma sale lag key multiple sclerosis drug topple
89,MYL,acorda therapeutic acor be aim save annually cut loose workforce drugmaker say judge invalidate patent protect multiple sclerosis drug ampyra cut have be still be much deeper janney analyst ken write note client thursday cut price target acorda stock keep neutral rating share acorda have previously speak cost save contingency plan be enact ampyra long term patent protection be lose say add have assume first round cut be deeper second round come time generic launch next year wall street have long suspect company mylan myl teva pharmaceutical teva be wait wing make copy ampyra ampyra be approve improve walking patient multiple sclerosis bring net sale estimate acorda employee feb be layer month acorda say majority head count reduction take place april expect severance related cost layoff be not expect person sale force say cut be expect effect research development department restructure be expect save month begin second quarter restructure allow acorda refocu parkinson disease drug cvt tozadenant acorda also work push ampyra milligram extend release pill july lose patent protection last several year have strategically diversify portfolio believe cvt tozadenant be platform significant future growth chief executive ron cohen say news release ibd take acorda therapeutic have ibd composite rating meaning underperform more stock term key growth metric better rate leader be celgene top class cr find best pick stock checkup acorda plan update financial guidance first quarter earning conference call april close stock market today acorda stock be flat day red similar news biogen biib recently win interference case vs forward pharma fwp ms drug tecfidera competitor roche rhhby celgene celg be line rival biogen ms market related acorda biogen forward fall multiple sclerosis drug fightacorda forward stock fall multiple sclerosis court rulingsacorda stave mylan teva generic protect ampyra rbc
90,MYL,abbott laboratory divest more stake mylan myl stock accord filing security exchange commission prompt mylan share dip friday abbott sell share apiece document file late thursday show divest portion represent abbott share mylan stock now abbott own share mylan total outstanding share mylan stock trade stock market today share be form latter portion cup handle begin august stock fall just day move average friday try hold support day line abbott stock other hand dip ibd take mylan announce generic version epipen several month face competition impax laboratory kaleo head ibd technology page prediction rivalry share close fraction thursday mylan confirm recall epipen country outside device fail emergency situation case patient be able use alternate epipen related mylan stock dip recall epipen outside trumpcare have momentum health stock be scramblingthese pharma stock be big loser trump drug pricing tweet
91,MYL,mylan myl stock topple premarket trading thursday generic drugmaker recall epipen australia new europe japan due device failure accord medium report mylan stock finished stock market today close fraction wednesday mylan stock be create handle cup handle formation begin august news recall first emerge late wednesday follow report epipen fail work emergency reuter say patient be able use alternate epipen provide lifesave allergy shot mylan tell ibd epipen failure follow month mylan announce generic version brand allergy shot mylan have come fire price epipen pack have rise recent year generic version drug cost half ibd take mylan have middling ibd composite rating meaning outperform third stock term key growth metric lag only eagle pharmaceutical generic drugmaker industry group head stock checkup list top generic pharma stock mylan generic drugmaker teva pharmaceutical teva be slew drugmaker face federal investigation allegation price fix related pharma stock be big loser trump drug pricing tweetmylan generic epipen swipe share impax kaleo analystmylan launch cheaper epipen generic drug pricing saga
92,MYL,depome depo stock tumble low wednesday not see year company pre release negative first quarter guidance see chief executive resign management shake senator probe opioid marketing close bell stock market today depome share fall earlier fall much share hit intraday month high late september be nearly then late tuesday depome guide first quarter sale lag analyst broader view guidance be revise conference call company also announce management shift see arthur higgin replace former ceo james schoeneck gavin molinelli william mckee be also add board higgin molinelli mckee be align activist investor starboard be know big stake hp enterprise hpe follow shake only board member be legacy member mizuho analyst irina koffler note report depome board change also follow report earlier day sen claire mo be seek marketing information sale record study manufacturer top selling opioid say sale prescription opioid have quadruple depome be name fifth top seller opioid cnbc report other leader list include purdue pharma johnson johnson jnj janssen division insys therapeutic insy mylan myl ibd take depome isn only company face activist investor analyst say bristol myer squibb be buy pressure mount investor such carl icahn bid bristol head ibd technology page deeper dive still depome sell only opioid vs industry leader purdue make oxycontin drug well know painkiller accord janney analyst ken see investigation pose little risk depome didn begin selling opioid acquire lazanda nucynta time diversion abuse prescription opioid medication be decrease koffler mizuho see depome be take starboard remain involved have raise expect probability takeout say generate hypothetical takeout value stock still allow starboard record modest gain initial investment alone depome be worth share takeout due lower sale estimate say koffler cut view scenario also trim price target depome stock keep neutral rating janney have buy rating depome stock related depome downgrade weakness base business stock run
93,MYL,stock open higher monday small cap gain strength dow jone industrial average tick nasdaq climb small cap outpaced group russell rise coca cola ko exxonmobil xom be fraction dow automaker be report march sale monday session tesla tsla get jump group share rise report sunday first quarter delivery top own target notch new record company stock poke cup base buy point be not able stay medical stock be busy premarket session unite therapeutic uthr stumble silver spring md base company announce postpone launch remosynch implantable system pulmonary arterial hypertension treatment remodulin company cite regulatory delay share fall day move average lowest level nov drugmaker mylan myl drop news late friday have expand voluntary recall emergency allergy treatment epipen europe initial recall lot affected device friday company say expand recall lot mylan share drop heavy trade last week big early action international biotech initial public offering include spike novocure nvcr leap israel base cellect biotech apop ibd list microchip technology mchp rise less veeva system veev be fraction microchip be form base buy point veeva be extend buy point other commodity trade be generally narrowly mixed oil price edge west texas intermediate barrel trading begin march dollar be mixed bond be flat year yield release minute federal open market committee march meeting friday payroll report provide week top datum point monday key march manufacturing purchasing manager index roll researcher markit et other institute supply management et also et commerce department report february construction spending number president william dudley new york federal reserve bank speak et overseas europe market be mixed frankfurt dax add cac paris hold decline afternoon trade market japan china stretched higher monday session hong kong hang seng index lead major benchmark related be top perform industry group tesla beat delivery target stock hit buy point monday
94,MYL,generic drugmaker mylan myl be likely recapture market share impax laboratory ipxl generic epipen back school shopping july september mizuho analyst irina koffler say tuesday mylan expand patient assistance program aftermath september epipen price controversy bring company bump cost pack epipen then mylan have also launch generic version half cost generic epipen have capture market week end feb koffler write research report meanwhile impax generic adrenaclick have see share stabilize past week expect market dynamic continue improve mylan seasonal buy be highest note comparison be much easier market disruption last year write mylan expect epipen represent sale decline koffler model epipen sale then decline expectation follow relaunch kaleo highly price auvi feb ibd take mylan have middling ibd composite rating best possible measure growth metric increase revenue profit rank third generic drugmaker group none stock be very highly rate better stock idea head ibd stock checkup head koffler be bullish mylan company be slate report fourth quarter metric midday wednesday part investor day new york analyst broadly expect mylan report sale earning share exclude certain item view mylan best position large generic player investor be still quite concern sector headwind be search bottom signal koffler say march mylan call investor day prove reassure management provide stable longer term outlook realistic revenue earning target analyst currently model adjust earning share sale koffler view sale earning share have buy rating price target mylan stock related teva downgrade lose ms drug patent doj probewill mylan glaukos supernus live growth view next week
95,MYL,share hospital medicaid focuse health insurer take leg friday divide house republican bill replace much obamacare appear narrow hospital tenet healthcare thc slide universal health service uhs hca holding hca lifepoint health lpnt medicaid focuse insurer molina healthcare moh lose fall close month low centene cnc slip other insurer be fare better friday anthem antm rise dow industrial component unitedhealth unh sink tuesday release house speaker paul ryan american health care act hospital stock have re-cover past few day mizuho security analyst sheryl skolnick note apparent willingness president trump back conservative want faster phaseout medicaid expansion get bill top house white house clarify friday support phase medicaid expansion current ahca do didn help health stock drug company biotechs include mylan myl teva pharmaceutical teva also sell tuesday ryan bill be scrutinize be likely due tuesday morning trump tweet be work new system be competition drug industry pricing american person come way friday teva share be friday stock market today mylan edge overall market be hold modest gain sizzling february job report dow jone industrial average index nasdaq be dow other major index be track break string straight weekly gain research note mizuho security analyst sheryl skolnick say upbeat assessment house majority whip steve scalise offer something wake call health care investor have become clear hospital investor be assume be very little chance draconian repeal bill pass skolnick write ibd take part president trump economic agenda investor be most excited tax cut infrastructure spending be stick line obamacare still leave plenty doubt anything resemble house bill get enough support senate gop senator have expressed serious concern unwinding medicaid expansion let alone expedite basis house conservative want see skolnick note trump support carry lot weight house not be true senator state maine colorado hillary clinton beat trump ohio gop sen rob portman far surpass trump vote tally yet skolnick be sticking bottom line repeal replace get do be clear don think gop go home pass repeal matter bad matter full repeal not skolnick do think bill emerge be bad hospital cover see increase adverse selection individual market reduce medicaid funding long term collapse exchange currently work soar number uninsured create real potential pressure hospital cash flow likely hit hospital valuation next year related reason trumpcare isn kill hospital insurer stock trump hail wonderful gop health plan everyone else biggest puzzle paul ryan obamacare repeal
96,MYL,president trump harp drug price tweet early tuesday prompt generic drugmaker teva pharmaceutical teva mylan myl dip even house proposal replace obamacare doesn touch drug price be work new system be competition drug industry trump write tweet open tuesday pricing american person come way drug biotech stock broadly dip response close stock market today ibd company generic drug industry group be fall much earlier touch week low share biotech specialty drug company fall nearly biggest stock loser be specialty drug firm supernus pharmaceutical supn be supernus however also settle patent dispute zydus pharmaceutical marketing generic version supernus seizure treatment trokendi zydus be only company allow market drug certain circumstance start also fall be share endo international endp valeant pharmaceutical vrx plunge trump specific method target drug price competition wasn immediately clear tuesday house release early version bill replace obama linchpin legislation affordable care act ibd take biotech leader celgene major breakthrough head ibd stock analysis deeper dive dub american healthcare act republican proposal end individual mandate bring penalty not have health insurance proposal also repeal medical device tax evercore analyst vijay kumar note latter point be positive general majority device company have be reinvest benefit current temporary repeal device tax be potential boon med tech maker medtronic mdt boston scientific bsx edward lifescience ew make heart valf bill still have long way go make way trump desk evercore analyst terry haine write research report need unanimous support house senate republican democrat likely be opposition be only begin legislative process part aca reform write continue think end june be realistic target document release late monday be merely tax revenue portion aca repeal congress use budget reconciliation process require only majority house portion haine write broader aca reform probably not be finalize year need bipartisanship succeed write today none be apparent be early day related quickly find top rate stock buy point
97,MYL,teva pharmaceutical teva wo be set deepen generic drug price be project topple argus analyst john eade katelyn bayone say tuesday downgrade stock share be trading year lows fall past quarter see increase past year teva stock lose index gain argus analyst write stock market today teva fall be right day move average stock have be day line more year argus downgrade teva stock hold buy cite plague problem teva recently lose patent protect multiple sclerosis drug copaxone former ceo erez vigodman step doj investigation bribery scandal russia ukraine mexico copaxone patent loss teva keep guidance sale earning share exclude certain item be flat respectively pfizer pfe momenta mnta be work copaxone copy be face manufacturing issue teva cut expectation full year sale copaxone expect have cent cent impact ep item company be appeal patent loss interim ceo yitzhak peterburg company earning conference call month say expect continue price erosion generic competition ibd take teva stock have low ibd composite rating meaning underperform more third stock term key growth metric ani pharmaceutical lead group better cr best possible visit ibd stock checkup other leader meanwhile teva be still slew generic drug maker include mylan myl face department justice antitrust investigation addition teva december agree pay government settle allegation bribe official russia mexico ukraine similar probe be ongoing israel risk be stack teva argus analyst write research note top struggle teva repay more debt next year include due other thing teva be pay acquisition actavis generic business former generic ceo sigurdur olafsson step december olafsson be well regard actavis argus analyst say have hold position company be expect be instrumental integration actavis generic business argus analyst say aftermath actavis generic acquisition copaxone sale be hit generic competition argus say teva engage grow be likely face antitrust hurdle be few attractive large target analyst write related momenta pfizer give teva pharma breathe room generic ms drugteva maintain guidance copaxone patent loss topsteva ceo step patent loss bribery settlement stock dife
98,MYL,generic drugmaker mylan myl be expect late wednesday report third consecutive quarter sale growth well earning re accelerate company dip red mylan report come week chock full health sector earning include biotech supernus pharmaceutical supn tuesday eye care firm glaukos gkos wednesday horizon pharma hznp perrigo prgo be slate report earning monday analyst poll thomson reuter expect mylan see earning share item sale respectively vs year earlier quarter ep fall quarters growth part investor day new york mylan also issue guidance analyst currently view sale grow ep item mylan stock be year well day move average rough see stock tumble ceo heather bresch be force defend bump price epipen pack share fall friday ibd take glaukos file initial public offer august be several stock outperform head ibd ipo analysis deep dive glaukos fellow outperform stock year end mylan introduce generic epipen half cost brand pack also late wednesday glaucoma cataract surgery firm glaukos be slate report sale break even ep ex item sale be expect grow year year company lose cent share year earlier quarter glaukos stock hit record high tuesday share rise friday late tuesday analyst expect supernus report cent ep ex item revenue rise supernus stock fall friday touch time high start month related momenta pfizer give teva breathe room generic ms drugacorda stave mylan teva generic protect ampyra rbcteva dife year low copaxone patent invalidate
99,MYL,momenta mnta pfizer pfe be unexpectedly give teva pharmaceutical teva breathe room generic version ms drug copaxone manufacturing delay announce late friday teva rival drug prompt teva stock rebound tuesday stock market today teva stock lift much week high close tuesday regular session momenta stock other hand tumble crash day move average momenta be partner novartis nvs subsidiary sandoz generic drug novartis stock slip tuesday food drug administration issue pfizer warning letter follow inspection fill finish factory factory be key piece momenta sandoz supply chain milligram glatopa generic rival copaxone momenta say unlikely fda approve mg drug fda policy approval application be dependent satisfactory resolution compliance observation pfizer facility used make final product momenta say late friday ibd take teva stock be rank ninth ibd company generic drug industry group composite rating best possible base key growth metric head ibd stock checkup list top generic drugmaker analyst broadly push back timeline glatopa mg launch letter doesn restrict production shipment mg glatopa already market sandoz delay also put mylan myl partner natco lead generic filing mizuho analyst irina koffler write research report have underperform rating price target teva stock mylan previously indicated copaxone first filer status be share unexpectedly put mylan molecule lead gain fda approval ahead momenta write currently model generic launch second half mylan stock edge tuesday koffler expect momenta mg glatopa launch mylan product rbc analyst randall stanicky call delay glatopa mg opportune teva related acorda stave mylan teva generic protect ampyrateva maintain guidance copaxone patent loss topsteva ceo step patent loss bribery settlement stock dife
100,MYL,acorda therapeutic acor keep patent stave generic competition mylan myl teva pharmaceutical teva roxane extend protection ms drug ampyra rbc analyst michael yee say tuesday biotech sue company plan file generic version ampyra be still await decision keep patent protect drug decision be expect first case day now ipr go march lose court case ipr parte review case then ampyra see generic enter court case define generic be infringe ipr define even keep patent yee write research report acorda stock jump close stock market today topple tuesday acorda early tuesday report sale top consensus view rise vs year earlier period acorda wrapped quarter cent earning share ex item miss view cent ibd take incyte be outperform ibd biotech group year date vs rise company industry group get insight incyte potential blockbuster new america much discussion acorda earning conference call analyst center ongoing ampyra litigation include ampyra model acorda see ampyra sale acorda say generic litigation remain filer be too close call accord evercore analyst mark schoenebaum see odd acorda case teva mylan roxane acorda adjust view lose court case janney analyst ken see acorda have better chance positive outcome remain neutral acorda stock wednesday downside risk wrong be simply too great write report still strength acorda pipeline analyst broadly expect cvt parkinson drug be approve last week acorda unveil good result phase trial acorda plan present more datum secondary endpoint june acorda access migraine market be limit cvt study pharmacokinetic pulmonary safety show reversible smoker asthmatic cvt advance phase year end label shrink janney say exclude smoker asthmatic shrink acorda potential market related acorda pop week high strong parkinson drug trialacorda rival lilly novel migraine drug faster onsetacorda scrapping stroke drug just small disappointment rbc
101,MYL,federal court delaware rule invalid key patent copaxone top selling multiple sclerosis drug teva pharmaceutical industry teva israel base teva pharma fall late trading hit be worst level teva share fall stock market today teva have be downtrend july court side mylan lab rise slightly late trading teva say appeal ruling
102,MYL,mylan myl make fortune stir controversy get epipen allergy shot stock school america now drugmaker want sell epipen restaurant sport venue potentially even boy troop set own pharmacy cut middleman lobbying new law expand sale biggest product plan obtain bloomberg news public record request bypass small town pharmacist chain cvs cvs walgreen wba let mylan sell drug directly public place company be look revitalize epipen sale begin slumping last summer congress question mylan epipen sixfold price increase extremely smart say mark baum founder chief executive san diego base imprimis pharmaceutical immy supply drug directly patient rationale other middleman get way just drive cost customer sale epipen fall third quarter price tag spark furor include question mylan ceo heather bresch congressional committee mid august share have fall last month mylan say cut fewer employee mylan decline request interview executive bresch have make secret strategy push state law allow so call entity prescription drug sell place rather person be continue open new market new access public entity legislation allow restaurant hotel really anywhere be congregate be access epipen bresch say september conference october mylan say reach settlement government accusation overcharge medicaid program classify epipen generic instead brand name drug order pay lower discount mylan new business plan revolutionize industry layer middleman critic say cost customer money country more eating drink establishment thousand more sport venue amusement park movie theater be gold mine mylan more american have food allergy severe reaction send patient emergency room minute accord food allergy research education epipen bring operate profit mylan say regulatory filing half america restaurant buy epipen pack year full price mylan generate more annual sale last month company begin selling authorize generic pack epipen deliver shot epinephrine stop severe reaction bee sting food such peanut shellfish have be provide free school mylan say school also buy additional epipen discount law state allow school stock administer epinephrine injector mylan spend help get federal legislation pass encourage state stock device school accord lobbying disclosure form file house representative now company be try replicate campaign mylan have funneled thousand campaign contribution state lawmaker accord campaign finance disclosure document post mylan already least state permit entity prescription school mylan involvement state have enact such legislation company say ohio state representative christina hagan sponsored bill receive donation mylan last year hagan say work waitress taught gravity food allergy republican say be unaware mylan campaign contribution bill be unanimously approve frank minear owner frank family restaurant alliance ohio say plan buy epipen have shellfish item contain peanut menu most severe allergic reaction happen home occur restaurant accord study look forward be first restaurant stark county supply epipen case need minear say lifesave thing mylan say pharmacy mylan health management be used distribute epipen only entity not individual accord company pharmacy license application obtain bloomberg news mylan first disclose existence unit security filing last year provide detail umer raffat analyst evercore isi report october pharmacy be create future opportunity isn operate mylan spokeswoman nina devlin say email prescription restaurant other entity likely be cash purchase so mylan wouldn have pay rebate drug benefit manager do prescription cover insurance own pharmacy mylan keep entity prescription migrate cheaper generic competitor emerge future describe new mylan location program help business offer immediate care emergency situation mylan save pharmacy distributor fee epipen prescription accord michael rea ceo overland park kansa base rx saving solution cut middleman mylan offer epipen give market discount make exact same profit rea say mylan approach backfire say george sillup chairman pharmaceutical health care marketing saint joseph university philadelphia someone proper training inflict harm injury say training requirement vary state american red cross offer minute online course pharmacist brad arthur own drugstore buffalo be past president national community pharmacist association say applaud program threat livelihood kind disruption pharmaceutical pricing model re ripe arthur say
103,MYL,marathon pharmaceutical face battle develop mallinckrodt mnk synacthen analyst say thursday mallinckrodt agree pay license drug indication end ftc antitrust probe stock market today mallinckrodt stock rise fall much wednesday news ftc investigation share close wednesday earlier touch lowest price november settlement mallinckrodt pay day additional day reimburse state fee also license synacthen synthetic acth marathon treat infantile spasm nephrotic syndrome mallinckrodt didn admit wrongdoing say settle remove distraction litigation company still market synacthen other indication globe work develop drug potential treatment duchenne muscular dystrophy ibd take donald trump have accuse drugmaker get away murder price product last week stock tank additional pledge trump ease price pharmaceutical see ibd industry theme deeper dive ironically ftc investigation stem suit former turing pharmaceutical ceo martin shkreli allege questcor acquire compete drug synacthen novartis nvs only shut then jack price own drug acthar mallinckrodt now own questcor synacthen have be market outside decade questcor come fire bump price vial acthar north last year vial cost ftc be investigate synacthen acquisition be keep acthar price high shkreli have be poster boy drug pricing debate turing ceo acquire daraprim parasitic spiked price pill mylan myl too have draw ire price boost epipen pair acquire product analyst seem unconcerned thursday mallinckrodt have license competitive drug indication be ns aren key area mallinckrodt outside be difficult not impossible marathon gain fda approval use drug baby mallinckrodt say entail convince patient parent infant patient fragile high risk population forgo exist approve effective treatment enroll experimental protocol risk receive less effective treatment treatment mallinckrodt say statement conference call analyst early thursday mallinckrodt executive say ascribe value be ns acquire questcor accord mizuho analyst irina koffler settlement isn expect have impact acthar sale koffler keep buy rating price target mallinckrodt stock stock remain conspiracy theory attractive valuation mallinckrodt diversify outside acthar say firm say recent investor gathering plan pursue accretive acquisition end related celgene ceo drug pricing debate hinge incentive innovation
104,MYL,first news conference surprise president elect trump wednesday indicated issue escalate drug price be priority used harsh word describe situation drug industry have be disastrous say trump drugmaker be subject new bidding procedure re get away murder say hit issue already have be get increase attention federal state lawmaker mylan myl ceo heather bresch be skewer house committee september plenty other have be heavily criticize include valeant pharmaceutical vrx teva pharmaceutical teva mylan teva acquire generic drugmaker actavis last year allergan agn be publicly trade company company december be sue attorney general state price fix charge field generic drug day earlier first action similar investigation justice department charge former ceo president privately hold heritage pharmaceutical price fix ibd take event such news conference president elect move stock see ibd stock move learn latest big mover number drugmaker currently move list interview time name magazine man year trump pledge bring high drug price wednesday marked first substantive comment subject pharma have lot lobby lot lobbyist lot power very little bidding drug say news conference re largest buyer drug world yet don bid properly re go start bidding re go save billion dollar period time actavis have boost price hydrocortisone tablet number year mylan epipen treat allergic reaction see price increase year end last year product treat potentially life threaten situation ishare nasdaq biotechnology ibb etf fall stock market today fall back day line already depress share mylan teva fall respectively wednesday valeant tumble ibd company biotech industry group fall again fall day day line larger biotech stock aldr fall spark therapeutic once plunge unite therapeutic uthr fall larger drugmaker amgen amgn end day regeneron pharmaceutical regn fall gilead science gild fall biogen biib tumble related trump drugmaker get away murder mylan teva sue allege price fix
105,MYL,san francisco celgene celg ceo mark alle parry back tuesday so call social contract patient allergan agn face drug pricing debate spiked last year mylan myl epipen turing pharmaceutical hiv medication debate be not new just new social medium say many pharma company have become public proclaim free access program interesting principle have be play celgene year speaking medium panel tuesday morgan healthcare conference san francisco alle outlined series program celgene offer less expensive free access revlimid key chemotherapy treat multiple myeloma myelodysplastic syndrome mantle cell lymphoma alle estimate celgene medicine go patient free year subsidize well reinvest cfo peter kellogg say celgene reinvest north accounting partnership company hike price year ibd take celgene stock have ibd composite rating meaning have outperformed stock key metric past month rank company ibd medical biom biotech industry group see company lead sector visit ibd stock checkup person think lower price be answer drug pricing debate say meant longer have threshold provide access patient don have safety net trouble be celgene isn alone annual price hike last july wall street journal find drug price have jump vs year earlier figure alle say number factor be play complicate matter consumer generally don understand costly drug development process instance run pivotal late stage trial cost average drug fail firm be million alle say welcome comprehensive transparency look forward evolve say incentive have exist company take risk create return biopharmas generic alike simply agree price illegal alle note late monday pair former heritage pharmaceutical executive admit price fix scheme april december involve generic antibiotic diabetes drug accord philly com ex ceo jeffrey glazer jason malek former senior vice president commercial operation plead guilty federal court philadelphia conspire manipulate drug price federal investigator be also look mylan teva pharmaceutical teva other drugmaker suspicion price fix do industry person want do alle say assured be pay list price drug celgene share fall stock market today celgene work consolidation buy point rise monday raise profit forecast
106,MYL,generic drugmaker mylan myl win hit earning goal organically citigroup analyst liav abraham predict late wednesday add mylan limit cash reduce option mylan be target earning share ex item consensus analyst poll thomson reuter expect mylan pull ep ex item respectively abraham prefer teva pharmaceutical teva cheaper stock buy more robust pipeline teva be generic drugmaker market cap remain skeptical regard attainment mylan target absence inorganic activity write research report company cash flow generation cash flow conversion have historically be volatile decline go forward epipen profitability decline ibd take drug price have come increase scrutiny wake election unitedhealth isn sweat donald trump pledge curb spiraling price get full scoop ibd new america abraham downgrade mylan stock neutral buy cut price target cite limit upside revise earning expectation stock market today mylan stock fall share fall mylan take ton heat capitol hill escalate price epipen injector used treat person possibly life threaten allergic reaction mylan be take glaxosmithkline gsk angle deliver generic version gsk asthma chronic obstructive pulmonary disease copd behemoth british gsk pull pound respiratory sale alone comprise total sale generic competition generic mylan have generic drug user fee act gdufa date march abraham see chance mylan get food drug administration approval do not underestimate importance generic advair mylan abraham write note gsk pricing flexibility advair limit opportunity mylan other generic player such hikma gain market share sandoz subsidiary switzerland base novartis nvs be also generic advair fight october sandoz file citizen petition effort persuade fda hold approve generic advair drug meet certain requirement related allergan outlook improve good trial colon drug credit suissedrastic drug price action trump card say needham mylan launch cheaper epipen generic drug pricing saga
107,MYL,mylan myl be prep cut workforce integrate year worth acquisition include swedish meda aktiebolag renaissance pharma topical generic business generic drugmaker say late tuesday company decline further comment ibd filing security exchange commission describe restructure program certain location streamline operation globally company have make number significant acquisition part holistic global integration acquisition company be focuse best optimize maximize asset organization geography mylan write sec filing less workforce be affected geography business mylan say mylan generic drugmaker market cap teva pharmaceutical teva have employee company spokeswoman tell reuter ibd take mylan have ibd composite rating meaning underperform more half stock term key growth metric rank third company trail ani pharmaceutical eagle pharmaceutical crs respectively do drug stock stack dive stock checkup more early wednesday mylan stock topple much touch month low close stock market today share be plunge be ibd company medical generic drug industry group be drug biotech stock be broadly wednesday commentary donald trump time magazine promising cut spiraling drug price share have lift originally election relief hillary clinton drug pricing proposal wouldn come fruition related mylan ep target jeopardy say trump make drug development great again drugmaker mylan slate growth follow price fix fracasteva allergan mylan rally follow sell doj antitrust probe
108,MYL,trading be tame friday open market begin final session major market average start session have turn lower nasdaq fall dow industrial lose dip dow rolled stock market today tout gain be nasdaq carry gain small cap remain stride ahead general market russell show year date gain head friday session bond market close today et stock bond market be close monday observance new year holiday dow stock goldman sachs gs dip investment banker share be year thursday july low stock be extend clear week cup base july have form week tight pattern nike nke be flat initial uptick nike share have drop more earning growth slow analyst expect end year single digit pace first time consensus view see ep growth pick back fiscal nike fiscal year end drugmaker mylan myl jump announce launch generic version pfizer pfe cerebyx injectable seizure treatment well generic tablet version johnson johnson jnj concerta treatment attention deficit hyperactivity disorder mylan share be deep month consolidation nvidia nvda fall friday morning chipmaker ibd stock reversed higher thursday end gain warning short seller citron research contribute nvidia early loss positive note goldman sachs detailed upcoming catalyst stock end thursday so far have be flash sign be due consolidation tesla motor tsla skip fraction analyst robert baird name carmaker top stock pick reiterate outperform rating price target tesla be form long base oil price ease west texas intermediate crude trading barrel gold edge higher ounce dollar be mixed vs yen euro bond be steady year yield basis point economic news december chicago purchasing manager index retreat december november year high regional manufacturing firm be upbeat baker hughe bhi weekly rig count be expect market europe erased early loss gain ground major benchmark show gain less afternoon trade year frankfurt dax be tracking gain cac paris be london ftse be trading year brexit vote june china market gain friday hong kong hang seng index rise shanghai composite japan tokyo nikkei dip mark decline week end week advance related fox netflix disney stall buy zone investing action plan nvidia volatile big drop upbeat reportweek review dow nvidia reverse amazon thrive
109,MYL,mylan myl teva pharmaceutical teva other drugmaker be sue wednesday allegation connive fix generic drug price only hour doj charge former heritage pharmaceutical exec same crime lawsuit come light thursday pit state attorney general mylan teva heritage aurobindo pharma citron pharma mayne pharma drugmaker be accuse fix price doxycycline hyclate antibiotic diabetes med glyburide heritage be characterize principal architect ringleader conspiracy heavily redact complaint outline activity former heritage ceo jeffrey glazer ex president jason malek allegedly manipulate drug price heritage enter doxy market compete mylan be sole doxy manufacturer time ag allege heritage mylan agree abstain compete doxy patient instead splitting market ibd take drug stock have slump late recent comment president elect donald trump tackle rise drug price objective be avoid price war reduce profitability company attorney say complaint mylan agree walk away least large national wholesaler large pharmacy chain allow heritage obtain business increase market share heritage plan increase price glyburide accord complaint rival time be aurobindo mayne order accomplish objective malek instruct member sale team immediately reach contact competitor list drug attempt reach agreement price increase complaint state accord complaint defendant know action be illegal thus agree avoid delete written communication heritage decline comment lawsuit instead refer statement wednesday note malek glazer be fire august follow internal investigation heritage say cooperate doj investigation recently heritage initiate own legal action same individual seek redress elaborate embezzlement self deal scheme spokesperson say be deeply disappoint misconduct be commit ensure do not happen again teva tell ibd be review complaint have not find evidence give rise civil criminal liability mylan say date know evidence mylan participate price fix stock market today teva stock fall mylan climb ibd company medical generic drug industry group be related incyte recoup loss price fix fracas strong chemo mylan slate growth follow price fix fracas
110,MYL,credit suisse reiterate outperform rating allergan agn stock friday company late thursday release positive trial result colon drug treat irritable bowel syndrome give current valuation see potential significant upside agn expectation be properly reset new product continue deliver investor begin
111,MYL,appreciate value see agn pipeline credit suisse analyst vamil divan write research note allergan stock rise stock market today year nov touch nearly year low be tough year general maker generic drug allergan receive department justice subpoena seek information actavis generic unit liability transfer teva teva acquire actavis august part ongoing wide range doj investigation possible price collusion generic field month doj charge former heritage pharmaceutical ceo jeffrey glazer president jason malek felony count related conspire fix price diabetes drug antibiotic drug next day attorney general state sue mylan myl teva heritage other maker generic drug price fix allegation ibd take allergan have be worst perform stock year other end scale drugmaker be celgene learn company make ibd leaderboard top stock breakout ironwood stock rise friday buy point flat base touch month high nov dublin ireland base allergan partner ironwood pharmaceutical irwd be base cambridge mass announce call positive top line datum phase clinical trial evaluate linaclotide colonic release cr colonic release cr formulation adult patient irritable bowel syndrome constipation ib constipation ib aim work fda start phase iii trial second half cr second phase iib trial cr patient constipation linaclotide ir immediate release brand name linzess be currently fda approve available treatment adult ib chronic idiopathic constipation cic new formulation linaclotide aim treat distal small intestine colon trail patient not experience constipation majority abdominal pain associate ib be believe originate allergan ironwood say news release abdominal pain be usually most difficult symptom treat patient ib pain be not treat sufficiently then drife patient back office again again dr philip schoenfeld chief section john dingell va medical center adjunct professor medicine university michigan school medicine say allergan news release encourage initial datum new formulation linaclotide produce additional relief abdominal pain patient ib related trump break republican push major drug price reform drastic drug price action trump card needhammylan epipen settlement remove concern
112,MYL,outspoken former pharmaceutical executive martin shkreli say national outrage drug pricing be blow proportion heighten presidential election concede have predict blowback better term regret maybe not see acutely ve be minor regret shkreli say interview bloomberg tv friday price increase have stick so speak don really main mission be raise price have generate increase revenue happened so happy respect privately hold turing pharmaceutical ag be company fire price increase older drug lack competition mylan myl maker emergency allergy shot epipen valeant pharmaceutical international vrx company have be question congress subject criticism public turing shkreli be include senate committee report release week call government stop monopoly business model employ drugmaker raise price drug former hedge fund manager post twitter frequently shkreli become face drug outrage turing raise price daraprim fight sometimes deadly parasitic infection more fold left turing be charge federal authority unrelated matter ask take same business strategy again year old say course concede put drug company run risk brash approach also call daraprim insignificant drug compare other larger product shkreli say be frustrated government many way be apparatus vengeance say pricing situation be blow proportion mentioned valeant pfizer pfe world second largest drugmaker other company have raise price recently turing do not respond request comment also say make many fan business world everybody do capitalism try get highest price product say be turn thoughtful sarcastic interview ask bloomberg anchor david westin ferro don know re familiar health care insurance say patient don feel brunt price increase drug make overall health care spending insurer often implement cost sharing patient increase premium patient pay response long term rise cost federal prosecutor have accuse shkreli defraud investor hedge fund used retrophin asset pay also allegedly hide control company unrestricted stock help pay debt be arrest december have plead not guilty say look forward upcoming trial schedule june re go landslide say evidence be clear do nothing wrong shkreli be know blunt opinion industry often try present unify front congressional hearing drug price february invoked fifth amendment right way refuse answer question then hearing call lawmaker imbecile twitter trial shkreli predict juror see somebody relate not figure claim be portray interview invariably person read headline martin shkreli hate martin shkreli get know martin shkreli love martin shkreli say tv interview shkreli bring federal fraud case co founder several associate hedge fund platinum partner have accuse platinum ponzi scheme platinum co founder mark nordlicht plead not guilty week shkreli say have tango hedge fund trade investigator bring case call investigation charge example government go interview bloomberg decline comment have speak federal investigator platinum case
113,MYL,president elect trump have promise action high drug price prospect government take control drug pricing have largely subside thank trump victory hillary clinton needham say bullish research report thursday specialty pharma sector furthermore trump state plan lower corporate taxe lessen tax burden company look bring cash back spark drug industry needham analyst serge belanger write research report belanger name acad pharmaceutical acad tiny corium international cori top pick specialty pharma coverage area interview time early month be name magazine man year trump give most definitive statement yet long simmer issue escalate drug price go bring drug price tell time don have happened drug price ibd take drug stock haven be boom see health care industry related company make latest ibd ranking stock have perform best past week emphasis most recent month comment hurt drug stock drug pricing remain issue trump didn expand comment interview subsequently belanger tell ibd email ask analyst amplify report even trump comment idea federal government negotiating drug price rather insurer seem far fetch now belander say email assume pricing scrutiny generic old drug continue pbm payer pharmacy benefit manager health insurer have be active area have previously be talk democrat have medicare other agency negotiate own drug price much va medicaid do now pricing control newly approve drug seem less issue now republican have board control mylan myl valeant pharmaceutical vrx be few company have receive most heat consumer lawmaker escalate drug price justice department be investigate possible price collusion maker generic drug company such mylan allergan agn teva pharmaceutical teva endo international endp be investigate first charge investigation doj month charge former heritage pharmaceutical ceo jeffrey glazer president jason malek felony count related conspire fix price diabetes drug antibiotic drug next day attorney general state sue mylan teva heritage other drugmaker price fix allegation less threat drastic drug price action belanger see much improve climate merger acquisition sector driver increase activity be likely be propose tax policy change new
114,MYL,administration write report also say trump effort ease repatriation overseas cash balance likely re energize entire health care sector big pharmas be company most overseas cash biggest tech company such apple aapl microsoft msft alphabet googl belanger cite amag top pick hit maternal health product development corium alzheimer drug amag stock be extend buy point first touch nov even fall stock market today corium stock fall small cap have partner teva have trade past month amag corium be part ibd huge company medical biom biotech industry group jump day follow surprise trump election have fall then group fall thursday related doj charge pharma exec price fixingwill trump break republican push major drug reform state sue mylan teva other price fix allegation
115,MYL,nasdaq composite session streak be jeopardy late afternoon trading wednesday weigh weakness biotech stock dow jone industrial average rise add nasdaq be flat volume nasdaq nyse be tracking higher tuesday level stock market today biotechs take heat president elect donald trump take aim pharmaceutical industry first press conference say new bidding procedure be need drug price meanwhile lockheed martin lmt give day move average trump vow increase competition fighter jet bring cost alexion alxn incyte incy mylan myl biogen biib celgene celg be top decliner nasdaq fall anywhere ishare nasdaq biotechnology ibb give merck mrk be high still bright spot dow rise fda be consider immunotherapy drug keytruda chemotherapy treat advanced lung cancer decision be expect merck be work new base buy point small cap barracuda network cuda rebound tuesday reversal high solid earning share rise nearly still buy range double bottom entry ibd take security software group have be lag market recent month group be home intriguing name solid fundamental see be ibd stock checkup ibd chipmaker microchip technology mchp add work tight flat base buy point sale growth have accelerate straight quarters market cap firm new york mercantile exchange february west texas intermediate crude oil future settle barrel nearly related trump say drugmaker get away murder cite ford fiateconomic optimism hit new year high trump rally continuestrump vow fighter jet competition big thing lockheed
116,MYL,promise mylan myl announce friday generic version own epipen injector cost half price exist epipen reach pharmacy next week mylan epipen have become last poster boy issue rapidly escalate drug price mylan ceo heather bresch get skewer house committee hearing september lawmaker ask question bresch own pay use private plane travel hearing bresch be daughter sen joe manchin va cost pen epipen pack have rise used treat often life threaten allergic reaction cause insect bite food drug more american be rightfully concern rise drug price now more ever patient family country be standing pharmacy counter struggle pay medication bresch say company announcement friday ibd take pricing issue have weigh drug stock group be do well find group be upswing regularly check ibd depth industry snapshot feature issue remain front burner president elect trump have not be expect focus drug pricing much ease drug approval process say time magazine interview publish month go bring drug price don have happened drug price thursday mylan be drugmaker sue state attorney general allegation fix price generic drug teva pharmaceutical teva also be sue teva mylan be largest generic drug maker market cap statement news mylan say date know evidence mylan participate price fix thursday news follow wednesday announcement department justice have charge former ceo former president new jersey base heritage pharmaceutical collude fix generic drug price charge be first year doj investigation drug price fix doj be look mylan teva group company include allergan agn endo international endp have disclose receive subpoena ag suit reveal thursday have name heritage principal architect ringleader conspiracy mylan stock year rise stock market today teva nearly year lose bresch mylan announcement friday say problem remain pharmaceutical pricing system be re-form address increase shift cost directly consumer pharmaceutical pricing be too far remove patient pharmacy counter not design today increasingly consumerize health care system authorize generic epipen auto injector have wholesale acquisition cost pack mylan say release generic version vs company own product be unprecedented action so anyone choose more expensive nongeneric epipen depend several factor example patient health insurance pocket cost epipen auto injector be more affordable option mylan spokeswoman julie knell tell ibd email mylan continue offer option patient so work health care professional determine best least expensive option related mylan teva sue allege price fixingdoj charge pharma exec price fix
117,MYL,drugmaker actavis face fine raise cost hydrocortisone tablet more british antitrust regulator say friday continue crackdown excessive pricing pharmaceutical industry division teva pharmaceutical industry teva break competition law charge excessive unfair price competition market authority say statement example company raise price milligram pack roughly cent currency teva acquire actavis allergan agn earlier year say defend allegation be lifesave drug rely thousand patient national health service nhs have choice continue purchasing say andrew grove cma senior responsible officer allege company have take advantage situation removal drug price regulation leave nhs ultimately taxpayer foot bill substantial price rise cma send actavis statement objection layer concern wider crackdown unfair drug pricing dec cma fine pfizer pfe flynn pharma record amount abuse dominant position charge unfair price unbranded version epanutin epilepsy drug regulator fine pfizer roughly flynn pharma increase price much september price increase occur pfizer transfer distribution right flynn sell medicine generic name phenytoin sodium teva be already process selling actavis operation inta pharmaceutical ltd say cma probe raise broader question regulation generic medication pricing actavis product investigation be never teva effective control teva believe intervention cma price generic medicine raise serious policy concern regard role cma department health teva say generic medicine continue be affordable alternative brand therapy statement objection often lead fine order change business practice regulator have power fine company find have abused dominant market position annual revenue hydrocortisone tablet be used primary replacement therapy person adrenal gland do not produce sufficient amount natural steroid hormone result condition such addison disease tablet be also used treat condition such arthritis blood hormone immune system disorder skin eye condition breathe problem cancer severe allergy actavis also increase price milligram hydrocortisone tablet nearly result charge nhs pack march cma say nhs have previously paid equivalent pack april nhs spend pound year hydrocortisone tablet nhs spend tablet have rise year steep price hike have put string drugmaker microscope company mylan myl valeant pharmaceutical international vrx bearing brunt public outrage president elect donald trump have be cite boon free market health care also declare opponent high drug price interview time magazine
118,MYL,allergan agn mylan myl teva pharmaceutical teva stock fall wednesday department justice accuse former pharmaceutical executive collude fix generic drug price former heritage pharmaceutical ceo jeffrey glazer jason malek ex president be charge wednesday philadelphia conspire fix price antibiotic diabetes med felony doj say release be fire heritage august accord bloomberg report cite lawsuit file last month new jersey heritage accuse glazer malek steal ten million dollar siphon profit various racketeering scheme fbi be prepared go pharma company violate antitrust law say special agent charge michael harpster statement filing charge drug price collusion skews market flout common decency say sad state affair pharmaceutical executive be determine further pad profit back person health depend company drug say ibd take biotechs have nearly return pre election level recent commentary donald trump work cut drug price wednesday teva stock fall mylan allergan ibd company medical generic drug industry group fall charge be first year investigation generic drugmaker include allergan mylan teva lannett lci impax laboratory ipxl covis pharma sun pharmaceutical mayne pharma taro pharmaceutical taro endo international endp email statement edison base heritage pharma say august follow internal investigation reveal variety serious misconduct individual charge today heritage pharmaceutical terminate be fully cooperate aspect department justice continue investigation recently heritage initiate own legal action same individual seek redress elaborate embezzlement self deal scheme be deeply disappoint misconduct be commit ensure do not happen again last month allergan sun pharma decline comment ibd mylan say have disclose subpoena regard antibiotic doxycycline be subpoena information pricing tactic digoxin blood pressure med ceo drug biotech market have comment rise drug price light recent commentary president elect donald trump go bring drug price hillary clinton be often see tougher drug price earlier wednesday express script esrx ceo timothy wentworth joined fracas say doesn see major impact business affordable care act be repeal say guidance call analyst overarch drug price conversation isn go away be question mind conversation be not go go away need demonstrate used tool client voice well demonstrate say accord marketwatch share pharmacy benefit management company tank much wednesday end day day line express script affirm earning share ex item view deliver line sale view related drugmaker mylan slate growth follow price fix fracasincyte recoup loss price fix fracas strong chemo result
119,MYL,donald trump criticize boee ba blast high drug price pressed apple aapl trump stock market rally continue economic optimism soar highly rate dave buster play broadcom avgo report strong earning nasdaq joined other major average hit record high big cap techs fiber optic stock offset weakness drug stock treasury yield be little change several week gain earning season have cool several highly rate company deliver upbeat result guidance donald trump take twitter twtr criticize plan boee ba order new air force presidential jet say be too expensive boee say be willing negotiate price heavy requirement presidential jet be reduce trump time person year tell magazine be go bring drug price also say want apple aapl build huge plant apple supplier foxconn confirm look expand operation boee share shrug trump rise month high week apple rise back day line mylan myl several other drug stock sell related trump target drug price apple seek minute offshore firmsdrug stock topple trump pledge bring pricestrump seek cancel air force order target boee ibd tipp economic optimism index rise point december highest november credit postelection euphoria least republican independent democrat however have be upbeat economy most past year see dark time ahead new stock market rally reflect fuel higher consumer sentiment related economic optimism hit year high trump democrat be blueoil price fall barrel week ahead saturday meeting opec producer work production cut russia kazakhstan mexico azerbaijan oman agree attend organization petroleum export country deal cut barrel day start january be contingent cartel member cut bpd opec be still pump now november production hit new high barrel day accord bloomberg survey energy information administration now see west texas intermediate average barrel next year prior forecast eia also say weekly oil stockpile fall barrel larger expect decline related oil fall opec ok not cut output cutsoil price fall opec russian output eia lift european central bank extend asset purchase program past march start april buy net euro worth month euro ecb expand bond buy include year debt asset yield deposit rate ecb president mario draghi say financial market have be more resilient expect face brexit italy referendum donald trump election euro initially rally then sell near year low related european central bank curb bond buy don call taperonline retail king amazon com amzn take dead aim physical store world introduce amazon go retail convenience store format be develop use computer vision deep learn algorithms let shopper just pick want exit store checkout procedure first amazon go store square foot convenience store be home base seattle be beta testing amazon employee only store open everyone early amazon be gain ground large retail market core market electronic medium putt commerce giant position strong performance say report cowen analyst john blackledge reiterate call amazon become largest retailer apparel accessory next year pass macy related amazon introduce amazon go retail store checkout linesamazon set disrupt retailer apparel grocery avgo earn share exclude item year year sale fiscal end oct analyst expect chip designer earn share ex item sale be broadcom third straight quarter accelerate sale earning growth most gain be attributable broadcom merger close february also double quarterly dividend share broadcome rise friday clear buy point related broadcom beat target double quarterly sbux outlined investor day year plan growth sale ep mid single digit comp gain annually java heavyweight intend open more store half be china cold drink lunch offering digital effort be expect drive sale company also announce partnership tencent tcehy bid boost china presence share rise best level late april related starbucks ceo say retail plan add storesgaming restaurant chain dave buster play third quarter result full year guidance top wall street estimate raymond james attribute revival comp momentum successful game introduction broader menu marketing initiative share soar week record high chipotle grill cmg meanwhile expressed uncertainty meeting financial outlook struggle rebound last year foodborne illness scare co ceo steve ell also say be not satisfied burrito chain recovery attempt improve customer service have be hurt employee give more attention keep new safety standard share fall week ciena cien earning miss analyst forecast share surge thursday fiber optic firm report highest ever order backlog group peer finisar fnsr late thursday report better expect earning outlook finisar share rise thursday reversed early friday gain optic stock lumentum lite break consolidation thursday pull back friday related finisar earning outlook top view optical party continue latedelta air line dal southwest luv break long basis week southwest report november traffic growth outpaced capacity airline have get lift recent week mostly brighter outlook unit revenue recent investment warren buffett berkshire hathaway brka however international air transport association thursday also say carry capacity continue exceed demand profit fall record rise oil price healthequity hqy have earn cent share revenue climb narrowly top asset management jump still see full year ep cent wall street view cent revenue midpoint consensus healthequity have benefit health saving account high deductible health insurance plan become more common healthequity fall modestly week so far share shot election many expect expand hsa role trump administration gop congress
120,MYL,day drug stock get boost defeat hillary clinton have promise look issue high drug price mylan myl be set release close mylan be latest poster boy high drug price issue congressional committee september grill ceo heather bresch steep increase price mylan epipen injection treat severe allergic reaction insect sting bite food price pack have rise oct mylan announce settlement justice department question medicaid have overpay epipen mylan say take pretax charge settlement wall street estimate analyst expect earning share item year earlier quarter sale big deceleration earning analyst model ep ex item revenue result earning share item revenue prior quarter ep ex item rise rise sale company guidance oct mylan lower ep ex item guidance full year company however maintain guidance post ep ex item stock mylan share be small fraction hour trading follow earn release close wednesday mylan be many drug company have good day postelection share rise stock market today mylan stock have steadily fall nearly touch time high april related drug stock fly clinton defeat
121,MYL,first time winning election donald trump vow take drug price go bring drug price don happened drug price trump tell time magazine name president elect person year investor continue assess trump policy mean market few word have jarring impact start trading wednesday share drugmaker biotechs be hit mylan myl stock market today ishare nasdaq biotechnology etf ibb pfizer pfe fall trump also double goal shift tide global trade get ceo phone minute want get list company have announce re leave tell magazine call minute apiece win be leave be plenty reason doubt just much impact trump have restore lose manufacturing job curb america trade deficit effort backfire extent trump be show fully engage challenge say tim cook ambition get apple aapl build great plant biggest best even only foot foot bigger place china tell time ibd take market assess trump trade policy work industrial company get most revenue home be biggest post election winner include nucor steel dynamic martin marietta check ibd leaderboard track stock be lead market analyst have cast doubt major shift iphone production china foxconn have chinese worker assemble apple iphone give trump small victory wednesday company confirm be eyee expansion operation apple share rise announcement come day masayoshi son ceo japan softbank own sprint meet trump discuss plan invest trump aggressive use bully pulpit plan bring corporate tax rate help convince unite technology utx unit carrier keep open indiana plant slate closure other company have feel be wrong side trump tweet rexnord rxn trump criticize plan move ball bearing production indiana have see share tumble wake call biotech investor come day trump tweet threat call boee ba air force cost spiraling control trump tell nbc wednesday later speak boee ceo dennis muilenburg say re go work continue insist cost come meanwhile trump tell time magazine build wall stop illegal immigration also indicated not deport so call dreamer child bring illegally parent re go work something go make person happy proud related drug stock topple trump pledge bring chief trump go negotiate air force pricetrump seek shoot air force target boee profittrump sell boee apple other stock junedonald trump fire tariff warning shot backfire
122,MYL,share key biotech etf plunge lowest point election president elect donald trump pledge interview time magazine curb spiraling drug price stock market today ishare nasdaq biotechnology index ibb exchange trade fund be fall intradayto index have jump nov trump beat hillary clinton race white house belief high drug price not be big focus trump have be clinton ibd company medical biom biotech industry group surge day trump relief drug pricing control promise clinton wouldn materialize new administration group be wednesday group stock get hit bluebird bio blue acceleron pharma xlrn respectively prothena prta be puma biotechnology pbyi be ibd company ethical drug industry group rise nov be ibd company generic drug group nov be wednesday group member akorn akrx mylan myl have announce layoff be nearly time interview trump make clear wall street have misread intention go bring drug price say interview don have happened drug price ibd take analyst potentially be rethink earlier thesis trump make drug development great again other trump proposal include tax reform be boon biotech company researcher say already happen health care tracker quintilesim institute project medicine market close revenue rise half growth im project annual growth brand medicine price erode more slowly continue grow accord im net price trickle bottom line grow only offset growth drug rebate discount time loss brand exclusivity include impact generic impact total spending tune next year more time impact last year biosimilar be development now related trump target drug price apple offshoringstock etfs mixed biotechs take ill single donald trump commentamgen biogen celgene eye trump pro biotech world
123,MYL,specialty drugmaker mallinckrodt mnk early tuesday post better expect earning sale fiscal lead revenue jump specialty brand biggest business unit post earning conference call mallinckrodt say see double digit generic revenue decline tumble fiscal mallinckrodt stock plunge more stock market today far record high march company become embroil drug price gouge issue have also hit such drug company valeant pharmaceutical vrx more recently mylan myl specialty brand drug acthar post sale year earlier quarter acthar gel be used treat certain type spasm infant certain effect multiple sclerosis adult more ibd take ibd company medical ethical drug industry group include mallinckrodt valeant have face challenge drug pricing issue lag just industry group track yet almost always be drug stock worth keep close track give time make latest ibd list top perform stock quarter end base company report earning share item continue operation ahead consensus estimate analyst poll thomson reuter say revenue continue operation rise analyst have modeled company say year have extra week vs last year be say result percentage point increase sale result exclude company nuclear imaging business august mallinckrodt announce agreement sell business belgium base iba molecular order focus drug business much faster grow business acquire invest strategy continue produce benefit scientific organization generate compelling new datum clinical evidence key brand commercial team bring datum physician patient help make better inform treatment decision company ceo mark trudeau say earning release related mallinckrodt shed imaging unit
124,MYL,mylan myl have add tuck acquisition next year reach earning target mizuho analyst irina koffler say friday cut estimate maker generic drug miss mylan stock be nov earning report sale miss earning share ex item be short cent mylan ceo heather bresch guide low midteen growth bresch also reiterate firm ep item target mylan generic drugmaker market cap teva pharmaceutical teva fall scrutiny year boost price pack epipen north re much more product much more country bresch say company earning conference call last week analyst differentiate multiple product mylan weather headwind epipen situation say hope response epipen situation again manage overall business be allow deliver give confidence target say ibd take biotech drug stock be thrive election donald trump uncertainty linger repeal affordable care act get ibd industry theme full scoop koffler say ep target win happen small acquisition way keep buy rating mylan stock cut price target also trim epipen view mylan earlier guidance epipen suffer inventory destock generic launch mylan year response criticism koffler expect epipen sale represent total sale likely be rebate generic mylan say cut direct consumer spending coupon copay deal still believe mylan be able capture significant portion market generic also expand overall market growth koffler write stock market today mylan share sank share touch more year low nov related trump make drug development great again mylan third quarter earning fall short stock steady
125,MYL,interview time selection news magazine man year bring president elect trump most definitive statement date drug price go bring drug price don have happened drug price incoming president have be short detail many observer say bigger focus be streamline food drug administration drug approval process effort get boost wednesday same day trump time interview be publish senate approve bill aim speeding approval drug medical device president obama be expect approve so call st century cure bill just action trump take remain unknown resolution issue drug price time jump exponentially critical need patient trump have vow repeal president obama affordable care act promise drain swamp special interest washington help contribute rise big pharma time interview hadn broach drug pricing issue just election boost drug stock ishare nasdaq biotechnologg etf ibb jump day nov election fall ibd company biom biotech industry group jump nov generic ethical drug group rise respectively group have give back gain trump ignore rise drug price say trevor william penn mutual asset management manage director trouble be businessman reality tv star be relative political enigma william tell ibd hard see be champion lower drug price same sense hillary have be so focuse dismantle aca william say trump not have political history really difficult telegraph go go policy proposal be tell trump pledge contract american voter fully repeal aca better know obamacare first day office replace health saving account vein say ll cut fda red tape be drug await approval especially want speed approval life save medication trump write contract trump crack fda be nothing new say credit suisse analyst vamil divan yet recent year fda have work expedite sorely need drug fast track designation prescription drug user fee act help fund drug quickly still be backlog approval generic drug divan tell ibd many proposal work have target make approval process generic drug cheaper drug similar drug long enough ve lose patent protection much easier trump platform remove barrier entry safe reliable cheaper product trump also allow broader label use number drug penn william say replacement plan aca remain somewhat ambiguous trump have backed earlier promise fully repeal act say ll maintain provision require insurer cover patient pre exist condition let parent cover child age obama didn touch pharmaceutical much obamacare legislative centerpiece say divan outside require drugmaker pay expand health care coverage trump completely do away aca be unlikely divan say fee disappear backroom negotiation aca let company come reasonably well divan say repeal aca put cash fee back drugmaker pocket yet wall street be anything reasonably sure trump care affect biotech drug firm trump doesn appear have vendetta pharmacy benefit manager pbms drugmaker pbm tactic undercut amgen amgn eli lilly lly prompt stock topple late october amgen offer dim view eli lilly see diabetes sale take hit pbms be third party administrator commercial government medicare health plan pbms use discount competition keep drug price low help patient raise conflict drugmaker amgen stock topple nearly oct sale enbrel come flat firm say doesn expect net selling price increase business be drive volume amgen executive anthony hooper say company earning conference call ibd take rebate chip away amgen enbrel sale do mean broader industry grab ibd industry theme deeper look eli lilly stock oct sale diabetes drug humalog fall higher volume be more offset lower realize price company say earning conference call ep revenue miss wall street target trump lack commentary pbms be tell divan tell ibd stand government be not involved drug price negotiation trump work change order lower drug price not be focus republican divan say trump be not typical republican question say be new administration willing go something big pharma politically score point general public drug company have own view course merck mrk ceo ken frazier month bloomberg interview say company have be restrain raise price always be individual drug individual year point say look large relation other look whole portfolio see merck have tend be rather restrain come drug price bloomberg report frazier say bloomberg also report month allergan agn ceo brent saunder say trump be more vicious more focuse take do something again term spiking price drug drug bloomberg have interview saunder frazier appear forbe healthcare summit new york dec question patient have have high drug price kaiser foundation find september american last year believe drug price be too high american generally support require firm release information price be set allow government negotiate drug price kaiser survey follow drug pricing controversy erupt september mylan myl boost price pair epipen ceo heather bresch be subject tough question house committee hearing last year similar controversy prompt capitol hill hearing involved turing pharmaceutical former ceo martin shkreli involve big hike decade old hiv drug valeant pharmaceutical vrx have also impose huge hike drug price justice department be investigate be expect file charge generic drug company price collusion year end yes analyst divan say don think issue be go away also say see fewer chance big change drug pricing policy trump related pfizer sale challenged eli lilly novartis breakup busteli lilly topple alzheimer darling sola fail biogen merck downcelgene kite spark look sidestep lilly alzheimer flopalder keel sixth day eu uphold teva migraine patent
126,MYL,president elect donald trump republican congress likely seek faster drug pipeline buoy medidata solution mdso other medical software firm keybanc analyst donald hooker say monday drug stock rise again emphasis faster pipeline come reduce drug pricing scrutiny trump plan incentivize repudiate cash credit suisse analyst kennen mackay write separate research report predict trump presidency likely keenly boost biotech sector stock market today medidata stock help lead ibd company computer software medical industry group be medidata stock be seventh straight gain hooker have overweight rating price target share say macro backdrop have improve medidata follow trump election ibd take biotech drug stock have fly trump uncertainty exist intention affordable care act check ibd industry theme full skinny rise drug price have become major political issue year hooker write research report monday instead price control suspect republican solution more likely involve regulatory reform speed approval new drug create greater competition trump make drug development great again quip hooker see organic growth medidata give likely improve regulatory legislative landscape information technology drug development medidata have enterprise deal bristol myer squibb bmy celgene celg biogen biib boehringer ingelheim ibd biotech industry group rise day election fall thursday friday company group be monday ibd company generic drug group have rise day election be monday hope trump regulation help industry democratic nominee hillary clinton be see tougher runaway drug price september biotech industry see stock tumble clinton call former turing pharmaceutical ceo martin shkreli boost cost decade old hiv pill september mylan myl draw national ire raise price pair epipen mylan allergan agn teva pharmaceutical teva be handful drugmaker currently investigation department justice allege price collusion trump likely win push back drug pricing mackay say investor be more bullish sector give trump proposal incentivize return cash still caution health care pricing be area mr trump make concession democrat write research report seattle genetic sgen stock react richly trump election note related incyte recoup loss price fix fracas strong chemo resultsmylan third quarter earning fall short stock steady
127,MYL,drugmaker mylan myl be slate report rise sale earning close wednesday just day fellow drug leader teva pharmaceutical teva allergan agn plummet news federal probe allege price collusion mylan be expect report earning share ex item sale respective vs year earlier quarter be mylan consecutive quarter sale ep growth ep be expect decelerate growth sale be see speeding growth prior quarter mylan have beat meet ep view consensus analyst poll thomson reuter past quarters sale have only beat twice ibd take mylan have ibd composite rating meaning perform middle stock term key growth metric get stock checkup see stock be better rate mylan stock be past week touch year low thursday company have attract national ire epipen price september ceo heather bresch be grilled congressional committee high price pack epipen price epipen be used treat severe allergic reaction insect sting bite food same time period ibd company medical generic drug industry group have fall include nose dive last thursday report emerge department justice investigation potential price collusion generic drugmaker close bell stock market today mylan stock end trading more related incyte recoup loss price fix fracas strong chemo result
128,MYL,teva pharmaceutical teva multiple sclerosis drug likely see generic rivalry crop company garner stock upgrade monday robust huntington disease chronic migraine front copaxone teva ms drug bring half firm specialty drug sale overall sale teva stock be investor worry generic sock copaxone sale give sell teva share feel most risk copaxone generic market be now price share credit suisse analyst vamil divan say monday research report outline trick ahead call valuation treat divan upgrade teva stock outperform neutral see long term opportunity cut price target loom competition mylan myl be expect release milligram generic competitor copaxone other prep mg version say potential trick teva term include earning report nov time expect company lower guidance reflect court decision teva copaxone patent ibd take share generic drugmaker be year other medical firm be flourishing volatile election season glaukos stock instance be year main trick not seem much treat check ibd new america more conference call offer clarity teva acquisition actavis upcoming catalyst include phase datum chronic migraine drug tev likelihood food drug administration approval huntington disease medication early generic believe drug pricing deflation remain expect range teva be able take advantage first file opportunity extract synergy actavis deal begin deliver meaningful margin expansion divan write research note stock market today teva stock rise still trading year lows ibd company medical generic drug industry group fall nearly monday nearly month low group be rank group track related mylan jump doj settlement remove linger concern amgen migraine drug likely beat eli lilly teva market
129,MYL,donald trump stunning drug biotech stock rally wednesday investor sector cheer hillary clinton have be see far more likely crack drug price takeover activity gilead science gild rise stock market today pfizer pfe shot amgen amgn merck mrk mylan lab myl fire epipen price hike leap mylan late wednesday posted earning fall short top bottom line share be fraction clinton have say go excessive drug price hike also likely have favore change government negotiate lower price drugmaker meanwhile republican retain control house congress also ease regular concern drugmaker aren clear be still populist anger price new old treatment trump time signale also go drug price meanwhile justice department reportedly be close filing charge vs mylan other generic drug maker price collusion related stock future well lows trump win white house
130,MYL,stock turn mixed soft start wednesday wall street digest news trump plunge more point overnight dow jone industrial average be mostly unchanged nasdaq lose ease early leader dow include pfizer pfe caterpillar cat merck mrk jpmorgan jpm goldman sachs gs also outperformed ibd take election result be describe shocking upset ibd tipp presidential tracking poll ultimately have right year treasury yield soar basis point december gold rally ounce drugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer industry group mallinckrodt mnk shire shpg allergan agn lead gain more hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid universal health service uhs drop coal mining stock soar consol energy csx arch coal arch add cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc martin marietta mlm higher martin marietta gap cup shape base buy point vulcan gap cup shape base buy point stock be still buy range early trading early gainer ibd include healthequity hqy eagle material exp gain pra health science prah morgan stanley ms add related clinton vs trump ibd tipp presidential election tracking pollafter initial fall stock rally trump victory agenda
131,MYL,stock open lower wednesday commodity currency market react tuesday come victory donald trump race presidency dow industrial rise nasdaq nasdaq future have fall overnight dow future sank more point lowsdrugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer pfe leap mylan myl merck mrk rise eli lilly lly add more early trade hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid lower universal health service uhs drop nearly coal mining stock moved generally higher arch coal arch soar consol energy cnx alliance holding ahgp show gain cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc vault martin marietta mlm martin marietta top buy point cup base vulcan also break clear buy point earning news tripadvisor trip swoon report third quarter earning narrowly top view revenue gain stop far short analyst expectation fragrance maker coty coty plunge miss analyst fiscal first quarter revenue earning target wide margin gopro gpro tank handful analyst downgrade stock news recall karma drone due battery failure issue ibd list eagle material exp pop gain stock top buy point cup base ibd stock royal gold rgld rumble gold price surge early wednesday gold miner be climb right side possible base pattern find support week move average ibd stock arista network anet fall inphi iphi fall fractionally momo momo rise more international market trade lower election news tokyo stock be hardest hit drop worst single day loss britain june brexit vote exporter market be session biggest loser lead toyota motor tm honda motor hmc nissan motor nsany china hong kong hang seng index shed shanghai composite decline europe cac paris frankfurt dax trim deep early loss turn fractionally higher afternoon trade london ftse rally climb commodity be widely mixed early action oil price hold mostly steady west texas intermediate fraction hold just barrel metal moved broadly higher gold jump almost ounce silver copper be also strongly dollar bounce back initial dive trading moderately lower vs euro pound yen surge bond be sharply lower year yield basis point stock market today show light economic calendar september wholesale inventory datum expect commerce department et energy information administration report weekly oil stockpile number et minneapoli federal reserve bank chairman neel kashkari be due speak et related time warner stock fall trump victorydrug stock rally relief clinton didn white house
132,MYL,incyte incy unveil positive result friday year study chemotherapy drug jakafi recoup thursday loss news break department justice investigation drugmaker suspect price gouge incyte wasn implicate investigation share fall thursday ibd company medical biom biotech industry group lose ibd company medical generic drug industry group topple teva pharmaceutical teva mylan myl fall respectively incyte curb loss friday stock market today incyte stock rise earlier rise much biotechs generic drug group rise more more respectively incyte most recent study pooled datum year phase study jakafi median overall survival os start jakafi be month patient crossed placebo be best available therapy bat time see median os month correct patient cross jakafi control group see median os month ibd take inctye stock be buy point achieve consolidation area decline trigger sell rule use ibd stock list keep eye stock buy zone thus result further support survival benefit jakafi treatment myelofibrosis mf suggest earlier initiation treatment jakafi provide greater survival advantage patient mf rbc analyst simo simeonidis write research report simeonidis reiterate outperform rating inctye stock incyte present full result jakafi abstract dec american society hematology annual meeting incyte positive jakafi datum follow strong earning report early tuesday sale grow year year cent earning share item swung cent loss year earlier quarter metric top consensus analyst poll thomson reuter cent loss incyte beat follow rival novartis nvs sale miss last week prompt stock drop follow day related align incyte grubhub best stock play goldmanincyte stoke fire deep durable melanoma drug resultsbiomarin incyte kite get thumb goldman sachs upgrade
133,MYL,biotechs drugmaker rally friday follow big drop thursday news department justice be investigate dozen company suspect price collusion include industry leader teva pharmaceutical teva mylan myl plunge thursday month low ibd company medical generic drug industry group rise stock market today group be second best performer group ibd company medical biom biotech industry group meanwhile rise be third best performer price collusion be new challenge industry already wrack controversy spiraling price illegal company agree set price coordinate discount september mylan ceo heather bresch be grilled congressional committee sixfold price increase epipen last year former turing pharmaceutical ceo martin shkreli draw national ire raise price aids medication factor prosecutor file first charge year end accord anonymous source cite bloomberg biotech drug stock plunge thursday follow report year investigation span more dozen company include teva mylan lannett lci impax laboratory ipxl covis pharma sun pharmaceutical mayne pharma taro pharmaceutical taro endo international endp subsidiary par pharmaceutical teva actavis unit acquire allergan august also have be implicate ibd take spdr biotech etf get nice boost friday rise buyback follow slump thursday other etfs wobble election season aim dynamic close next week etfs be proxy broad market see winning ibd etfs fund page several company have acknowledge doj investigation security exchange commission filing allergan agn receive doj subpoena request information generic business liability have be transfer teva acquire allergan generic business actavis august teva twice disclose subpoena doj connecticut attorney general allergan decline comment previous disclosure liability transfer teva spokeswoman denise bradley tell ibd teva be not aware fact give rise exposure company respect subpoena mylan have already disclose subpoena regard antibiotic doxycycline be subpoena information regard pricing tactic digoxin blood pressure drug mylan mayne par actavis sun lannett make digoxin covis make lanoxin brand version mylan be have always be commit cooperate antitrust division investigation spokeswoman lauren kashtan tell ibd email date know evidence mylan participate price fix sun pharma decline comment say continue cooperate doj lannett impax covis mayne taro endo didn immediately return request comment credit suisse analyst vamil divan didn immediately see news create long term damage outside term overhang stock allergan stock lose thursday teva fall allergan stock rise friday teva rise mylan drag allergan be inappropriate consider actavis sale write research report teva case sharper deluge be likely overreaction say acknowledge investigation likely be overhang teva generic space have more clarity outcome understand potential financial criminal penalty be impose divan write related generic drug maker crash report doj plan collusion chargeseagle pharma teva pharma diverge surprise leukemia drug winteva pharma have generic trick ahead valuation treat mylan jump doj settlement remove linger concern ariad follow gilead mylan route drug price battle
134,MYL,teva pharmaceutical teva mylan myl endo pharmaceutical endp lannett lci other generic drug maker tumble thursday afternoon bloomberg report justice department be investigate possible price collusion charge likely year end doj be probe more dozen generic drug maker collude pricing accord bloomberg mylan issue follow statement mylan be have always be commit cooperate antitrust division investigation date know evidence mylan participate price fix teva pharmaceutical have disclose subpoena be cooperate bloomberg add lannett also have receive subpoena wall street journal say antitrust probe be year old cover dozen drug bloomberg say cite source grand jury be examine executive agree raise price teva share plunge stock market today fall lowest level november mylan lose lannett crash endo pharmaceutical akorn akrx taro pharmaceutical taro fall doj collusion probe news be latest sign drug industry face increase regulatory political pressure price hillary clinton have vow crack drug price former democratic rival bernie sander have hit specific drug stock negative tweet latest report hit more just drugmaker cvs health cvs drug store giant pharmacy benefit manager lose pure play pbm express script esrx sank drug distributor abc mckesson mck cardinal health cah fall nearly follow huge loss oct mckesson miss warn cite competitive pressure price mckesson lose nearly day cardinal nearly diplomat pharmacy dplo crash huge miss late wednesday price concession lower demand hepatitis drug
135,MYL,mylan myl take big heat high price potentially lifesave epipen injector late friday announce have agree settlement department justice classification epipen medicaid drug rebate program mylan stock shot hour trading friday news company also lower earning guidance year controversy have hurt stock close friday year low mylan chief executive heather bresch be shred house committee oversight government reform hearing price epipen treat dangerous allergic reaction have rise sixfold more pack self administer product mylan become latest poster child huge ongoing issue high price certain drug soon criticism mount presidential candidate hillary clinton critic mylan announce introduce generic version half price bresch tell panel mylan profit injector come subsequent wall street journal investigation find profit be roughly double exclude taxe hearing panel criticize most everything mylan include ceo pay bresch total compensation come last year hearing say compensation be somewhere middle peer very pro business be sicken rep john duncan tenn say hearing greed be astounding sickening friday announcement mylan say term settlement do not provide find wrongdoing part mylan release say question underlie matter be epipen auto injector be properly classify center medicaid medicare service cms innovator drug applicable definition medicaid rebate statute subject formula be used calculate rebate medicaid such drug epipen auto injector have be classify cms innovator drug mylan acquire product base long standing written guidance federal government addition mylan say now expect adjust earning share year earlier guidance company say lower guidance most result previously announce change epipen auto injector access program upcoming launch generic epipen auto injector
136,MYL,mylan myl half price version epipen allergy shot not be available end year drugmaker say email potentially month timeline company give august authorize generic version epipen be available end year mylan spokeswoman nina devlin say email monday week statement aug company say expect introduce generic version several week mylan generic version cost pack half brand version price expect launch year once have assured sufficient inventory be available meet anticipate order create necessary packaging product create necessary labele product devlin say be diligently work complete effort order provide generic soon possible mylan have attract wrath congress increase list price epipen more fold more package quell grow furor epipen price announce cheaper authorize generic version devlin decline be more specific generic version be available drugmaker don need advance approval food drug administration bring authorize generic product market say theresa eisenman fda spokeswoman do however have notify agency annual report pfizer pfe manufacturer brand version epipen mylan have not announce manufacturing issue delay production authorize generic last month hearing house committee oversight government reform mylan chief executive heather bresch face skeptical lawmaker grilled drugmaker profit executive pay hearing say mylan make profit pair epipen letter demand more detailed information mylan lawmaker say figure include tax assumption have underrepresent mylan profit monday close mylan share be aug last day trading lawmaker begin question drugmaker epipen pricing stock dip close tuesday
137,MYL,pfizer pfe doesn expect donald trump election republican congress ease drug pricing debate firm be optimistic potential tax reform credit suisse analyst vamil divan say friday biotech drug stock have rally follow trump election assume ll be less likely tackle pricing reform hillary clinton ibd generic drug group be biotechs group be election pfizer isn ready change view postelection pricing divan say debate drug pricing not go away not get easier write research report pfizer have not change assumption pricing election ibd take drug biotechs aren only sector prime success failure election result check ibd industry snapshot figure stock rocket tank trump drug pricing have be hot topic several year september former turing pharmaceutical ceo martin shkreli draw national criticism hike price pill decade old hiv drug september mylan myl ceo heather bresch defend congressional committee company sixfold increase pricing epipen pack epipen now cost north pfizer be optimistic potential tax reform trump administration propose incentive cash repatriation be time fix key be move territorial system divan write follow meeting pfizer politic aside pfizer still have number catalyst upcoming year year end stock rocket phase datum vaccine combat diarrhea bacterium clostridium diff europe approval xeljanz inflammatory cancer drug belong class call jak inhibitor analyst say divan expect pfizer do well food drug administration approval crisaborole eczema drug be development anacor pharmaceutical pfizer acquire firm june pfizer also have combination datum darmstadt germany base merck kgaa due avelumab inlyta multiple type cancer divan edge earning share ex item expectation pfizer now see pfizer pull earlier model reiterate view stock market today pfizer stock dip share have be day downtrend still be nearly election editor note correct third last graph properly identify company merck kgaa be unaffiliated base merck related gilead scoop incyte cancer drug prove not good enough pfizer spike report mull consumer care sale
138,MYL,ariad pharmaceutical aria stock be feel mylan pharmaceutical myl pressure monday congress loom deadline submit information regard price increase rare cancer drug past year ariad up price inclusig annually rbc analyst michael yee write research report inclusig treat specific class chronic myeloid leukemia acute lymphoblastic leukemia ariad sell milligram mg bottle lion share patient be mg dose yee write latter have buy mg bottle thus pay double price yee doesn see much stem congress pressure recently mylan agree make generic less costly version epipen device treat anaphylaxis emergency allergic reaction hike device cost ibd take biotech earning season be full swing merck eli lilly vertex edward lifescience slate tuesday ibd recently look biotech giant top expectation medivation mdvn be be acquire pfizer pfe feel congressional heat earlier year price tag prostate cancer drug later get letter sen bernie sander gilead science gild come hot water earlier year hike price drug congressional request information didn result much yee write reasonably likely congressional inquiry blow time yee say ariad have nov deliver information price hike include spending sale distribution tactic ariad have argue inclusig isn mylan epipen other ariad have year history financial loss unprofitability far higher spend revenue historical spending internally develop commercialize inclusig yee write orphan drug tend be more costly standpoint yee keep sector perform rating ariad stock jpmorgan downgrade share neutral underweight close bell stock market today ariad fall nearly month low ariad be so far month
139,MYL,mylan myl stock jump monday investor digest drugmaker announcement late friday have reach settlement department justice classification epipen medicaid drug rebate program doj settlement remove significant overhang have be weigh stock rbc capital market analyst randall stanicky write mostly upbeat research note monday maintain sector perform rating price target mylan stock mylan stock rise stock market today earlier rise first time friday regular session mylan stock hit year low be less mylan ebit earning interest taxe stanicky point agreement remove linger concern larger cash call ongoing negative headline here represent important step move forward write government have say epipen potentially lifesave injector treat dangerous allergic reaction have be classify innovator drug accord rule set center medicare medicaid service thus say stanicky subject higher rebate formula vs agreement win end heat mylan continue face lawmaker patient patient family fold increase epipen price pack react heat mylan recently announce generic version roughly half price augustexpand eligibility patient assistance program issue high drug price isn go away mylan late friday also lower guidance year stanicky lower own estimate result also note expect competition teva pharmaceutical teva generic rival product say further impact see sustainable growth myl lower peer anticipate due erosion epipen have be important driver stanicky say ibd take look medical industry winning stock great place check be ibd leaderboard only top stock make list be never very many current leaderboard stock however include abiom edward lifescience related mylan announce epipen settlementmylan expand epipen discount program
140,MYL,mylan myl be criticize profit make high pay executive drugmaker repeatedly raise price epipen allergy shot house representative hearing wednesday company business practice house committee oversight government reform chairman jason chaffetz utah republican say find mylan argument make only profit pen little hard believe re here tell make profit chaffetz say open remark tell middleman make more do here doesn add lot person believe person believe profit profit motivation have executive year earn compensation mylan chief executive heather bresch appear committee latest congressional hearing focuse high drug price company become target outraged lawmaker consumer raise price epipen self administer injection used treat dangerous allergic reaction sixfold mylan share be close wednesday share have be consolidate december hearing panel top democrat rep elijah cumming demand bresch apologize even predict nothing change hearing call legislation today hold yet hearing industry take punch then go right ahead keep raise price cumming say prepared statement fly back mansion private jet laugh way bank constituent suffer file bankruptcy watch child get sicker case die bresch be daughter democratic senator joe manchin west virginia try make case lawmaker congress recognize mylan have increase access drug say prepared testimony mylan only take home rebate fee discount pack shot look back wish have better anticipate magnitude acceleration rise financial issue grow minority patient have pay full list price more say prepared testimony never intend company be run canonsburg pa be officially register netherlands so call tax inversion be face multiple inquiry lawmaker law enforcement probe include state attorney general investigate possible medicaid fraud well legislative committee demand internal document company epipen price cumming didn offer specific legislative proposal statement democratic presidential candidate hillary clinton have call group review sudden unjustified price increase especially older drug mylan buy right sell market epipen germany base merck kgaa then have raise price product more pack have subsequently say introduce lower price authorize generic mylan raise price epipen also help push policy have school stock shot be now dominant epinephrine auto injector addition have lead campaign raise awareness dangerous allergic reaction get parent child carry epipen rapid use cumming say document mylan handed committee show drugmaker spend advertising marketing last year
141,MYL,street tweak target gopro gpro apple aapl chip supplier skywork solution swks qorvo qrvo couple analyst change mind teva pharmaceutical teva system ddd follow third quarter report featured expect loss revenue jpmorgan cut price target wedbush reduce price goal action camera maker also offer earning sale guidance important holiday quarter also come well view cite production issue share fall low intraday close stock market today craig hallum up price target skywork cowen give bump cowen rate skywork buy qorvo market perform trim latter price target skywork top view late thursday offer outlook also beat meanwhile fellow apple chip supplier qorvo turn mixed result guidance fall short street expectation share skywork close qorvo tumble generic drugmaker stock get pummeled thursday trade bloomberg report federal probe possible price collusion teva mylan myl endo pharmaceutical endp other nose dive hsbc downgrade teva hold friday share rise friday sink thursday gabelli co upgrade printer maker buy company report first quarter year year revenue gain straight quarters decline figure still come forecast share rise initially reversed hard close related generic drug maker crash report doj plan collusion chargesgopro qorvo monster miss skywork sand twilio cbs top system stratasys show sign turnaround printer market
142,MYL,twilio twlo monday post worst loss ipo cloud communication platform firm disclose plan sell share follow offer late friday twilio fall stock market today undercut day line first time twilio come public share late june surge friday close twilio peaked twilio disclose plan sec filing twilio sell stock exist shareholder sell undisclosed amount twilio move come acacia communication acia tumble friday close day move average first time fiber optic gear maker come public acacia price stock offer most proceed go exist holder acacia have tumble announce stock offer plan acacia fall monday also fall day line other monday action mylan myl jump announce settlement justice department epipen pricing late friday related acacia lose key support stock offer price mylan announce epipen settlement doj pay
143,MYL,facebook fb alibaba baba report strong earning stock sell drug stock suffer several blow major average fall earning tumble oil price new uncertainty surround presidential election fall week close just day line benchmark index have fall straight session longest such streak year nasdaq fall worst weekly loss month facebook fb be many lead stock tumble earning report outlook apple aapl alphabet googl also undercut buy point plunge oil price sank energy stock facebook cruised past third quarter earning estimate share fall sharply social networking giant say growth rate slow facebook report earning share item beating consensus cent year year revenue rise beating consensus facebook say pace ad place decelerate revenue growth also expect be aggressive year capital spending facebook fall week crash day line multiple buy point related facebook dife forecast meaningfully slower ad revenue growthalibaba baba report better expect fiscal earning sale fuel growth core commerce business boom cloud compute service earning rise cent share revenue rise revenue alibaba core commerce market rise alibaba cloud compute revenue soar alibaba end quarter mobile monthly active user year year alibaba be prepare nov single day world biggest day online shopping alibaba share fall week crude future tumble barrel worst weekly decline january lose prior week crude stockpile jump barrel week end oct largest ever increase base datum do back energy information administration say meanwhile opec major oil producer couldn agree production curb raise doubt ll reach deal shale bellwether continental resource clr report result short wall street view plan increase completion year carrizo oil gas crzo report surprise rise profit apache apa post loss wasn bad analyst fear bp bp lower capital expenditure outlook be cautious royal dutch shell rdsa downgrade spending outlook next year general electric ge baker hughe bhi say combine oil gas operation analyst expect deal pass regulator add job last month slightly less expect august september payroll be revise average hourly wage rise vs year earlier best gain meanwhile october ism manufacturing index rise slightly signale modestly faster factory growth ism service sector gauge fall more expect indicate slower rate expansion federal reserve hold rate steady expect say case rate hike have continue strengthen odd rate hike december be high have come bit donald trump poll number rebound financial market stumble video game publisher electronic art ea take interactive software get lift september quarter earning report activision blizzard atvi sank activision beat estimate sale earning guidance holiday quarter be lighter expect december quarter activision forecast gaap earning share cent sale wall street be modele cent activision friday release many analyst expect be top selling game year call duty infinite warfare latest company lucrative call duty franchise meanwhile ea take top expectation september quarter raise guidance merger acquisition have overshadowed earning report several major chipmaker mobile chip maker qualcomm qcom plan buy nxp wednesday say fiscal earning share exclude item rise sale rise analyst expect ep sale thursday share chipmaker microsemi mscc soar report fellow mixed signal chip expert skywork solution swks have approach potential acquisition skywork late thursday deliver lower earning sale top view separately chipmaker broadcom avgo agree buy brocade communication system brcd cash net debt broadcom plan retain brocade fibre channel storage area network san switch business centurylink ctl agree buy level communication lvlt cash stock combine company be stronger rival verizon vz market business service broomfield colo base level operate world largest internet backbone centurylink be nation third largest local phone company verizon centurylink plunge week rise prior week deal buzz level initially rally reversed nearly week soar prior week related centurylink buy level cash stockoptical component maker oclaro oclr inphi iphi apply optoelectronic aaoi report earning top expectation oclaro ep rise iphi report ep jump say acquire clariphy communication cash apply optoelectronic ep fall however neophotonic nptn miss top bottom line telecom fiber optic group have be volatile mixed guidance lumentum holding lite disappointing revenue infinera infn prior week once white hot ipo acacia communication acia report nov oclaro inphi rise nearly week apply opto neophotonic crash related apply optoelectronic earning beat neophotonic missesgeneral motor gm fiat chrysler fcau ford motor toyota tm other major automaker report lower sale october vs very tough comparison year earlier industrywide sale fall vs year earlier be best estimate ford release figure day rival due monday fire knock power datum system dearborn mich headquarters teva pharmaceutical teva mylan myl lannett lci tumble thursday report justice department have be probe more generic drugmaker possible price collusion charge likely year end report also appear hit drug distributor pharmacy benefit manager meanwhile pfizer pfe miss earning estimate cut full year ep target end work cholesterol drug allergan miss ep revenue target related generic drug maker crash report doj plan collusion chargespfizer end cholesterol drug development lower ep guidancepapa john pzza top third quarter forecast follow strong earning domino pizza dpz pizza chain attempt draw more consumer digital order platform similarly starbucks sbux say mobile payment have drive more transaction volume coffee chain beat fiscal fourth quarter estimate issue profit guidance miss view papa john rise nearly week close friday right day line starbucks rise friday hit month low thursday match group mtch operate date site match com tinder top ep estimate miss revenue match share fall nearly week cloud base human payroll human capital software firm paycom payc top view guide light rival paylocity pcty top fiscal result stock fall week hulu strike content deal st century fox foxa walt disney hulu part owner live online tv stream service gannett gci drop bid tronc trnc time warner twx fox top view meanwhile wall street journal be shrink staff consolidate print coverage nov thomson reuter tri be cut position
144,MYL,presidential campaign mercifully come end let briefly look back large publicly trade company candidate have trash democrat hillary clinton denounce well fargo wfc fake account scandal accuse valeant pharmaceutical vrx mylan myl price gouge upbraided auto part maker johnson control jci tax inversion merger republican
145,MYL,stock open higher monday session bank bond market remain close columbus day holiday rise dow jone industrial average just retake day move average have act resistance level index nasdaq already day line climb bank bond market be back action tuesday third quarter report season kick gear early report due alcoa aa fastenal fast bank ozark ozrk big drugmaker be key mover early action stock market today merck mrk climb more report positive result trial keytruda treat patient metastatic small cell lung cancer netherlands base drugmaker mylan myl surge early trade company announce late friday have agree settlement department justice epipen product be classify medicaid drug rebate program management also lower company full year earning guidance tesaro tsro biotech base waltham mass bolt report positive result ovarian cancer treatment know niraparib bristol myer squibb bmy crash company report result number clinical trial include disappointing result cancer drug opdivo tesla motor tsla climb sunday tweet chief executive elon musk contradict friday regulatory filing say company raise additional capital equity debt offering musk say neither be necessary company introduce new product next week tesla share have be downtrend struggle hold support april ibd stock trade narrow range fashion acacia communication acia edge stock be pull back high end friday test support day move average gigamon gimo rise networking gear market pull back last week week rally end well week line twitter twtr fall nearly bloomberg report salesforce com crm meet rise shareholder pressure acquire micro blog site interest walt disney alphabet googl google have cool oil trade more lift west texas intermediate back barrel gold add almost trade ounce dollar gain euro yen europe stock build early gain afternoon trade london ftse be frankfurt dax rise cac paris add shanghai composite jump exchange re open holiday exchange tokyo hong kong be close monday day holiday chicago federal reserve bank president charle evan speak et
146,MYL,stock rise early gain monday oil price surge dow re-cover key support level dow jone industrial average nasdaq rally add dow regain day move average line nasdaq be near time high volume be tracking lighter nyse nasdaq vs same time friday energy steel automaker lead upside stock market today oil stock get boost more rise west texas intermediate crude price barrel hope output deal top producer meet istanbul retailer ethical drugmaker be few underperform group bristol myer squibb bmy sank heavy trade year low positive clinical trial datum merck rival lung cancer drug merck mrk leap lead dow clear flat base buy point healthy trade announce positive result study keytruda treat patient metastatic nonsmall cell lung cancer mylan myl gap rise robust volume drugmaker friday reach settlement justice department charge medicaid epipen allergy medication share netherlands base company be still respective day day move average line ibd momo momo jump fast turnover track new close high chinese social network provider stock be far extend buy point be december offer price also callon petroleum cpe surge new high heavy volume related oil top hope output deal saudis hint
147,MYL,oct court ruling be just latest boost give coal producer long slow battle regulator economic change district court judge rule environmental protection agency have fail assess effect coal mining job cause agency tighten power plant emission restriction issue clean air
148,MYL,push come shove mylan myl couldn find friend republican even say wish defend drugmaker congressional hearing washington wednesday gop lawmaker describe free market pro business say drugmaker aggressive pricing epipen allergy shot cost go sixfold mylan acquire have go too far describe upset price increase well chief executive heather bresch award pay be very pro business republican yet be really sicken ve hear situation rep john duncan tenn say house committee oversight government reform session nobody really earn deserve much money say company have become latest lawmaker sight party have make drug price focus oversight effort most discussion regulate industry pricing practice have be lead democrat include presidential candidate hillary clinton have proposal monitor push back increase drugmaker certainly isn only business republican have recently take task earlier week well fargo co wfc be call fraud completely touch sen pat toomey pa bank employee open account customer permission mylan hearing rep mick mulvaney gesture colleague say many have little idea business corporate world work then turn bresch describe company lobbying effort behalf law encourage require school keep device epipen hand shot now cost pack vast majority state now require encourage school stock epinephrine device come ask government get business so here be today mulvaney say want come washington want come state capital lobby make buy stuff be get get level scrutiny level treatment ordinarily curl hair ask bresch defend drugmaker say price increase have help fund better patient access actually collect less half list price wish have better anticipate magnitude acceleration rise financial issue grow minority patient end pay full list price say bresch be daughter sen joe manchin wva mulvaney be founding member house freedom caucus group house republican often break speaker paul ryan committee member blake farenthold texas republican be member congress republican study committee conservative policy group take bresch task well think have behaved very badly invite government regulation farenthold lecture ceo be very much free market whole drug pricing system have right now make sense free market operate system person be consumer don understand rep jason chaffetz utah chair committee say couldn sympathize mylan be charge hundred dollar medicine epipen cost try dive depth individual drug pricing be not something set initially do chaffetz say start hearing bresch defend company say be surprised outrage chaffetz ask never anticipate raise price do think be go happen mylan be run canonsburg pa be officially register netherlands so call tax inversion share have drop week lawmaker start raise question epipen share be early trading
149,MYL,election year have add pressure hit biotechnology stock hard look hood sibling biotech etfs be reveal show more speculative company extremely heterogeneous industry cause much hurt bioshare biotechnology product bbp be year date oct invest establish company have bring least drug market stock holding exchange trade fund include biogen biib amgen amgn celgene celg gilead science gild regeneron regn ibd take largest cap weight biotech etfs stand benefit most top company climb wall worry have build industry bioshare biotechnology clinical trial bbc be so far invest young smaller company drug be experimental testing stage portfolio include sarepta therapeutic srpt share rocket september fda approve drug treat duchenne muscular dystrophy approval mean sarepta move bbp portfolio bioshare etfs next rebalance december etf pair allow investor decide much mix term combine more risky less risky biotechs say paul yook founder bioshare bbp focus household name make relatively less volatile fund contrast bbc hold riskiest biotechs highflying company share double triple overnight crash burn just well yook describe bbp bbc only exchange trade fund separate clinical trial company product company distinct stand alone investment investor don seem much enamored idea custom tailor risk fund be extremely small thinly trade nearly year debut have however see combine net inflow first quarters bbp fund be best performer biotech etfs so far year bbc worst meanwhile bellwether ishare nasdaq biotechnology ibb have give year date sit december high biotechnology etfs crumble past year come pressure lackluster earning well negative scrutiny health care peer valeant pharmaceutical vrx mylan myl politically charge season wall worry industry group least analyst have favorable outlook biotechs nov presidential election yook point promising sign pickup mouthwater sticker price target company allergan agn announce september acquire vitae pharmaceutical vtae roughly premium share biotechs be attractively price too be rare corner stock market valuation be cheaper have be historically yook tell ibd phone interview many etf investor be wait buy biotechnology stock november election believe fear hillary clinton presidency be price democratic presidential contender remark drug price gouge have trigger sharp biotech decline yook add most political scrutiny be face specialty pharmaceutical company such valeant mylan horizon hznp bioshare fund avoid related top biotechs climb wall worry rbc call rally
150,MYL,banking other financial stock lead broad market sell thursday nasdaq fall dow jone industrial average be index trade poorly head close be mid afternoon lows small cap suffer more russell shaving volume be run sharply higher board loss be broad only energy sector still show gain today trading lose stock lead winner significantly financial be roil bloomberg report number fund clear derivative trade deutsche bank db take excess cash position accord internal document see news agency addition be concern recent justice department request settle investigation german bank mortgage backed security spdr financial xlf exchange trade fund slide well fargo wfc etf largest holding be lowest level february bank continue be grilled fabricate customer account scandal share well fargo drop financial stock hold well be ellie mae elli share rise provider software mortgage application industry hold most gain rise past buy point volume have fade average not powerful medical stock also be weaker unusually heavy volume mylan myl have be hound steep price epipen allergy treatment lose more fall intraday lowest level nearly year nephew snn british maker wound care orthopaedic other medical product fall very heavy trade be stock highest relative volume stock move be news company related concern mount deutsche bank hedge fund withdraw cashdeutsche bank be lehman big bank stock break supportpepsico earning top north america sale
151,MYL,stock advanced moderately late morning trade monday volume picked nasdaq add rise blue chip dow jone industrial average be ahead volume be run higher stock market today early volume figure often change epipen maker mylan myl initially rise reversed trade modestly lower netherlands base company have attract bad publicity price increase have boost pack epipen device list price monday company announce offer generic version allergic treatment product half current price flap have bring negative publicity mylan more awareness epipen cheaper rival adrenaclick example offer less expensive product doctor have point syringe bottle patent epinephrine be buy epipen patent be related delivery device meanwhile blue chip stock be mostly higher dow financial stock jpmorgan chase jpm goldman sachs gs rise talk interest rate hike have be lift bank stock citizen financial cfg advanced fast trade monday add friday gain volume be routine friday heavy early trade monday bancorp usb super regional gain brisk trade ibd list top stock fundamental technical lgi home lgih rolled higher fresh high dave buster entertainment play gain
152,MYL,share generic drugmaker perrigo prgo have fall half past year jump monday activist hedge fund investor starboard value announce have take ownership stake be ask change company believe perrigo be deeply undervalue significant opportunity exist create value benefit shareholder base action be control management board starboard write letter address perrigo ceo john hendrickson believe change be need reverse trajectory poor operate financial performance reposition perrigo future success believe significant opportunity exist improve performance perrigo core business perrigo share rise stock market today have be downtrend go back more year ibd take generic drug sector have be ibd medical biom biotech industry group rank solid group recent coverage offer advice look earning report spot sale volume growth vs price hike growth identify biotechs keep eye month perrigo elevated hendrickson president ceo april company former ceo joseph papa resign take top job valeant pharmaceutical vrx generic drugmaker have be pressure continue price competition ibd company medical generic drug group have fall more year teva pharmaceutical teva friday give update product include competitor mylan myl epipen say be market late next year huge overall issue high drug price sprang again last month lawmaker democratic presidential candidate hillary clinton sharply criticize cost emergency allergy treatment research note late sunday rbc capital market analyst randall stanicky be unimpressed teva update outlook sector overall teva update write research note do not think be enough assuage pre exist investor concern overall generic outlook drive street number higher continue see teva best position generic sector visibility be still challenge november perrigo shareholder recommend perrigo management turn propose buyout mylan value share letter monday starboard sharply criticize move perrigo management unfortunately time result have go decidedly wrong direction management promise have be woefully unfulfilled starboard write specifically company have severely mismanage omega pharma invest omega now perrigo brand consumer healthcare business integration commit numerous execution error significantly lower financial guidance past earning call perrigo form brand consumer health care business bch acquire omega pharma last year perrigo have say bch have be perform weaker expect lower expectation new product launch related mylan make own generic own epipenis epipen price fda fault hold competition
153,MYL,allergan agn acquire gene therapy eye disease tuesday ceo separately criticize predatory drug pricing pledge limit company price increase allergan agree pay upfront acquire retrosense therapeutic unspecified future milestone payment tie success rst gene therapy eye disease retinitis pigmentosa spark therapeutic once have gene therapy same disease late stage development platform take different approach note evercore isi analyst umer raffat spark gene therapy be only aim specific defect however retinitis pigmentosa be cause very heterogeneous set mutation encompass gene raffat write email client simple word allergan approach theory address heterogeneous disease irrespective mutation cause ibd take spark therapeutic stock have be hover buy point breaking cup handle base early last month learn more basis see ibd buy stock allergan stock rise stock market today still more year spark stock fall more year also tuesday allergan ceo brent saunder write blog post drug pricing lately have be tremendous focus cost medicine have be very appropriately target outlier have take dramatic price increase write naming name doubt refer political outcry mylan myl epipen last couple week saunder go detail see social contract drugmaker public say such price increase violate other thing make specific promise regard allergan price increase increase price brand therapeutic medicine take price increase more once year do be limit single digit percentage increase expectation be overall cost drug net rebate discount not increase more low mid single digit percentage year slightly current annual rate inflation saunder also say allergan stop increase price be corresponding increase cost practice often take drug near patent expiration practice allergan have take past admit related allergan carve middle path spending open science be epipen price fda fault
154,MYL,spending health care service surge greater expect year second quarter accord census bureau datum release thursday acceleration spending growth be worry sign period moderate growth follow obamacare fuel rise medicaid individual market coverage expansion obvious concern be latest surge isn tie more person get coverage faster person cost growth altarum institute track health spending have expect year year rise spending health service equal year year growth first quarter consistent gradually moderate trend surprising re acceleration spending sustain create more headach health care sector have already feel rise political heat due drug pricing spiraling premium obamacare exchange coverage democrat be push government insurance option compete private insurer unitedhealth unh aetna aet humana hum have pull back group insurance market higher spending growth also step pace obamacare create independent payment advisory board have propose cost cut restrain medicare growth meanwhile presidential candidate have talk let medicare negotiate drug price hillary clinton have be quick capitalize drug pricing controversy lead criticism mylan myl epipen price hike political risk hard predict election year have help make health care worst perform major sector year just gain investment strategist ed yardeni yardeni research note earlier week sector have be haunt controversy egregious drug pricing insurer pull obamacare disappointing news new drug front write ibd take overall health care have lag other stock sector year have be plenty health related winner include intuitive surgical veeva system healthequity ibd help investor identify best stock stage ibd write best investment candidate feature such new america include list such ibd sector leader ibd also even help find best buy point rule selling spending health care service report census quarterly service survey easily eclipse year year growth report recession exception first quarter see growth health service spending reflect obamacare enrollment gain partly due healthcare gov technology glitch didn noticeably begin push health expense second half service report doesn detail prescription drug spending health insurance spending hospital revenue jump year even number inpatient day dip meanwhile hospital expense labor supply overhead rise more moderate signale increase profitability case improvement be due tax exempt sector profit hospital such run tenet healthcare thc hca holding hca actually see expense growth outpace revenue growth yet profit hospital still have higher profit margin tax exempt sector spending ambulatory care service jump year category outpatient care center spending rise home health care service medical diagnostic lab show relatively slow growth spending nursing residential care facility rise overall spending health care service account total growth service spending make straight quarters health care have account least fourth total growth year year service spending twice big share growth see recently second quarter
155,MYL,sudden outbreak political debate mylan epipen late august lead grand circle finger point member congress presidential candidate hillary clinton blame mylan myl greed price increase best selling anaphylactic shock treatment treatment severe allergic reaction mylan ceo heather bresch say various middleman insurer distributor pharmacy benefit manager be take so much epipen list price company have set high make money turn lead protest pbms chief lobbying group pharmaceutical care management association pcma blame payer massive price hike be red herring doesn pass laugh test policymaker pcma say aug statement ibd take drug have proven be tough investment year due controversy surround larger medical field be still haven investor seek stability medical related stock account ibd big cap list high rate large cap organization fall short blame government do recommend fda speed approval process patent drug product such epipen have competition such drug have spark several price controversy last month turing pharmaceutical daraprim valeant pharmaceutical vrx nitropress isuprel be subject triple quadruple digit percentage hike be acquire company get away have competitor mylan eventually bow pressure announce generic version epipen half price meantime potential epipen competitor have run series problem fda so be agency blame just be simple answer expert say bigger picture fact tend be ignore generic drug price overall have be pressure year main reason be number new drug come market have accelerate only unusual circumstance have enabled drug epipen have rival owner thus have free hand pricing fda approval overall have be speeding new drug be file today have notably greater success rate do decade generic drug approval have lag however way generic drug process be new drug approval be year mylan keep epipen price prop competitor keep hit snag drug contain epinephrine be easy enough come pen deliver precise dose have be tricky replicate impax laboratory ipxl have compete product available call adrenaclick study have show take more competitor really drive drug price generic fact be price war usually start adrenaclick retail vary somewhat location sanofi sny have competitor call auvi be recall october device malfunctioned teva pharmaceutical teva have device fail first attempt fda approval company expect refile soon not purely case here fda not approve thing quickly say craig garthwaite co director health enterprise management program northwestern university kellogg school management be neither pro mylan think epipen do way quite amazing way quite simple give consistent dose time person training lifesave drug be used many different situation drug daraprim nitropress isuprel other hand don require fancy equipment give niche say garthwaite be market be tiny only few dose deliver year here expense development become prohibitive general rule smaller market be more regulation be person enter harder go be get multiple entrant say epipen do not have problem market be big get drug approve have become more expensive due generic drug user fee amendment gdufa attach food drug administration safety innovation act gdufa be modeled prescription drug user fee act pdufa be pass due aids activist protest new drug approval take too long law drug company paid fee filing drug approval fda used fee invest thing hire review staff help agency meet performance benchmark improve review process later addition grant propose drug fast track breakthrough therapy designation also give fda way hasten review certain drug time help streamline process new drug approval also improve success rate number new drug approve year jump make first attempt last year vs decade earlier lesson pdufa experience however be change big bureaucracy be slow take decade law bear significant fruit meanwhile fda still face problem induced gdufa begin huge backlog generic drug filing know abbreviated new drug application anda part challenge be anda submission keep outpace approval base activity april year be look likely again write rbc capital market analyst randall stanicky research report assume be more anda submission be clearly not go happen even fda double monthly approval output anda still take year work current backlog nonetheless new approval have be tick anda be approve last year vs year be enough be feel big generic drugmaker year endo international endp teva mylan have miss wall street estimate generic side business blame price erosion due increase competition still clear backlog wouldn solve problem small market generic drug gdufa fee other expense make enter field more expensive worth northwestern garthwaite favor not so much loosen regulation go such special case import drug other country approval system trust european union already be do drug shortage be also clinton proposal new plan release friday deal issue plan didn directly deal drug approval process do promise fully fund fda office generic drug clear multus year generic drug approval backlog drug approval pricing remain big issue more discussion come soon same time member congress be ask mylan document possible hearing member house committee energy commerce have ask fda explain problem mylan competitor agency have answer related biotech stock make big move september
156,MYL,embattled drug giant mylan myl say monday take unusual step launch generic competitor own product epipen half price original mylan spend last week defend criticism senate presidential candidate hillary clinton multiple price hike epipen emergency allergy treatment thursday mylan say expand patient assistance epipen actually lower price monday say next few week release generic version pack compare current price brand decision launch generic alternative epipen be extraordinary commercial response require cooperation partner say mylan ceo heather bresch statement presumably refer pfizer pfe draw royalty product however complexity opaqueness today brand pharmaceutical supply chain increase shift cost patient result high deductible health plan determine bypass brand system case offer additional alternative be best option ibd take mylan misadventure show rely price increase growth be risky strategy find much other drugmaker be do same check recent rundown price vs volume growth big biotechs later monday however rep jason chaffetz utah chairman house committee energy commerce ranking committee member elijah cumming md send letter bresch ask documentation relate mylan income profit epipen well patient assistance program government funding arrangement pfizer lobbying activity republican member house committee energy commerce also send letter fda ask process approve epipen generic competitor have come fire quarters take so long mylan also intend bypass system complexity launch direct ship program epipen customer potentially get middleman bresch say last week take cut most epipen list price normally generic competition threaten drug developer make deal generic drugmaker sell exclusive authorize generic first month other competitor come market however mylan main business be generic drug essentially be generic partner epipen have be patent generic version drug contain epinephrene be already available injection device deliver precise dose drug proven tricky replicate sanofi sny have competitor call auvi be recall last october device malfunctioned teva pharmaceutical industry teva have device fail first attempt fda approval company expect re file come month estimate mylan launch epipen authorize generic ag have impact epipen sale estimate modest impact ep forecast leerink analyst jason gerberry write research note estimate ag impact do not account reduction sg sale general administrative spending commitment epipen mylan look initiate order mitigate ep downside mylan initially rally much generic epipen news close stock market today teva stock be
157,MYL,federal reserve say case rate hike have strengthen stock rally policymaker indicated path increase be even slower congress grilled big ceo federal government announce autonomous drive guideline yahoo yhoo facebook fb make embarrass disclosure nasdaq climb time high fuel fed decision further lower likely rate hike trajectory rise close day retake key support thursday oil metal mining stock fared well retail group struggle federal reserve hold interest rate steady wednesday signale hike key rate december still market be pleased fed member own projection point just hike meanwhile bank japan say intervene keep year government bond yield roughly say now aim overshoot inflation target neither move currency impressed investor yen rise close year high boj meeting divide fed hold rate hike see slower tighten pathnote fed job market just take wrong department transportation unveil long await federal autonomous vehicle guideline new rule provide tesla motor tsla ford motor alphabet googl general motor gm other be develop self drive car framework safety guideline pre empt state law dot say new guideline be root view automate vehicle hold enormous potential benefit safety mobility sustainability alphabet be early pioneer self drive car tesla have be most aggressive push technology tesla update autopilot driver assistance technology greater emphasis radar apple aapl reportedly have hit brake develop car house have approach mclaren technology group british luxury car maker possible acquisition financial time report new york time report apple have hold talk mclaren investment company mclaren deny report say company be not discussion apple respect potential investment related tesla just make big move be key futureapple talk buy luxury car maker mclaren reportyahoo yhoo disclose confidential information be take least user account late likely state sponsored actor password be steal not payment information yahoo urge user change password security question haven be update unclear affect sale yahoo core operation verizon vz include regulatory legal issue yahoo share fall week twitter twtr share spiked friday report struggle social network be mull putt sale salesforce crm alphabet googl possible buyer facebook fb disclose late thursday give advertiser inflate figure long person watch video year facebook fall move slightly buy point be good week initial public offering most active week year winner be apptio apti cloud provider information technology management tool pop first trading day friday tech winner digital ad company trade desk ttd jump first trading day wednesday low cost cosmetic provider beauty surge trading debut thursday cloud vendor twilio fiber optic company acacia communication acia japanese messaging firm line ln have help boost outlook ipos be forecast shift high gear rest year ipos earlier year have see strong gain twilio twlo hit new high week largest ipo week be valvoline vvv quick lube chain auto lubricant maker raise adobe system adbe late tuesday say earn cent share exclude item year year sale fiscal third quarter end current quarter medium marketing software company expect gaap earning share cent sale top view adobe share rise nearly record high enterprise software provider red hat rht wednesday also beat view earn cent share item sale fiscal end aug give guidance top wall street expectation share rise more shipping giant raise full year ep outlook exclude tnt express related acquisition cost previous guidance slower economic growth prospect say integration dutch company be go smoothly fedex fdx report fiscal ep jump beating estimate revenue climb top view company also reiterate boost shipping rate service fedex share jump nearly gapping day average hit highest level june exist home sale unexpectedly fall second straight month august housing start decline more expect builder sentiment gauge rise year high meanwhile kb home kbh report better expect earning lennar len also top earning order margin fall lennar also buy wci community wcic fed slower rate hike path also be good news housing sector related exist home sale unexpectedly fall august ratebotox maker allergan agn jump tuesday battle nonalcoholic steatohepatitis nash announce plan acquire tobira therapeutic tbra tobira stock shot tuesday later day allergan paid akarna therapeutic nash developer nash avenue allergan compete gilead gild intercept icpt novartis nvs enanta enta also last week allergan announce plan buy vitae pharmaceutical work combat psoriasis eczema autoimmune disorder ophthalmology gene therapist retrosense various opec member hint support output curb ahead informal meeting top opec opec producer algerium week other downplay likelihood decision oil price rise barrel week drop friday energy information administration say wednesday crude stockpile fall barrel barrel month low gasoline inventory fall barrel pioneer natural resource pxd chief executive scott sheffield tell bloomberg oil rig be add permian next year join eog eog diamondback energy fang chevron cvx other bullish texas play france total tot say cut overall investment year related texas shale leader see permian boom french oil major cut backmylan myl ceo heather bresch be lambaste wednesday congressional meeting probe company price tag pack lifesave epipen used allergy treatment bresch argue mylan only profit pack republican democrat alike criticize benefit facto monopoly epipen still mylan stock rise fractionally week well fargo wfc ceo john stumpf become senate panel punch bag tuesday sen elizabeth warren mass urge resign bank cross selling scandal stumpf say learn issue say be deeply sorry sale practice bank say be end retail banking sale goal authority say well employee start least open unauthorized consumer account attempt hit sale target analyst say financial fallout fine regulator investigation intensify appear limit now share rise week drop nearly prior week goldman sachs communacopia medium conference big medium seem unworried cord cut cbs cbs chief moonfe say netflix nflx star trek licensing right deal paid cost cbs new star trek series disney ceo bob iger be already think star war film slate time warner twx st century fox foxa exec wave less well receive summer movie related netflix lose key support subscriber churn concernsnetflix star trek deal help cbs chief moonfe sleep nightdisney already look star war film next decade
158,MYL,create job august slower pace suggest fed rate hike soon eu say apple aapl repay taxe mylan myl buckled pressure offer half price generic epipen salesforce crm give weak guidance unite airline ual hire key american airline aal executive major market average rise modestly week continue long string sideway action record high nasdaq composite rise dow industrial climb investor see fed rate hike september even less likely now fiber optic stock remain hot generic drug rebound apparel store be notable loser european union executive arm order apple repay euro back taxe interest ireland part broader crackdown eu member nation special tax treatment big multinational apple ceo tim cook vow appeal decision criticize commission unprecedented action total political crap apple set plan event widespread expectation unveil iphone apple share rise week approach point add job august view gain july june meanwhile ism manufacturing index august signale first contraction month odd september rate hike already low fall further market still expect year end hike ford motor general motor gm most other big automaker report lower sale august vs year earlier fiat chrysler automobile fcau sale rise be only top seller report higher demand sale totale vehicle seasonally adjust annualize rate vs pace july gm joined ford forecasting lower domestic sale industry hit record level last year gm ford share fall modestly thursday auto sale news rise slightly week tesla motor tsla tumble month low cash crunch concern electric car maker takeover target solarcity scty crude oil price fall barrel worst weekly loss early july crude inventory rise second straight week mixed economic datum also weigh oil rig count edge higher month high drugmaker mylan myl launch generic epipen monday respond frenzy criticism price hike allergy treatment face new lawmaker call epipen related document other ask fda explanation be hold approval other generic version friday lawmaker accuse mylan overcharge medicaid epipen democratic presidential nominee hillary clinton say crack drug price hike mylan fall week tumble prior week palo alto network panw earn cent share exclude item meeting fiscal view gain revenue growth top ep guidance current be weak indicated yet quarter decelerate palo alto growth very high level solid full year ep guidance buyback plan share fall wednesday rally weekly gain just day line chipmaker broadcom avgo ambarella amba late thursday post top bottom line beat quarters end july give guidance top wall street stock fall friday week problem be investor analyst have doubt crucial product be announce key customer ciena cien major fiber optic company earn cent share exclude item fiscal beating cent sale grow slightly view ciena stock break consolidation rise week ciena cisco csco be lead vendor major gigabit metro rollout verizon vz telecom cloud compute giant china be see huge demand fiber optic gear lift hot ipo acacia communication acia other salesforce com report earning revenue beat estimate billing be expectation guidance imply billing growth tick again salesforce say see softness demand project fiscal revenue vs wall street consensus expect ep item cent cent consensus cent salesforce stock fall week trading day line first time end march closeout retailer ollie bargain outlet olli top earning sale forecast guide full year estimate higher centric retailer give weak third quarter guidance follow murky forecast target tgt dollar general dg dollar tree dltr result come wal mart wmt begin own price cut campaign potentially draw customer away rival discounter ollie stock rise week retake buy point fall day line fall extend lose streak straight session lululemon athletica lulu meet earning estimate cent share mark growth miss revenue sale grow vs forecast currency neutral same store sale rise yogawear maker retailer analyst be anticipate earning turnaround lululemon issue cautious guidance share sank erase virtually lululemon gain prior earning report share unite airline ual jump week scott kirby joined carrier american airline aal have serve president kirby now unite president be see industry best revenue strategist move round unite recent effort shake executive team compete american delta air line dal unite rise week retake day line american climb delta report august unit revenue fall vs year earlier suffer outage force cancellation rise hawaiian holding parent hawaiian airline rise breaking past buy point light volume wesson swhc late thursday report first quarter result easily beat wall street forecast raise full year guidance help new acquisition share gunmaker slide friday month low back day line part due fbi datum august background check loose indicator firearm demand didn exhibit surge see previous month share rival sturm ruger rgr fall friday stun gun maker taser tasr break short consolidation tuesday then crash fall week diving day line veeva system veev be expect report soft due lumpiness booking veeva earning beat estimate sale growth also surprised analyst credit strong uptake vault content management system stock rise week hit best level late keep place ibd
159,MYL,share generic drug giant mylan myl rebound early trading thursday then lose steam company say expand patient assistance controversially price drug epipen move hit share pharmacy benefit manager pbm express script esrx pharmacy chain cvs health cvs mylan stock have be fall week member congress call investigation pricing emergency allergy drug have go last few year wednesday presidential candidate hillary clinton also criticize company promise act high drug price president statement demolish drug stock rally last few day thursday mylan issue press release say be double eligibility patient assistance program epipen poverty level meaning family make year pay nothing also offer saving card defray pocket cost frugal insurance plan ibd take mylan trouble be foresee industry not alone see june article drugmaker be next price war casualty evercore isi analyst umer raffat roughly estimate new program have most annual impact mylan epipen sale earlier week note be evidence heavy rebate already go epipen provide mylan revenue notice net sale increase vs be roughly volume price year year raffat write email client speak contractual arrangement epipen mylan ceo heather bresch make similar point interview cnbc late wednesday say middleman mylan have go strip large chunk price leerink analyst david larsen write research note be likely express script cvs health be selling thursday obviously imply cvs express script pbms be reap significant profit epipen larsen write therefore reduction epipen price presumably be feel well say express script stock fall thursday hit month low intraday cvs stock be larsen also note fellow generic drugmaker teva pharmaceutical industry teva have epipen competitor hit market generic launch be pending believe mylan have be get slightly more aggressive pricing write mylan rise much early trading stock market today have lose more previous day stock close related astrazeneca sell antibiotic business mallinckrodt shed imaging unit
160,MYL,stock open higher monday brisk overseas action draw sharp contrast sedate premarket session dow industrial be nasdaq add open stock market today market china also post quiet session end narrow loss japan tokyo nikkei surge apparently buoy speculation possible federal reserve rate hike japan be schedule release monthly official household spending unemployment datum monday evening time europe stock moved sharply lower cac paris frankfurt dax lower midsession london stock exchange be close day bank holiday gainer decliner run even dow premarket session verizon communication vz merck mrk open less higher most ibd list stock remain flat ahead open broadcom avgo be drugmaker mylan myl climb nearly open stock fall last week hurt controversy price increase company epipen allergy treatment netherlands base company say monday release lower price generic epipen alternative symantec symc rise barron article saturday estimate cost cut measure software maker recent acquisition blue coat system point upside share price fiber optic networking gear maker oclaro oclr flash higher san jose calif base company be networking leader discuss ibd article outline trend fiber optic networking market also include acacia communication acia inphi iphi other oclaro share be price inphi acacia be ibd stock acacia share rise open personal income chug ahead july line consensus expectation commerce department also revise initial increase estimate june upwards personal spending rise also inline projection commerce also revise june spending estimate gain downward increase core pce price index tick line view equal gain june dalla federal reserve bank deliver regional manufacturing survey august et oil future slump more west texas intermediate crude continue find support barrel gold dip fraction ounce dollar gain ground euro yen year treasury yield slip basis point
161,MYL,federal reserve chief janet yellen say case rate hike be stronger now investor weren sure make pfizer pfe paid drug biotech share drug pharma supply chain company sell mylan myl epipen price hike draw outrage best buy bby earning surprised investor dollar store come pressure week nasdaq fall dow major average be still sideway action drug stock be big mover pfizer medivation mdvn deal mylan epipen furor dollar store suffer heavy loss competition wal mart wmt be heating fed chair janet yellen say friday long await speech case interest rate hike have strengthen recent month follow other modestly hawkish statement fellow fed policymaker however vice chairman stanley fischer say yellen comment be consistent september rate increase see possibility rate hike year market have already price fed move perhaps december don expect quick follow upnew home sale soar annual rate july far highest october commerce department report rise june surprised economist look slight dip luxury homebuilder toll bro tol confirm high end market be prosper report jump third quarter earning share rise revenue strong backlog order exist home sale fall more expect july be june cycle high application loan buy home fall month low toll share soar month high move day move average generic drugmaker mylan sell week member senate other politician start inquiring price increase emergency allergy drug device epipen fuel selling drug biotech stock mylan ceo heather bresch daughter sen joe machin say only fraction list price make back mylan due middleman lead share express script esrx cvs health cvs abc fall well big pharma pfizer agree buy medivation cash snatch cancer drug specialist sanofi sny have be try month acquire medivation biotechs rally monday news biomarin pharmaceutical bmrn jump rumor be sanofi second choice target wednesday pfizer agree buy antibiotic business astrazeneca azn possible future milestone sale payment royalty amount oil price be settle trading range mid high range opec member give conflict signal support production freeze goldman sachs say such move not be sufficient support price much further meanwhile energy information administration say crude inventory rise barrel vs expectation small drop domestic production fall slightly road self drive car get little more crowd mobileye mbly announce partner general motor gm supplier delphi automotive dlph jointly develop shelf autonomous drive technology automaker company co develop market first turnkey level automate drive solution mobileye already have deal bmw bmwyy intel intc bring autonomous vehicle market mobileye share spiked tuesday delphi news briefly top buy point share rise week tesla motor tsla be end business relationship mobileye introduce new version model boost speed drive range power update battery technology tesla say upgrade model be now fastest accelerate car commercial production tesla share fall close day line just day line tesla partner nvidia nvda unveil new processor autonomous drive say more powerful other mobile processor beauty product retailer report better expect earning sale yet quarter double digit same store growth ulta beauty ulta also raise full year ep guidance profit range be little cautious ulta share have be strong run so have be price perfection ulta share tumble friday undercut day move average workday wday report wider expect adjust loss top key metric include revenue rise share cloud base human resource software maker rise hit high thursday july ipo talend tlnd lose adjust share accord late thursday release french big datum firm later clarify bottom line actually meet estimate loss cent share adjust share count follow initial offer revenue rise just beating talend see loss line view guide revenue slightly higher share fall much bigger intraday loss best buy bby stock jump week month high better expect sale earning fiscal second quarter include surprise increase same store sale consumer electronic retailer credit rise demand wearable technology appliance home theater system increase video game electronic retailer gamestop gme disappoint investor line ep forecast sale discount retailer dollar general dg dollar tree dltr suffer double digit share price loss report second quarter result come short wall street expectation fall grocery price tougher competition hurt sale result come wal mart be wage own campaign cut price move draw more customer have become more cautious spending meanwhile jeweler tif hold full year outlook ep beat view help boost share however signet jeweler sig parent mall jeweler kay jared zale slash fiscal year outlook partly due difficulty energy dependent region region economy have be hurt cheap oil other commodity hp inc hpq report fiscal earning share time item jump fiscal cent decline sale better view current quarter printer pc maker see gaap ep cent vs consensus cent hp be reduce printing supply inventory be deeply discounting printer expand install base share close little change brief thursday morning sell
162,MYL,drug stock slip wednesday rally earlier day politic drug pricing resurface ibd biotech biomedical group hit month high wednesday morning group continue momentum start monday announcement pfizer pfe deal buy medivation mdvn raise hope more biotech continue especially incyte incy biomarin bmrn gabelli co argue make especially attractive target incyte rise more early trading stock market today end day just fraction biomarin initially gain almost then sharply reversed end proximate cause decline seem be presidential candidate hillary clinton criticize generic drug giant mylan myl pricing allergy treatment epipen mylan multiple price hike epipen have already attract discussion industry week senate get act demand mylan ceo heather bresch explain epipen high price clinton weigh midday wednesday ibd take long term outlook get cloudy look ibd swing trader tip short term trading note month biotech stock rally last week have be drive partly fact drug pricing have fade political debate group hit month high aug surpass early wednesday rbc capital market analyst randall stanicky write research note drug pricing comeback politic be be also stark reminder political scrutiny pricing remain high sector unlikely dissipate anytime soon head november election stanicky write nonetheless familiar ibd chart read technique be still lead biotechs be worth keep eye incyte have be bounce buy sell zone pop cup handle base last month financial be also improve turn more consistently profitable last few quarters biogen biib also break cup handle start month then blast right past buy point next day buyout rumor then moved sideway wednesday reversal bring close buy zone again be more celgene celg have be upslope consolidation start july last year still hasn form specific buy point celgene biogen be strong stock overall composite rating putt top stock generic drug group also have be rally last week still low rank go ibd list industry group group be again wednesday lannett lci beat expectation late tuesday lannett stock jump wednesday generic drug however be most direct target senate inquiry group fall wednesday earlier hit month high mylan stock fall wednesday fall tuesday related hunting biotech stock understand earning formula first
163,MYL,stock fall wednesday sell gold silver crude oil batter mining energy share generic drug maker mylan myl fall sharply second day nasdaq lose fall dow jone industrial average slip volume rise nasdaq compare tuesday accord preliminary datum close workday wday developer cloud base software human resource application rise more quarterly earning report hp inc hpq drop more follow quarterly result close stock hit new high intraday reverse lower end regular session stock market today mylan fall more heavy volume mount criticism huge price increase allergy drug epipen democratic presidential candidate hillary clinton call mylan drop price epipen have increase price past decade clinton call price hike outrageous mylan be so far week have slice day day move average meanwhile gold stock fall price yellow metal sank goldcorp gg plunge regulator say be investigate canadian miner leak contaminate water country biggest mine goldcorp drop freeport mcmoran fcx sank more also wednesday oil price drop nearly unexpected increase inventory oil producer denbury resource dnr sank burlington store burl dollar tree dltr dollar general dg ulta beauty ulta be company due report quarterly earning thursday economic datum due thursday include new jobless claim week end aug durable good order july
164,MYL,flagship etfs tracking major index close lower thursday ahead weekend conclave policymaker wyoming investor remain edge upbeat job datum oil rally await friday speech fed chairwoman janet yellen offer clue path interest rate hike restrain mood stock market today few asset class score big advance vaneck vector gold miner gdx advanced re-cover tumble previous session see fall solidly key day move average etf invest gold mining stock year best perform industry group biotech stock surrender early rally spdr biotech xbi give back gain more close wednesday session remark democratic presidential candidate hillary clinton have trigger steep sell exchange trade fund clinton member congress question drugmaker mylan myl price epipen have see price increase past decade clinton call price hike outrageous mylan respond thursday expand exist program patient be face higher pocket cost stock climb nearly intraday end red clinton tweet back september price gouge drug industry have trigger plunge xbi span few trading session ibd take exchange trade fund offer investor exposure diversify basket stock lower portfolio risk always good take deeper dive best biotech stock portfolio dave mazza head research spdr etfs say political rhetoric shine light drug industry possible negative way be fairly typical stage election cycle expect primary driver biotech stock lead november vote be political outlook rather company specific fundamental presidential election biotechs benefit calmer environment investor find attractive valuation space interim tell ibd phone call xbi sit week high have gain third quarter aug recently aug biotech biomedical group hit multimonth high be hold level follow monday announcement pfizer pfe deal buy medivation mdvn here major exchange trade fund major asset class perform today ibd relative price strength rating rs rating be measure stock price performance last month compare stock etfs scale best possible follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related be gold etf rally technical analyst think not
165,MYL,usual specialty generic drugmaker come fore earning season near end several interesting stock deck allergan agn report early monday have somewhat complicate financial just sell huge generic business teva teva have be count discontinue operation deal lengthy approval process exclude consensus sale estimate be flat vs year earlier quarter ep estimate share be modestly accord leerink ibd take outfit look acquire biogen have pay pretty price biogen boost buyout rumor be latest ibd big cap screen company deliver big gain have less volatility smaller stock teva deal close aug leave allergan fat wad cash fuel buyout speculation already anonymously source report have company explore acquisition biogen biib allergan stock trade mostly flat week close friday fraction valeant pharmaceutical vrx be look shrink quarter report early tuesday continue recent wo pricing pressure profit be see fall share sale drop company accept broad price cut partnership year walgreen wba stock rise july walgreen make positive comment deal own earning report valeant be start launch oral version constipation drug relistor be near possible launch psoriasis drug brodalumab have skeptic wall street valeant stock more week high close week fraction lower jazz pharmaceutical jazz report close tuesday be still growth train sale expect climb profit share jazz stock be still elevated rise nearly july patent board reject competitor request review patent jazz lead drug xyrem have be subject increase patent challenge age overall share be high however end week fraction also late tuesday generic drug giant mylan myl be expect record sale growth profit gain share company launch new generic drug alone pricing pressure space have be issue last few quarters mylan close buyout swedish rival meda friday deal be not hugely popular investor be announce february combine earning miss drive stock re-cover somewhat then friday mylan stock close week
166,MYL,stock moved sideway time high week week be packed market move news alibaba baba break growth accelerate acacia communication acia explode fiber optic ipo growth name spark macy trigger huge relief rally wal mart wmt buy jet com better compete vs amazon amzn oil price rebound solar stock crash week dow industrial hit time high nasdaq eclipse peak major index rise fractionally week nasdaq dow close climb point more quality breakout appear retailer energy play hot growth stock lead market earning report higher oil price solar stock tumble weak sunpower spwr guidance reit struggle investor seek growth name worry store closure alibaba report revenue beating wall street consensus estimate revenue rise local currency term best gain alibaba september ipo ep rise cent beating consensus cent jd com report revenue slightly consensus local currency report earning share cent double cent consensus revenue estimate fall short projection company show strong growth mobile user alibaba stock soar week breaking base highest level january jd com leap nearly next week messaging giant tencent tcehy perhaps alibaba biggest chinese rival report earning so do mobile gaming portal netease nte flash commerce seller vipshop vip ibd take market record high many growth name large small be breaking get depth look alibaba acacia other top rate stock fare vs rival go ibd stock checkup develop watch list saudi energy minister khalid al falih hint production freeze come meeting sideline international energy forum next month russia energy minister say didn see reason renew talk international energy agency say oil glut have disappear warn weaker demand dimmer macroeconomic outlook opec say saudi arabia pump record amount crude oil july cartel left demand outlook unchanged barrel day energy information administration say stockpile rise barrel week end aug production fall barrel second straight week decline oil rig operation rise week end aug baker hughe say seventh straight weekly gain highest level late february still crude oil price close week barrel wal mart store look keep pace amazon agree buy jet com wal mart have sizable online sale growth have be decelerate wal mart also put jet com ceo marc lore charge wal mart commerce operation jet com remain separately lore previously founder quidsi parent diaper com amazon buy wal mart stock rise hit month high week solar stock sunpower cut guidance inverter supplier solaredge sedg cite slowdown installer sunpower revenue growth adjust loss top estimate sunpower see revenue just vs consensus demand utility scale solar project tumble sunpower also cut view miss analyst view solaredge fiscal sale miss analyst expectation cent ep item beat nickel midpoint current quarter sale guidance trail consensus ep miss penny solarcity scty have agree takeover deal tesla tsla top analyst projection adjust loss revenue current quarter view revenue lag consensus sunpower stock crash year low chipmaker nvidia nvda involved everything gaming autonomous drive ai rise week fresh high tesla partner report sale cent earning share top consensus cent be respectively vs last year nvidia see current quarter sale beating analyst model china telecom datum center spending heavily higher speed connection maker fiber optic component be see huge demand hot ipo acacia communication say revenue rise adjust earning soar lumentum lite inphi iphi also report stronger expect figure neophotonic nptn sale growth fall short due sluggish demand older part production gigabit gear be ramp ibd company telecom fiber optic industry group hit year high thursday rank group acacia rise friday nearly week blast new high lumentum rise more inphi also new high neophotonic climb clear buy point friday related ibd take acacia communication be several tech leader have rise past buy point putt profit take zone sell top stock ibd latest tech leader column explain hold winning stock rule apply acacia weibo other right now recent ipo twilio twlo communication software firm report narrower expect gaap loss revenue jump vs wall street estimate sale top customer facebook fb own whatsapp fall year year twilio full year guidance edge consensus estimate twilio share surge week hit new high medpace holding medp soar thursday debut pricing high end expect ipo range share edge friday medpace provide outsourced clinical development service drug medical device company specialty drugmaker end have be strong season drug industry more ambiguous note allergan agn freshly divest generic business beat expectation slightly trim sale guidance share fall week valeant pharmaceutical vrx miss number affirm guidance reorganize say deal walgreen wba be finally turn profitable be willing sell worth core asset stock soar tuesday pare weekly gain report valeant face criminal charge defraud insurer medivation mdvn report hum quarter profit likely be flat expect market expansion drug xtandi share rise month high just barely buy range entry jazz pharmaceutical jazz miss ep estimate lower guidance partly due change tax report partly due higher cost stock drop mylan myl beat profit estimate slightly affirm guidance controversially high price epipen make light generic drug sale mylan close week unchanged walt disney top wall street estimate late tuesday say have buy stake stream company bamtech vie remain competitive digital medium conglomerate plan launch espn brand top service not include current espn content ep rise revenue growth share be week fail hold day line southwest luv cut third quarter unit revenue outlook say expect higher unit cost due flight cancellation july single router failure blac much technological infrastructure guidance come delta air line dal spend much week try recover own flight cancellation cause outage early monday american airline aal meanwhile forecast improvement unit revenue southwest delta share fall american air climb macy kohl kss report lower sale macy also have decline earning say cut store top forecast week bad news consumer stock such ford mcdonald mcd so macy kohl sky-rocket respectively week jwn jcpenney jcp top earning miss revenue share also soar week overall retail sale be flat july exclude auto accord commerce department home depot hd lowe low wal mart ross store rost be retailer report come week ibd tipp economic optimism index rise month high august climb point still neutral level
167,MYL,here investing action plan need know investor come week alibaba baba walt disney nvidia nvda headline quarterly earning report tech leader facebook fb alphabet googl microsoft msft start week buy range more drugmaker report top department store chain signal more trouble
168,MYL,drug pricing be wall street mind again friday well fargo tap mylan myl next target activist rbc consider impact potential new law limit price california well fargo analyst david maris write valeant pharmaceutical vrx turing pharmaceutical be haul front congress scrutinize press policy drastically hike price recently acquire drug be keep eye other company universe have be do lot price increase last month mylan have raise price more product more product maris write research note late thursday mylan have take exceptionally large price increase include increase ursodiol generic medication used treat gallstone increase metoclopramide generic medication commonly used treat reflux disease gerd gastroparesis increase dicyclomine medication used treat irritable bowel syndrome maris add last month mylan add price tag biggest product contribute revenue most recent quarter believe give regulatory environment pricing action bring greater regulatory scrutiny headline risk additionally wonder aggressive price increase be be used make ep target offset disappointing sale other area mylan respond follow statement mylan have always be know have industry broadest most globally diversify business model portfolio have successfully manage balancing numerous variable include natural price reduction have always be inherent generic industry flaw analysis focuse small number product more product mylan sell globally approx product sell north america be simply self serve mislead investor be especially true give generic product represent extremely small percentage mylan approx north american generic business mylan business model be not today have ever be premised price hike mylan stock fall stock market today fall low valeant retreat friday week rbc capital market biotech analyst michael yee be also ponder drug pricing friday calculate potential impact california drug price relief act cdpra stock universe include amgen amgn gilead science gild celgene celg biogen biib vertex pharmaceutical vrtx cdpra go popular vote california proposition system november require state health care payer medical buy drug similar price veteran administration usually obtain large discount believe cdpra create slippery slope measure encourage other state follow suit ohio have also propose be get signature yee write think such attempt reduce drug cost merely prompt drug maker just raise va drug price thus help less person not result real saving benefit nonetheless yee estimate similar law pass state shave annual ep cover company discussion large cap biotech company suggest firm be aware wouldn be surprised proposal pass so note investor very least be inform potential headline model pricing risk write drug stock be friday rest market amgen fall gilead biogen celgene vertex pharma dip
169,MYL,stock market be set open narrowly mixed monday major buyout dominate early headline apple aapl report show optimistic development future nasdaq be fraction dow jone industrial average be lower germany bayer bayry announce bid share agricultural product maker share be premarket trading apple be higher ahead bell company be ask supplier gear production copy next iphone version barron com say quote taiwan economic daily caesarstone cste fall nearly announce ceo yos shiran be step run maker quartz countertop order pursue other interest caesarstone stock have be deep correction even many other build product stock lead market mylan myl rise company announce launch generic version mayne doryx treatment severe acne mylan be award day marketing exclusivity oil price fall nearly early monday west texas intermediate crude trading barrel europe german dax french cac be ftse decline london asia nikkei average close lower shanghai composite add hang seng index ease
170,MYL,market have worst open week pressured commodity price decline heavy selling overseas market nasdaq slide dow jone industrial average small cap russell be also stock early motion include goldman sachs gs mylan myl mattress firm mfrm deutsche bank db friday economic calendar be light preliminary read june consumer sentiment expect university michigan et treasury department serve budget number dow jpmorgan jpm goldman sachs fall block hrb bang gain stock rise much thursday regular session dividend hike compensate narrow fiscal fourth quarter earning miss netherlands base drug maker mylan slide stock be boost early week food drug administration rejection emergency allergic reaction treatment adamis pharmaceutical admp mylan rise speculation rejection benefit epipen product adamis plunge more thursday mattress firm tumble report deeper expect loss rise revenue management also cut guidance view raymond james bank america downgrade stock eurozone bank brook hard hit deutsche bank royal bank scotland rb barclay bcs banco santander san be more oil price retreat more putt west texas intermediate back barrel still week gold ease slightly ounce more last friday settlement price dollar be vs euro lag vs yen strong gain bond climb putt year treasury yield basis point late thursday hong kong market open day holiday fall friday notch gain week shanghai stock exchange remain close dragon boat festival tokyo nikkei slip friday take loss week europe market face stiff selling frankfurt dax be cac paris drop london ftse sag week dax cac be tracking loss better apiece ftse trade last friday close
171,MYL,stock future be early lows head tuesday open bell dow industrial nasdaq future trade fair market value
172,MYL,stock market today feel early pressure overseas weak manufacturing datum left china market sharply divide place pressure global commodity price commodity turn weigh international stock action london base researcher markit report marginal deterioration china manufacturing sector april output remain same march new order stagnate export fall fifth straight month inflationary pressure higher input cost rise fastest pace january shanghai composite advanced hong kong hang seng index fall eurozone benchmark be nearly late morning trade london ftse be japan tokyo stock exchange be holiday thursday economic news fiat chrysler fcau report sale rise april jeep brand sale rise sale dodge truck other auto maker be expect report april sale session key earning report factor heavily premarket action cvs health cvs climb almost halliburton hal slip report first quarter result coty coty shed sprint muscle follow respectively fiscal fiscal result drug maker stake early lead premarket action pfizer pfe narrow early gain earning revenue easily top consensus expectation be pfizer second ep gain quarters management raise full year earning guidance forecast lift revenue guidance high end expectation company statement say late stage product pipeline be increasingly ready deliver next set prospective growth driver stock end monday buy point cup handle base mylan myl lead mixed first quarter report ibd stock premarket gain be volatile loss be bit more steady inc research incr drop almost downgrade robert baird pra health science prah also retreat announce share secondary offer monday close big foreign bank be take early hit ub ub drop report deutsche bank db royal bank scotland rb tank credit suisse cs slump oil price slip more west texas intermediate trading just barrel gold be almost half percent hover ounce company schedule report close be avis budget group car agrium agu illumina ilmn
173,MYL,april auto sale release tuesday be catalyst general motor gm ford motor fiat chrysler automobile fcau earning pfizer pfe mylan myl cvs cvs be also top list need watch gm ford fiat chrysler miss analyst estimate sale march expert projection industry sale level several year boom growth edmund com expect seasonally adjust annualize rate saar sale reach april march last april power lmc automotive joint forecast see sale saar month gm have shape cup handle base buy point find support day line currently trading buy point week high dip fraction monday ford be week high share be try find support downward slope day line ford add intraday trade fiat chrysler be trading day line day line share be week high monday drug giant pfizer mylan issue quarterly report tuesday morning pfizer earning be project rise cent share revenue increase pfizer scrap inversion buyout plan allergan agn last month treasury department issue new rule curb tax beneficial deal pfizer be able retake day line early april end session lose streak monday add share be trading week high meanwhile mylan be expect see earning rise cent share gain revenue last quarter mylan miss expectation stock crumble company also announce be buy sweden meda mylan breach day line last week snap straight session decline monday stock be trading week peak climb monday drugstore chain be expect see earning rise share report tuesday morning revenue be project jump cvs find support day line be able retake day line rise monday day recently crossed day stock performance have improve share be trading high reach last july continue consolidate
174,MYL,biggest player global life science industry have be move cloud veeva system veev go public have be help get cloud base customer relationship management crm marketing project management solution roster client include amgen amgn biogen biib pfizer pfe merck mrk bayer bayry cardinal health ticker
175,MYL,abbott laboratory agree buy st jude medical stj deal value maker heart device make biggest ever acquisition industry consolidate gain bargaining power hospital st jude medical shareholder receive cash share abbott common stock represent total approximately share accord statement thursday medical device maker be merge get access new technology hospital push lower price st jude last year acquire thoratec add left ventricular pump device take fail heart combine abbott st jude medical company have pipeline new medical device product cardiovascular diabetes vision neuromodulation patient care accord statement abbott say statement have financing st jude medical plan acquisition alere alr send alere share higher early trading stock market today abbott chief executive officer mile white decline reiterate commitment alere deal last week company earning call alere hasn yet file report regulator have be subpoena justice department st jude medical close wednesday give company market value stock jump market open new york abbott drop percent early trading alere rise percent acquisition further reshape abbott split brand name pharmaceutical business abbvie abbv then company have shy away major acquisition pursue many smaller deal even ceo talk often desire larger purchase abbott have cash hand obtain selling generic drug business medicine market europe develop world mylan myl
176,MYL,last month forbe release annual fast tech list fastest grow public tech company veeva system veev come grubhub grub arista network anet facebook fb provider cloud base sale marketing software life science industry sport year annual ep growth rate year annual
177,MYL,share valeant pharmaceutical international vrx rise sharply fellow specialty drugmaker perrigo prgo fall friday report former be hire away latter ceo late thursday wall street journal quote anonymous source say valeant be hire joseph papa get perrigo board void noncompete clause contract friday morning perrigo issue brief statement say not comment speculation be only official word company so far valeant have be hunting new ceo march activist investor william ackman moved board try order company grow chaos stock lose more value scandal related pharmacy partner break last september force valeant strike new distribution deal boot alliance wba be accompany board price cut disastrous report guidance cut internal investigation accuse former cfo current board member howard schiller misconduct eventually turn even bullish analyst valeant management papa meanwhile have run perrigo year have largely successful track record watch company revenue have more triple stock have climb eightfold inversion deal moved headquarters low tax dublin mylan myl attempt hostile takeover perrigo successfully fought ibd take perrigo be once hot stock not lately learn ibd stock checkupperrigo once steady profit growth have get uneven last couple year however stock have decline more mylan induced high last april currently hold mediocre ibd composite rating change have lead analyst worry implication papa departure perrigo papa have become face perrigo long tenure ceo write jeffery analyst david steinberg research note however exception cfo judy brown company other executive include john hendrickson be appoint president oct be largely unfamiliar investment community further timing couldn have be more inopportune mr papa be potentially depart prior announcement result follow string difficult quarterly financial particularly company flagship consumer business guggenheim analyst louise chen agree note perrigo be widely expect miss estimate lower guidance have be debate senior management change perrigo don think street be think actually happen be soon chen write perrigo stock be late afternoon trading stock market today hit lowest level intraday august valeant stock be
178,MYL,here investing action plan need know investor come week earning season remain remain busy report tesla motor tsla alibaba baba top shale producer april job report provide more clue federal reserve take interest rate tesla mobileye auto giant luxury electric vehicle
179,MYL,sucampo pharmaceutical scmp pop month high tuesday earning beat estimate sucampo say make cent share quarter exclude time item year earlier quarter beat analyst consensus cent accord thomson reuter gaap basis sucampo make cent share sale climb consensus full year sucampo make cent share revenue rise current year company affirm previous guidance cent ep sale sucampo stock jump almost early trading highest point jan close just company lead drug amitiza provide most revenue prescription grow sucampo income derive royalty paid partner takeda mylan myl japan sucampo also take milestone payment mylan quarter part partnership result include acquisition tech ueno december give sucampo greater share amitiza global economic well pipeline product key revenue driver amitiza be do better expect outside even sale remain strong end market sale report takeda royalty calculation be vs estimate write ub analyst ami fadium research note be first report quarter include tech deal be start see improvement earning be expect deal guggenheim analyst louise chen lower earning estimate slightly due guidance say several factor provide upside year datum readout pipeline product year new formulation indication amitiza be currently used constipation estimate sucampo have financial capacity make buyout range
180,MYL,allergan agn stock dive tuesday treasury ir announce plan new rule aim curb tax inversion practice allow company avoid taxe buy foreign company move headquarters overseas impact pending deal pfizer pfe ireland base allergan set close year latter be result several recent inversion company say statement late monday be conduct review department treasury action announce today prior complete review win speculate potential impact allergan fall nearly premarket trading be lowest level october pfizer rise nearly latest treasury action limit ability inverted company lend money american subsidiary create deductible interest reduce taxable income treat certain debt issuance stock serial inverter be also target new rule year limit foreign company bulk asset avoid ownership requirement later inversion deal be third set inversion curb rule issue treasury secretary jacob lew last few year lew say office be continue explore additional way limit inversion america corporate tax system give company strong incentive shift headquarters overseas combine federal state corporate rate be highest industrialize world america most nation taxe overseas earning inverted company still have pay tax rate american profit be get relief earning elsewhere other notable recent inversion involved mylan myl medtronic mdt burger king now call restaurant brand qsr deal have already close
181,MYL,generic drug giant mylan myl announce buyout swedish counterpart meda late wednesday also report earning miss estimate stock tumble hour trading mylan say acquisition be immediately accretive earning add cent ep next year allow company hit previously state
182,MYL,valeant pharmaceutical vrx perrigo prgo share continue tumble monday generally pull drug sector allergan agn be exception rise strong earning valeant late monday tumble low be lowest march dow jone report valeant pharmaceutical likely restate earning hour later valeant say restatement earning be expect related sale drug ex distributor philidor valeant say sale late have be recognize later valeant expect earning be lower cent share ep lift cent regular session valeant share close stock market today extend loss bearish report well fargo friday valeant share dive nearly day well fargo initiate coverage maker brand drug treat eye disease acne depression other ailment underperform say be unanswered question accounting method strategic direction earlier monday drugstore giant cvs health cvs say plan restrict use valeant jublia toenail fungus drug part initiative cut cost dermatology treatment jublia retail milliliter bottle accord goodrx valeant stock price have plunge intraday high double digit quarterly earning revenue growth nearly year bill ackman persh square hedge fund be significantly year partly fund large stake valeant valeant have already be batter series event include absence ceo michael pearson be be treat severe pneumonia complication jan valeant board name board member former chief financial officer howard schiller interim ceo earlier month valeant interim ceo schiller be call congress explain company decide increase price cardiac drug schiller promise end era sharp price hike perrigo business model be divide private label counter prescription generic drug fall monday lowest level late stock have lose session perrigo report weak fourth quarter result thursday subsequently have negative report jeffery friday goldman sachs monday jeffery cut price target maintain buy rating goldman sachs however downgrade stock neutral sell price target report say perrigo report ep time item cent estimate be company first earning miss quarters revenue grow analyst expect mylan myl last year make offer perrigo perrigo shareholder mid november reject mylan rise monday big pharma allergan agn report expect be final full earning report independent drug maker agree november be buy pfizer pfe allergan ep ex item rise hike revenue wall street expect ep revenue allergan share climb pfizer rise ibd generic drug ethical brand drug group be rare loser otherwise strong day stock
183,MYL,generic drugmaker perrigo prgo dip morning trading thursday earning miss estimate guidance also low side exclude time item perrigo make share quarter year earlier quarter miss analyst consensus cent accord thomson reuter revenue rise consensus
184,MYL,generic drug giant mylan myl agree develop biosimilar drug biotech momenta pharmaceutical mnta friday also announce retirement cfo momenta get upgrade result mylan agree pay upfront milestone payment candidate be successful exchange right momenta have option co commercialize support commercial role approve product unite state accord company statement momenta didn name candidate expect be biosimilar version bristol myer squibb bmy rheumatoid arthritis drug orencia orencia sell last year be project sell momenta ceo craig wheeler say conference call analyst however main patent be due expire so wheeler expect launch commercially momenta stock rise nearly early trading stock market today late afternoon be more momenta partner novartis nvs launch first biosimilar last year future be uncertain baxalta bxlt decide not pursue more joint project momenta follow development biosimilar abbvie abbv humira maxim group analyst jason kolbert lift rating momenta hold sell recall element sell thesis be base view move away complex generic copaxone biosimilar be significant transition momenta kolbert write research note upfront commitment mylan be validate mylan meanwhile announce cfo john be retire april year company have not yet find successor mylan stock be more late afternoon trading friday follow amy reeve twitter ibd_areeve facebook
185,MYL,perrigo shareholder reject hostile takeover bid fellow generic drug maker mylan friday morning send perrigo stock mylan long acrimonious battle end
186,MYL,mylan myl say press release et deadline perrigo prgo share have be validly tender miss require takeover succeed
187,MYL,grow alone
188,MYL,mylan management maintain statement be fine perrigo
189,MYL,mylan focuse approach organic inorganic growth have deliver compound annual growth rate adjust diluted earning share ep shareholder strategically consistently expand business say mylan ceo heather bresch recent financial result continue demonstrate power stand alone platform double digit growth legacy business well enhance double digit growth epd business
190,MYL,mylan shareholder seem agree stock rise close perrigo stock fall management claim victory
191,MYL,have say offer mylan be bad deal shareholder significantly undervalue durable business model industry lead future growth prospect perrigo ceo joseph papa say statement strong organic growth discipline approach transparent accessible corporate governance policy be foundation successful business strategy
192,MYL,mylan first propose buy perrigo back april cash mylan share perrigo share later lift share mylan share time
193,MYL,time mylan launch tender offer stock portion offer have lose considerable value result teva pharmaceutical industry teva abandon own hostile bid mylan buy generic business allergan agn also general drug stock sell perrigo stock have fall also however lead mylan argue perrigo shareholder still make money deal
194,MYL,perrigo leadership have steadfastly opposed mylan overture criticize offer mylan business mylan corporate governance same time ve seek mollify shareholder operational improvement share buyback plan latter papa say friday go ahead now vote be
195,MYL,accord anonymously source report perrigo buyout prospect be also hold mylan issue be resolve wall street journal report wednesday summer perrigo be talk endo international endp possible combination
196,MYL,not do deal
197,MYL,capital iq analyst jeffrey loo write expect more perrigo future
198,MYL,do not see many synergistic fit company now mylan issue be believe perrigo begin pursue acquisition likely consumer health care unit loo write research note maintain buy rating perrigo mylan
199,MYL,morningstar analyst michael also write see mylan stay hunt
200,MYL,generic drug industry still remain relatively fragmented view possible asset sale pfizer pfe sanofi sny provide mylan other opportunity merger acquisition especially asset have greater cost synergy potential perrigo mostly counter business write research note perrigo shareholder reject hostile takeover bid fellow generic drug maker mylan friday morning send perrigo stock mylan long acrimonious battle end mylan myl say press release et deadline perrigo prgo share have be validly tender miss require takeover succeed grow alonemylan management maintain statement be fine perrigo mylan focuse approach organic inorganic growth have deliver compound annual growth rate adjust diluted earning share ep shareholder strategically consistently expand business say mylan ceo heather bresch recent financial result continue demonstrate power stand alone platform double digit growth legacy business well enhance double digit growth epd business mylan shareholder seem agree stock rise close perrigo stock fall management claim victory have say offer mylan be bad deal shareholder significantly undervalue durable business model industry lead future growth prospect perrigo ceo joseph papa say statement strong organic growth discipline approach transparent accessible corporate governance policy be foundation successful business strategy mylan first propose buy perrigo back april cash mylan share perrigo share later lift share mylan share time time mylan launch tender offer stock portion offer have lose considerable value result teva pharmaceutical industry teva abandon own hostile bid mylan buy generic business allergan agn also general drug stock sell perrigo stock have fall also however lead mylan argue perrigo shareholder still make money deal perrigo leadership have steadfastly opposed mylan overture criticize offer mylan business mylan corporate governance same time ve seek mollify shareholder operational improvement share buyback plan latter papa say friday go ahead now vote be accord anonymously source report perrigo buyout prospect be also hold mylan issue be resolve wall street journal report wednesday summer perrigo be talk endo international endp possible combination not do deal capital iq analyst jeffrey loo write expect more perrigo future do not see many synergistic fit company now mylan issue be believe perrigo begin pursue acquisition likely consumer health care unit loo write research note maintain buy rating perrigo mylan morningstar analyst michael also write see mylan stay hunt generic drug industry still remain relatively fragmented view possible asset sale pfizer pfe sanofi sny provide mylan other opportunity merger acquisition especially asset have greater cost synergy potential perrigo mostly counter business write research note
201,MYL,pfizer pfe be massive deal buy allergan agn redomicile ireland multiple report say even treasury department plan impose new restriction tax inversion pfizer be discuss deal pay share botox maker allergan bloomberg reuter report late wednesday allergan rise wednesday retreat hour follow news inversion rule allergan trade low oct pfizer allergan deal buzz picked pfizer rise wednesday be little change late wednesday share be takeover largest health care deal ever biggest takeover kind year bloomberg say company want announce deal soon monday reuter say announcement be not necessarily imminent say treasury wednesday announcement issue target tax inversion guidance later week affect timing agreement acquire irish drugmaker pfizer be able limit exposure punitive corporate tax system america corporate rate be highest industrial world country taxe company overseas profit be repatriate treasury issue restriction tax inversion september stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead unclear new limit treasury impose obama administration ban inversion addition inversion benefit pfizer beef brand name drug boost pipeline treatment mid late stage trial pfizer use allergan deal lead pfizer breakup company follow ed carson twitter ibd_ecarson facebook
202,MYL,war word heated generic drug maker mylan myl perrigo prgo week company strive shareholder vote set friday mylan hostile takeover attempt mylan first propose buy perrigo back april cash mylan share perrigo share later lift
203,MYL,treasury department say wednesday announce target guidance intend discourage so call tax inversion deal used business relocate lower tax nation
204,MYL,later week intend issue additional target guidance reduce further economic benefit corporate inversion treasury secretary jack lew say letter senior lawmaker further detail be unavailable
205,MYL,be important emphasize however treasury stop inversion new statutory authority lew say congress act creative accountant lawyer continue find new way company move tax residence overseas avoid pay taxe here home
206,MYL,share allergan agn ireland base drugmaker have be mull inversion deal pfizer pfe pfizer be little change hour allergan fall late trade nearly wipe regular session gain allergan be still sharply late october level pfizer buzz begin
207,MYL,treasury department first begin attempt crack tax inversion september follow series inversion attempt particularly pharmaceutical business rule stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead
208,MYL,tax inversion company seek move be technically be acquire practice relocate company run combine business
209,MYL,many say deal deplete tax revenue allow company much operation dodge taxe many business community say inversion wouldn be need corporate tax rate be lower have world highest tax rate industrial world taxe overseas profit be repatriate here
210,MYL,follow bill peter twitter ibd_bpeter treasury department say wednesday announce target guidance intend discourage so call tax inversion deal used business relocate lower tax nation later week intend issue additional target guidance reduce further economic benefit corporate inversion treasury secretary jack lew say letter senior lawmaker further detail be unavailable be important emphasize however treasury stop inversion new statutory authority lew say congress act creative accountant lawyer continue find new way company move tax residence overseas avoid pay taxe here home share allergan agn ireland base drugmaker have be mull inversion deal pfizer pfe pfizer be little change hour allergan fall late trade nearly wipe regular session gain allergan be still sharply late october level pfizer buzz begin treasury department first begin attempt crack tax inversion september follow series inversion attempt particularly pharmaceutical business rule stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead tax inversion company seek move be technically be acquire practice relocate company run combine business many say deal deplete tax revenue allow company much operation dodge taxe many business community say inversion wouldn be need corporate tax rate be lower have world highest tax rate industrial world taxe overseas profit be repatriate here follow bill peter twitter ibd_bpeter
211,MYL,stock again open narrow loss friday retail sector stock experience unusually heavy selling nasdaq hurt worst dow jone industrial average carved decline fall
212,MYL,trade be mixed nasdaq lower nyse compare action same time thursday
213,MYL,stock market today feel early drag company report compound raft weaker forecast producer price retail sale datum
214,MYL,business inventory expand commerce department say vs consensus view change
215,MYL,consumer sentiment offer bright spot university michigan november consumer sentiment index jump september view improvement be index best read july
216,MYL,stock number heavy premarket move hold regular session
217,MYL,generic drug maker mylan myl surge perrigo prgo slump mylan fail attempt hostile takeover michigan base perrigo wall street journal report mylan cash stock tender offer garner only perrigo share mylan need least successful takeover offer expire friday
218,MYL,switzerland base seed strain herbicide giant syngenta syt leap bloomberg report company reject takeover offer state own china national chemical corp syngenta refuse offer earlier year
219,MYL,retail group show market worst loss industry first half hour trade fossil group fosl collapse jwn crumble report weak quarterly result late thursday
220,MYL,video game retailer gamestop gme drop grilled chicken chain el pollo unraveled
221,MYL,chip equipment maker apply material amat climb santa clara cal outfit report line fiscal result thursday close management say quarterly conference call company be open possibility merger apply material have be climb september low remain deep month consolidation
222,MYL,lead stock open session lousy mood more stock ibd list lose ground early action
223,MYL,china base tal education xrs post best move group almost peck new high provider kindergarten grade school tutor service be now nearly past buy point cup handle base
224,MYL,low end list paycom software payc lop oklahoma city base provider online human capital management program price share offer discount thursday close price loss drag share back buy point left stock day line support
225,MYL,follow alan elliott twitter ibd_aelliott facebookstock again open narrow loss friday retail sector stock experience unusually heavy selling nasdaq hurt worst dow jone industrial average carved decline fall trade be mixed nasdaq lower nyse compare action same time stock market today feel early drag company report compound raft weaker forecast producer price retail sale datum business inventory expand commerce department say vs consensus view change consumer sentiment offer bright spot university michigan november consumer sentiment index jump september view improvement be index best read july stock number heavy premarket move hold regular session generic drug maker mylan myl surge perrigo prgo slump mylan fail attempt hostile takeover michigan base perrigo wall street journal report mylan cash stock tender offer garner only perrigo share mylan need least successful takeover offer expire friday switzerland base seed strain herbicide giant syngenta syt leap bloomberg report company reject takeover offer state own china national chemical corp syngenta refuse offer earlier year retail group show market worst loss industry first half hour trade fossil group fosl collapse jwn crumble report weak quarterly result late thursday video game retailer gamestop gme drop grilled chicken chain el pollo unraveled chip equipment maker apply material amat climb santa clara cal outfit report line fiscal result thursday close management say quarterly conference call company be open possibility merger apply material have be climb september low remain deep month consolidation lead stock open session lousy mood more stock ibd list lose ground early action china base tal education xrs post best move group almost peck new high provider kindergarten grade school tutor service be now nearly past buy point cup handle base low end list paycom software payc lop oklahoma city base provider online human capital management program price share offer discount thursday close price loss drag share back buy point left stock day line support follow alan elliott twitter ibd_aelliott facebook
226,MYL,sell retail stock weigh major average midday friday october retail sale datum miss expectation big drop oil price didn help matter
227,MYL,dow jone industrial average nasdaq lose give small cap hold relatively well russell only nasdaq volume be tracking higher thursday level stock market today volume nyse be tracking close thursday level
228,MYL,retail sale rise october consensus estimate exclude auto sale rise also expectation worst perform group market friday hailed retail sector
229,MYL,new york mercantile exchange december crude oil future slump barrel thursday government report seventh straight weekly increase crude supply
230,MYL,downside ulta beauty ulta be need makeover share slump heavy volume earning be due dec
231,MYL,other lead retail stock be pressured include signet jeweler sig restoration hardware rh
232,MYL,meanwhile perrigo prgo slump shareholder reject hostile takeover bid fellow generic drug maker mylan lab myl share mylan soar
233,MYL,paycom software payc slump nearly company price share offer
234,MYL,day gainer recent new issue planet fitness plnt jump report earning late thursday share be recently trading slightly august ipo price planet fitness still have lot work do complete proper ipo base still high
235,MYL,follow ken shreve twitter ibd_kshreve facebook sell retail stock weigh major average midday friday october retail sale datum miss expectation big drop oil price didn help matter dow jone industrial average nasdaq lose give small cap hold relatively well russell only nasdaq volume be tracking higher thursday level stock market today volume nyse be tracking close thursday level retail sale rise october consensus estimate exclude auto sale rise also expectation worst perform group market friday hailed retail sector new york mercantile exchange december crude oil future slump barrel thursday government report seventh straight weekly increase crude supply downside ulta beauty ulta be need makeover share slump heavy volume earning be due dec other lead retail stock be pressured include signet jeweler sig restoration hardware rh meanwhile perrigo prgo slump shareholder reject hostile takeover bid fellow generic drug maker mylan lab myl share mylan soar paycom software payc slump nearly company price share offer day gainer recent new issue planet fitness plnt jump report earning late thursday share be recently trading slightly august ipo price planet fitness still have lot work do complete proper ipo base still high follow ken shreve twitter ibd_kshreve facebook
236,MYL,stock future narrow early loss abruptly approach start bell friday overseas market continue trade lower dow future show point decline vs point tumble hour earlier
237,MYL,nasdaq future halved hour earlier loss trade point fair market value future be point lower improve point loss small cap remain pressure russell future ease early loss point decline
238,MYL,stock market today get roll converge day move average nasdaq day line only market post day healthy gain wednesday also include federal reserve launch interest rate tighten cycle big news big hurdle market clear
239,MYL,friday premarket action be not encourage nasdaq do open session gain week be ahead index have gain past week
240,MYL,economic calendar close week quiet note only preliminary read service due researcher markit et regional survey expect atlanta federal reserve bank kansa city federal reserve baker hughe bhi release weekly rig count datum pm
241,MYL,half dow stock moved lower other half remain flat premarket trade johnson johnson jnj boee ba chevron cvx dip more dupont dd be sole gainer
242,MYL,several late season earning report whip action bell
243,MYL,carmax kmx dive open report third quarter sale earning stop short analyst estimate same store sale rise vs expectation increase stock have be scoop consolidation tight trade june
244,MYL,homebuilder lennar len rise more fiscal earning easily beat consensus view revenue growth stop just short forecast new home delivery rise order even newer home jump lennar share have be gradually weaken consolidation august
245,MYL,handheld device maker blackberry bbry grab gain ontario canada firm report not bad expect sale loss
246,MYL,leader open source software developer red hat rht jump more lead ibd list raleigh company late thursday deliver revenue earning consensus forecast management revenue guidance be earning guidance be analyst consensus view stock have be work retake day move average end thursday cup base buy point
247,MYL,qihoo technology qihu climb almost finally inking deal be take private group investor lead company chairman zhou hongyi zhou have propose deal earlier year market china slump serious correction
248,MYL,oil price slip west texas intermediate crude shed more barrel just week brent crude be fraction lower just almost week gold rise fraction still standing tight ounce level copper future pop leave price effectively level week
249,MYL,overseas market be broadly lower friday trading higher week japan nikkei tokyo topple leave index loss week shanghai composite end flat friday week hong kong hang seng end friday weekly gain
250,MYL,europe stock be pressure midday cac paris be frankfurt dax dip london ftse show decline week ftse track gain cac be dax show gain stock future narrow early loss abruptly approach start bell friday overseas market continue trade lower dow future show point decline vs point tumble hour earlier nasdaq future halved hour earlier loss trade point fair market value future be point lower improve point loss small cap remain pressure russell future ease early loss point decline stock market today get roll converge day move average nasdaq day line only market post day healthy gain wednesday also include federal reserve launch interest rate tighten cycle big news big hurdle market clear friday premarket action be not encourage nasdaq do open session gain week be ahead index have gain past week economic calendar close week quiet note only preliminary read service due researcher markit et regional survey expect atlanta federal reserve bank kansa city federal reserve baker hughe bhi release weekly rig count datum pm half dow stock moved lower other half remain flat premarket trade johnson johnson jnj boee ba chevron cvx dip more dupont dd be sole gainer several late season earning report whip action bell carmax kmx dive open report third quarter sale earning stop short analyst estimate same store sale rise vs expectation increase stock have be scoop consolidation tight trade june homebuilder lennar len rise more fiscal earning easily beat consensus view revenue growth stop just short forecast new home delivery rise order even newer home jump lennar share have be gradually weaken consolidation august handheld device maker blackberry bbry grab gain ontario canada firm report not bad expect sale loss leader open source software developer red hat rht jump more lead ibd list raleigh company late thursday deliver revenue earning consensus forecast management revenue guidance be earning guidance be analyst consensus view stock have be work retake day move average end thursday cup base buy point qihoo technology qihu climb almost finally inking deal be take private group investor lead company chairman zhou hongyi zhou have propose deal earlier year market china slump serious correction oil price slip west texas intermediate crude shed more barrel just week brent crude be fraction lower just almost week gold rise fraction still standing tight ounce level copper future pop leave price effectively level week overseas market be broadly lower friday trading higher week japan nikkei tokyo topple leave index loss week shanghai composite end flat friday week hong kong hang seng end friday weekly gain europe stock be pressure midday cac paris be frankfurt dax dip london ftse show decline week ftse track gain cac be dax show gain
251,MYL,expect treasury department late thursday issue tougher rule govern tax inversion company buy overseas firm then move headquarters country get more favorable tax treatment wasn clear immediately new rule impact possible pfizer pfe acquisition ireland base allergan agn deal value
252,MYL,analyst come defense canadian drug giant valeant pharmaceutical vrx tuesday stock sell word member congress be target pricing policy valeant stock plunge monday partly due larger drug sell also group congressional democrat send letter rep jason chaffetz
253,MYL,stock stage late rally thursday still end modestly lower weaker expect economic datum nasdaq fall dow jone industrial average dip ease fraction volume fall nyse nasdaq compare wednesday accord preliminary datum
254,MYL,economic news gdp expand annual rate wall street estimate gain well increase weekly jobless claim fall more expect pending home sale september be much weaker expect
255,MYL,top rate homebuilder slump weak housing datum horton dhi lennar len lgi home lgih fall
256,MYL,tech stock lead decline stock market today
257,MYL,network ffiv plunge bmo capital market rbc capital market downgrade stock network application cybersecurity company quarterly revenue guidance miss analyst expectation stock hit lowest level more year intraday thursday be week high
258,MYL,linkedin lnkd soar close strong earning report stock have be languish end regular session week high also day line have be day line june add sign weakness
259,MYL,starbucks sbux be post session trading follow quarterly earning report profit latest quarter rise cent match wall street estimate revenue rise beating view coffee seller outlook current quarter be weaker expect
260,MYL,stock end buy point thursday just buy range
261,MYL,solarcity scty plunge post session trade solar panel installer result disappoint investor earlier rival sunpower spwr gap soar much better expect report
262,MYL,cvs cvs exxon mobil xom chevron cvx mylan myl be company schedule report quarterly earning friday
263,MYL,economic report due friday include personal income spending september chicago purchasing manager index october university michigan consumer sentiment index october stock stage late rally thursday still end modestly lower weaker expect economic datum nasdaq fall dow jone industrial average dip ease fraction volume fall nyse nasdaq compare wednesday accord preliminary datum economic news gdp expand annual rate wall street estimate gain well increase weekly jobless claim fall more expect pending home sale september be much weaker expect top rate homebuilder slump weak housing datum horton dhi lennar len lgi home lgih fall tech stock lead decline stock market today network ffiv plunge bmo capital market rbc capital market downgrade stock network application cybersecurity company quarterly revenue guidance miss analyst expectation stock hit lowest level more year intraday thursday be week high linkedin lnkd soar close strong earning report stock have be languish end regular session week high also day line have be day line june add sign weakness starbucks sbux be post session trading follow quarterly earning report profit latest quarter rise cent match wall street estimate revenue rise beating view coffee seller outlook current quarter be weaker expect stock end buy point thursday just buy range solarcity scty plunge post session trade solar panel installer result disappoint investor earlier rival sunpower spwr gap soar much better expect report cvs cvs exxon mobil xom chevron cvx mylan myl be company schedule report quarterly earning friday economic report due friday include personal income spending september chicago purchasing manager index october university michigan consumer sentiment index october
264,MYL,tyson food tsn boee ba be company expect benefit tran pacific partnership trade agreement drugmaker biotechs primarily develop brand drug have emerge top loser nation accord include mexico canada japan australia vietnam be agree monday still require ratification congress agreement give brand
265,MYL,shareholder generic drug giant mylan myl friday vote favor continue firm hostile bid perrigo prgo launch be protracted battle mylan say third shareholder have approve transaction issuance share perrigo shareholder cash stock bid mylan last formal proposal april be worth
266,MYL,be sell not be sell be course question lie generic drug maker perrigo prgo regardless answer analyst say be plenty reason investor take interest dublin base company owing ability capitalize trend generic prescription drug counter sale first thing first friday stockholder drugmaker mylan myl be schedule vote approve hostile takeover bid perrigo move ahead tender offer perrigo ceo joseph papa speaking month analyst company latest quarterly earning call reiterate own opposition offer unanimous rejection perrigo board make prediction mylan shareholder vote want remind everyone include mylan shareholder proceed tender offer perrigo not be easy path be painting be papa say express confidence perrigo investor support stand alone ambition mylan begin pursue perrigo earlier year follow several refusal mylan recently offer share cash share perrigo share mylan need approval own shareholder support perrigo investor more share seal deal mylan insist new decisionin letter shareholder public statement most recent earning call papa have say mylan have undervalue perrigo mylan do shareholder vote initiate tender process ll make strategic decision board right thing do company say expect close vote analyst observer say deal ever get do not talk surround perrigo have attract positive attention be sticking buy rating perrigo see path upside share stand alone basis hopefully supplement acquisition large scale context sale mylan party deutsche bank analyst write perhaps deal talk lead even stronger bid mylan suitor potential investor sam pappas ceo mystic asset management veteran health care industry investor tell ibd many pharma company be hunting acquisition so not surprise more buyer show serious interest perrigo build pipeline say be efficient way do other hand mylan takeover attempt falter other suitor do not immediately enter fray perrigo be freed month long distraction focus anew organic growth acquisition own lawrence white economist new york university stern school business long time observer market tell ibd pharma industry bigger player often capitalize scale more efficiently distribute medication manufacture takeout target be not always case add say fast growth company have such robust pipeline proven growth sale simply interfere already solid expansion path perrigo establish be indeed case own shareholder back vote mylan takeover add important dose confidence investor feed biggest isn always best be lot move part address come distribute pharmaceutical tend favor larger company white say be not be biggest be always best rule here analyst say perrigo be indeed well position growth remain stand alone entity company be lead maker distributor private label counter generic prescription drug analyst say frugal consumer be increasingly move away national brand store brand away expensive prescription otc alternative outcome aside continue fundamental perrigo story give global leadership position store brand otc ability capitalize rx otc switch william blair analyst say august report perrigo spend absorb own acquisition dublin base elan sell treatment everything smoking cessation pain relief stock have ibd composite rating ibd medical general drug industry group rank st industry group perrigo be rank allergan agn quarter end june perrigo report earning cent share exclude time item generate ep revenue firm cite strength new brand consumer health care line include recent acquisition omega pharma expansion pharmaceutical revenue brand consumer health care generate sale sale perrigo prescription pharmaceutical segment increase more bolt on company also recently inked deal buy patheon operation mexico well portfolio otc drug glaxosmithkline gsk analyst anticipate perrigo pursue more such bolt deal remain stand alone operation post quarterly result earlier august perrigo executive project ep increase midpoint sale ahead midpoint executive say addition company specific trend perrigo also stand benefit general ongoing demographic health care development give megatrend have talk many year include age population increase use medication individual get older rise health care cost perrigo be well position meet future need global health care community papa chief executive say earning call
267,MYL,specialty drug maker ibd stock endo international beat wall street expectation monday didn change guidance digest major acquisition endo endp stock fall much early monday end day fraction endo earning continue operation rise year earlier quarter share beating
268,MYL,specialty drugmaker sucampo pharmaceutical scmp beat expectation raise guidance early wednesday send stock new high early trading pull back later however possibly word get sole market drug be be exclude cvs cvs prefer formulary next year sucampo report earning cent share just cent year earlier quarter cent analyst consensus accord thomson reuter revenue grow more analyst expect company raise full year ep guidance cent top street estimate cent sucampo revenue come constipation drug amitiza be still grow even be market year prescription grow sucampo royalty revenue marketing partner takeda grow japan royalty revenue marketing partner mylan myl double second quarter deliver outstanding earning growth drive mainly amitiza continue growth japan sucampo ceo peter greenleaf say statement financial strength fuel continue transformation business transformation include launch second drug cobiprostone be midstage testing oral mucositis many street have be wait sucampo acquire company drug help fill thin pipeline greenleaf have tell ibd actively look opportunity now company still depend product become greater issue pharmacy giant cvs prefer formulary list leak online amitiza wasn have be year formulary cvs knock favor allergan agn linzess nonetheless guggenheim analyst louise chen raise price target sucampo affirm buy rating sucampo still expect mid high single digit growth amitiza amitiza be put cvs exclusion list amitiza have also have formulary win negotiation reimbursement be still ongoing chen write research note wednesday sucampo stock have be volatile emerge cup base mid july volatility continue stock market today share shot new high early then reversed fall low stock be midday stock boast highest possible ibd composite rating meaning sucampo top other stock base range key fundamental technical factor follow amy reeve twitter ibd_areeve
269,MYL,teva pharmaceutical teva confirm report monday buy allergan agn generic drug business drop hostile takeover bid mylan pharmaceutical myl deal teva pay cash share deal be expect close teva say buyout boost adjust earning share double digit deal allow allergan focus brand drug business give teva revenue source face competition multiple sclerosis drug copaxone acquisition allergan generic establish strong foundation long term sustainable growth anchor lead generic capability world class late stage pipeline accelerate ability build exceptional portfolio product generic specialty well intersection say teva ceo erez vigodman teva share jump premarket trading stock market today allergan climb mylan share plunge hostile bid mylan mylan say continue pursue perrigo prgo mylan shareholder vote acquisition next several week accord company perrigo share rally premarket global health care have hit july vs year accord datum cite reuter teva also report strong preliminary result raise full year ep outlook analyst poll thomson reuter be expect teva announce official result thursday follow gillian rich twitter ibd_grich
270,MYL,day teva pharmaceutical teva break base fellow drugmaker amgen amgn be clear buy point amgen report second quarter result close thursday earning be project rise slowdown first quarter growth
271,MYL,stock climb big volume stock market today clear early buy point
272,MYL,amgen be also near conventional buy point currently trading level
273,MYL,monday teva gap new high giant volume breaking cup base buy point share be still trading buy range today be
274,MYL,teva announce preliminary result top expectation raise guidance
275,MYL,company also drop hostile bid mylan myl have agree buy allergan agn generic drug arm actavis
276,MYL,analyst speculate amgen abbvie abbv biogen biib shire shpg be allergan next potential takeover target
277,MYL,follow alissa william twitter ibd_awilliam day teva pharmaceutical teva break base fellow drugmaker amgen amgn be clear buy point amgen report second quarter result close thursday earning be project rise slowdown first quarter growth stock climb big volume stock market today clear early buy point amgen be also near conventional buy point currently trading level monday teva gap new high giant volume breaking cup base buy point share be still trading buy range today be teva announce preliminary result top expectation raise guidance company also drop hostile bid mylan myl have agree buy allergan agn generic drug arm actavis analyst speculate amgen abbvie abbv biogen biib shire shpg be allergan next potential takeover target follow alissa william twitter ibd_awilliam
278,MYL,israeli drug giant teva pharmaceutical industry drop hostile bid mylan instead agree buy global generic drug business allergan monday teva allergan stock jump new high mylan drop teva teva agree pay cash stock allergan agn actavis business
279,MYL,stock step rebound effort hit fresh session high tuesday afternoon major average have recoup more half monday steep loss more earning report mixed economic datum
280,MYL,lead pack gain monday benchmark index slump find support day line meanwhile dow jone industrial average nasdaq climb respectively volume be tracking modestly higher major exchange stock market today
281,MYL,lead stock icon iclr gap rocket retook day move average mixed result provider drug development service post second quarter earning view sale be mixed ep rise cent share revenue rise icon also raise full year profit outlook trim revenue guidance company also add stock buyback icon clear buy point flat base aggressive buyer have enter stock early entry
282,MYL,cadence design system cdns gap bolt clear day line reaction late monday better expect earning software maker post profit cent share year marked biggest gain quarters company also announce stock buyback cadence clear buy point flat base
283,MYL,downside baidu bidu gap plunge nearly report mixed result give weak revenue guidance late monday multiple analyst downgrade stock chinese internet stock hit month low
284,MYL,mylan myl be session low still fast trade news teva pharmaceutical teva buy allergan agn generic drug business send mylan share nearly monday stock step rebound effort hit fresh session high tuesday afternoon major average have recoup more half monday steep loss more earning report mixed economic datum lead pack gain monday benchmark index slump find support day line meanwhile dow jone industrial average nasdaq climb respectively volume be tracking modestly higher major exchange stock market today lead stock icon iclr gap rocket retook day move average mixed result provider drug development service post second quarter earning view sale be mixed ep rise cent share revenue rise icon also raise full year profit outlook trim revenue guidance company also add stock buyback icon clear buy point flat base aggressive buyer have enter stock early entry cadence design system cdns gap bolt clear day line reaction late monday better expect earning software maker post profit cent share year marked biggest gain quarters company also announce stock buyback cadence clear buy point flat base downside baidu bidu gap plunge nearly report mixed result give weak revenue guidance late monday multiple analyst downgrade stock chinese internet stock hit month low mylan myl be session low still fast trade news teva pharmaceutical teva buy allergan agn generic drug business send mylan share nearly monday
285,MYL,stock future change tune point slightly weaker start stock market today nasdaq future fall point vs fair value future lose point future dow jone industrial average give point
286,MYL,stock market end week winning streak last week pickup distribution day prompt downgrade market outlook
287,MYL,stock market overseas be mixed europe france cac slip friday series attack islamic state left more dead germany dax rise london ftse climb
288,MYL,asia hong kong hang seng fall japan nikkei slump shanghai composite reversed higher gain
289,MYL,crude oil jump more barrel potential supply disruption oil price hit lowest level month last week
290,MYL,safe haven instrument such bond dollar be trading higher gold be also higher ounce
291,MYL,economic news empire state index november come vs consensus estimate econoday
292,MYL,number central bank official be speaking week start tuesday fed governor jerome powell minute fed october meeting be due wednesday
293,MYL,stock starwood hotel resort hot fall premarket trading news be buy marriott international mar cash stock deal create world biggest hotel chain
294,MYL,dd slump premarket trading post disappointing quarterly result department store operator say earn share include tax credit cent share sale slip view be ep revenue rival macy plunge last week disappointing quarterly sale weak outlook
295,MYL,airline stock be lower premaket activity concern friday attack tourism share american airline group aal delta air line dal unite continental ual ryanair ryaay be more
296,MYL,nyse nasdaq observe minute silence et victim paris terrorist attack friday
297,MYL,follow vincent mao twitter ibd_vmao stock future change tune point slightly weaker start stock market today nasdaq future fall point vs fair value future lose point future dow jone industrial average give point stock market end week winning streak last week pickup distribution day prompt downgrade market outlook stock market overseas be mixed europe france cac slip friday series attack islamic state left more dead germany dax rise london ftse climb asia hong kong hang seng fall japan nikkei slump shanghai composite reversed higher gain crude oil jump more barrel potential supply disruption oil price hit lowest level month last week safe haven instrument such bond dollar be trading higher gold be also higher ounce economic news empire state index november come vs consensus estimate econoday number central bank official be speaking week start tuesday fed governor jerome powell minute fed october meeting be due wednesday stock starwood hotel resort hot fall premarket trading news be buy marriott international mar cash stock deal create world biggest hotel chain dd slump premarket trading post disappointing quarterly result department store operator say earn share include tax credit cent share sale slip view be ep revenue rival macy plunge last week disappointing quarterly sale weak outlook airline stock be lower premaket activity concern friday attack tourism share american airline group aal delta air line dal unite continental ual ryanair ryaay be more nyse nasdaq observe minute silence et victim paris terrorist attack friday follow vincent mao twitter ibd_vmao
298,MYL,market knock healthy early gain monday broad range stock rebound last week slump dow jone industrial average grab gain nasdaq climb volume stock market today open mixed trade rise nyse possibly good sign rebound day move average volume dip nasdaq index retook day line
299,MYL,stock precision castpart pcp lead soar news acquisition berkshire hathaway brka
300,MYL,dow issue moved higher start trade apple aapl boee ba lead nearly chip stock drugmaker stake high ground nasdaq issue texas instrument txn kla tencor klac rise so do alexion alxn mylan myl
301,MYL,ibd list cyberark software cybr investment wetf swat better gain
302,MYL,cyberark move lift share back stock day move average attempt begin right side month consolidation
303,MYL,be climb day move average trading past cup base buy point
304,MYL,june quarter earning season be slow today hour session be nevertheless busy big name such hertz global htz kraft heinz khc report smaller name shake shack shak vipshop vip schedule report market knock healthy early gain monday broad range stock rebound last week slump dow jone industrial average grab gain nasdaq climb volume stock market today open mixed trade rise nyse possibly good sign rebound day move average volume dip nasdaq index retook day line stock precision castpart pcp lead soar news acquisition berkshire hathaway brka dow issue moved higher start trade apple aapl boee ba lead nearly chip stock drugmaker stake high ground nasdaq issue texas instrument txn kla tencor klac rise so do alexion alxn mylan myl ibd list cyberark software cybr investment wetf swat better gain cyberark move lift share back stock day move average attempt begin right side month consolidation be climb day move average trading past cup base buy point june quarter earning season be slow today hour session be nevertheless busy big name such hertz global htz kraft heinz khc report smaller name shake shack shak vipshop vip schedule report
305,MYL,momenta pharmaceutical mnta stock drop thursday ub downgrade sell say company recent good news have already be price stock analyst marc goodman write last month launch momenta partner novartis nvs generic version teva pharmaceutical teva blockbuster copaxone drive term earning growth say double
306,MYL,barely hatch independent company drugmaker baxalta bxlt get unsolicited buyout proposal shire shpg send stock sharply early trading tuesday shire say july propose stock transaction exchange shire adr share baxalta imply value share base
307,MYL,drugmaker medicine company mdco eagle pharmaceutical egrx be rise bullish analyst action monday wake thursday court ruling overturn patent medicine cardiovascular drug angiomax bivalirudin appeal court decision seem be bad news medicine mizuho security analyst mario corso upgrade stock buy neutral monday
308,MYL,share generic drug maker perrigo prgo rise much tuesday bmo capital market launch coverage outperform rating say perrigo stock be undervalue regardless mylan myl succeed acquire company
309,MYL,analyst david maris write trend favor perrigo business model be divide private label counter prescription generic drug
310,MYL,continue movement consumer national brand store brand product prescription otc switch combine increase health care cost age population drive global demand store brand otc medication write
311,MYL,maris also say perrigo be try resist unsolicited bid mylan be likely especially careful guidance give perrigo miss estimate unsolicited bid period defense unwanted deal have think perrigo guidance be conservative side write
312,MYL,maris admit mylan bid fail perrigo stock fall short term say fundamental growth eventually make loss
313,MYL,add also potential upside biogen biib report positive result trial tysabri multiple sclerosis drug biogen be pay perrigo royalty thank perrigo acquisition elan
314,MYL,trial be due readout later year be testing tysabri secondary progressive ms stroke prevention wall street be not give great odd success so add revenue indication be not consensus expectation write
315,MYL,maris set price target stock midday trading stock market today perrigo stock be nearly
316,MYL,follow amy reeve twitter ibd_areeve
317,MYL,related
318,MYL,perrigo glaxo buy make too pricey share generic drug maker perrigo prgo rise much tuesday bmo capital market launch coverage outperform rating say perrigo stock be undervalue regardless mylan myl succeed acquire company analyst david maris write trend favor perrigo business model be divide private label counter prescription generic drug continue movement consumer national brand store brand product prescription otc switch combine increase health care cost age population drive global demand store brand otc medication write maris also say perrigo be try resist unsolicited bid mylan be likely especially careful guidance give perrigo miss estimate unsolicited bid period defense unwanted deal have think perrigo guidance be conservative side write maris admit mylan bid fail perrigo stock fall short term say fundamental growth eventually make loss add also potential upside biogen biib report positive result trial tysabri multiple sclerosis drug biogen be pay perrigo royalty thank perrigo acquisition elan trial be due readout later year be testing tysabri secondary progressive ms stroke prevention wall street be not give great odd success so add revenue indication be not consensus expectation write maris set price target stock midday trading stock market today perrigo stock be nearly follow amy reeve twitter ibd_areeve related perrigo glaxo buy make too pricey
319,MYL,eagle pharmaceutical have soar new height wall street signing key licensing pact enhance company prospect hit market soon big money make drug eagle pharmaceutical egrx stock have leap feb company announce have inked exclusive license agreement cephalon wholly own subsidiary israeli drug giant teva pharmaceutical industry teva eagle bendamustine hydrochloride hcl rapid infusion product treat patient chronic lymphocytic leukemia cll patient indolent cell hodgkin lymphoma nhl teva dealteva be responsible product commercial activity include promotion distribution eagle be responsible obtain regulatory approval conduct post approval clinical study require initially supply drug product teva term pact eagle receive upfront cash payment be recognize income be eligible receive additional milestone payment milestone payment eagle say get double digit percentage royalty net sale product assume food drug administration approval draw investor be eagle have very credible partner teva have ability deliver royalty william blair analyst tim lugo tell ibd lugo estimate royalty payment eagle get teva start product sale eagle be focuse develop commercialize injectable drug product primarily critical care oncology area improve exist drug go speak stakeholder physician nurse doctor find gap be product need be improve ceo founder scott tarriff tell ibd reformulate drug hopefully bring drug market customer be ask hopefully re improve patient outcome drug introduction strategyeagle strategy be introduce product later first generic competitor brand reference product say company filing security exchange commission eagle bendamustine rapid infusion product be improve formulation teva bendamustine hcl product treanda expect teva convert nearly treanda product market eagle formulation tarriff say be eagle product better treanda eagle product be administer approximately minute low volume milliliter admixture vs treanda milliliter admixture require infusion last minute tarriff say benefit eagle product be less chair time patient less nursing time require tarriff add fda accept new drug application nda filing dec expect decision date approve rapid infusion bendamustine product treat patient cll patient indolent cell nhl have progressed month treatment rituximab rituximab contain regimen eagle used fda nda regulatory pathway section expressly permit fda rely approval nda datum not develop applicant such publish literature agency find safety effectiveness previously approve drug product accord fda patent trademark office grant new patent pertain rapid infusion bendamustine product eagle announce last month patent expire march product have receive orphan drug designation cll indolent cell nhl therefore be eligible year exclusivity approval eagle say press release tarriff estimate market treanda be tarriff say founding eagle have be develop drug have change agreement teva tarriff call big breakthrough be transition development company commercial company say tarriff teva use eagle bendamustine rapid infusion product own life cycle product used capital infusionlugo say agreement teva be game changer eagle company have significant royalty start say question street be be company go deploy capital eagle go public february turn first profit first quarter company earn share vs loss cent year earlier revenue jump lugo say upfront cash payment teva drive eagle profit however add profit win be sustainable company gain fda approval bendamustine rapid infusion product approval come fourth quarter drive profitability lugo say analyst poll thomson reuter expect company show full year earning cent share expect earning increase see rise eagle treatment portfolioeagle have portfolio drug have drug market ryanodex injectable suspension treat rare life threaten condition call malignant hyperthermia fda approve last summer fda designate ryanodex orphan drug malignant hyperthermia fda have grant year market exclusivity ryanodex treat condition eagle announce february first quarter ryanodex sale be higher prior quarter reflect successful execution product launch last fall ongoing effort sale force say tarriff press release eagle be research potential ryanodex be apply exertional heat stroke eagle also have file ndas fda other drug be work clinical trial yet drug lugo say eagle bendamustine rapid infusion product be key drug company have several other drug pipeline be promising eagle be part ibd medical generic drug industry group have composite rating possible other member group include allergan agn lead group composite rating mylan myl have composite rating
320,MYL,israeli drug giant teva pharmaceutical industry teva report positive result recently acquire drug tuesday teva stock be fraction however company also face new roadblock effort take mylan myl
321,MYL,teva say sd drug have gain buyout auspex pharmaceutical last month hit primary endpoint pivotal trial dyskinesia movement disorder sometimes afflict person take psychotic medication news follow successful trial sd huntington disease teva say dyskinesia be larger market potentially pass year peak sale
322,MYL,importantly study also show favorable safety tolerability profile include low rate depression somnolence insomnia akathisia movement disorder be differentiate factor competitive landscape maxim group analyst jason kolbert write research note tuesday
323,MYL,evercore isi analyst umer raffat note efficacy seem broadly similar neurocrine bioscience nbix candidate nbi agree email safety tolerability continue look excellent teva drug be very important commercial differentiator
324,MYL,also tuesday abbott laboratory own stake mylan say vote support mylan attempt acquire perrigo prgo mylan have be pursue april support acquisition be problem teva pursuit mylan teva offer company late april same time make clear not interested perrigo business
325,MYL,neither perrigo mylan want be buy investor not care company want perrigo stock be nearly afternoon trading stock market today mylan stock be
326,MYL,follow amy reeve twitter ibd_areeve israeli drug giant teva pharmaceutical industry teva report positive result recently acquire drug tuesday teva stock be fraction however company also face new roadblock effort take mylan myl teva say sd drug have gain buyout auspex pharmaceutical last month hit primary endpoint pivotal trial dyskinesia movement disorder sometimes afflict person take psychotic medication news follow successful trial sd huntington disease teva say dyskinesia be larger market potentially pass year peak sale importantly study also show favorable safety tolerability profile include low rate depression somnolence insomnia akathisia movement disorder be differentiate factor competitive landscape maxim group analyst jason kolbert write research note tuesday evercore isi analyst umer raffat note efficacy seem broadly similar neurocrine bioscience nbix candidate nbi agree email safety tolerability continue look excellent teva drug be very important commercial differentiator also tuesday abbott laboratory own stake mylan say vote support mylan attempt acquire perrigo prgo mylan have be pursue april support acquisition be problem teva pursuit mylan teva offer company late april same time make clear not interested perrigo business neither perrigo mylan want be buy investor not care company want perrigo stock be nearly afternoon trading stock market today mylan stock be follow amy reeve twitter ibd_areeve
327,MYL,embattled generic drugmaker perrigo prgo agree buy portfolio counter drug glaxosmithkline gsk tuesday move interpreted help fend advance mylan myl
328,MYL,undisclosed sum perrigo agree acquire variety product include cold flu medicine nicotine patch cold sore treatment sale totale last year largely european market glaxo part sell product meet antitrust requirement allow form consumer health joint venture novartis nvs
329,MYL,acquisition demonstrate perrigo ability execute base strategy make selective accretive transaction expand durable base business perrigo ceo joseph papa say statement be build global platform establish omega pharma acquisition capture even greater share european otc market opportunity several well establish complementary brand bolster otc product portfolio
330,MYL,perrigo hold short conference call deal tuesday morning say expect new brand perform consistently perrigo annual revenue growth profile lack price tag make calculation difficult leerink analyst jason gerberry see economic favorable
331,MYL,expect deal be accretive ep potential upside prgo re accelerate growth brand gerberry write research note tuesday add buyout be also strategically sound prgo leverage omega ex commercial infrastructure continue look further deal maximize platform
332,MYL,hold conference call deal size be unusual rbc capital market analyst randall stanicky theorize have be drive mylan unsolicited pursuit perrigo
333,MYL,give myl bid assume want use announcement highlight value omega platform perceive value be able discuss deal broadly give irish law constraint stanicky write research note tuesday
334,MYL,stanicky say glaxo deal make perrigo more expensive acquire therefore decrease odd mylan acquisition happen
335,MYL,view turn increase odd teva pharmaceutical industry teva succeed unsolicited pursuit mylan fact mylan ceo accuse teva violate antitrust law latter reveal late monday
336,MYL,perrigo stock be more midday trading glaxo stock be flat mylan stock be fraction
337,MYL,follow amy reeve twitter ibd_areeve embattled generic drugmaker perrigo prgo agree buy portfolio counter drug glaxosmithkline gsk tuesday move interpreted help fend advance mylan myl undisclosed sum perrigo agree acquire variety product include cold flu medicine nicotine patch cold sore treatment sale totale last year largely european market glaxo part sell product meet antitrust requirement allow form consumer health joint venture novartis nvs acquisition demonstrate perrigo ability execute base strategy make selective accretive transaction expand durable base business perrigo ceo joseph papa say statement be build global platform establish omega pharma acquisition capture even greater share european otc market opportunity several well establish complementary brand bolster otc product portfolio perrigo hold short conference call deal tuesday morning say expect new brand perform consistently perrigo annual revenue growth profile lack price tag make calculation difficult leerink analyst jason gerberry see economic favorable expect deal be accretive ep potential upside prgo re accelerate growth brand gerberry write research note tuesday add buyout be also strategically sound prgo leverage omega ex commercial infrastructure continue look further deal maximize platform hold conference call deal size be unusual rbc capital market analyst randall stanicky theorize have be drive mylan unsolicited pursuit perrigo give myl bid assume want use announcement highlight value omega platform perceive value be able discuss deal broadly give irish law constraint stanicky write research note tuesday stanicky say glaxo deal make perrigo more expensive acquire therefore decrease odd mylan acquisition happen view turn increase odd teva pharmaceutical industry teva succeed unsolicited pursuit mylan fact mylan ceo accuse teva violate antitrust law latter reveal late monday perrigo stock be more midday trading glaxo stock be flat mylan stock be fraction follow amy reeve twitter ibd_areeve
338,MYL,etfs ride price momentum wave re packed stock such mylan myl skywork solution swks have have big upward move smart beta expert hold momentum factor lead outperformance also make investor uneasy so call glamour stock make big price move too tend have little substance so be
339,MYL,specialty drug giant ibd stock actavis act beat wall street estimate monday first time offer guidance include newly acquire allergan be line expectation actavis stock be early trading monday moved week move average company say earning quarter rise
340,MYL,aspiring specialty drug giant endo international agree buy major generic drug maker par pharmaceutical holding monday deal endo say make top generic drug maker world investor be less enthusiastic however endo stock fall close endo endp agree shell
341,MYL,big health insurer want get bigger cut cost fatten profit course seem be move faster now consolidate response merger elsewhere health care system
342,MYL,bigger pharmaceutical company merge hospital require larger more powerful insurer represent patient
343,MYL,so eager perhaps prove determination investor anthem antm last week take unusual step publicize detail takeover talk cigna ci lead bloomfield conn base cigna publicly admit deeply disappoint anthem disclose latest offer
344,MYL,meanwhile humana hum have offer sale be be pursue aetna aet reportedly be be court unitedhealth group unh nation largest health insurer
345,MYL,possible post merger scenario include anthem aetna unitedhealth lord health insurance sector be just anthem unitedhealth dust settle
346,MYL,now big insurer also be feel more pressure merge soon possible know subsequent proposal invite greater antitrust scrutiny
347,MYL,big health insurer be too big too late avoid critic
348,MYL,lack competition clearly exist today speak loudly further consolidation health insurance industry chairman american academy family physician write federal trade commission month
349,MYL,address rise cost
350,MYL,still reason cut cost gain leverage merger
351,MYL,last year prescription drug spending rise record accord im institute healthcare informatic hepatitis treatment most expensive new blockbuster
352,MYL,consolidation give insurer more leverage negotiate price doctor hospital drugmaker other sector health care industry have consolidated rapidly lately
353,MYL,re try scale order get more leverage contract drug manufacturer other health care provider say jeffrey loo analyst capital iq
354,MYL,insurer be feel more pressure grow now have just absorb new patient
355,MYL,obamacare creation federally subsidize insurance exchange used state have provide new option million newly insure consumer only last year
356,MYL,health care be busiest industry consolidation year rite aid rad agree buy envision pharmaceutical service february next month unitedhealth buy pharmacy benefit manager catamaran ctrx cvs health cvs agree month pay buy target tgt pharmacy state
357,MYL,tenet healthcare thc hca hca other major hospital operator have gobble smaller player recent year
358,MYL,drugmaker be slouch department april teva pharmaceutical industry teva bid mylan myl perrigo prgo reject mylan bid march dublin base actavis complete acquisition allergan create world top pharmaceutical company sale estimate june actavis change name allergan agn
359,MYL,nonprofit such kaiser permanente blue cross blue shield be seek grow exchange morningstar vishnu lekraj say
360,MYL,medicaid expansion federal government be ripple rest market
361,MYL,big health insurer revenue have be grow high single digit margin have be relatively flat loo say
362,MYL,striking hot iron
363,MYL,merger mania have strike health insurance sector big time stock be best performer market anthem cigna aetna share hit record high again tuesday unitedhealth gain so far year record tuesday jan humana share flattened tuesday ibd medical manage care industry group have rise past year compare gain
364,MYL,kind consolidation big company say gerald kominski director ucla center health policy research really only way grow faster organic growth big health insurer want get bigger cut cost fatten profit course seem be move faster now consolidate response merger elsewhere health care system bigger pharmaceutical company merge hospital require larger more powerful insurer represent patient so eager perhaps prove determination investor anthem antm last week take unusual step publicize detail takeover talk cigna ci lead bloomfield conn base cigna publicly admit deeply disappoint anthem disclose latest offer meanwhile humana hum have offer sale be be pursue aetna aet reportedly be be court unitedhealth group unh nation largest health insurer possible post merger scenario include anthem aetna unitedhealth lord health insurance sector be just anthem unitedhealth dust settle now big insurer also be feel more pressure merge soon possible know subsequent proposal invite greater antitrust scrutiny big health insurer be too big too late avoid critic lack competition clearly exist today speak loudly further consolidation health insurance industry chairman american academy family physician write federal trade commission month address rise reason cut cost gain leverage merger last year prescription drug spending rise record accord im institute healthcare informatic hepatitis treatment most expensive new blockbuster consolidation give insurer more leverage negotiate price doctor hospital drugmaker other sector health care industry have consolidated rapidly lately re try scale order get more leverage contract drug manufacturer other health care provider say jeffrey loo analyst capital iq insurer be feel more pressure grow now have just absorb new patient obamacare creation federally subsidize insurance exchange used state have provide new option million newly insure consumer only last year health care be busiest industry consolidation year rite aid rad agree buy envision pharmaceutical service february next month unitedhealth buy pharmacy benefit manager catamaran ctrx cvs health cvs agree month pay buy target tgt pharmacy state tenet healthcare thc hca hca other major hospital operator have gobble smaller player recent year drugmaker be slouch department april teva pharmaceutical industry teva bid mylan myl perrigo prgo reject mylan bid march dublin base actavis complete acquisition allergan create world top pharmaceutical company sale estimate june actavis change name allergan agn nonprofit such kaiser permanente blue cross blue shield be seek grow exchange morningstar vishnu lekraj say medicaid expansion federal government be ripple rest market big health insurer revenue have be grow high single digit margin have be relatively flat loo say striking hot ironsmerger mania have strike health insurance sector big time stock be best performer market anthem cigna aetna share hit record high again tuesday unitedhealth gain so far year record tuesday jan humana share flattened tuesday ibd medical manage care industry group have rise past year compare gain kind consolidation big company say gerald kominski director ucla center health policy research really only way grow faster organic growth
365,MYL,selling pressure market drug distribution giant abc have continue show support resilience american century mutual fund manager david hollond note recent interview ibd obamacare be boost give more person access health insurance prescription drug hollond also say year get lift
366,MYL,stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge
367,MYL,volume nasdaq nyse be tracking tuesday level
368,MYL,fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis
369,MYL,stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast
370,MYL,stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation
371,MYL,solar stock be day best performer lead first solar fslr jump new high heavy volume
372,MYL,maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar
373,MYL,downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy
374,MYL,meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge volume nasdaq nyse be tracking tuesday level fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation solar stock be day best performer lead first solar fslr jump new high heavy volume maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise
375,MYL,generic drug giant mylan deliver mixed first quarter report late tuesday other top rate medical stock issue more positive report earlier day share slip fraction hour trading mylan myl profit rise year earlier quarter cent share beating analyst consensus penny accord thomson reuter sale increase
376,MYL,cross border merger boom be boost etfs hold catamaran ctrx dresser rand drc other pharma energy company be hot takeover target merger arbitrage exchange trade fund profit difference stock price deal be announce final purchase price typically upward move cross border merger acquisition have totale roughly
377,MYL,specialty drug giant ibd stock actavis beat wall street first quarter estimate monday first time offer earning guidance include newly acquire allergan highly rate ligand pharmaceutical lgnd endo international endp also top ep target actavis act earning rise vs year earlier share cent analyst consensus accord
378,MYL,generic drug maker mylan myl raise offer drugstore supplier perrigo wednesday get reject again
379,MYL,mylan offer share cash mylan share perrigo prgo share significant increase april bid cash mylan share
380,MYL,base mylan share price april first propose buy perrigo most recent offer come perrigo share
381,MYL,perrigo however have be argue mylan stock price have be drive speculation be buy teva pharmaceutical industry teva eventual bid mylan reject monday
382,MYL,teva have make clear not interested perrigo outside mylan perrigo consider real mylan stock price be be close teva acquisition rumor start march
383,MYL,today announcement mylan continue propose price lower previously reject proposal perrigo say
384,MYL,research note wednesday leerink analyst jason gerberry write likely herald raise teva bid
385,MYL,morning catch teva ir recap company recent investor meeting myl shareholder write come away convince teva be commit get myl deal do have room sweeten offer
386,MYL,midday trading stock market today mylan stock be perrigo stock be fraction teva stock be fraction
387,MYL,follow amy reeve twitter ibd_areeve generic drug maker mylan myl raise offer drugstore supplier perrigo wednesday get reject again mylan offer share cash mylan share perrigo prgo share significant increase april bid cash mylan share base mylan share price april first propose buy perrigo most recent offer come perrigo share perrigo however have be argue mylan stock price have be drive speculation be buy teva pharmaceutical industry teva eventual bid mylan reject monday teva have make clear not interested perrigo outside mylan perrigo consider real mylan stock price be be close teva acquisition rumor start march today announcement mylan continue propose price lower previously reject proposal perrigo say research note wednesday leerink analyst jason gerberry write likely herald raise teva bid morning catch teva ir recap company recent investor meeting myl shareholder write come away convince teva be commit get myl deal do have room sweeten offer midday trading stock market today mylan stock be perrigo stock be fraction teva stock be fraction follow amy reeve twitter ibd_areeve
388,MYL,mylan myl reject takeover bid teva pharmaceutical teva monday say be still be commit offer perrigo prgo generic pharmaceutical company say offer undervalue company require mylan shareholder believe be low quality teva share exchange high quality mylan share many analyst
389,MYL,big cap drugmaker report mostly solid first quarters thursday morning market give decidedly mixed reception israeli generic drug giant teva pharmaceutical teva report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter sale decline fraction beat
390,MYL,teva pharmaceutical industry teva make long rumore bid smaller generic rival mylan myl tuesday share stock rise pre market trading counter product maker perrigo prgo have offer mylan fall early trading
391,MYL,israeli base teva offer buy mylan share equal part cash stock
392,MYL,propose combination teva mylan create lead company pharmaceutical industry well position transform global generic space teva say statement combine company leverage significantly more efficient advanced infrastructure enhance scale production network end end product portfolio capability geographic reach
393,MYL,mylan share rise open stock market today teva climb
394,MYL,mylan last week various teva buzz say plan remain standalone company april offer share perrigo many analyst speculate be effort prevent mylan be takeover target perrigo fall pre market trading
395,MYL,teva proposal also provide mylan stockholder more attractive alternative mylan propose acquisition perrigo company plc announce april well mylan standalone basis teva say teva pharmaceutical industry teva make long rumore bid smaller generic rival mylan myl tuesday share stock rise pre market trading counter product maker perrigo prgo have offer mylan fall early trading israeli base teva offer buy mylan share equal part cash stock propose combination teva mylan create lead company pharmaceutical industry well position transform global generic space teva say statement combine company leverage significantly more efficient advanced infrastructure enhance scale production network end end product portfolio capability geographic reach mylan share rise open stock market today teva climb mylan last week various teva buzz say plan remain standalone company april offer share perrigo many analyst speculate be effort prevent mylan be takeover target perrigo fall pre market trading teva proposal also provide mylan stockholder more attractive alternative mylan propose acquisition perrigo company plc announce april well mylan standalone basis teva say
396,MYL,pharmaceutical company search new market energy business seek growth have fuel rate company buy overseas asset year high
397,MYL,cross border merger acquisition worldwide year totale thursday year biggest year date total accord thomson reuter
398,MYL,announce cross border deal comprise total so far largest annual share cross border transaction amount so far year have be announce transaction also most not deal have yet close
399,MYL,megadeal have be full force deal value more make nearly half cross border total so far year
400,MYL,company be lead charge have keen eye european target so far overseas deal have take place europe point last year company switzerland be most popular target value
401,MYL,more attractive european
402,MYL,europe rise popularity come continental value be damage great recession eurozone lurch crisis next persistent strength dollar make euro property more affordable american hope stronger economic growth indeed europe economy have grow faster recent month
403,MYL,last year person begin feel more comfortable business model european company be solidify little bit say matthew toole thomson reuter director deal intelligence
404,MYL,energy sector have be batter depress crude oil price translate fall earning revenue have be most active sector cross border year energy company have value deal year total more double year date energy sector value deal total
405,MYL,royal dutch shell rdsa announce deal acquire read england base bg group be biggest announce cross border energy deal so far
406,MYL,health care sector lead big pharma have generate deal ytd total year
407,MYL,include reject megadeal offer st loui base agribusiness giant offer buy switzerland base syngenta syt offer reject purportedly undervalue company underestimate regulatory issue generic drug maker mylan myl reject offer rival teva pharmaceutical teva canonsburg pa base mylan currently be engineering hostile takeover bid irish drugmaker perrigo prgo
408,MYL,obama administration last year crack tax inversion company buy foreign business relocate headquarters lower corporate tax rate hasn slow health care company desire expand new market
409,MYL,pretty obvious inversion cross border piece have business rationale toole say be look new area business
410,MYL,pfizer pfe valeant vrx abbvie abbv abandon attempt acquisition foreign target include astrazeneca azn have turn eye acquire domestic company just thursday pfizer say be ask federal trade commission more information propose merger hospira hsp pharmaceutical company search new market energy business seek growth have fuel rate company buy overseas asset year high cross border merger acquisition worldwide year totale thursday year biggest year date total accord thomson reuter announce cross border deal comprise total so far largest annual share cross border transaction amount so far year have be announce transaction also most not deal have yet close megadeal have be full force deal value more make nearly half cross border total so far year company be lead charge have keen eye european target so far overseas deal have take place europe point last year company switzerland be most popular target value more attractive europeanseurope rise popularity come continental value be damage great recession eurozone lurch crisis next persistent strength dollar make euro property more affordable american hope stronger economic growth indeed europe economy have grow faster recent month last year person begin feel more comfortable business model european company be solidify little bit say matthew toole thomson reuter director deal intelligence energy sector have be batter depress crude oil price translate fall earning revenue have be most active sector cross border year energy company have value deal year total more double year date energy sector value deal total royal dutch shell rdsa announce deal acquire read england base bg group be biggest announce cross border energy deal so far health care sector lead big pharma have generate deal ytd total year include reject megadeal offer st loui base agribusiness giant offer buy switzerland base syngenta syt offer reject purportedly undervalue company underestimate regulatory issue generic drug maker mylan myl reject offer rival teva pharmaceutical teva canonsburg pa base mylan currently be engineering hostile takeover bid irish drugmaker perrigo prgo obama administration last year crack tax inversion company buy foreign business relocate headquarters lower corporate tax rate hasn slow health care company desire expand new market pretty obvious inversion cross border piece have business rationale toole say be look new area business pfizer pfe valeant vrx abbvie abbv abandon attempt acquisition foreign target include astrazeneca azn have turn eye acquire domestic company just thursday pfizer say be ask federal trade commission more information propose merger hospira hsp
411,MYL,nasdaq lead stock market lower monday medical stock be rout
412,MYL,composite close loss hurt large part biotechs
413,MYL,top perform industry group slide broadly ishare nasdaq biotechnology ibb exchange trade fund plunge more
414,MYL,generic drug company mylan myl reject teva teva buyout bid seem have deflate effect health care sector
415,MYL,akorn akrx make matter generic drug industry share plummet company disclose restate financial have overstate revenue pretax income continue operation
416,MYL,fall dow jone industrial average give
417,MYL,small cap loss be even russell slide index close session lows
418,MYL,volume rise especially nasdaq loser lead winner nyse nasdaq
419,MYL,medical transportation retail sector be weakest stock market today
420,MYL,monster beverage mnst clear buy point flat base energy drink stock close entry volume be unimpressive
421,MYL,several medical company report earning tuesday include pfizer pfe idexx laboratory idxx bristol myer squibb bmy nasdaq lead stock market lower monday medical stock be rout composite close loss hurt large part biotechs top perform industry group slide broadly ishare nasdaq biotechnology ibb exchange trade fund plunge more generic drug company mylan myl reject teva teva buyout bid seem have deflate effect health care sector akorn akrx make matter generic drug industry share plummet company disclose restate financial have overstate revenue pretax income continue operation fall dow jone industrial average give small cap loss be even russell slide index close session lows volume rise especially nasdaq loser lead winner nyse nasdaq medical transportation retail sector be weakest stock market today monster beverage mnst clear buy point flat base energy drink stock close entry volume be unimpressive several medical company report earning tuesday include pfizer pfe idexx laboratory idxx bristol myer squibb bmy
422,MYL,merger acquisition be nothing new generic specialty drug space latest round have take quality romantic farce everybody chasing someone chasing somebody else grow number investor analyst be wonder actual wedding season be nearly do past month teva pharmaceutical industry ticker
423,MYL,biggest drugmaker world be report earning week quarters be expect be dampen patent loss foreign exchange headwind have potential growth story work
424,MYL,tuesday trio big pharmas be due report pfizer pfe be expect report drop year earlier earning cent share accord thomson reuter poll analyst sale be see fall
425,MYL,side subscription datum recently approve breast cancer drug ibrance be point strong launch tuesday bring first official report drug sale february launch company be also expect give update outlook still progress acquisition hospira hsp
426,MYL,wall street be also hope more visibility part financial structure pfizer create be widely see prelude split
427,MYL,pfe be expect provide further balance sheet disclosure business leerink analyst seamus fernandez write preview note sunday expect add discussion target stand alone value innovative establish product business
428,MYL,such speculation have help drive pfizer stock touch year high april afternoon trading stock market today pfizer stock be
429,MYL,bristol myer opdivo focus
430,MYL,also report early tuesday be bristol myer squibb bmy be expect return profit growth analyst expect earning rise cent share revenue be expect decline fraction
431,MYL,evercore isi analyst mark schoenebaum write preview note monday investor be focuse development pd inhibitor opdivo triumph lung cancer trial last week actual quarterly report be go be complicate add
432,MYL,be few more move part number other quarters include launch opdivo hcv hepatitis virus franchise potential lumpiness yervoy sale due approval bmy opdivo merck mrk keytruda melanoma step sale mature product other core asset year expiry portion otsuka agreement late april high gross margin product abilify bms report first abilify net sale higher royalty astrazeneca azn due structure payment divestiture diabetes business feb write
433,MYL,bristol myer stock also have be do well lately ibd relative strength rating have be slide past week monday afternoon share be fraction
434,MYL,merck fight patent cliff
435,MYL,merck also be report tuesday morning earning be estimate be cent share sale fall nearly merck be also suffering patent cliff problem last week announce filing own pd inhibitor keytruda lung cancer schoenebaum say probably draw question conference call
436,MYL,schoenebaum write investor also be listen detail merck hepatitis program yielded more positive study international liver congress late last week
437,MYL,merck stock hasn be do well lately rs rating just be fraction afternoon trading monday
438,MYL,teva drama continue
439,MYL,thursday open israeli generic specialty drug giant teva pharmaceutical industry teva be expect report earning growth share sale fall
440,MYL,teva share be normally rather staid have be middle lot drama lately first generic competition blockbuster drug copaxone arrive earlier expect then bid mylan myl not unrelated development
441,MYL,monday mylan reject teva bid rather harsh term thorough consideration mylan board unanimously determine teva proposal grossly undervalue mylan require mylan shareholder believe be low quality teva share exchange high quality mylan share transaction lack industrial logic carry significant global antitrust risk say mylan ceo robert coury statement
442,MYL,addition also believe proposal do not address serious challenge integrate fundamentally different conflict culture teva board leadership team poor record deliver sustainable shareholder value say
443,MYL,market be not pleased afternoon trading monday teva stock be mylan stock be nearly
444,MYL,follow amy reeve twitter ibd_areeve biggest drugmaker world be report earning week quarters be expect be dampen patent loss foreign exchange headwind have potential growth story work tuesday trio big pharmas be due report pfizer pfe be expect report drop year earlier earning cent share accord thomson reuter poll analyst sale be see fall side subscription datum recently approve breast cancer drug ibrance be point strong launch tuesday bring first official report drug sale february launch company be also expect give update outlook still progress acquisition hospira hsp wall street be also hope more visibility part financial structure pfizer create be widely see prelude split pfe be expect provide further balance sheet disclosure business leerink analyst seamus fernandez write preview note sunday expect add discussion target stand alone value innovative establish product business such speculation have help drive pfizer stock touch year high april afternoon trading stock market today pfizer stock be bristol myer opdivo focusalso report early tuesday be bristol myer squibb bmy be expect return profit growth analyst expect earning rise cent share revenue be expect decline fraction evercore isi analyst mark schoenebaum write preview note monday investor be focuse development pd inhibitor opdivo triumph lung cancer trial last week actual quarterly report be go be complicate add be few more move part number other quarters include launch opdivo hcv hepatitis virus franchise potential lumpiness yervoy sale due approval bmy opdivo merck mrk keytruda melanoma step sale mature product other core asset year expiry portion otsuka agreement late april high gross margin product abilify bms report first abilify net sale higher royalty astrazeneca azn due structure payment divestiture diabetes business feb write bristol myer stock also have be do well lately ibd relative strength rating have be slide past week monday afternoon share be fraction merck fight patent cliffmerck also be report tuesday morning earning be estimate be cent share sale fall nearly merck be also suffering patent cliff problem last week announce filing own pd inhibitor keytruda lung cancer schoenebaum say probably draw question conference call schoenebaum write investor also be listen detail merck hepatitis program yielded more positive study international liver congress late last week merck stock hasn be do well lately rs rating just be fraction afternoon trading monday teva drama continueson thursday open israeli generic specialty drug giant teva pharmaceutical industry teva be expect report earning growth share sale fall teva share be normally rather staid have be middle lot drama lately first generic competition blockbuster drug copaxone arrive earlier expect then bid mylan myl not unrelated development monday mylan reject teva bid rather harsh term thorough consideration mylan board unanimously determine teva proposal grossly undervalue mylan require mylan shareholder believe be low quality teva share exchange high quality mylan share transaction lack industrial logic carry significant global antitrust risk say mylan ceo robert coury statement addition also believe proposal do not address serious challenge integrate fundamentally different conflict culture teva board leadership team poor record deliver sustainable shareholder value say market be not pleased afternoon trading monday teva stock be mylan stock be nearly follow amy reeve twitter ibd_areeve
445,MYL,share teva pharmaceutical industry teva abruptly rebound friday afternoon report drugmaker be think seriously bidding mylan anonymous source say teva not make offer be evaluate idea have approach adviser subject bloomberg report most wall street have be assume teva be think
446,MYL,sandoz generic division novartis nvs biotech partner momenta pharmaceutical win fda approval thursday first generic version popular multiple sclerosis drug copaxone
447,MYL,fda deny citizen petition copaxone manufacturer teva pharmaceutical industry teva request further proof similarity safety generic version drug momenta mnta say press release generic drug call glatopa be fully substitutable pharmacy level copaxone
448,MYL,early afternoon announcement momenta stock spiked high highest nearly year mid afternoon trading momenta be stock market today
449,MYL,teva drop novartis have lot other source revenue rise
450,MYL,teva last ditch attempt stop drug company guidance have be assume generic competition top selling drug year not only novartis momenta mylan myl partner natco pharma however december teva modeled september launch product so fda decision suggest rival come bit earlier expect
451,MYL,nonetheless evercore isi analyst umer raffat write email client sandoz still have september launch
452,MYL,supreme court decision january have validate patent copaxone mg be clear supreme court rule legality case favor teva remand back appeal court raffat write unclear novartis interested do risk launch ahead patent expiry
453,MYL,momenta release say sandoz be currently evaluate launch timing
454,MYL,copaxone have be do bit annually last few year analyst be forecasting drop next year due generic competition teva have also be roll long act mg version copaxone patent run launch be still early stage so much depend teva be able convert exist copaxone user raffat say have already converted region drug have launch
455,MYL,mylan share rise intraday
456,MYL,follow amy reeve twitter ibd_areeve sandoz generic division novartis nvs biotech partner momenta pharmaceutical win fda approval thursday first generic version popular multiple sclerosis drug copaxone fda deny citizen petition copaxone manufacturer teva pharmaceutical industry teva request further proof similarity safety generic version drug momenta mnta say press release generic drug call glatopa be fully substitutable pharmacy level copaxone early afternoon announcement momenta stock spiked high highest nearly year mid afternoon trading momenta be stock market today teva drop novartis have lot other source revenue rise teva last ditch attempt stop drug company guidance have be assume generic competition top selling drug year not only novartis momenta mylan myl partner natco pharma however december teva modeled september launch product so fda decision suggest rival come bit earlier expect nonetheless evercore isi analyst umer raffat write email client sandoz still have september launch supreme court decision january have validate patent copaxone mg be clear supreme court rule legality case favor teva remand back appeal court raffat write unclear novartis interested do risk launch ahead patent expiry momenta release say sandoz be currently evaluate launch timing copaxone have be do bit annually last few year analyst be forecasting drop next year due generic competition teva have also be roll long act mg version copaxone patent run launch be still early stage so much depend teva be able convert exist copaxone user raffat say have already converted region drug have launch mylan share rise intraday follow amy reeve twitter ibd_areeve
457,MYL,yesterday note today be quiet day ahead rest week be packed datum look retest last week high ish fail quiet be fail do yesterday morning market trade right open bell test high last week
458,MYL,stock end mixed tuesday gain tech stock offset decline elsewhere nasdaq rise dow jone industrial average fall slip volume rise modestly board stock market today climb nasdaq nyse compare monday accord preliminary datum nasdaq be buoy merger activity share generic drugmaker mylan myl jump new high israel base teva pharmaceutical teva offer company meanwhile harley davidson hog lead lower investor look past better expect earning report focuse instead company reduce full year forecast motorcycle shipment stock drop nearly lowest level october property casualty insurer traveler trv fall lead dow lower disappointing quarterly earning report dupont dd sank say strong dollar dampen full year earning
459,MYL,stock future tuesday advanced open second straight day show bit more strength monday premarket session
460,MYL,dow future be ahead point well monday premarket level rise nasdaq future climb point fair market value future show healthy point gain small cap also look good shape russell future point
461,MYL,stock market today roll december automaker release november sale number session fiat chrysler fcau report gain sale best level november year jeep sale drive result rise vs decline chrysler product slip dodge fall fiat auto
462,MYL,auto researcher edmund forecast total light vehicle sell month year accurate make best november automaker
463,MYL,institute supply management release november ism index commerce department report october construction spending
464,MYL,retailer strong online presence get bump datum release adobe system adbe show shopper spend total cyber monday monday follow black friday launch holiday shopping season be designate day technology online shopping special amount be record last year cyber monday sale adobe say adobe also estimate thanksgiving cyber monday receipt top year year also record
465,MYL,third dow issue be positive premarket action rest be flat best gain come home depot hd add
466,MYL,adobe system rise lead nasdaq baidu bidu post nasdaq largest decline nearly
467,MYL,automate network control specialist infoblox blox rocket higher open santa clara calif base company report late monday fiscal first quarter earning revenue guidance expectation management announce share buyback initiative
468,MYL,mattress firm hold mfrm bounce higher announce late monday buy hmk mattress hold owner sleepy retail chain deal company say expect year cost saving mattress firm also announce fiscal sale rise say expect ep gain line consensus view
469,MYL,china base qihoo technology qihu add wall street journal report investor group be prepared offer take internet security content provider market american depositary receipt deal be complete come week report say plan then call relisting company china domestic exchange
470,MYL,qihoo be most recent wave privatization china base company trading china base issue ikang healthcare kang announce monday be be take private group investor adr
471,MYL,leader stock ibd list be quiet ahead open most group remain flat few gain loss hold less same be true stock ibd weekly review list
472,MYL,overseas market asia gain pmi gauge tracking china manufacturing service sector show further divergence month european market be narrowly mixed midday
473,MYL,follow alan elliott twitter ibd_aelliott stock future tuesday advanced open second straight day show bit more strength monday premarket session dow future be ahead point well monday premarket level rise nasdaq future climb point fair market value future show healthy point gain small cap also look good shape russell future point stock market today roll december automaker release november sale number session fiat chrysler fcau report gain sale best level november year jeep sale drive result rise vs decline chrysler product slip dodge fall fiat auto auto researcher edmund forecast total light vehicle sell month year accurate make best november automaker institute supply management release november ism index commerce department report october construction spending retailer strong online presence get bump datum release adobe system adbe show shopper spend total cyber monday monday follow black friday launch holiday shopping season be designate day technology online shopping special amount be record last year cyber monday sale adobe say adobe also estimate thanksgiving cyber monday receipt top year year also record third dow issue be positive premarket action rest be flat best gain come home depot hd add adobe system rise lead nasdaq baidu bidu post nasdaq largest decline nearly automate network control specialist infoblox blox rocket higher open santa clara calif base company report late monday fiscal first quarter earning revenue guidance expectation management announce share buyback initiative mattress firm hold mfrm bounce higher announce late monday buy hmk mattress hold owner sleepy retail chain deal company say expect year cost saving mattress firm also announce fiscal sale rise say expect ep gain line consensus view china base qihoo technology qihu add wall street journal report investor group be prepared offer take internet security content provider market american depositary receipt deal be complete come week report say plan then call relisting company china domestic exchange qihoo be most recent wave privatization china base company trading china base issue ikang healthcare kang announce monday be be take private group investor adr leader stock ibd list be quiet ahead open most group remain flat few gain loss hold less same be true stock ibd weekly review list overseas market asia gain pmi gauge tracking china manufacturing service sector show further divergence month european market be narrowly mixed midday follow alan elliott twitter ibd_aelliott
474,MYL,stock be pace higher start monday corporate earning continue take center stage
475,MYL,nasdaq future rally point vs fair value future climb point future dow jone industrial average gain point
476,MYL,stock be look push further milestone territory last week hit time high even many underlie company note strong dollar affected quarterly sale nasdaq logged record close high
477,MYL,key earning report day be apple aapl be report close maker iphone imacs be expect deliver fiscal profit share year sale be expect stock be flat base buy point
478,MYL,result barracuda network cuda jone lang lasalle jll mylan myl norwegian cruise line holding nclh silicon motion technology simo be also due close
479,MYL,premarket action apply material amat tumble scrapping takeover tokyo electron due antitrust concern
480,MYL,deutsche bank db slump premarket trading report steep drop earning announce overhaul hurt legal charge bank profit fall half
481,MYL,sohu com sohu fall post smaller expect quarterly loss higher expect sale
482,MYL,economic front markit flash service pmi be et stock market today consensus estimate econoday be
483,MYL,federal reserve start day meeting tuesday stock be pace higher start monday corporate earning continue take center stage nasdaq future rally point vs fair value future climb point future dow jone industrial average gain point stock be look push further milestone territory last week hit time high even many underlie company note strong dollar affected quarterly sale nasdaq logged record close high key earning report day be apple aapl be report close maker iphone imacs be expect deliver fiscal profit share year sale be expect stock be flat base buy point result barracuda network cuda jone lang lasalle jll mylan myl norwegian cruise line holding nclh silicon motion technology simo be also due close premarket action apply material amat tumble scrapping takeover tokyo electron due antitrust concern deutsche bank db slump premarket trading report steep drop earning announce overhaul hurt legal charge bank profit fall half sohu com sohu fall post smaller expect quarterly loss higher expect sale economic front markit flash service pmi be et stock market today consensus estimate econoday be federal reserve start day meeting tuesday
484,MYL,least highly rate stock weekly review stage fresh breakout week market look build recent success epam system epam clear buy point healthy volume thursday pattern have look flat base volatile session stretched depth pattern
485,MYL,israeli drug giant teva pharmaceutical industry make long await bid competitor mylan tuesday offer share consensus wall street say price have go higher teva teva proposal half cash half stock create giant generic specialty drug space annual
486,MYL,stock jab higher open then quickly turn mixed rise volume tuesday morning
487,MYL,nasdaq tick respectively dow jone industrial average shed
488,MYL,volume rise stock market today nasdaq nyse compare same time monday
489,MYL,chemical maker dupont dd dive more follow mixed first quarter result weigh heavily dow software giant sap sap pop report continue advance january low harley davidson hog dive nearly report mixed take worst early hit stock
490,MYL,chip equipment maker lam research lrcx spiked bell fremont calif base maker wafer fabrication tool report late monday fiscal third quarter sale earning clear consensus estimate revenue guidance be also view gain put share back critical level support month consolidation
491,MYL,mylan myl rumble start trade teva pharmaceutical teva bid acquire pennsylvania base drugmaker teva share proposal project annual cost saving teva say deal be more advantageous mylan effort acquire perrigo prgo
492,MYL,mylan last week say combination teva be sound industrial logic cultural fit be significant overlap company teva share rise start bell tuesday gain put mylan flat base buy point
493,MYL,noah holding noah surge new high china base financial adviser be month clear buy point april stock jab higher open then quickly turn mixed rise volume tuesday morning nasdaq tick respectively dow jone industrial average shed volume rise stock market today nasdaq nyse compare same time monday chemical maker dupont dd dive more follow mixed first quarter result weigh heavily dow software giant sap sap pop report continue advance january low harley davidson hog dive nearly report mixed take worst early hit stock chip equipment maker lam research lrcx spiked bell fremont calif base maker wafer fabrication tool report late monday fiscal third quarter sale earning clear consensus estimate revenue guidance be also view gain put share back critical level support month consolidation mylan myl rumble start trade teva pharmaceutical teva bid acquire pennsylvania base drugmaker teva share proposal project annual cost saving teva say deal be more advantageous mylan effort acquire perrigo prgo mylan last week say combination teva be sound industrial logic cultural fit be significant overlap company teva share rise start bell tuesday gain put mylan flat base buy point noah holding noah surge new high china base financial adviser be month clear buy point april
494,MYL,israeli drug giant teva pharmaceutical industry teva make long await bid competitor mylan tuesday offer share stock rise news
495,MYL,teva proposal half cash half stock be unsolicited mylan myl adopt poison pill provision month initial report teva interest emerge
496,MYL,april mylan make own unsolicited bid fellow generic drug maker perrigo prgo tune observer say be do least partly fend teva bid
497,MYL,mylan reiterate stance last friday fresh rumor teva interest emerge say not only combination doesn make strategic sense run antitrust issue due product overlap
498,MYL,evercore isi analyst umer raffat say webinar tuesday morning team analysis estimate teva have divest worth product satisfy federal trade commission requirement still only total annual revenue combine company teva spokesman have tell number be bit lower raffat say
499,MYL,product divest be mylan generic version teva blockbuster multiple sclerosis drug copaxone just last week fda approve first generic copaxone make team momenta pharmaceutical mnta novartis nvs generic unit sandoz mylan have own version be expect also be approve sometime soon
500,MYL,also hit list be epipen injectable emergency anaphylaxis be mylan single biggest selling product
501,MYL,raffat also say teva current bid have rise whisper number go street mylan worth be share capital iq analyst jeffrey loo agree
502,MYL,teva current offer value myl ep estimate slightly peer think teva need raise bid lower stock portion myl loo write note tuesday
503,MYL,mylan stock hit new high early stock market today late morning be more teva stock be perrigo stock be nearly
504,MYL,follow amy reeve twitter ibd_areeve israeli drug giant teva pharmaceutical industry teva make long await bid competitor mylan tuesday offer share stock rise news teva proposal half cash half stock be unsolicited mylan myl adopt poison pill provision month initial report teva interest emerge april mylan make own unsolicited bid fellow generic drug maker perrigo prgo tune observer say be do least partly fend teva bid mylan reiterate stance last friday fresh rumor teva interest emerge say not only combination doesn make strategic sense run antitrust issue due product overlap evercore isi analyst umer raffat say webinar tuesday morning team analysis estimate teva have divest worth product satisfy federal trade commission requirement still only total annual revenue combine company teva spokesman have tell number be bit lower raffat say product divest be mylan generic version teva blockbuster multiple sclerosis drug copaxone just last week fda approve first generic copaxone make team momenta pharmaceutical mnta novartis nvs generic unit sandoz mylan have own version be expect also be approve sometime soon also hit list be epipen injectable emergency anaphylaxis be mylan single biggest selling product raffat also say teva current bid have rise whisper number go street mylan worth be share capital iq analyst jeffrey loo agree teva current offer value myl ep estimate slightly peer think teva need raise bid lower stock portion myl loo write note tuesday mylan stock hit new high early stock market today late morning be more teva stock be perrigo stock be nearly follow amy reeve twitter ibd_areeve
505,MYL,seek avoid be takeover mylan myl raise offer perrigo prgo promptly reject bid say proposal be generic drugmaker mylan bid cash mylan share share perrigo be worth friday close higher informal offer unspecified cash
506,MYL,stock rise tuesday ahead highly anticipate day meeting federal reserve apparent bet fed only mildly tinker interest rate
507,MYL,nasdaq rise gain dow jone industrial average advanced stock market today volume be higher major exchange accord preliminary datum
508,MYL,close hewlett packard hpq announce restructure send stock lower company say deliver annual cost reduction person leave company
509,MYL,unite natural food unfi be volatile close report adjust ep cent share guidance be line estimate company say michael zechmeister replace mark shamber cfo mid october
510,MYL,open wednesday bureau labor statistic report consumer price index august economist forecast change open weekly crude oil inventory be report energy information administration recent report have cause volatility energy market
511,MYL,federal open market committee begin day meeting end thursday announcement fed raise interest rate current fed fund target be cme group fedwatch be forecasting chance raise rate
512,MYL,also open fedex fdx report first quarter fiscal result analyst be expect share be increase year earlier
513,MYL,also cracker barrel old country store cbrl report result analyst be expect earning share increase year earlier stock rise tuesday ahead highly anticipate day meeting federal reserve apparent bet fed only mildly tinker interest rate nasdaq rise gain dow jone industrial average advanced stock market today volume be higher major exchange accord preliminary datum close hewlett packard hpq announce restructure send stock lower company say deliver annual cost reduction person leave company unite natural food unfi be volatile close report adjust ep cent share guidance be line estimate company say michael zechmeister replace mark shamber cfo mid october open wednesday bureau labor statistic report consumer price index august economist forecast change open weekly crude oil inventory be report energy information administration recent report have cause volatility energy market federal open market committee begin day meeting end thursday announcement fed raise interest rate current fed fund target be cme group fedwatch be forecasting chance raise rate also open fedex fdx report first quarter fiscal result analyst be expect share be increase year earlier also cracker barrel old country store cbrl report result analyst be expect earning share increase year earlier
514,MYL,generic drug giant mylan myl announce wednesday have bid share cash stock sizable peer perrigo send stock soar
515,MYL,perrigo prgo apparently hadn agree deal mylan statement indicated be talk
516,MYL,proposal be culmination number prior discussion mylan perrigo compelling strategic financial logic combination mylan ceo robert coury say press release combination result meaningful immediate long term value creation proposal be design deliver value shareholder other stakeholder company
517,MYL,mylan note company combine revenue be say combination increase earning operate profit margin total value offer be nearly time late morning announcement equity component be set increase mylan stock be more midday trading stock market today new high perrigo stock also hit new high cruise nearly past be less midday trading
518,MYL,wall street analyst have be speculate mylan be involved major most popular idea have be combination teva pharmaceutical industry teva fact just hour news break jpmorgan analyst chris schott theorize research note mylan go upward share such deal however add believe mylan look own larger transaction
519,MYL,mylan be highest rate stock large drugmaker sporting ibd composite rating perrigo be formerly top rating stock profit growth have recently flattened leave cr
520,MYL,follow amy reeve twitter ibd_areeve generic drug giant mylan myl announce wednesday have bid share cash stock sizable peer perrigo send stock soar perrigo prgo apparently hadn agree deal mylan statement indicated be talk proposal be culmination number prior discussion mylan perrigo compelling strategic financial logic combination mylan ceo robert coury say press release combination result meaningful immediate long term value creation proposal be design deliver value shareholder other stakeholder company mylan note company combine revenue be say combination increase earning operate profit margin total value offer be nearly time late morning announcement equity component be set increase mylan stock be more midday trading stock market today new high perrigo stock also hit new high cruise nearly past be less midday trading wall street analyst have be speculate mylan be involved major most popular idea have be combination teva pharmaceutical industry teva fact just hour news break jpmorgan analyst chris schott theorize research note mylan go upward share such deal however add believe mylan look own larger transaction mylan be highest rate stock large drugmaker sporting ibd composite rating perrigo be formerly top rating stock profit growth have recently flattened leave cr follow amy reeve twitter ibd_areeve
521,MYL,stock worsen late trading friday already have be pressured day new chinese regulation trading worry greece nasdaq tumble putt slightly day move average meanwhile dow jone industrial average be respectively volume be run sharply higher board stock market today friday be option expiration day tend boost turnover
522,MYL,stock number leader be hard hit
523,MYL,servicenow now gap dive disappointing outlook stock fall more buy point cup handle base share hit month low
524,MYL,tableau software datum drop breach day line intraday slump buy point flat base clear thursday loss be cut top da davidson start coverage buy rating price target
525,MYL,elsewhere athm noah holding noah be cut loss
526,MYL,upside mylan myl jump dow jone report teva pharmaceutical industry teva be consider make bid company
527,MYL,taser international tasr be still fast trade share be nearly intraday stock clear early buy point cup base thursday stock worsen late trading friday already have be pressured day new chinese regulation trading worry greece nasdaq tumble putt slightly day move average meanwhile dow jone industrial average be respectively volume be run sharply higher board stock market today friday be option expiration day tend boost turnover stock number leader be hard hit servicenow now gap dive disappointing outlook stock fall more buy point cup handle base share hit month low tableau software datum drop breach day line intraday slump buy point flat base clear thursday loss be cut top da davidson start coverage buy rating price target elsewhere athm noah holding noah be cut loss upside mylan myl jump dow jone report teva pharmaceutical industry teva be consider make bid company taser international tasr be still fast trade share be nearly intraday stock clear early buy point cup base thursday
528,MYL,stock be sharply lower today nasdaq suffering worst loss month here look ibd stock buck market sell horizon pharma hznp gain much early session ease midafternoon trade horizon share have rise year have have strong week pinnacle entertainment pnk
529,MYL,mylan myl perrigo continue climb stock market thursday wall street analyze speculate possible combination day mylan unsolicited proposal leerink analyst jason gerberry write research note mylan come ahead land perrigo prgo not doesn say teva
530,MYL,stock close strong rise trade wednesday nasdaq lead healthy advance add dow jone industrial average weigh weakness oil still dow manage find support day move average retake line monday
531,MYL,russell snap short streak advance preliminary number show volume higher board stock market today
532,MYL,generic drug group be day top performer news potential industry consolidation mylan myl soar time high announce bid buy rival generic drug maker perrigo prgo
533,MYL,airline biotech security software stock also outperformed
534,MYL,oil gas stock be hurt sharp drop crude price
535,MYL,elsewhere nike nke visa home depot hd climb lead dow stock be highly rate well composite rating
536,MYL,global payment gpn gap new high reaction third quarter result top analyst earning expectation company also raise full year guidance announce accelerate share buyback program share rise volume surge more average stock close strong rise trade wednesday nasdaq lead healthy advance add dow jone industrial average weigh weakness oil still dow manage find support day move average retake line monday russell snap short streak advance preliminary number show volume higher board stock market today generic drug group be day top performer news potential industry consolidation mylan myl soar time high announce bid buy rival generic drug maker perrigo prgo airline biotech security software stock also outperformed oil gas stock be hurt sharp drop crude price elsewhere nike nke visa home depot hd climb lead dow stock be highly rate well composite rating global payment gpn gap new high reaction third quarter result top analyst earning expectation company also raise full year guidance announce accelerate share buyback program share rise volume surge more average
537,MYL,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
538,MYL,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
539,MYL,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
540,MYL,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
541,MYL,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
542,MYL,share real estate zillow be hour follow result
543,MYL,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
544,MYL,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
545,MYL,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
546,MYL,dow jone industrial average surrender early gain tuesday nasdaq outperformed
547,MYL,nasdaq rise dow lose give volume be tracking higher exchange stock market today
548,MYL,dow be hold underwater dupont dd traveler trv issue disappointing report dupont say earning decline be result strong dollar traveler sale miss expectation
549,MYL,verizon vz dow component beat analyst estimateshttp news investor com technology verizon stock fall mixed wireless earning htm add fewer core customer wall street expect be less regain most early loss
550,MYL,palo alto network panw be bright spot share plow new high ground gain heavy volume imperial capital re initiate coverage outperform rating price target
551,MYL,mylan myl gap new high teva pharmaceutical teva launch bid company be report last week teva make bid mylan say be fully commit stand alone strategy teva be
552,MYL,ibd stock be higher be lower mylan be best performer follow noah holding noah share rise more also new high
553,MYL,worst ibd performer be armour ua more report earning cent share decline year
554,MYL,hormel hrl lead meat company lower report flock more iowa chicken have be destroy bird flu outbreak fall pilgrim pride ppc be tyson food tsn drop dow jone industrial average surrender early gain tuesday nasdaq outperformed nasdaq rise dow lose give volume be tracking higher exchange stock market today dow be hold underwater dupont dd traveler trv issue disappointing report dupont say earning decline be result strong dollar traveler sale miss expectation verizon vz dow component beat analyst estimateshttp news investor com technology verizon stock fall mixed wireless earning htm add fewer core customer wall street expect be less regain most early loss palo alto network panw be bright spot share plow new high ground gain heavy volume imperial capital re initiate coverage outperform rating price target mylan myl gap new high teva pharmaceutical teva launch bid company be report last week teva make bid mylan say be fully commit stand alone strategy teva be ibd stock be higher be lower mylan be best performer follow noah holding noah share rise more also new high worst ibd performer be armour ua more report earning cent share decline year agohormel hrl lead meat company lower report flock more iowa chicken have be destroy bird flu outbreak fall pilgrim pride ppc be tyson food tsn drop
555,MYL,mylan lab myl gap lower monday morning announce abbott laboratory sell third recently acquire stake generic drug maker mylan share bounce key support level mylan offer share behalf abbott abbott stake mylan underwriter also have right buy
556,MYL,stock rolled early gain wednesday china stock show strength oil price ease day rally
557,MYL,nasdaq lead advance dow jone industrial average pop show gain volume be narrowly mixed nyse lower nasdaq compare trade same time tuesday
558,MYL,stock market today be watch afternoon release minute federal open market committee march meeting seek sign pending action delay interest rate increase
559,MYL,crude oil price dig bit deeper benchmark west texas intermediate more still hold barrel price come pressure late tuesday american petroleum institute estimate larger expect build weekly oil inventory energy information administration release weekly storage datum et
560,MYL,stock mcdonald mcd merck mrk lead dow rise more
561,MYL,china base stock be pound significant early gain buoy wednesday rally hong kong stock exchange yanzhou coal mining yzc spiked aluminum corp china leap
562,MYL,noah holding noah pop punch seventh straight advance take new high move also break stock past buy point sloppy month base
563,MYL,netflix nflx rise nearly very strong trade provider online movie rental original content gain prior session climb back day move average stock be mid february high
564,MYL,lead stock open upsweep more ibd stock advance start trade
565,MYL,mylan myl lead group rise more canonsburg pa base drugmaker be work fourth straight advance rebound test week support wednesday move lift share buy point flat base stock rolled early gain wednesday china stock show strength oil price ease day rally nasdaq lead advance dow jone industrial average pop show gain volume be narrowly mixed nyse lower nasdaq compare trade same time tuesday stock market today be watch afternoon release minute federal open market committee march meeting seek sign pending action delay interest rate increase crude oil price dig bit deeper benchmark west texas intermediate more still hold barrel price come pressure late tuesday american petroleum institute estimate larger expect build weekly oil inventory energy information administration release weekly storage datum et stock mcdonald mcd merck mrk lead dow rise more china base stock be pound significant early gain buoy wednesday rally hong kong stock exchange yanzhou coal mining yzc spiked aluminum corp china leap noah holding noah pop punch seventh straight advance take new high move also break stock past buy point sloppy month base netflix nflx rise nearly very strong trade provider online movie rental original content gain prior session climb back day move average stock be mid february high lead stock open upsweep more ibd stock advance start trade mylan myl lead group rise more canonsburg pa base drugmaker be work fourth straight advance rebound test week support wednesday move lift share buy point flat base
566,MYL,generic drug giant mylan announce wednesday have bid share cash stock sizable peer perrigo send stock soar perrigo prgo hadn agree deal mylan myl indicated have be talk proposal be culmination number prior discussion mylan perrigo compelling strategic
567,MYL,mylan myl shot almost wednesday rumor have hire investment banker be sell fellow generic drugmaker teva pharmaceutical industry teva stock also get boost launch new drug treat pain opioid dependence manage sobriety patient chronic alcoholism key fundamental quarters
568,MYL,israeli drug giant teva pharmaceutical industry teva report successful midstage trial result novel migraine treatment appoint new head business development monday send stock year high teva report result phase study tev calcitonin gene related peptide cgrp monoclonal antibody treat episodic migraine trial meet endpoint
569,MYL,stock continue hold best level session late monday rally hope stimulus china number buyout nasdaq be respectively be pace biggest gain march meanwhile dow jone industrial average lead jump only intel intc be lower blue chip index lead stock madison square garden msg cool record high be still friday announcement split company focus sport entertainment other medium fading madison square garden be still past buy point flat base clear early february ambarella amba rally time high canaccord genuity bump price target stock be now past buy point break late stage base signet jeweler limit sig rise time high nomura raise price target share be nearly past buy point flat base retailer deliver better expect earning last week downside mylan myl pare loss more half earlier stock market today drugmaker announce offer share be be sell subsidiary abbott laboratory mylan test buy point flat base
570,MYL,stock close sharply lower worst level day concern greece new chinese regulation weigh session
571,MYL,nasdaq dow jone industrial average sank give index breach day move average nasdaq manage find support line preliminary datum show sharply higher volume board partly due option expiration
572,MYL,only ibd stock manage buck downtrend stock market today mylan myl gain heavy trade be now extend past buy point clear last month share soar rumor generic drug maker be takeover target teva pharmaceutical teva teva climb casino operator pinnacle entertainment pnk akorn akrx actavis act fleetmatic group fltx score small gain
573,MYL,downside universal insurance holding uve lannett lci athm be worst performer universal slice day line lannett find support line remain cup base buy point
574,MYL,few industry group be spare sell include leisure toy game hobby buoy jump mattel mat late thursday report result be better analyst forecast basic chemical tobacco stock also advanced
575,MYL,software maker lead downside internet retailer consumer electronic retailer servicenow now gap sank massive volume fall day move average month low cloud base enterprise software maker offer disappointing revenue bill guidance close thursday
576,MYL,apple aapl dip more close day line first time jan volume initially run higher have tailed session suggest institutional investor weren selling stock flat base buy point remain intact
577,MYL,aside chicago fed national activity index due report et economic calendar be light monday
578,MYL,follow nancy gondo twitter ibd_ngondo stock close sharply lower worst level day concern greece new chinese regulation weigh session nasdaq dow jone industrial average sank give index breach day move average nasdaq manage find support line preliminary datum show sharply higher volume board partly due option expiration only ibd stock manage buck downtrend stock market today mylan myl gain heavy trade be now extend past buy point clear last month share soar rumor generic drug maker be takeover target teva pharmaceutical teva teva climb casino operator pinnacle entertainment pnk akorn akrx actavis act fleetmatic group fltx score small gain downside universal insurance holding uve lannett lci athm be worst performer universal slice day line lannett find support line remain cup base buy point few industry group be spare sell include leisure toy game hobby buoy jump mattel mat late thursday report result be better analyst forecast basic chemical tobacco stock also advanced software maker lead downside internet retailer consumer electronic retailer servicenow now gap sank massive volume fall day move average month low cloud base enterprise software maker offer disappointing revenue bill guidance close thursday apple aapl dip more close day line first time jan volume initially run higher have tailed session suggest institutional investor weren selling stock flat base buy point remain intact aside chicago fed national activity index due report et economic calendar be light monday follow nancy gondo twitter ibd_ngondo
579,MYL,best mutual fund april performance report
580,MYL,country top perform stock mutual fund past month have be add tech issue portfolio recently computer software firm cyberark software cybr paycom software payc qualys qlys palo alto network panw manhattan associate manh be strong performer
581,MYL,manager lead stock mutual fund be also favore chip stock such ambarella amba nxp semiconductor nxpi skywork solution swks cirrus logic crus tuesday chip design be rank industry week
582,MYL,handful giant medical stock book spot top fund portfolio include mylan myl unite therapeutic uthr abc pharmacyclic pcyc
583,MYL,leisure stock norwegian cruise line holding nclh also see heavy buy best perform fund top fund have add cruise liner investing estimate
584,MYL,ibd spot lead stock mutual fund load cyberark software investing estimate well fargo advantage discovery fund add share latest report period
585,MYL,israeli base firm ipo september offer security solution protect organization cyberattack
586,MYL,analyst believe cyberark capitalize grow need internal internet security slew company databasis client info be hack recent year have firm investing more budget preventative measure
587,MYL,cyberark have post straight quarters solid earning accelerate double digit revenue growth
588,MYL,stock sky-rocket month long consolidation february high etching handle part second stage cup handle base trading high
589,MYL,sell side
590,MYL,lead fund have be let go financial such payment processor visa euronet worldwide eeft latest report period bank such city national cyn morgan stanley ms svb financial group sivb have also be sell net fund unloaded martin marietta material mlm stock break flat base last thursday best mutual fund april performance country top perform stock mutual fund past month have be add tech issue portfolio recently computer software firm cyberark software cybr paycom software payc qualys qlys palo alto network panw manhattan associate manh be strong performer manager lead stock mutual fund be also favore chip stock such ambarella amba nxp semiconductor nxpi skywork solution swks cirrus logic crus tuesday chip design be rank industry week handful giant medical stock book spot top fund portfolio include mylan myl unite therapeutic uthr abc pharmacyclic pcyc leisure stock norwegian cruise line holding nclh also see heavy buy best perform fund top fund have add cruise liner investing estimate ibd spot lead stock mutual fund load cyberark software investing estimate well fargo advantage discovery fund add share latest report period israeli base firm ipo september offer security solution protect organization cyberattack analyst believe cyberark capitalize grow need internal internet security slew company databasis client info be hack recent year have firm investing more budget preventative measure cyberark have post straight quarters solid earning accelerate double digit revenue growth stock sky-rocket month long consolidation february high etching handle part second stage cup handle base trading high sell sidelead fund have be let go financial such payment processor visa euronet worldwide eeft latest report period bank such city national cyn morgan stanley ms svb financial group sivb have also be sell net fund unloaded martin marietta material mlm stock break flat base last thursday
591,MYL,generic drug giant mylan myl late monday report earning guidance line wall street expectation shortly close major buyout mylan profit rise year earlier quarter share exactly analyst expect accord thomson reuter revenue gain slightly consensus still mylan stock be nearly hour trading monday company release december quarter result year profit rise share revenue friday mylan close stock swap deal acquire abbott laboratory business selling generic drug develop market add annual revenue officially relocate company lower tax netherlands be reflect mylan guidance sale ep guidance range bracket consensus be great start recent completion acquisition abbott develop market specialty brand generic business announcement propose acquisition famy care woman health care business expect mylan deliver revenue growth adjust diluted ep growth constant currency basis mylan ceo heather bresch say statement addition exciting activity have previously state continue expect aggressively pursue additional acquisition opportunity make financial strategic sense company mylan hold excellent ibd composite rating be likely improve growth ramp stock have be form possible flat base hit new high nov regular trading stock market today mylan stock rise close follow amy reeve twitter ibd_areeve
592,MYL,startup key rite passage come founder hand rein ceo take next stage life sucampo pharmaceutical take year happen judge wall street reaction not moment soon sucampo scmp be founder married japanese
593,MYL,shaky market several ibd stock be buy point still buy range breaking reilly automotive orly be form flat base potential buy point part base base formation company operate more auto part store growth have be extremely steady company have fail grow
594,MYL,big cap be show be good representation today market leadership technology health care consumer stock dominate list glance ibd smart nyse nasdaq table show chip medical apparel retail other technology sector make most top sector fitting reflection find big cap most stock be categorize area technology couple chipmaker rank lead big cap business service tech company analog device adi be more interesting chart stock break cup shape base feb have rise entry chipmaker earn cent share exclude item january end quarter beating expectation sale rise top line continue accelerate trend growth analyst note strength industrial automotive market apple aapl tech leader be view consumer stock too be high tech stock find home big cap stock be new high extend past last month medical sector drugmaker biogen idec biib pharmacyclic pcyc valeant pharmaceutical vrx have rally recent week account best percentage gain big cap past couple week unitedhealth group unh cigna ci be part broad rally hmo stock medical leader be extend mylan myl be set base buy point however share fall moderately close monday company report earning share increase sale rise mylan forecast revenue consumer stock big cap leader run gamut auto part chain reilly automotive orly starbucks sbux discount retailer ross store rost ross store shine friday earning report send share gapping gain record high first month big cap have acquit quite satisfactorily rise far better gain be broad gauge big capitalization stock qorvo qrvo be unfamiliar name list filled familiar brand company be name adopt rf micro device triquint merged create lead manufacturer cellular radio frequency technology used wireless communication military other application stock be consolidate find support week move average
595,MYL,stock stride ahead thursday volume be only slightly higher nasdaq chalk gain dow jone industrial average add respectively small cap rise ibd gain volume be slightly major exchange dow retook day
596,MYL,stock market close modestly lower wednesday little movement index nasdaq dow jone industrial average fall small cap however come ahead russell climb volume be lower seem fitting give day dull trading medical chip stock lead stock market today endo international endp confirm make bid share salix pharmaceutical slxp top offer share valeant pharmaceutical vrx endo valeant reversed lower salix soar new high mylan myl rally stock break flat base share close buy point resistance be alternative entry mylan transportation metal financial stock also be strong day dow transport rally food stock be laggard partly bird flu be find arkansa send poultry stock lower
597,MYL,name qorvo qrvo doesn mean much most investor least not yet new name triquint rf micro device have merged merger have put company firmly big cap week
598,MYL,qorvo make high performance radio frequency product work mobile device
599,MYL,combine company have triple digit earning growth past few quarters analyst be forecasting year year earning increase current quarter
600,MYL,qorvo trail quarter return equity be impressive well standard investor seek tax margin be
601,MYL,stock be consolidate novice look form cup handle base have consolidated just week shy week minimum proper cup handle be better treat pattern cup handle
602,MYL,kroger kr seem unlikely growth stock operator grocery store have redesign store be offer more organic natural food keep pace change customer taste competitor whole food market wfm
603,MYL,whole food be big cap member
604,MYL,earning growth kroger have accelerate next report analyst forecast year year increase ep
605,MYL,revenue past year have run high single digit low double digit zone be fairly typical industry return equity be number boost debt
606,MYL,grocery store minimart industry group rank industry group monday ibd unusually high position typically defensive industry
607,MYL,kroger have year annualize ep growth rate boast steady earning growth earning stability factor be scale low number correspond steady growth
608,MYL,reilly automotive orly break late stage base monday finishing just buy point volume be average
609,MYL,case accelerate earning growth analyst be forecasting ep increase current quarter
610,MYL,reilly year annualize ep growth rate company earning stability factor be
611,MYL,company operate more auto part store nation
612,MYL,drugmaker mylan myl break flat base last week have hover buy point then
613,MYL,most recent quarter earning grow sale name qorvo qrvo doesn mean much most investor least not yet new name triquint rf micro device have merged merger have put company firmly big cap week qorvo make high performance radio frequency product work mobile device combine company have triple digit earning growth past few quarters analyst be forecasting year year earning increase current quarter qorvo trail quarter return equity be impressive well standard investor seek tax margin be stock be consolidate novice look form cup handle base have consolidated just week shy week minimum proper cup handle be better treat pattern cup handle kroger kr seem unlikely growth stock operator grocery store have redesign store be offer more organic natural food keep pace change customer taste competitor whole food market wfm whole food be big cap member earning growth kroger have accelerate next report analyst forecast year year increase ep revenue past year have run high single digit low double digit zone be fairly typical industry return equity be number boost debt grocery store minimart industry group rank industry group monday ibd unusually high position typically defensive industry kroger have year annualize ep growth rate boast steady earning growth earning stability factor be scale low number correspond steady growth reilly automotive orly break late stage base monday finishing just buy point volume be average case accelerate earning growth analyst be forecasting ep increase current quarter reilly year annualize ep growth rate company earning stability factor be company operate more auto part store nation drugmaker mylan myl break flat base last week have hover buy point then most recent quarter earning grow sale
614,MYL,market health have weaken recently not stock be feel same pressure stock diverse group monday sector leader be keep composure generic drug maker lannett lci hit new high early friday share break past week tight buy point stout gain didn last stock reversed lower
615,MYL,endo pharmaceutical bid share snatch distressed specialty drugmaker valeant pharmaceutical company announce wednesday salix pharmaceutical slxp have already agree feb be buy valeant vrx share include debt stock have be trading range then word endo endp bid
616,MYL,stock be mixed just hour left tuesday session dow jone industrial average give back early gain nasdaq hung buoy strength security software stock
617,MYL,dow lose weigh soft result dupont dd ease less nasdaq add nyse nasdaq volume be tracking slightly higher monday level
618,MYL,stock market today security software stock help fuel nasdaq outperformance fortinet ftnt gap new high strong earning biggest quarterly billing growth ipo share rise nearly
619,MYL,barracuda network cuda cyberark software cybr palo alto network panw be other strong performer group rise cyberark gap reclaim cup handle buy point
620,MYL,elsewhere signature bank sbny surge yearlong consolidation rise strong earning be catalyst new york base bank clear buy point
621,MYL,news mylan myl jump teva teva offer value mylan share earlier month mylan make unsolicited bid generic drugmaker perrigo prgo say offer be make fend teva bid
622,MYL,meanwhile armour ua report quarter strong top line growth share fall fast trade profit cent share be line expectation year sale rise forecast sale tad consensus estimate
623,MYL,chipotle cmg rally ahead earning report set be release close quarterly profit be expect rise year share chipotle gap day move average april heavy volume strengthen chart stock be mixed just hour left tuesday session dow jone industrial average give back early gain nasdaq hung buoy strength security software stock dow lose weigh soft result dupont dd ease less nasdaq add nyse nasdaq volume be tracking slightly higher monday level stock market today security software stock help fuel nasdaq outperformance fortinet ftnt gap new high strong earning biggest quarterly billing growth ipo share rise nearly barracuda network cuda cyberark software cybr palo alto network panw be other strong performer group rise cyberark gap reclaim cup handle buy point elsewhere signature bank sbny surge yearlong consolidation rise strong earning be catalyst new york base bank clear buy point news mylan myl jump teva teva offer value mylan share earlier month mylan make unsolicited bid generic drugmaker perrigo prgo say offer be make fend teva bid meanwhile armour ua report quarter strong top line growth share fall fast trade profit cent share be line expectation year sale rise forecast sale tad consensus estimate chipotle cmg rally ahead earning report set be release close quarterly profit be expect rise year share chipotle gap day move average april heavy volume strengthen chart
624,MYL,go thursday trading mylan myl stock stand chance enter buy range
625,MYL,share close wednesday briefly rise past buy point day product launch chatter be sale maybe teva pharmaceutical industry teva
626,MYL,mylan stock open thursday morning be trading early
627,MYL,mylan be top rate stock generic drug industry akorn akrx actavis act lannett co lci mallinckrodt mnk
628,MYL,watch video mylan stock chart analysis more news industry ranking
629,MYL,follow donna howell twitter ibd_dhowell go thursday trading mylan myl stock stand chance enter buy range share close wednesday briefly rise past buy point day product launch chatter be sale maybe teva pharmaceutical industry teva mylan stock open thursday morning be trading early mylan be top rate stock generic drug industry akorn akrx actavis act lannett co lci mallinckrodt mnk watch video mylan stock chart analysis more news industry ranking follow donna howell twitter ibd_dhowell
630,MYL,tech stock lead mixed show wall street tuesday earning report activity dominate headline early gain turn loss close dow also reversed lower fall weigh sluggish result dupont dd nasdaq trade tight range day end
631,MYL,mylan myl stock break wednesday rumor circulate twitter generic brand drugmaker be sale possibly teva announce drug launch mylan stock rise wednesday briefly pass buy point ease teva pharmaceutical industry teva gain analyst be divide logic
632,MYL,stock hold solid gain early afternoon trading weakness dollar keep seller bay volume be run slightly ahead thursday pace stock market today nasdaq rise dow jone industrial average ibd stock be higher be lower best performer be noah holding noah volatile issue report earning close monday wall street be expect ep cent same year quarter noah be work volatile late stage base mylan myl ibd name gain rise wednesday wednesday company launch generic drug rumor also surface company be sale mylan be still buy range buy point worst ibd performer be akorn akrx more tuesday competitor actavis act launch own version eczema psoriasis cream be akorn biggest seller stock be struggle hold day move average paychex payx rise more be clear flat base buy point dollar general dg rise report quarterly earning share year revenue grow clip company say add store year addition floor space stock be still buy range flat base buy point airline be generally strong price crude oil drop more jetblue jblu be nearly company say february traffic rise capacity grow
633,MYL,midweek several recent new america stock be buy range be set basis
634,MYL,online food delivery startup grubhub grub be also ibd leaderboard stock enter buy range cup handle buy point last week point wednesday close so still buy range
635,MYL,foot locker fl nike nke most important shoe retailer have be set base too
636,MYL,ibd new america look fast grow company sound technical stock performance indicator
637,MYL,watch video quick analysis grubhub foot locker chart drug company mylan myl lannett co lci
638,MYL,follow donna howell twitter ibd_dhowell midweek several recent new america stock be buy range be set basis online food delivery startup grubhub grub be also ibd leaderboard stock enter buy range cup handle buy point last week point wednesday close so still buy range foot locker fl nike nke most important shoe retailer have be set base too ibd new america look fast grow company sound technical stock performance indicator watch video quick analysis grubhub foot locker chart drug company mylan myl lannett co lci follow donna howell twitter ibd_dhowell
639,MYL,health care stock dominate new high list wednesday continue theme have leg time now resm rmd rise top week flat base rise light trade buy point be boast composite rating single digit ep gain recent quarters mylan myl soar
640,MYL,stock turn higher hour wednesday session undeterred least now strong dollar effect corporate earning
641,MYL,dow jone industrial average lead way nasdaq rise nyse volume be tracking lower tuesday nasdaq volume be tracking close tuesday level
642,MYL,head wednesday powershare db dollar bullish etf uup be past trading session rise again wednesday strong dollar hurt earning firm large foreign operation other hand strong dollar keep inflation check cut price import
643,MYL,stock market today mylan myl soar drugmaker launch generic drug used treat opioid dependence mylan be fast approach buy point
644,MYL,ibd akorn akrx gain find support day move average tuesday share take hit tuesday analyst lower price target actavis act launch generic competitor akorn steroid base inflammatory skin cream
645,MYL,find support day line ibd component amtrust financial afsi rise work cup handle base buy point
646,MYL,meanwhile couple fast grow restaurant stock be earning close shake shack shak lose ahead result thomson reuter consensus estimate be loss cent share meanwhile zoe kitchen zoe be set potential cup handle base ahead earning report analyst expect loss cent share share fall stock turn higher hour wednesday session undeterred least now strong dollar effect corporate earning dow jone industrial average lead way nasdaq rise nyse volume be tracking lower tuesday nasdaq volume be tracking close tuesday level head wednesday powershare db dollar bullish etf uup be past trading session rise again wednesday strong dollar hurt earning firm large foreign operation other hand strong dollar keep inflation check cut price import stock market today mylan myl soar drugmaker launch generic drug used treat opioid dependence mylan be fast approach buy point ibd akorn akrx gain find support day move average tuesday share take hit tuesday analyst lower price target actavis act launch generic competitor akorn steroid base inflammatory skin cream find support day line ibd component amtrust financial afsi rise work cup handle base buy point meanwhile couple fast grow restaurant stock be earning close shake shack shak lose ahead result thomson reuter consensus estimate be loss cent share meanwhile zoe kitchen zoe be set potential cup handle base ahead earning report analyst expect loss cent share share fall
647,MYL,stock quietly step solid gain early trade thursday company report dip unemployment claim focal point early action
648,MYL,dow jone industrial average rise nasdaq climb apiece volume be soft nasdaq lower nyse compare trade same time wednesday
649,MYL,stock market today earning beat forecast management say sale accelerate march april stock have be work regain week move average shallow week consolidation
650,MYL,more ibd stock moved higher start trade gain be moderate many evaporate quickly newlink genetic nlnk drop almost slip week line support
651,MYL,close el pollo dd jwn symantec symc be long list company expect post quarterly result stock quietly step solid gain early trade thursday company report dip unemployment claim focal point early action dow jone industrial average rise nasdaq climb apiece volume be soft nasdaq lower nyse compare trade same time wednesday stock market today earning beat forecast management say sale accelerate march april stock have be work regain week move average shallow week consolidation more ibd stock moved higher start trade gain be moderate many evaporate quickly newlink genetic nlnk drop almost slip week line support close el pollo dd jwn symantec symc be long list company expect post quarterly result
652,MYL,quiet start week thursday new high list explode thank solid gain major index wednesday session stock make new high screen number triple thursday recent ambarella amba be work nicely stock close low early strength fall latest base
653,MYL,stock be lower midday wednesday follow disappointing job datum warning federal reserve head janet yellen equity valuation be quite high
654,MYL,nasdaq dow jone industrial average be index be now day move average volume be run higher nasdaq be fractionally lower nyse compare tuesday
655,MYL,yellen speaking conference washington say equity market valuation point generally be quite high add be potential danger however say doesn see bubble form
656,MYL,meanwhile private employer add job april fewest january accord payroll processor adp government key nonfarm payroll report april be due friday
657,MYL,stock market today apple aapl weigh nasdaq slide heavy volume early session iphone maker fall nearly flat base buy point key ibd sell say sell stock fall purchase price
658,MYL,alexion pharmaceutical alxn drop biotech company say buy synageva biopharma geva cash stock acquisition value synageva share more double synageva close price tuesday synageva be midday
659,MYL,meanwhile game developer electronic art ea rise new high follow better expect quarterly earning report stock be lower midday wednesday follow disappointing job datum warning federal reserve head janet yellen equity valuation be quite high nasdaq dow jone industrial average be index be now day move average volume be run higher nasdaq be fractionally lower nyse compare tuesday yellen speaking conference washington say equity market valuation point generally be quite high add be potential danger however say doesn see bubble form meanwhile private employer add job april fewest january accord payroll processor adp government key nonfarm payroll report april be due friday stock market today apple aapl weigh nasdaq slide heavy volume early session iphone maker fall nearly flat base buy point key ibd sell say sell stock fall purchase price alexion pharmaceutical alxn drop biotech company say buy synageva biopharma geva cash stock acquisition value synageva share more double synageva close price tuesday synageva be midday meanwhile game developer electronic art ea rise new high follow better expect quarterly earning report
660,MYL,stock rally close fed minute indicated central bank be concern global risk inflation lead gain dow jone industrial average rise nasdaq climb volume be lower board accord preliminary datum winner top loser margin nyse narrow ratio nasdaq be weigh software biotech internet retailer railcar maker energy machinery related stock lead upside stock market today automaker underperform again tesla motor tsla extend current week decline share slide fall day move average volume only dow component give ground apple aapl be biggest blue chip loser slip iphone maker continue find resistance level nike nke run more lead dow share athletic shoe apparel maker be extend buy point clear breakaway gap chevron cvx gain boost jump crude oil price ibd stock advanced decline global payment gpn surge fast trade extend wednesday gain earning beat foot locker fl be big gainer too jump heavy volume still day line buy point argus research start coverage buy rating price target follow nancy gondo twitter ibd_ngondo
661,MYL,most stock spotlight name be well extend past proper buy point market improve doesn hurt keep watch new opportunity buy generic drugmaker list akorn akrx mallinckrodt mnk be extend ve outperformed lead group moved monday ibd
662,MYL,generic drug maker lannett co recent quarters have surge price increase more recently volume gain key prescription medication other drug company news week lannett lci be hunt potential acquisition help expand offering extend global reach lower tax base philadelphia base firm develop
663,MYL,rapidly consolidate industry re hunter prey mylan be former mylan myl make generic brand drug treat illness cardiovascular central nervous system other disorder operate segment generic specialty generic unit make generic brand generic product tablet capsule injectable transdermal patch form active
664,MYL,stock end modestly lower wednesday federal reserve chief janet yellen say be live possibility interest rate hike next month fall dow jone industrial average edge nasdaq dip volume be mixed dip nyse rise nasdaq compare tuesday accord preliminary datum maker consumer stock be biggest loser stock market today motorola solution msi make way radio other communication product plunge more better expect profit sale result stock have be work flat base crash day move average finally steadying just day line tesla motor tsla lead share automaker higher soar electric vehicle maker delivery outlook trump weaker expect quarterly earning report stock be testing resistance day line remain week higher homeaway away rocket post session trading expedia expe agree buy online marketplace vacation rental deal be expect close first quarter next year pending regulatory approval be expect help expedia compete home rental business such airbnb meanwhile facebook fb rise hour trading follow earning report profit period rise cent share gain revenue top wall street estimate company say number daily active user rise year average september mobile daily active user jump average month facebook rise regular session buy range buy point qualcomm qcom be sharply hour outlook fiscal first quarter end december trail analyst estimate outweighed better expect result latest period disney celgene celg cyberark software cybr nvidia nvda be company schedule report quarterly earning thursday economic report due thursday include initial jobless claim week end oct productivity datum
665,MYL,market knock healthy early gain monday broad range stock rebound last week slump dow jone industrial average grab gain nasdaq climb volume stock market today open mixed trade rise nyse possibly good sign rebound day move average volume dip nasdaq index retook day line
666,MYL,stock precision castpart pcp lead soar news acquisition berkshire hathaway brka
667,MYL,dow issue moved higher start trade apple aapl boee ba lead nearly chip stock drugmaker stake high ground nasdaq issue texas instrument txn kla tencor klac rise so do alexion alxn mylan myl
668,MYL,ibd list cyberark software cybr investment wetf swat better gain
669,MYL,cyberark move lift share back stock day move average attempt begin right side month consolidation
670,MYL,be climb day move average trading past cup base buy point
671,MYL,june quarter earning season be slow today hour session be nevertheless busy big name such hertz global htz kraft heinz khc report smaller name shake shack shak vipshop vip schedule report market knock healthy early gain monday broad range stock rebound last week slump dow jone industrial average grab gain nasdaq climb volume stock market today open mixed trade rise nyse possibly good sign rebound day move average volume dip nasdaq index retook day line stock precision castpart pcp lead soar news acquisition berkshire hathaway brka dow issue moved higher start trade apple aapl boee ba lead nearly chip stock drugmaker stake high ground nasdaq issue texas instrument txn kla tencor klac rise so do alexion alxn mylan myl ibd list cyberark software cybr investment wetf swat better gain cyberark move lift share back stock day move average attempt begin right side month consolidation be climb day move average trading past cup base buy point june quarter earning season be slow today hour session be nevertheless busy big name such hertz global htz kraft heinz khc report smaller name shake shack shak vipshop vip schedule report
672,MYL,last week space several big cap stock show healthy earning sale increase be discuss week column ask question big cap name be make most sale growth other word much profit be generate dollar sale profit margin tell well
673,MYL,major average be flat slightly higher early afternoon trading lack deal greece eurozone nasdaq dow jone industrial average be volume continue track lower board stock market today vs time friday consumer electronic maker generic drug stock biotechs be biggest mover generic drug maker be lead gain lannett lci actavis act impax laboratory ipxl mylan myl office supply retailer gold miner oil gas stock lag gold price be crude future slide apple aapl inched average volume extend advance try sixth straight session stock be extend flat base buy point definitively clear last week iphone maker have be generate lot buzz lately upcoming apple watch slate april launch more recent talk apple car ibd stock actavis climb new high average trade stock be past flat base buy point regain feb analyst expect actavis grow earning share revenue hike dublin base drugmaker report wednesday close downside hollysys automation holi plunge heavy volume lowest level nearly month stock be now flat base entry fall friday report fiscal profit late thursday miss view follow nancy gondo twitter ibd_ngondo
674,MYL,ibd composite rating stock price trading time high recent run robust financial growth generic drug maker akorn akrx be already top stock show even more strength future quarters thank several trend work favor report last month ibd lake forest ill base company have
675,MYL,generic drug giant mylan myl announce monday buy asset india base woman health company mylan also buy lung disease drug candidate mylan agree pay upfront contingent payment certain female health care business famy care mylan have have partnership
676,MYL,stock big cap screen be work basis have form secondary pattern earning report loom mylan myl maker generic drug be work flat base base pattern buy point stock rebound day move average monday heavy volume profit fourth quarter
677,MYL,top ibd composite rating straight quarters accelerate ep growth generic drug maker akorn akrx be already do pretty well new analyst report outline even more reason be bullish stock lake forest ill base akorn make diagnostic therapeutic ophthalmic pharmaceutical niche hospital drug injectable pharmaceutical much attention year have focuse pair high profit deal akorn april buyout tech pharmacal acquisition vpi holding akorn regularly deliver double digit revenue growth have grow ep double digit last quarters new report rbc capital market analyst randall stanicky cite few reason investor be bullish akorn new year expect easy earning beat akorn akorn be due report fourth quarter result first week march analyst poll thomson reuter expect ep cent vs cent year earlier host recent breakfast akorn chief financial officer tim dick stanicky see reason company shouldn breeze past fourth quarter view run rate already imply low hurdle consensus re leave forecast unchanged expect akrx exclude new approval usual point think ultimate earning power ultimately come well street forecast recent akorn product approval benefit product collectively target market opportunity stanicky note have fewer competitor only tobramycin september gatifloxacin october atropine sulfate december have launch imply most benefit fall stanicky say akorn competitive advantage july akorn receive food drug administration approval atropine sulfate ophthalmic solution be used eye exam treat certain eye condition product launch january stanicky call player market akorn join novartis nvs valeant pharmaceutical vrx however expect other competitor be remove be major re pricing opportunity akorn be single market player akorn belong ibd medical generic drug group rank industry track other group composite rating include actavis act mylan myl taro pharmaceutical taro composite rating be ibd proprietary stock ranking factor thing such earning growth stock price gain akorn share initially rise thursday morning stock market today reversed major market average akorn stock peaked oct steep sell share moved sideway fashion akorn stock retook day move average jan be try work right side base
678,MYL,drug industry recent spate deal get shot arm monday bristol myer squibb announce plan acquire privately hold drugmaker day valeant pharmaceutical international vrx say buy salix pharmaceutical bristol myer squibb bmy early monday agree buy flexus bioscience san carlos
679,MYL,strength market year hasn be small cap ibd big cap hasn benefit much trend
680,MYL,small cap measure be vs nasdaq respectively however big cap be only year
681,MYL,more recently whole group index peg short term low dec big cap be then lag gain nasdaq same period small cap be lead market least brief spell
682,MYL,week big cap be way study frustration
683,MYL,stock big cap have be hot cold story
684,MYL,example biogen idec biib sketch flat base november early january biotech stock break jan advanced high march
685,MYL,key ibd rule be take profit stock be most stock begin consolidate such gain individual investor lock profit be probably glad sell
686,MYL,biogen hasn be able do much march high stock break july december gain much
687,MYL,other medical stock big cap such epipen maker mylan myl prescription drug manufacturer valeant pharmaceutical vrx sketch similar action doesn mean stock fail deliver good return biogen be year mylan valeant however do mean investor miss early gain wasn much left play
688,MYL,outside medical sector thing haven be much better
689,MYL,tech service provider business process outsourcer cognizant technology solution ctsh regain day line february then rise stock begin consolidate march hasn make much progress
690,MYL,action have be choppy doesn inspire confidence
691,MYL,be bright spot consolidation story
692,MYL,linkedin lnkd raise interesting question story be different stock mentioned linkedin be only expect step earning growth
693,MYL,street expect ep roll increase estimate see growth crank internet platform business professional
694,MYL,linkedin deliver good run stock begin downward consolidation linkedin have now sketch flat pattern potential buy point
695,MYL,stock be suffering overhead supply buyer left side pattern look sell be long consolidation drive weak holder strength market year hasn be small cap ibd big cap hasn benefit much trend small cap measure be vs nasdaq respectively however big cap be only year more recently whole group index peg short term low dec big cap be then lag gain nasdaq same period small cap be lead market least brief spell week big cap be way study frustration stock big cap have be hot cold story example biogen idec biib sketch flat base november early january biotech stock break jan advanced high march key ibd rule be take profit stock be most stock begin consolidate such gain individual investor lock profit be probably glad sell biogen hasn be able do much march high stock break july december gain much other medical stock big cap such epipen maker mylan myl prescription drug manufacturer valeant pharmaceutical vrx sketch similar action doesn mean stock fail deliver good return biogen be year mylan valeant however do mean investor miss early gain wasn much left play outside medical sector thing haven be much better tech service provider business process outsourcer cognizant technology solution ctsh regain day line february then rise stock begin consolidate march hasn make much progress action have be choppy doesn inspire confidence be bright spot consolidation story linkedin lnkd raise interesting question story be different stock mentioned linkedin be only expect step earning growth street expect ep roll increase estimate see growth crank internet platform business professional linkedin deliver good run stock begin downward consolidation linkedin have now sketch flat pattern potential buy point stock be suffering overhead supply buyer left side pattern look sell be long consolidation drive weak holder
696,MYL,sterne agee upgrade israeli drug giant teva pharmaceutical industry teva buy neutral friday say outlook multiple sclerosis drug copaxone be better most investor think teva issue guidance thursday morning revenue slightly expectation ep high side revenue guidance be
697,MYL,stock future nose higher ahead monday open earning news contend effect rise dollar
698,MYL,dow future rise point fair market value nearly double gain hour earlier nasdaq future be point also rise future keep point gain
699,MYL,stock market today roll nasdaq fight hold fresh high inked late last week press resistance marked high stock set sail fresh market status investor
700,MYL,bank reopen today greece hint more progress new normal be earning season continue look somewhat better forecast ease overseas tension allow currency trader focus more directly potential rate increase federal reserve later year send dollar surge early trade monday place downward pressure stock
701,MYL,economic calendar be blank today pick steady stream housing datum begin wednesday
702,MYL,aerospace lockheed martin lmt unite technology utx rise news report say lockheed agree buy unite tech sikorsky helicopter unit more
703,MYL,deal lockheed largest combination martin marietta give lockheed unite technology black hawk helicopter business
704,MYL,morgan stanley ms top early earning news climb second quarter sale earning top analyst projection revenue bond security trading surge investment banking revenue slip stock end friday buy range rebound week support
705,MYL,halliburton hal tick revenue earning decline less expect earning fall revenue slip vs expectation decline respectively revenue north america fall halliburton share fall past week stall attempt climb deep month consolidation
706,MYL,morning injured list show cal maine food calm pare early loss mississippi base egg producer distributor fiscal revenue earning stop well short analyst expectation
707,MYL,company focuse primarily southern eastern market be widely see investor miss many negative effect avian flu affect much industry benefit corresponding increase egg price stock end friday flattish consolidation testing week support high
708,MYL,overseas europe lead index sketch moderate gain midday china market post narrowly mixed close shanghai hong kong tokyo nikkei add
709,MYL,gold fall nearly trading ounce lowest level early oil price slip few penny west texas intermediate trading barrel natural gas dip almost british thermal unit stock future nose higher ahead monday open earning news contend effect rise dollar dow future rise point fair market value nearly double gain hour earlier nasdaq future be point also rise future keep point gain stock market today roll nasdaq fight hold fresh high inked late last week press resistance marked high stock set sail fresh market status investor bank reopen today greece hint more progress new normal be earning season continue look somewhat better forecast ease overseas tension allow currency trader focus more directly potential rate increase federal reserve later year send dollar surge early trade monday place downward pressure stock economic calendar be blank today pick steady stream housing datum begin wednesday aerospace lockheed martin lmt unite technology utx rise news report say lockheed agree buy unite tech sikorsky helicopter unit more deal lockheed largest combination martin marietta give lockheed unite technology black hawk helicopter business morgan stanley ms top early earning news climb second quarter sale earning top analyst projection revenue bond security trading surge investment banking revenue slip stock end friday buy range rebound week support halliburton hal tick revenue earning decline less expect earning fall revenue slip vs expectation decline respectively revenue north america fall halliburton share fall past week stall attempt climb deep month consolidation morning injured list show cal maine food calm pare early loss mississippi base egg producer distributor fiscal revenue earning stop well short analyst expectation company focuse primarily southern eastern market be widely see investor miss many negative effect avian flu affect much industry benefit corresponding increase egg price stock end friday flattish consolidation testing week support high overseas europe lead index sketch moderate gain midday china market post narrowly mixed close shanghai hong kong tokyo nikkei add gold fall nearly trading ounce lowest level early oil price slip few penny west texas intermediate trading barrel natural gas dip almost british thermal unit
710,MYL,stock be mixed early wednesday afternoon follow conflict economic report
711,MYL,nasdaq rise gain dow jone industrial average slip volume be run lower main exchange compare time tuesday
712,MYL,stock market today generic drug maker mylan myl climb new high stock be still buy range past buy point handle long base
713,MYL,hain celestial hain rise new high heavy volume day company shareholder approve stock split maker distributor natural organic food be extend rebound week move average
714,MYL,meanwhile hewlett packard hpq reversed higher be solid volume breaking undefined base report earning close tuesday be same quarter last year line analyst expectation
715,MYL,downside aerovironment avav plunge heavy volume maker unmanned aircraft electric vehicle charge system report greater expect loss cent share latest quarter
716,MYL,economic report wednesday be mixed weekly unemployment claim expect durable good order better expect stock be mixed early wednesday afternoon follow conflict economic report nasdaq rise gain dow jone industrial average slip volume be run lower main exchange compare time tuesday stock market today generic drug maker mylan myl climb new high stock be still buy range past buy point handle long base hain celestial hain rise new high heavy volume day company shareholder approve stock split maker distributor natural organic food be extend rebound week move average meanwhile hewlett packard hpq reversed higher be solid volume breaking undefined base report earning close tuesday be same quarter last year line analyst expectation downside aerovironment avav plunge heavy volume maker unmanned aircraft electric vehicle charge system report greater expect loss cent share latest quarter economic report wednesday be mixed weekly unemployment claim expect durable good order better expect
717,MYL,tool be useful look sign institutional buy volume ratio ibd proprietary accumulation distribution rating be gauge volume ratio divide total volume day past day total volume day ratio greater point positive demand stock accumulation distribution rating
718,MYL,medical stock continue dominate top reach weekly review most be extend have make advance base point profit be take
719,MYL,remain just buy zone be drugmaker mylan myl break cup handle base buy point
720,MYL,mylan make drug treat disorder central nervous cardiovascular system other disorder earning most recent quarter rise company best year year gain year analyst forecast increase next report
721,MYL,year annualize earning growth rate be trail quarter return equity be number boost high debt
722,MYL,get weekly review be publish friday ibd stock have ep rating least relative strength rating least list be sort industry group stock top group appear top
723,MYL,top group be computer software security stock make screen group qualys qlys vasco datum security vdsi be more extend breakout range profit be take
724,MYL,fair isaac fico computer software financial industry group have break week tight pattern buy point be trading level october break double bottom pattern buy point few day later report earning be year number send stock higher next day begin form week tight pattern
725,MYL,technology avgo electronic semiconductor fabless industry group be buy range late stage shape cup base thursday report wednesday evening ep grow stock gap buy range news medical stock continue dominate top reach weekly review most be extend have make advance base point profit be take remain just buy zone be drugmaker mylan myl break cup handle base buy point mylan make drug treat disorder central nervous cardiovascular system other disorder earning most recent quarter rise company best year year gain year analyst forecast increase next report year annualize earning growth rate be trail quarter return equity be number boost high debt get weekly review be publish friday ibd stock have ep rating least relative strength rating least list be sort industry group stock top group appear top top group be computer software security stock make screen group qualys qlys vasco datum security vdsi be more extend breakout range profit be take fair isaac fico computer software financial industry group have break week tight pattern buy point be trading level october break double bottom pattern buy point few day later report earning be year number send stock higher next day begin form week tight pattern technology avgo electronic semiconductor fabless industry group be buy range late stage shape cup base thursday report wednesday evening ep grow stock gap buy range news
726,MYL,big pharma merck affirm tuesday go ahead acquisition biotech cubist pharmaceutical even cubist lead drug look face generic competition sooner expect merck mrk stock be morning trading stock market today cubist pharmaceutical cbst stock be more merck announce cubist acquisition
727,MYL,stock variety industry break new high ground wednesday hewlett packard hpq reversed higher surge clear buy point heavy trade stock be now entry highest level more year late tuesday pc maker report fiscal earning
728,MYL,mylan myl be early trading stock market today drugmaker beat estimate late thursday earlier stock be more nearly month high
729,MYL,earning come high end raise guidance range mylan offer oct share be year earlier quarter cent higher analyst consensus accord thomson reuter sale rise ahead street consensus
730,MYL,mylan also raise narrow full year ep guidance give oct now lower revenue guidance however range
731,MYL,leerink analyst jason gerberry write beat be drive sale epipen adrenaline self injection device treat anaphylaxis help push specialty pharma revenue larger generic drug business be line expectation bit light europe
732,MYL,many question conference call analyst be mylan pending deal buy develop market segment abbott laboratory establish product business be base netherlands mylan say go ahead deal treasury department propose new rule limit ability company lower taxe buy overseas firm
733,MYL,company reiterate pro tax rate low cfo expect tax rate step high teen next few year gerberry say research note thursday abbvie abbv board walk away shire shpg transaction concern relate treasury notice generally agree myl management notice remain recommendation ultimately not pass law
734,MYL,mylan be largest highest rate company ibd generic drug group composite rating have be consolidation pattern hit time high march
735,MYL,follow amy reeve twitter ibd_areeve mylan myl be early trading stock market today drugmaker beat estimate late thursday earlier stock be more nearly month high earning come high end raise guidance range mylan offer oct share be year earlier quarter cent higher analyst consensus accord thomson reuter sale rise ahead street consensus mylan also raise narrow full year ep guidance give oct now lower revenue guidance however range leerink analyst jason gerberry write beat be drive sale epipen adrenaline self injection device treat anaphylaxis help push specialty pharma revenue larger generic drug business be line expectation bit light europe many question conference call analyst be mylan pending deal buy develop market segment abbott laboratory establish product business be base netherlands mylan say go ahead deal treasury department propose new rule limit ability company lower taxe buy overseas firm company reiterate pro tax rate low cfo expect tax rate step high teen next few year gerberry say research note thursday abbvie abbv board walk away shire shpg transaction concern relate treasury notice generally agree myl management notice remain recommendation ultimately not pass law mylan be largest highest rate company ibd generic drug group composite rating have be consolidation pattern hit time high march follow amy reeve twitter ibd_areeve
736,MYL,big cap name week be medical related field reveal leadership name past few year have continue october correction whittle more nasdaq alexion pharmaceutical alxn develop drug treat blood disorder be extend buy point cup handle base
737,MYL,big cap medical firm biogen idec abbott laboratory thermo fisher scientific underwhelm investor third quarter earning guidance wednesday biogen stock especially punish company say patient have die take lead drug biogen biib earning rise year earlier quarter share beating analyst estimate cent
738,MYL,stock sprint start gate friday economic news quarterly report international market add lift
739,MYL,nasdaq stake early lead asmylan myl analog device adi expedia expe open more higher dow jone industrial average advanced volume be firmly higher nasdaq higher nyse compare trade same time thursday
740,MYL,stock market today track strong gain post international market friday investor largely mildly disappointing september consumer spending datum personal income saving rate be positive
741,MYL,chicago region manufacturing jump october send kingsbury international chicago purchasing manager index vs september economist have expect see change
742,MYL,consumer outlook also come positive side university michigan consumer index rise be october prior estimate well september tally consensus have project final read
743,MYL,stock argentina base online marketplace mercadolibre meli spiked open third quarter sale earning report late thursday sail past analyst expectation send share buy point yearlong cup handle base
744,MYL,gopro gpro also punch raft analyst upgrade follow solid third quarter result report thursday close surge lift share back day line support leave oct high
745,MYL,generic drug maker mylan step gain open canonsburg pa base operation report narrow beat third quarter revenue earning growth management raise full year earning guidance consensus view trim full year revenue outlook gain send share more buy point month cup base
746,MYL,leader set fine form essentially ibd list advanced open bell
747,MYL,ambarella amba heavy trade supplier chip gopro camera rise possible sympathy move gopro spike ambarella share be extend rebound week support stock sprint start gate friday economic news quarterly report international market add lift nasdaq stake early lead asmylan myl analog device adi expedia expe open more higher dow jone industrial average advanced volume be firmly higher nasdaq higher nyse compare trade same time thursday stock market today track strong gain post international market friday investor largely mildly disappointing september consumer spending datum personal income saving rate be positive chicago region manufacturing jump october send kingsbury international chicago purchasing manager index vs september economist have expect see change consumer outlook also come positive side university michigan consumer index rise be october prior estimate well september tally consensus have project final read stock argentina base online marketplace mercadolibre meli spiked open third quarter sale earning report late thursday sail past analyst expectation send share buy point yearlong cup handle base gopro gpro also punch raft analyst upgrade follow solid third quarter result report thursday close surge lift share back day line support leave oct high generic drug maker mylan step gain open canonsburg pa base operation report narrow beat third quarter revenue earning growth management raise full year earning guidance consensus view trim full year revenue outlook gain send share more buy point month cup base leader set fine form essentially ibd list advanced open bell ambarella amba heavy trade supplier chip gopro camera rise possible sympathy move gopro spike ambarella share be extend rebound week support
748,MYL,stock get healthy start friday solid job market september send unemployment rate first time
749,MYL,nasdaq rattle gain dow jone industrial average haul gain
750,MYL,trade climb nasdaq higher nyse
751,MYL,stock market today open positive payroll number september corroborate thursday decent unemployment layoff report help counterbalance wednesday weak factory datum general market remain correction banner nasdaq attempt retake support day move average
752,MYL,service datum be less rosy institute supply management september manufacturing index slip gauge lowest read june be august just forecast
753,MYL,stock generic drug maker mylan myl bolt higher boost third quarter full year earning guidance stock have be double dip correction march friday move send share back week move average
754,MYL,leader trade formation general market more ibd stock gain early trade
755,MYL,salix pharmaceutical slxp lead group gain raleigh base drugmaker announce end effort merge cosmo technology subsidiary italian drug maker cosmo pharmaceutical company cite recent change rule affect such overseas inversion type merger change strategy
756,MYL,strong volume gain act rebound support stock day move average
757,MYL,china base yy yy also advanced continue rebound test support week move average stock fail attempt deep late stage cup handle base august
758,MYL,mobileye mbly vault new high very heavy trade maker autonomous vehicle control technology stock have not see buy point opportunity brief ipo base
759,MYL,overseas europe market also buck higher job news cac paris climb narrowing loss week london ftse jump leave so far week
760,MYL,dollar continue gain vs euro yen oil natural gas be essentially steady gold price fall hard more ounce stock get healthy start friday solid job market september send unemployment rate first time nasdaq rattle gain dow jone industrial average haul gain trade climb nasdaq higher nyse stock market today open positive payroll number september corroborate thursday decent unemployment layoff report help counterbalance wednesday weak factory datum general market remain correction banner nasdaq attempt retake support day move average service datum be less rosy institute supply management september manufacturing index slip gauge lowest read june be august just forecast stock generic drug maker mylan myl bolt higher boost third quarter full year earning guidance stock have be double dip correction march friday move send share back week move average leader trade formation general market more ibd stock gain early trade salix pharmaceutical slxp lead group gain raleigh base drugmaker announce end effort merge cosmo technology subsidiary italian drug maker cosmo pharmaceutical company cite recent change rule affect such overseas inversion type merger change strategy strong volume gain act rebound support stock day move average china base yy yy also advanced continue rebound test support week move average stock fail attempt deep late stage cup handle base august mobileye mbly vault new high very heavy trade maker autonomous vehicle control technology stock have not see buy point opportunity brief ipo base overseas europe market also buck higher job news cac paris climb narrowing loss week london ftse jump leave so far week dollar continue gain vs euro yen oil natural gas be essentially steady gold price fall hard more ounce
761,MYL,share specialty drugmaker shire plummet stock market today word get late tuesday big pharma abbvie be reconsider buyout company shire shpg confirm report wednesday morning statement say abbvie abbv board intend consider withdraw modify recommendation light
762,MYL,big cap biotech ibd stock gilead science gild say monday licensing megablockbuster hepatitis drug sovaldi indian generic drug company improve access develop country gilead stock fall stock market today
763,MYL,sovaldi licensing deal include big name indian drug business such ranbaxy lab cipla well base mylan myl drugmaker be able set own price version sofosbuvir sovaldi be call generically presumably serious discount price week course treatment gilead have already price drug much lower different market instance egypt be poorer have severe hepatitis problem round treatment only cost gilead point press release strategy be first develop gilead hiv drug such viread truvada make gilead original fortune be otherwise price reach many person world need
764,MYL,release also say company be authorize make sofosbuvir combination other medicine include gilead ledipasvir gilead be currently await approval sofosbuvir ledipasvir pill have show be better sofosbuvir alone treat patient most common genotype virus also bristol myer squibb bmy daklinza have be approve europe use combination sofosbuvir indian company presumably have make own deal bristol manufacture together
765,MYL,news wasn surprise rumor generic sovaldi deal be circulate earlier month add volatility stock however analyst have be less concern base long experience do same thing hiv drug
766,MYL,follow amy reeve twitter ibd_areeve big cap biotech ibd stock gilead science gild say monday licensing megablockbuster hepatitis drug sovaldi indian generic drug company improve access develop country gilead stock fall stock market today sovaldi licensing deal include big name indian drug business such ranbaxy lab cipla well base mylan myl drugmaker be able set own price version sofosbuvir sovaldi be call generically presumably serious discount price week course treatment gilead have already price drug much lower different market instance egypt be poorer have severe hepatitis problem round treatment only cost gilead point press release strategy be first develop gilead hiv drug such viread truvada make gilead original fortune be otherwise price reach many person world need release also say company be authorize make sofosbuvir combination other medicine include gilead ledipasvir gilead be currently await approval sofosbuvir ledipasvir pill have show be better sofosbuvir alone treat patient most common genotype virus also bristol myer squibb bmy daklinza have be approve europe use combination sofosbuvir indian company presumably have make own deal bristol manufacture together news wasn surprise rumor generic sovaldi deal be circulate earlier month add volatility stock however analyst have be less concern base long experience do same thing hiv drug follow amy reeve twitter ibd_areeve
767,MYL,country worldwide have cut corporate tax rate past decade germany lower top rate canada go ireland average top rate country go
768,MYL,unite state have buck trend stubbornly cling top rate slightly more federal level average state
769,MYL,tax foundation scour country find only top corporate tax burden higher unite arab emirate chad
770,MYL,adopt global norm
771,MYL,lower corporate tax rate global norm further politically feasible doubt benefit company investor move global mainstream corporate taxe even hold carrot political class more corporate tax revenue
772,MYL,high corporate tax rate make sense increasingly global economy high rate don raise revenue once do estimate receipt fiscal year even high rate encourage tax drive tactic strategy economy
773,MYL,ve see company move job operation country lower tax rate ve see american company stash nearly profit overseas avoid tax bite
774,MYL,ve see company such burger king worldwide bkw chiquita brand international cqb medtronic mdt abbvie abbv mylan myl announce corporate inversion merger acquisition transfer headquarters overseas just year first month more be likely follow
775,MYL,political class harrumph howl perfectly legal tax avoidance brand company unpatriotic
776,MYL,catcall divert attention politician already have hand fiscally sound economically sensible way keep company america lower country punish corporate tax rate
777,MYL,other country cut corporate rate weren merely kowtow corporate power politician understood lower taxe help keep company home bolster nation economy pay faster growth higher employment add tax revenue
778,MYL,apply laffer curve
779,MYL,unite state doesn necessarily have choose larger budget deficit fix onerous corporate tax system step rest world
780,MYL,economist arthur laffer famously put forward proposition tax rate be so high choke economic activity actually reduce revenue so lower rate raise tax receipt very well be case corporate taxe
781,MYL,american enterprise institute economist kevin hassett alex brill determine tax revenue maximize top corporate rate go late
782,MYL,reason decline increase international mobility capital other country cut corporate tax rate
783,MYL,other country have keep cut corporate tax rate so revenue maximize rate have probably come few percentage point then ll stick hassett brill see take
784,MYL,go revenue maximize rate add third corporate tax receipt lower taxe reduce incentive move abroad stash profit overseas
785,MYL,more important encourage american foreign company expand invest unite state raise overall economic growth corporate earning tax receipt
786,MYL,sound too good be true tax foundation william mcbride take look canada top rate corporate tax revenue averaged gdp
787,MYL,country reduce rate corporate tax revenue rise gdp comparison high corporate tax rate have yielded average revenue just gdp
788,MYL,cut corporate tax rate raise tax earning good news company shareholder
789,MYL,tax kick come greater incentive do business so see more company stay home more transplant overseas more new business more investment domestic foreign source more economic growth lead higher corporate revenue profit
790,MYL,tax gain be more direct profit firm now keep rather stock price gain depend several factor include much actual tax relief company get other country respond more tax cut back envelope calculation suggest market gain be substantial go today high rate even lower
791,MYL,corporate tax rate closer worldwide norm find easier change flaw corporate tax system be handful country tax worldwide revenue force american company pay high rate overseas earning most other country use territorial approach tax only profit earn country
792,MYL,england switch territorial system so british company make profit ireland pay country multinational pay ireland still owe taxe irish earning difference ireland low rate much higher rate
793,MYL,year now democrat republican have call cut corporate tax rate nothing be do sign paralysis grip nation capital
794,MYL,hubbub burger king propose move canada wasn encourage member congress administration seem more interested chastising corporate escapee lower tax penalty ve impose do business here
795,MYL,cox be director neil center global market freedom smu cox school business former chief economist dalla federal reserve
796,MYL,alm be writer residence center country worldwide have cut corporate tax rate past decade germany lower top rate canada go ireland average top rate country go unite state have buck trend stubbornly cling top rate slightly more federal level average state tax foundation scour country find only top corporate tax burden higher unite arab emirate chad adopt global normslowering corporate tax rate global norm further politically feasible doubt benefit company investor move global mainstream corporate taxe even hold carrot political class more corporate tax revenue high corporate tax rate make sense increasingly global economy high rate don raise revenue once do estimate receipt fiscal year even high rate encourage tax drive tactic strategy economy ve see company move job operation country lower tax rate ve see american company stash nearly profit overseas avoid tax bite ve see company such burger king worldwide bkw chiquita brand international cqb medtronic mdt abbvie abbv mylan myl announce corporate inversion merger acquisition transfer headquarters overseas just year first month more be likely follow political class harrumph howl perfectly legal tax avoidance brand company unpatriotic catcall divert attention politician already have hand fiscally sound economically sensible way keep company america lower country punish corporate tax rate other country cut corporate rate weren merely kowtow corporate power politician understood lower taxe help keep company home bolster nation economy pay faster growth higher employment add tax revenue apply laffer unite state doesn necessarily have choose larger budget deficit fix onerous corporate tax system step rest world economist arthur laffer famously put forward proposition tax rate be so high choke economic activity actually reduce revenue so lower rate raise tax receipt very well be case corporate taxe american enterprise institute economist kevin hassett alex brill determine tax revenue maximize top corporate rate go late reason decline increase international mobility capital other country cut corporate tax rate other country have keep cut corporate tax rate so revenue maximize rate have probably come few percentage point then ll stick hassett brill see take go revenue maximize rate add third corporate tax receipt lower taxe reduce incentive move abroad stash profit overseas more important encourage american foreign company expand invest unite state raise overall economic growth corporate earning tax receipt sound too good be true tax foundation william mcbride take look canada top rate corporate tax revenue averaged gdp country reduce rate corporate tax revenue rise gdp comparison high corporate tax rate have yielded average revenue just gdp cut corporate tax rate raise tax earning good news company shareholder tax kick come greater incentive do business so see more company stay home more transplant overseas more new business more investment domestic foreign source more economic growth lead higher corporate revenue profit tax gain be more direct profit firm now keep rather stock price gain depend several factor include much actual tax relief company get other country respond more tax cut back envelope calculation suggest market gain be substantial go today high rate even lower corporate tax rate closer worldwide norm find easier change flaw corporate tax system be handful country tax worldwide revenue force american company pay high rate overseas earning most other country use territorial approach tax only profit earn country england switch territorial system so british company make profit ireland pay country multinational pay ireland still owe taxe irish earning difference ireland low rate much higher rate year now democrat republican have call cut corporate tax rate nothing be do sign paralysis grip nation capital hubbub burger king propose move canada wasn encourage member congress administration seem more interested chastising corporate escapee lower tax penalty ve impose do business here cox be director neil center global market freedom smu cox school business former chief economist dalla federal reserve alm be writer residence center
797,MYL,specialty drugmaker salix pharmaceutical announce oct be do something unusual back merger close back july salix slxp have agree acquire cosmo technology irish subsidiary italian drugmaker cosmo pharmaceutical stock swap value deal have allow salix so many
798,MYL,burger king bkw be apparently unfazed pressure wag face drugstore giant decide used foreign acquisition move headquarters low tax country fast food chain sunday confirm report be talk ontario canada base tim horton thi purchasing company burger king say move
799,MYL,wag reportedly remain domicile company political backlash american company used foreign acquisition lower taxe share company be more stock market today sky news report soon wednesday drugstore giant announce plan take rest swiss base alliance boot
800,MYL,earning report specialty drugmaker continue roll thursday lead stock stumble early go stock market today danish diabetes giant nordisk nvo report profit kroner cent share year earlier quarter beating analyst consensus sale kroner however
801,MYL,name former kraft krft cfo timothy mclevish new evp cfo ahead national drugstore chain decision acquire rest alliance boot share wag rise stock market today buy alliance boot have be mull move europe
802,MYL,ibd stock salix pharmaceutical miss expectation second quarter report late thursday end disappointing day several large specialty drug maker salix slxp say earning more double vs year earlier quarter share miss analyst consensus cent sale rise analyst estimate full year guidance be also light
803,MYL,wag mull use loophole tax law save million dollar move headquarters europe former treasury official argue white house close loophole congressional approval article publish monday tax note journal accountant tax lawyer stephen shay former treasury
804,MYL,push company move overseas keep investor busy monday mylan agree buy part abbott laboratory generic drug business relocate netherlands mean abbott former proprietary drug unit abbvie close deal anglo irish shire pharmaceutical fifth offer abbott keep brand generic business emerge market
805,MYL,push company move overseas keep investor busy monday mylan agree buy part abbott laboratory generic drug business relocate netherlands mean abbott former proprietary drug unit abbvie close deal anglo irish shire pharmaceutical fifth offer abbott keep brand generic business emerge market
806,MYL,actavis have make acquisition transform generic focuse drugmaker bigger player prescription drug now find enviable position thrive home base ireland expect generate revenue be now large diverse enough forge ahead international power pharmaceutical industry yet
807,MYL,just few year drug generate small slice revenue jazz pharmaceutical drug xyrem target small patient population narcolepsy sufferer person prone fall suddenly asleep middle day high price make sale effort worthwhile jazz pharmaceutical jazz keep raise price
808,MYL,american company such abbvie abbv mylan myl edge closer merger firm base overseas obama administration be push end inversion practice company reincorporate abroad reduce taxe letter member house way mean committee treasury secretary jacob lew urge lawmaker immediately
809,MYL,stock ease intraday high monday afternoon be still higher bounce back last week weakness
810,MYL,nasdaq be rise much respectively monday high dow jone industrial average outperformed gain volume be tracking higher major exchange stock market today
811,MYL,trade be run only touch higher nyse
812,MYL,kandi technology kndi gap bolt month high huge trade chinese automaker announce kandi electric vehicle group joint venture shanghai maple guorun automobile sell electric vehicle first quarter kandi lose money past quarters sale growth accelerate straight period
813,MYL,mylan myl be session high still active trading share be nearly news agree acquire piece abbott laboratory generic drug business mylan also move netherlands lower tax bill
814,MYL,facebook fb rise fast trade extend rebound day move average stock regain buy point cup handle facebook fall nearly trigger rebound
815,MYL,oppenheimer co project strong result base channel check investment boutique stay outperform rating share facebook report result close july
816,MYL,downside william lyon home wlh erased early gain fall pace sixth straight loss potential cup handle base take shape last month newport beach calif base homebuilder agree buy residential homebuilding business polygon northwest company cash buyout mark expansion pacific northwest stock ease intraday high monday afternoon be still higher bounce back last week weakness nasdaq be rise much respectively monday high dow jone industrial average outperformed gain volume be tracking higher major exchange stock market today trade be run only touch higher nyse kandi technology kndi gap bolt month high huge trade chinese automaker announce kandi electric vehicle group joint venture shanghai maple guorun automobile sell electric vehicle first quarter kandi lose money past quarters sale growth accelerate straight period mylan myl be session high still active trading share be nearly news agree acquire piece abbott laboratory generic drug business mylan also move netherlands lower tax bill facebook fb rise fast trade extend rebound day move average stock regain buy point cup handle facebook fall nearly trigger rebound oppenheimer co project strong result base channel check investment boutique stay outperform rating share facebook report result close july downside william lyon home wlh erased early gain fall pace sixth straight loss potential cup handle base take shape last month newport beach calif base homebuilder agree buy residential homebuilding business polygon northwest company cash buyout mark expansion pacific northwest
817,MYL,medical product giant st jude medical abbott laboratory beat analyst expectation raise guidance wednesday share have bumpy ride market fresh attack drug industry merger abbott report first sale beat quarters revenue rise consensus earning climb cent share beating estimate cent company add few penny full year ep guidance now analyst average be conference call analyst discuss result abbott cfo thomas freyman say revenue rise low mid single digit be high side analyst expectation growth freyman also guide sale growth similar range say earning be cent cent year be line street estimate have be bit show story last few quarters company work headwind establish product generic drug nutritional business leerink analyst danielle antalffy write research note wednesday now sale ep beat hand prompt ep guidance raise recent transaction execute optimize portfolio include acquisition cfr pharmaceutical chilean base brand generic company divestiture develop market establish product business be near potential sale growth inflection point monday abbott announce be selling develop market establish product business mylan myl plan take opportunity re incorporate netherlands follow virtual stampede drugmaker lower tax country wednesday however treasury secretary jack lew issue letter congress urge moratorium such arrangement comprehensive tax reform be enact lew want ban be retroactive view be caution be certainly warrant concern pending recently announce deal such mylan announce acquisition abbott establish product business bmo capital market analyst david maris write research note wednesday perhaps abbott stock seesaw trading wednesday open then drop midday eventually close fraction analyst be impressed abbott cost control result improvement gross profit margin rbc capital market analyst glenn novarro say make quality beat morgan stanley analyst david lewis project basis point improvement operate margin second half year st jude stj have plan tax inversion say earning rise year earlier quarter share beating analyst consensus cent sale climb vs street company guide ep cent cent bracketing consensus sale guidance miss analyst year st jude guide ep sale slightly higher previous guidance line expectation st jude see share gainson conference call discuss result st jude ceo daniel stark say growth start accelerate second half year due mainly new product launch say ramp continue next year revenue growth mid high single digit vs year expect range stark also say st jude be still gain share implantable cardioverter defibrillator icd market sale division rise st jude say overall market continue shrink stark admit however first quarter firm didn know exactly icd market be do rival boston scientific bsx medtronic mdt have report quarters later earning medtronic boston scientific be still road result however have indicated st jude gain basis point market share still analyst antalffy write st jude guidance be disappointing give beat also point stock be richly value hit time high july trading wednesday do almost reverse abbott drop nearly early recover somewhat close nearly
818,MYL,leader buy range get tougher find market uptrend continue stock break new high
819,MYL,raft medical play today weekly review be show fairly healthy action work basis move buy point few institutional quality drugmaker have even successfully break third stage later basis tend be riskier
820,MYL,nordisk nvo be form right side second stage cup base doesn carve handle potential buy point be danish drugmaker key diabetes therapy include novolog victoza be await fda approval next generation insulin treatment tresiba be already market country have maintain double digit quarterly share profit growth mid analyst expect gain
821,MYL,generic drugmakermylan myl round trip gain last form third stage base possible buy point weekly chart show few wide price swing have tighten recently be better see more upside volume right side build
822,MYL,myriad genetic mygn kick current second stage base early reset base count late last year regain week line last week be still potential entry genetic product maker profit growth be solid have slow
823,MYL,thinly trade taro pharmaceutical industry taro be near buy point flat base be work week generic drugmaker rally flat base september so current base be second stage pattern
824,MYL,other lead medical related stock have clear third stage later basis include actavis act illumina ilmn salix pharmaceutical slxp leader buy range get tougher find market uptrend continue stock break new high raft medical play today weekly review be show fairly healthy action work basis move buy point few institutional quality drugmaker have even successfully break third stage later basis tend be riskier nordisk nvo be form right side second stage cup base doesn carve handle potential buy point be danish drugmaker key diabetes therapy include novolog victoza be await fda approval next generation insulin treatment tresiba be already market country have maintain double digit quarterly share profit growth mid analyst expect gain generic drugmakermylan myl round trip gain last form third stage base possible buy point weekly chart show few wide price swing have tighten recently be better see more upside volume right side build myriad genetic mygn kick current second stage base early reset base count late last year regain week line last week be still potential entry genetic product maker profit growth be solid have slow thinly trade taro pharmaceutical industry taro be near buy point flat base be work week generic drugmaker rally flat base september so current base be second stage pattern other lead medical related stock have clear third stage later basis include actavis act illumina ilmn salix pharmaceutical slxp
825,MYL,stock future upshifted ahead friday open forecast read march payroll
826,MYL,dow future double early gain point fair market value nasdaq future jump point climb point also double early gain
827,MYL,stock have trim week gain thursday stock market today still open solid lead week nasdaq be thursday be ahead uptrend distribution day count remain problematic nasdaq action day line continue provide fodder optimist
828,MYL,highly anticipate march payroll report nonfarm payroll expand month be labor department initial estimate february upward revision new job february well consensus estimate increase march
829,MYL,private payroll also expand february expectation new hire unemployment rate hold steady disappointing forecast downtick average hourly earning be also not snuff show gain march vs february increase estimate gain
830,MYL,stock drugmaker mylan myl open possibly due multiple news report company purchase swedish specialty drugmaker meda unnamed source say company have hold preliminary talk meda chairman bert ake eriksson reportedly confirm swedish news agency contact have be make meda provide announcement later day
831,MYL,mylan have be bounce back forth new high clear month consolidation february
832,MYL,gaslog glog jump start trade operator liquefy natural gas carrier fleet be extend have be scratch new high rebound week support mid january
833,MYL,overseas china market close narrowly mixed friday sharply week hong kong hang seng post weekly gain shanghai composite
834,MYL,european stock hover mild gain midsession week london ftse frankfurt dax hold gain cac paris trade last friday close
835,MYL,dollar strike year high vs euro comment european central bank official add expectation eurozone monetary support dollar be flat yen friday week
836,MYL,commodity oil be almost bump back barrel thursday crude future be fraction lower so far week natural gas ebb penny lower be slightly week gold higher trade absolutely flat week stock future upshifted ahead friday open forecast read march payroll dow future double early gain point fair market value nasdaq future jump point climb point also double early gain stock have trim week gain thursday stock market today still open solid lead week nasdaq be thursday be ahead uptrend distribution day count remain problematic nasdaq action day line continue provide fodder optimist highly anticipate march payroll report nonfarm payroll expand month be labor department initial estimate february upward revision new job february well consensus estimate increase march private payroll also expand february expectation new hire unemployment rate hold steady disappointing forecast downtick average hourly earning be also not snuff show gain march vs february increase estimate gain stock drugmaker mylan myl open possibly due multiple news report company purchase swedish specialty drugmaker meda unnamed source say company have hold preliminary talk meda chairman bert ake eriksson reportedly confirm swedish news agency contact have be make meda provide announcement later day mylan have be bounce back forth new high clear month consolidation february gaslog glog jump start trade operator liquefy natural gas carrier fleet be extend have be scratch new high rebound week support mid january overseas china market close narrowly mixed friday sharply week hong kong hang seng post weekly gain shanghai composite european stock hover mild gain midsession week london ftse frankfurt dax hold gain cac paris trade last friday close dollar strike year high vs euro comment european central bank official add expectation eurozone monetary support dollar be flat yen friday week commodity oil be almost bump back barrel thursday crude future be fraction lower so far week natural gas ebb penny lower be slightly week gold higher trade absolutely flat week
837,MYL,stock remain lower early afternoon trading tuesday analyst warning new apple iphone hurt share company supplier nasdaq be dow jone industrial average be volume be tracking lower nyse higher nasdaq decline stock have small edge advancer nyse loser lead nasdaq solar energy automaker staffing dairy product company be poorest performer stock market today tesla tsla skid more sink deeper day day move average metal retail utility real estate investment trust industry group be best tuesday supplier apple aapl iphone be lower credit suisse warn company be cut back component order iphone model apple share gap loss average volume cirrus logic crus slide busy trading fall day move average skywork solution swks gap day move average shed heavy trading side ruth hospitality ruth better know ruth chris steak house clear buy point double bottom base active trading company beat earning expectation couple week ep jump restaurant industry group have be trend lower ibd group ranking
838,MYL,salix pharmaceutical slxp announce tax inversion merger last month be several ibd drug stock report earning week july salix announce plan merge italy cosmo pharmaceutical irish subsidiary cosmo technology new headquarters be ireland boast lower taxe drug company focus find treatment
839,MYL,specialty drugmaker forest laboratory frx agree pay cash smaller counterpart furiex pharmaceutical furx monday send latter stock more midday trading stock market today forest be process be buy actavis act pay share premium friday close price
840,MYL,generic drug giant mylan myl friday lose takeover bid swedish counterpart meda stock be still more midday trading stock market late thursday britain financial time report mylan meda be talk didn say exactly mylan bid say be significant premium
841,MYL,big pharma pfizer pfe briefly halter trading wednesday afternoon announce patent best selling arthritis drug celebrex have be invalidate district court trading resume share be nearly stock market today pfizer have sue maker generic drug teva pharmaceutical industry teva mylan myl watson laboratory now part actavis ticker
842,MYL,stock market close mixed thursday earlier gain vanished afternoon nasdaq fall nearly dow jone industrial average add
843,MYL,main index negative price reversal be latest instance volatility have plague stock past couple week
844,MYL,loser top winner nyse side be even nasdaq volume be lower accord early number
845,MYL,food chip telecom solar stock lead stock market today homebuilder continue show relative strength lgi home lgih make new high wci community wcic climb back buy point industry group have be trend higher rank thursday ibd group
846,MYL,biotechs airline be leader day earlier rank thursday weakest do discount retailer mining stock
847,MYL,google googl fall stock continue find support day move average
848,MYL,ibd be evenly split winner loser outsized loss weigh performance slide discounter sale miss view company issue weak guidance stock promising new issue have be consolidate november
849,MYL,ambarella amba have be selling deliver quarterly result wednesday guide revenue analyst expectation bearish outlook raise fear demand wearable camera rattle camera maker gopro gpro ambarella supply video chip gopro be week lows stock market close mixed thursday earlier gain vanished afternoon nasdaq fall nearly dow jone industrial average add main index negative price reversal be latest instance volatility have plague stock past couple week loser top winner nyse side be even nasdaq volume be lower accord early number food chip telecom solar stock lead stock market today homebuilder continue show relative strength lgi home lgih make new high wci community wcic climb back buy point industry group have be trend higher rank thursday ibd group biotechs airline be leader day earlier rank thursday weakest do discount retailer mining stock google googl fall stock continue find support day move average ibd be evenly split winner loser outsized loss weigh performance slide discounter sale miss view company issue weak guidance stock promising new issue have be consolidate november ambarella amba have be selling deliver quarterly result wednesday guide revenue analyst expectation bearish outlook raise fear demand wearable camera rattle camera maker gopro gpro ambarella supply video chip gopro be week lows
850,MYL,stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge
851,MYL,volume nasdaq nyse be tracking tuesday level
852,MYL,fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis
853,MYL,stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast
854,MYL,stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation
855,MYL,solar stock be day best performer lead first solar fslr jump new high heavy volume
856,MYL,maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar
857,MYL,downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy
858,MYL,meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge volume nasdaq nyse be tracking tuesday level fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation solar stock be day best performer lead first solar fslr jump new high heavy volume maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise
859,MYL,stock market close mixed thursday earlier gain vanished afternoon nasdaq fall nearly dow jone industrial average add
860,MYL,main index negative price reversal be latest instance volatility have plague stock past couple week
861,MYL,loser top winner nyse side be even nasdaq volume be lower accord early number
862,MYL,food chip telecom solar stock lead stock market today homebuilder continue show relative strength lgi home lgih make new high wci community wcic climb back buy point industry group have be trend higher rank thursday ibd group
863,MYL,biotechs airline be leader day earlier rank thursday weakest do discount retailer mining stock
864,MYL,google googl fall stock continue find support day move average
865,MYL,ibd be evenly split winner loser outsized loss weigh performance slide discounter sale miss view company issue weak guidance stock promising new issue have be consolidate november
866,MYL,ambarella amba have be selling deliver quarterly result wednesday guide revenue analyst expectation bearish outlook raise fear demand wearable camera rattle camera maker gopro gpro ambarella supply video chip gopro be week lows stock market close mixed thursday earlier gain vanished afternoon nasdaq fall nearly dow jone industrial average add main index negative price reversal be latest instance volatility have plague stock past couple week loser top winner nyse side be even nasdaq volume be lower accord early number food chip telecom solar stock lead stock market today homebuilder continue show relative strength lgi home lgih make new high wci community wcic climb back buy point industry group have be trend higher rank thursday ibd group biotechs airline be leader day earlier rank thursday weakest do discount retailer mining stock google googl fall stock continue find support day move average ibd be evenly split winner loser outsized loss weigh performance slide discounter sale miss view company issue weak guidance stock promising new issue have be consolidate november ambarella amba have be selling deliver quarterly result wednesday guide revenue analyst expectation bearish outlook raise fear demand wearable camera rattle camera maker gopro gpro ambarella supply video chip gopro be week lows
867,MYL,nasdaq take beating again friday institutional investor continue take profit growth stock nearly half stock ibd fall more
868,MYL,nasdaq plunge be day move average again briefly reclaim support level lose dow jone industrial average ease nyse nasdaq volume be tracking well thursday level stock market today
869,MYL,institutional investor rotate growth stock not surprising see scad blue chip name hold well better look chart currently be find dow name such caterpillar cat dupont dd walt disney johnson johnson jnj other
870,MYL,economic news economy add job march consensus estimate unemployment rate be unchanged february job growth be revise higher initially report money flow bond market news year treasury yield fall basis point
871,MYL,weakness biotech stock have be weigh nasdaq be more same friday ibd medical biom biotech group lose nearly feb high group have lose
872,MYL,not surprisingly gold utility stock outperformed
873,MYL,bright spot friday be mylan myl share rise news be interested acquire swiss firm meda meda reject proposal
874,MYL,bright spot friday be cement maker group rise bloomberg report industry titan swiss firm holcim french firm lafarge be explore possible merger group leader eagle material exp hit time high rise nearly nasdaq take beating again friday institutional investor continue take profit growth stock nearly half stock ibd fall more nasdaq plunge be day move average again briefly reclaim support level lose dow jone industrial average ease nyse nasdaq volume be tracking well thursday level stock market today institutional investor rotate growth stock not surprising see scad blue chip name hold well better look chart currently be find dow name such caterpillar cat dupont dd walt disney johnson johnson jnj other economic news economy add job march consensus estimate unemployment rate be unchanged february job growth be revise higher initially report money flow bond market news year treasury yield fall basis point weakness biotech stock have be weigh nasdaq be more same friday ibd medical biom biotech group lose nearly feb high group have lose not surprisingly gold utility stock outperformed bright spot friday be mylan myl share rise news be interested acquire swiss firm meda meda reject proposal bright spot friday be cement maker group rise bloomberg report industry titan swiss firm holcim french firm lafarge be explore possible merger group leader eagle material exp hit time high rise nearly
875,MYL,large cap drugmaker actavis be look acquisition expand generic domain brand prescription drug realm heel strong profit gain actavis act first quarter adjust earning soar year earlier top analyst view share revenue rise ep rise
876,MYL,canada valeant pharmaceutical international vrx be chastise stock market thursday revenue miss estimate executive focuse long view firm absorb acquisition
877,MYL,valeant stock last week hit time high fall
878,MYL,valeant cash ep totale year earlier quarter cent analyst consensus exclude financing cost buyout contact lens giant bausch lomb complete august firm make share sale jump short estimate
879,MYL,valeant shave similar amount full year revenue guidance now vs last year tighten ep guidance middle range now vs last year
880,MYL,exchange rate head wind
881,MYL,conference call analyst discuss result ceo michael pearson say valeant face head wind foreign exchange rate unexpectedly early approval generic competitor acne medicine retin micro august loss pile unexpectedly early approval mylan myl generic version herpes cream zovirax earlier year well expect competition antidepressant wellbutrin xl fourth quarter pearson say expect generic competitor together knock year total revenue
882,MYL,say get better here look forward next year see be far toughest year say
883,MYL,next year patent loss be estimate subtract
884,MYL,pearson also say valeant product mix have be profoundly change bausch lomb acquisition acquisition give valeant business drug patent be largely irrelevant
885,MYL,bausch revenue rise
886,MYL,bausch lomb acquisition also deliver nearer term organic growth year year valeant cfo howard schiller say integration firm be ahead schedule be expect generate cost synergy come end year
887,MYL,schiller say valeant have examine global business have target certain country restructure hope boost growth future year
888,MYL,analyst generally seem explanation miss instead focuse potential merger
889,MYL,unexpected generic competition retin micro raise concern other product firm portfolio be expose potential generic competition do not see serious concern impact generic competition be minimal go forward write morningstar analyst david kempra research note thursday valeant have just revenue year face patent loss
890,MYL,kempra also note year merger acquisition single product account more valeant sale maintain fair value estimate price stock
891,MYL,goldman sachs analyst gary nachman maintain conviction buy rating price target be clearly transition quarter lot move part consider deal close aug overall seem lot fundamental make vrx attractive be track write research note include good exposure high growth emerge market opportunity expand region very strong diversification weather impact generic competition certain product develop market
892,MYL,aegis capital ram selvaraju reiterate buy rating
893,MYL,legacy business unit perform well dermatology unit continue demonstrate brand product growth aesthetic division gain ground dysport orapharma generate double digit revenue expansion xenazine tetrabenazine also improve sale write canada valeant pharmaceutical international vrx be chastise stock market thursday revenue miss estimate executive focuse long view firm absorb acquisition valeant stock last week hit time high fall valeant cash ep totale year earlier quarter cent analyst consensus exclude financing cost buyout contact lens giant bausch lomb complete august firm make share sale jump short estimate valeant shave similar amount full year revenue guidance now vs last year tighten ep guidance middle range now vs last year exchange rate head windson conference call analyst discuss result ceo michael pearson say valeant face head wind foreign exchange rate unexpectedly early approval generic competitor acne medicine retin micro august loss pile unexpectedly early approval mylan myl generic version herpes cream zovirax earlier year well expect competition antidepressant wellbutrin xl fourth quarter pearson say expect generic competitor together knock year total revenue say get better here look forward next year see be far toughest year say next year patent loss be estimate subtract pearson also say valeant product mix have be profoundly change bausch lomb acquisition acquisition give valeant business drug patent be largely irrelevant bausch revenue rise bausch lomb acquisition also deliver nearer term organic growth year year valeant cfo howard schiller say integration firm be ahead schedule be expect generate cost synergy come end year schiller say valeant have examine global business have target certain country restructure hope boost growth future year analyst generally seem explanation miss instead focuse potential merger unexpected generic competition retin micro raise concern other product firm portfolio be expose potential generic competition do not see serious concern impact generic competition be minimal go forward write morningstar analyst david kempra research note thursday valeant have just revenue year face patent loss kempra also note year merger acquisition single product account more valeant sale maintain fair value estimate price stock goldman sachs analyst gary nachman maintain conviction buy rating price target be clearly transition quarter lot move part consider deal close aug overall seem lot fundamental make vrx attractive be track write research note include good exposure high growth emerge market opportunity expand region very strong diversification weather impact generic competition certain product develop market aegis capital ram selvaraju reiterate buy rating legacy business unit perform well dermatology unit continue demonstrate brand product growth aesthetic division gain ground dysport orapharma generate double digit revenue expansion xenazine tetrabenazine also improve sale write
894,MYL,nasdaq lead market rally thursday week high buyer continue have upper hand
895,MYL,close tech heavy index add dow jone industrial average add preliminary datum show nyse nasdaq volume come slightly lower wednesday level
896,MYL,speech front senate banking committee fed chief janet yellen acknowledge recent softness economic datum repeat recent fed assurance pullback stimulus be not preset course
897,MYL,stock market today baidu bidu rise nearly strong earning sale growth accelerate third straight quarter rise flat single digit earning growth past quarters give pause still company end more active mobile customer
898,MYL,generic drugmaker mylan myl surge strong earning stock continue perform well recent flat base january industry group medical generic drug have be hotbed acquisition activity lately ceo heather bresch say company be well poise transaction
899,MYL,china base athm hit time high rise monday nasty reversal earlier week company report surge quarterly profit sale company be online destination car buyer china currently world largest car market sale volume new automobile
900,MYL,downside questcor pharmaceutical qcor slump recent be go nowhere fast day decline now stand note short seller citron research issue negative report company share drugmaker surge nearly feb ahead earning report company report quarter solid growth wednesday
901,MYL,close watch earning report splunk splk salesforce com crm air lease al chuy chuy gap gps monster beverage mnst nasdaq lead market rally thursday week high buyer continue have upper hand close tech heavy index add dow jone industrial average add preliminary datum show nyse nasdaq volume come slightly lower wednesday level speech front senate banking committee fed chief janet yellen acknowledge recent softness economic datum repeat recent fed assurance pullback stimulus be not preset course stock market today baidu bidu rise nearly strong earning sale growth accelerate third straight quarter rise flat single digit earning growth past quarters give pause still company end more active mobile customer generic drugmaker mylan myl surge strong earning stock continue perform well recent flat base january industry group medical generic drug have be hotbed acquisition activity lately ceo heather bresch say company be well poise transaction china base athm hit time high rise monday nasty reversal earlier week company report surge quarterly profit sale company be online destination car buyer china currently world largest car market sale volume new automobile downside questcor pharmaceutical qcor slump recent be go nowhere fast day decline now stand note short seller citron research issue negative report company share drugmaker surge nearly feb ahead earning report company report quarter solid growth wednesday close watch earning report splunk splk salesforce com crm air lease al chuy chuy gap gps monster beverage mnst
902,MYL,stock market close lower thursday index erased early gain nasdaq have be nearly trip loss shed dow jone industrial average less selling intensified final minute trading index close session lows volume increase nyse fall nasdaq accord preliminary figure close loser lead winner more earlier be just opposite winner lead breakout hanesbrand hbi methode electronic hold spansion code close buy point market rally early news european central bank have adopt new stimulus strategy move be expect wall street have just elect sell news cleveland fed president loretta mester make comment support back away fed considerable period guidance raise interest rate index be lower comment crossed wire market also have be jittery ahead friday employment report maker apparel auto steel lead market retail do fairly well too energy number health care industry group lag most bell el pollo report first result go public share rise early extend trading
903,MYL,drugmaker aptalis holding file go public thursday ipo expect raise half dollar company formerly trade axcan pharma return new incarnation private equity firm tpg capital acquire axcan have merged several other company notably pharmaceutical acquire company have
904,MYL,stock future signale lower open wednesday follow prior session rebound
905,MYL,dow nasdaq future be ahead bell
906,MYL,tuesday wall street record biggest day gain volatile day trading ongoing fear economy
907,MYL,reuter poll say economist figure chance have recession mean fed launch round monetary ease
908,MYL,elsewhere gold price remain record high ounce
909,MYL,corporate front macy logged second quarter earning cent share cent prior year nickel view
910,MYL,disney also beat earning sale estimate thank part strong result espn theme park division
911,MYL,overseas tokyo nikkei index rise hong kong hang seng climb europe major index be afternoon trading stock future signale lower open wednesday follow prior session rebound dow nasdaq future be ahead bell tuesday wall street record biggest day gain volatile day trading ongoing fear economy reuter poll say economist figure chance have recession mean fed launch round monetary ease elsewhere gold price remain record high ounce corporate front macy logged second quarter earning cent share cent prior year nickel view disney also beat earning sale estimate thank part strong result espn theme park division overseas tokyo nikkei index rise hong kong hang seng climb europe major index be afternoon trading
912,MYL,drugmaker akorn akrx acquire right eye drop brand merck mrk division inspire pharmaceutical friday send akorn stock new high midday trading market akorn paid variant glaucoma treatment cosopt bacterial conjunctivitis move add akorn strategy become top player ophthalmology
913,MYL,share woman health company hologic holx gap heavy trading stock market thursday activist investor carl icahn buy large position firm
914,MYL,late wednesday icahn company report own hologic share share outstanding report person acquire position share belief be undervalue state schedule filing security exchange commission report person intend have conversation member hologic management discuss way enhance shareholder value
915,MYL,analyst say investor unhappiness reach critical level string miss quarters now be good time sort aggressive intervention icahn be know last year help engineer sale imclone eli lilly lly medimmune astrazeneca azn also threaten hostile takeover prevent mylan myl expensive buyout king pharmaceutical ultimately didn happen mylan deny be icahn
916,MYL,expect investor react very favorably activist involvement holx share management team have be often criticize destroy shareholder value overpay large acquisition such cytyc lesser extent gen probe write analyst glenn novarro rbc capital market client note open
917,MYL,analyst vijay kumar isi group note hologic have adopt poison pill provision prevent takeover believe management be too unpopular stop major change
918,MYL,look icahn nominate slate director board remove member management then look create shareholder value sale restructure kumar write email client poison pill act mean stop further acquisition holx share icahn associate do not believe have impact ultimate outcome here be likely too little too late share woman health company hologic holx gap heavy trading stock market thursday activist investor carl icahn buy large position firm late wednesday icahn company report own hologic share share outstanding report person acquire position share belief be undervalue state schedule filing security exchange commission report person intend have conversation member hologic management discuss way enhance shareholder value analyst say investor unhappiness reach critical level string miss quarters now be good time sort aggressive intervention icahn be know last year help engineer sale imclone eli lilly lly medimmune astrazeneca azn also threaten hostile takeover prevent mylan myl expensive buyout king pharmaceutical ultimately didn happen mylan deny be icahn expect investor react very favorably activist involvement holx share management team have be often criticize destroy shareholder value overpay large acquisition such cytyc lesser extent gen probe write analyst glenn novarro rbc capital market client note open analyst vijay kumar isi group note hologic have adopt poison pill provision prevent takeover believe management be too unpopular stop major change look icahn nominate slate director board remove member management then look create shareholder value sale restructure kumar write email client poison pill act mean stop further acquisition holx share icahn associate do not believe have impact ultimate outcome here be likely too little too late
919,MYL,stock jump start gate monday accord sort eurozone greece brushed global market bit optimism
920,MYL,nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday
921,MYL,stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july
922,MYL,europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro
923,MYL,stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece
924,MYL,gps device leader garmin grmn wynn resort wynn climb run head nasdaq
925,MYL,head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump
926,MYL,newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation
927,MYL,very few ibd stock post early decline ambarella amba taser international tasr be stock jump start gate monday accord sort eurozone greece brushed global market bit optimism nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece gps device leader garmin grmn wynn resort wynn climb run head nasdaq head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation very few ibd stock post early decline ambarella amba taser international tasr be
928,MYL,stock step sharply lower thin trade quiet earning economic calendar monday market keep watch debt budget negotiation washington
929,MYL,dow jone industrial average slump apiece nasdaq hold loss volume be weak stock market today nasdaq lower nyse compare same time friday
930,MYL,expedia expe slump deutsche bank downgrade stock hold buy note cite last week ouster travel deal provider hotel com management team second major brand level management overhaul year
931,MYL,stock have be correct miss analyst second quarter earning expectation tumble july
932,MYL,liberty interactive linta surge strong trade follow upgrade outperform market perform well fargo bank raise stock price target cite add value plan spin separate tracking stock qvc shopping network
933,MYL,move drive share new high past buy point cup handle base
934,MYL,leader stock ibd list open lower monday deep premarket loss narrow significantly open however only few stock list fall much
935,MYL,mylan myl drop pennsylvania base generic drug maker be trading just oct high comfortably day line
936,MYL,facebook fb slip start third week consolidation high week move average social networking leader reportedly acquire israel datum compression start onavo accord blog post onavo chief executive stock step sharply lower thin trade quiet earning economic calendar monday market keep watch debt budget negotiation washington dow jone industrial average slump apiece nasdaq hold loss volume be weak stock market today nasdaq lower nyse compare same time friday expedia expe slump deutsche bank downgrade stock hold buy note cite last week ouster travel deal provider hotel com management team second major brand level management overhaul year stock have be correct miss analyst second quarter earning expectation tumble july liberty interactive linta surge strong trade follow upgrade outperform market perform well fargo bank raise stock price target cite add value plan spin separate tracking stock qvc shopping network move drive share new high past buy point cup handle base leader stock ibd list open lower monday deep premarket loss narrow significantly open however only few stock list fall much mylan myl drop pennsylvania base generic drug maker be trading just oct high comfortably day line facebook fb slip start third week consolidation high week move average social networking leader reportedly acquire israel datum compression start onavo accord blog post onavo chief executive
937,MYL,biotech stockviropharma vphm lead list stock hit new high monday blast agree sell shire shpg base viropharma flagship drug be antibiotic vancocin soar buyout base shire way viropharma clear resistance viropharma have be face competition
938,MYL,now actavis act have receive shareholder approval acquisition warner chilcott wcrx generic drugmaker focus integrate buy learn life be much bigger entity shareholder company approve deal tuesday set stage creation become third largest specialty pharmaceutical firm
939,MYL,actavis act be hold tight recent high remain buy area clear flat base entry drugmaker be just buy point breaking july more double average daily volume strong quarterly earning report stock have go sideway then tight trading be sign hold well even market uptrend come pressure base be third stage however reduce chance success actavis formerly know watson pharmaceutical be top stock member medical generic drug industry group include fellow ibd stock mylan myl group be rank industry ibd track friday actavis develop generic brand drug treat disease such hypertension high cholesterol boast best possible composite rating earning share rating best group accumulation distribution rating be indicate strong demand share company announce july profit rise share edge wall street expectation revenue rise accelerate second straight quarter zack equity research say thursday actavis plan acquire ireland base warner chilcott wcrx create lead global specialty pharmaceutical company annual revenue company debt equity ratio be elevated acquisition be expect close later year friday france competition authority approve deal actavis also recently acquire global right palau pharmaceutical antifungal drug albaconazole be phase ii trial
940,MYL,actavis act generic drug maker design build brand drug business have plenty reason feel good future
941,MYL,thing company get shareholder approval buyout irish drugmaker warner chilcott wcrx set stage creation become third largest specialty pharmaceutical firm
942,MYL,actavis week launch generic version lidoderm patch used relieve pain postherpetic neuralgia occur shingle infection
943,MYL,lidoderm brand version be make endo health solution endp have annual sale
944,MYL,generic lidoderm provide immediate boost actavis sale most recent attention have focuse long term prospect warner chilcott buyout
945,MYL,actavis announce plan acquire warner chilcott specialize brand drug woman health dermatology urology shareholder company give deal thumb
946,MYL,benefit deal be cut actavis dependence core generic drug business quarters revenue last year
947,MYL,buyout benefit
948,MYL,warner chilcott actavis get revenue specialty brand product vs standalone company
949,MYL,good combination definitely make actavis much bigger company brand side say tim chiang analyst crt capital group
950,MYL,deal close end year be expect be more accretive actavis gaap ep include anticipate synergy
951,MYL,priority front be help warner chilcott improve financial performance company have run straight quarters sale decline straight quarters lower earning
952,MYL,number win prize actavis isn expect implement big change
953,MYL,win do anything drastic turn thing say kevin kedra analyst gabelli co warner chilcott fit very nicely specialty pharma business actavis have so expect continue run business similar warner have do be more function pull strength company
954,MYL,positive be actavis have plenty experience integrate acquisition company frequently make tuck acquisition smaller generic drug firm occasionally make whopper deal line warner chilcott
955,MYL,current incarnation actavis be form october complete merger watson pharmaceutical
956,MYL,actavis do lot deal ve execute well kendra say deal generic drug tend be very accretive
957,MYL,report jpmorgan analyst chris schott say merger watson buyout warner chilcott represent highly step actavis
958,MYL,deal significantly increase company profile internationally brand generic schott add
959,MYL,warner chilcott deal close actavis be expect produce annual revenue last year logged revenue new entity incorporate ireland produce tax benefit
960,MYL,financially actavis have have much better go warner chilcott actavis have deliver double digit sale growth quarters row earning have rise double digit last quarters
961,MYL,generic lift sale
962,MYL,company post second quarter earning share exclude special item be prior year cent consensus analyst view revenue gain edge past estimate
963,MYL,generic drug sale lead way quarter rise sale specialty drug include rapaflo enlarged prostate kadian pain management climb sale actavis distribution business rise
964,MYL,analyst expect actavis grow full year earning share
965,MYL,company get nice lift generic lidoderm get final approval food drug administration august be still own watson pharmaceutical
966,MYL,term agreement endo actual product launch be delay more year
967,MYL,actavis be only generic lidoderm so be nice boost generic business kedra say
968,MYL,even actavis move closer finalize deal warner chilcott analyst expect company keep pursue buyout next several quarters
969,MYL,not be surprised see actavis pursue larger brand transaction point next month right asset be available jpmorgan schott note
970,MYL,reckon main target area be dermatology fertility drug
971,MYL,actavis share have be trend higher late february hit record high stock currently trade
972,MYL,other generic drug company have set new high recently include mylan myl taro pharmaceutical industry taro actavis act generic drug maker design build brand drug business have plenty reason feel good future thing company get shareholder approval buyout irish drugmaker warner chilcott wcrx set stage creation become third largest specialty pharmaceutical firm actavis week launch generic version lidoderm patch used relieve pain postherpetic neuralgia occur shingle infection lidoderm brand version be make endo health solution endp have annual sale generic lidoderm provide immediate boost actavis sale most recent attention have focuse long term prospect warner chilcott buyout actavis announce plan acquire warner chilcott specialize brand drug woman health dermatology urology shareholder company give deal thumb benefit deal be cut actavis dependence core generic drug business quarters revenue last year buyout warner chilcott actavis get revenue specialty brand product vs standalone company good combination definitely make actavis much bigger company brand side say tim chiang analyst crt capital group deal close end year be expect be more accretive actavis gaap ep include anticipate synergy priority front be help warner chilcott improve financial performance company have run straight quarters sale decline straight quarters lower earning number win prize actavis isn expect implement big change win do anything drastic turn thing say kevin kedra analyst gabelli co warner chilcott fit very nicely specialty pharma business actavis have so expect continue run business similar warner have do be more function pull strength company positive be actavis have plenty experience integrate acquisition company frequently make tuck acquisition smaller generic drug firm occasionally make whopper deal line warner chilcott current incarnation actavis be form october complete merger watson pharmaceutical actavis do lot deal ve execute well kendra say deal generic drug tend be very accretive report jpmorgan analyst chris schott say merger watson buyout warner chilcott represent highly step actavis deal significantly increase company profile internationally brand generic schott add warner chilcott deal close actavis be expect produce annual revenue last year logged revenue new entity incorporate ireland produce tax benefit financially actavis have have much better go warner chilcott actavis have deliver double digit sale growth quarters row earning have rise double digit last quarters generic lift company post second quarter earning share exclude special item be prior year cent consensus analyst view revenue gain edge past estimate generic drug sale lead way quarter rise sale specialty drug include rapaflo enlarged prostate kadian pain management climb sale actavis distribution business rise analyst expect actavis grow full year earning share company get nice lift generic lidoderm get final approval food drug administration august be still own watson pharmaceutical term agreement endo actual product launch be delay more year actavis be only generic lidoderm so be nice boost generic business kedra say even actavis move closer finalize deal warner chilcott analyst expect company keep pursue buyout next several quarters not be surprised see actavis pursue larger brand transaction point next month right asset be available jpmorgan schott note reckon main target area be dermatology fertility drug actavis share have be trend higher late february hit record high stock currently trade other generic drug company have set new high recently include mylan myl taro pharmaceutical industry taro
973,MYL,top perform mutual fund add position drugmake stock recent month include actavis act maker generic remedy ibd find fund buy stock most recent report period investing estimate company be leader industry be add size acquisition agreement buy warner chilcott
974,MYL,share small specialty drug company horizon pharma hznp have be move report third quarter result early november thank expectation firm novel drug treat arthritis pain inflammatory condition company have yet make profit share shot result show gain sale
975,MYL,specialty drug company horizon pharma hznp be roll arthritis drug duexis vimovo treat arthritis pain protect ulcer bang most other drug treat arthritis don provide most arthritis drug use nonsteroidal inflammatory drug nsaid add roll layer ulcer protect compound
976,MYL,canadian drugmaker valeant pharmaceutical international vrx beat analyst earning estimate wednesday raise guidance account complete acquisition contact lens giant bausch lomb
977,MYL,stock already trading record high hit new peak early wednesday close
978,MYL,valeant report cash ep share year earlier quarter cent analyst consensus sale rise line estimate
979,MYL,company close buyout bausch lomb tuesday consequently raise full year guidance quite bit management add more sale range now ep range be vs previous guidance post ep sale
980,MYL,earning conference call analyst cfo howard schiller say valeant expect exceed target cost saving merger plan reduce combine head count most come general administrative expense little impact sale force brand pharmaceutical still make majority combine business schiller point quarters revenue now come cash payment private insurance be significant give pricing pressure drug government payer especially europe
981,MYL,morningstar analyst david krempa research report caution deal synergy be partly offset higher expect interest rate valeant still be relatively small player ophthalmology vs rival such johnson johnson jnj novartis nvs nonetheless add still believe valeant exemplary stewardship be be undervalue market
982,MYL,highly acquisitive valeant be already swollen quarter buyout skin cream maker obagi medical product close late april obagi buyout turn complement last year acquisition medicis bring valeant dysport wrinkle injection similar allergan agn botox conference call valeant ceo michael pearson say dysport be gain market share botox other rival merz xeomin
983,MYL,exclude impact various smaller buyout sale rise more modest develop market emerge market develop market sale take hit unexpected early entry generic competition herpes cream zovirax mylan myl win fda approval knock early april pearson say push promote product sale apart zovirax rest portfolio grow
984,MYL,outside eastern europe be standout organic growth russia first half year poland mexico also do well organic growth pearson note have be slowdown latin america overall market growth say valeant have manage outperform
985,MYL,pearson also offer valeant annual review performance recent large acquisition case cover deal october overall compound annual growth rate acquire company be brazilian nutritional company probiotica lead way growth february buyout
986,MYL,valeant be pull less annual revenue recently pearson have repeatedly say plan turn company large global drugmaker lead ub analyst marc goodman ask call valeant be go have go more mainstream product order get even bigger
987,MYL,pearson answer valeant strategy remain same think be successful not do large pharma company be do say do put big aspiration approach motivational person certainly be hope achieve canadian drugmaker valeant pharmaceutical international vrx beat analyst earning estimate wednesday raise guidance account complete acquisition contact lens giant bausch lomb stock already trading record high hit new peak early wednesday close valeant report cash ep share year earlier quarter cent analyst consensus sale rise line estimate company close buyout bausch lomb tuesday consequently raise full year guidance quite bit management add more sale range now ep range be vs previous guidance post ep sale earning conference call analyst cfo howard schiller say valeant expect exceed target cost saving merger plan reduce combine head count most come general administrative expense little impact sale force brand pharmaceutical still make majority combine business schiller point quarters revenue now come cash payment private insurance be significant give pricing pressure drug government payer especially europe morningstar analyst david krempa research report caution deal synergy be partly offset higher expect interest rate valeant still be relatively small player ophthalmology vs rival such johnson johnson jnj novartis nvs nonetheless add still believe valeant exemplary stewardship be be undervalue market highly acquisitive valeant be already swollen quarter buyout skin cream maker obagi medical product close late april obagi buyout turn complement last year acquisition medicis bring valeant dysport wrinkle injection similar allergan agn botox conference call valeant ceo michael pearson say dysport be gain market share botox other rival merz xeomin exclude impact various smaller buyout sale rise more modest develop market emerge market develop market sale take hit unexpected early entry generic competition herpes cream zovirax mylan myl win fda approval knock early april pearson say push promote product sale apart zovirax rest portfolio grow outside eastern europe be standout organic growth russia first half year poland mexico also do well organic growth pearson note have be slowdown latin america overall market growth say valeant have manage outperform pearson also offer valeant annual review performance recent large acquisition case cover deal october overall compound annual growth rate acquire company be brazilian nutritional company probiotica lead way growth february buyout valeant be pull less annual revenue recently pearson have repeatedly say plan turn company large global drugmaker lead ub analyst marc goodman ask call valeant be go have go more mainstream product order get even bigger pearson answer valeant strategy remain same think be successful not do large pharma company be do say do put big aspiration approach motivational person certainly be hope achieve
988,MYL,generic drugmaker actavis act say monday buy specialty drugmaker warner chilcott deal send stock time high transaction stock assumption debt create company annual revenue be biggest generic drugmaker
989,MYL,canadian drugmaker valeant pharmaceutical international vrx early thursday report strong earning weakness revenue send share bit stock market today meanwhile rumore buyout target actavis act also report mixed quarter stock react more positively valeant say quarterly sale totale year quarter short analyst
990,MYL,generic drugmaker actavis act say monday buy specialty drugmaker warner chilcott deal send stock time high transaction stock assumption debt create company annual revenue be biggest generic drugmaker
991,MYL,valeant pharmaceutical vrx sell right antibiotic actavis act wednesday prepared report result open thursday
992,MYL,valeant announce press release selling metronidazole vaginal gel actavis cash also make profit sharing arrangement actavis decide launch generic version wasn quite deal many investor be hope report merger talk company surface last weekend show company be still talk even merger be reportedly hold
993,MYL,meanwhile valeant be expect report cash ep accord analyst poll thomson reuter year quarter sale be expect rise
994,MYL,preview note last week rbc capital market analyst dougla miehm write doesn expect valeant raise guidance usually do mylan myl unexpectedly early launch generic version herpes cream zovirax valeant say time affect guidance put full detail quarterly report
995,MYL,do not expect typical raise guidance year believe vrx still increase guidance year end miehm add additional deal robust product launch higher expect synergy medicis obagi be few factor lead additional upside
996,MYL,valeant acquire medicis december close acquisition obagi medical product last week
997,MYL,valeant stock be flirt new time high stock market week afternoon trading wednesday stock have pull back nearly rank ibd wednesday update ibd ranking top perform stock valeant pharmaceutical vrx sell right antibiotic actavis act wednesday prepared report result open thursday valeant announce press release selling metronidazole vaginal gel actavis cash also make profit sharing arrangement actavis decide launch generic version wasn quite deal many investor be hope report merger talk company surface last weekend show company be still talk even merger be reportedly hold meanwhile valeant be expect report cash ep accord analyst poll thomson reuter year quarter sale be expect rise preview note last week rbc capital market analyst dougla miehm write doesn expect valeant raise guidance usually do mylan myl unexpectedly early launch generic version herpes cream zovirax valeant say time affect guidance put full detail quarterly report do not expect typical raise guidance year believe vrx still increase guidance year end miehm add additional deal robust product launch higher expect synergy medicis obagi be few factor lead additional upside valeant acquire medicis december close acquisition obagi medical product last week valeant stock be flirt new time high stock market week afternoon trading wednesday stock have pull back nearly rank ibd wednesday update ibd ranking top perform stock
998,MYL,share obagi medical product ompi retreat nearly early trading monday short bidding war merz pharma valeant pharmaceutical vrx end valeant favor
999,MYL,merz say be not willing top price share valeant offer last week be hike original merger deal merz make bid share obagi stock vault various offer be announce
1000,MYL,valeant stock be fraction stock market today still have good ibd relative strength rating be monday ibd ranking top stock valeant share get whack last week mylan myl gain unexpected approval generic version valeant herpes cream zovirax valeant ceo michael pearson say time hit earning other activity mitigate impact presumably include acquisition obagi bring nu derm skin cream line various other dermatology product pearson say provide more specific ep forecast earning report share obagi medical product ompi retreat nearly early trading monday short bidding war merz pharma valeant pharmaceutical vrx end valeant favor merz say be not willing top price share valeant offer last week be hike original merger deal merz make bid share obagi stock vault various offer be announce valeant stock be fraction stock market today still have good ibd relative strength rating be monday ibd ranking top stock valeant share get whack last week mylan myl gain unexpected approval generic version valeant herpes cream zovirax valeant ceo michael pearson say time hit earning other activity mitigate impact presumably include acquisition obagi bring nu derm skin cream line various other dermatology product pearson say provide more specific ep forecast earning report
1001,MYL,teva pharmaceutical industry teva have agree let mylan laboratory myl launch compete generic version sleep drug provigil settle legal dispute
1002,MYL,provigil be blockbuster cephalon hammer deal teva license generic go patent last fall however teva wound resolve issue buy cephalon launch license generic late march fda grant teva day market exclusivity mylan sue
1003,MYL,new agreement accord mylan press release release friday allow mylan launch own version provigil aug other detail settlement be keep confidential
1004,MYL,share mylan teva be fraction midday trading friday teva pharmaceutical industry teva have agree let mylan laboratory myl launch compete generic version sleep drug provigil settle legal dispute provigil be blockbuster cephalon hammer deal teva license generic go patent last fall however teva wound resolve issue buy cephalon launch license generic late march fda grant teva day market exclusivity mylan sue new agreement accord mylan press release release friday allow mylan launch own version provigil aug other detail settlement be keep confidential share mylan teva be fraction midday trading friday
1005,MYL,valeant pharmaceutical international vrx trim earning guidance thursday generic rival come market earlier expect wednesday afternoon mylan myl win fda approval generic version herpes ointment zovirax provide sale last year news cause mylan stock bounce
1006,MYL,stock have be tread unchanged mark wednesday day thanksgiving news arrived hamas israel cease fire have be reach good news add lift stock volume be run well prior session pace
1007,MYL,dow jone industrial average be lead way ahead gain be nasdaq be rise volume be tracking lower major exchange
1008,MYL,india base hdfc bank hdb spurt ahead fast trade stock score time high break flat base buy point hdfc have be hold well market correction result relative strength rating surge rs line company be featured ibd new america section monday
1009,MYL,mylan myl rise eke year high tuesday maker generic brand drug say moody investor service standard poor upgrade credit rating mylan also say board stock buyback
1010,MYL,gun maker sturm ruger rgr rise largest move ibd stock firearm maker gap gain tuesday announce special dividend share
1011,MYL,stock have pull back test support week line clear buy point cup handle base end tuesday just buy point
1012,MYL,deere be diving have slice day line deliver mixed quarterly result open heavy equipment maker report fiscal earning climb miss estimate cent stronger dollar higher material cost hurt bottom line sale rise stock have be tread unchanged mark wednesday day thanksgiving news arrived hamas israel cease fire have be reach good news add lift stock volume be run well prior session pace dow jone industrial average be lead way ahead gain be nasdaq be rise volume be tracking lower major exchange india base hdfc bank hdb spurt ahead fast trade stock score time high break flat base buy point hdfc have be hold well market correction result relative strength rating surge rs line company be featured ibd new america section monday mylan myl rise eke year high tuesday maker generic brand drug say moody investor service standard poor upgrade credit rating mylan also say board stock buyback gun maker sturm ruger rgr rise largest move ibd stock firearm maker gap gain tuesday announce special dividend share stock have pull back test support week line clear buy point cup handle base end tuesday just buy point deere be diving have slice day line deliver mixed quarterly result open heavy equipment maker report fiscal earning climb miss estimate cent stronger dollar higher material cost hurt bottom line sale rise
1013,MYL,stock future edge higher ahead wednesday open disappointing housing start build permit datum june dow future warm point future push point gain nasdaq future drift point stock market today plow thick earning season heavy slate report due
1014,MYL,stock add gain afternoon action thursday hit fresh session high aim stretch winning streak day nasdaq rise dow jone industrial average moved volume stock market today continue track wednesday level nasdaq
1015,MYL,stock hold gain midafternoon tuesday major index trade multiyear high nasdaq be dow jone industrial average rise volume remain solidly higher nyse nasdaq compare same time monday stock market today dow
1016,MYL,share watson pharmaceutical wpi hit new time high friday company receive fda approval generic version lidoderm watson announce thursday begin selling product deliver painkiller lidocaine skin patch september lengthy delay be due agreement watson make lidoderm manufacturer
1017,MYL,teva pharmaceutical industry teva gap monday several generic drugmaker get hammer court decision weekend support teva patent copaxone teva have sue mylan laboratory myl momenta pharmaceutical mnta novartis nvs sandoz unit natco pharmaceutical prevent selling generic version teva flagship multiple sclerosis drug teva own several patent
1018,MYL,pfizer pfe settle patent dispute generic drugmaker mylan myl bladder control drug detrol la set generic version launch early pfizer settle similar dispute impax laboratory ipxl last month do not release detail settlement big pharma be still mum most detail latest settlement also
1019,MYL,stock be modestly higher wednesday halftime bounce back mild loss ahead thanksgiving holiday blue chip lead pack rise dow jone industrial average thank gain boee ba ibm ibm nasdaq be turnover be lower board compare
1020,MYL,new high monday fundamentally strong stock be once again scarce stock make new high be often good place find buy candidate current market isn offer investor much consider shortage new high be natural market correction however trouble go back further sluggishness have be market recur tone
1021,MYL,watson pharmaceutical wpi lead charge wednesday generic drug maker seek take kingdom lipitor pfizer pfe mega blockbuster cholesterol drug lose patent wednesday leave open market draw more sale last year watson call largest generic product launch history watson be able launch drug
1022,MYL,watson pharmaceutical wpi lead charge wednesday generic drug maker seek take kingdom lipitor pfizer pfe mega blockbuster cholesterol drug lose patent wednesday leave open market draw more sale last year watson call largest generic product launch history watson be able launch drug
1023,MYL,even market muster modest rebound friday top rate stock hit new high be short supply highlight weakness general market fleetcor technology flt score time high close well friday best level late thursday provider fuel card other payment product easily beat expectation earning jump
1024,MYL,new high list be see larger weighting construction latin american stock day same time ibd screen stock make week time high monday show healthy scoop company have ep rs rating higher such drugmaker mylan myl monday clear
1025,MYL,thursday new high list include mixed bag breakout reversal reminder many stock be still proper buy range noteworthy breakout most dramatic be lifeway food lway thinly trade stock soar more time average volume company make cultured dairy product know
1026,MYL,share teva pharmaceutical industry teva be fraction early trading friday earlier fall nearly drugmaker issue guidance wall street estimate teva set ep range well analyst consensus revenue forecast be little less still short
1027,MYL,stock open slightly lower quickly turn mixed thursday investor respond economic datum spate earning report nasdaq be add dow jone industrial average be fraction red volume be brisk nasdaq higher nyse compare wednesday action
1028,MYL,stock market capped week long rally several dozen stock make new high medical sector continue attract institutional fund accounting friday new high gilead science gild inched new high stock have become extend buy point flat base biotech industry have be perform well
1029,MYL,stock edge mildly midday tuesday recoup loss follow mixed january retail sale cloud compute firm rackspace host rax paint maker valspar val hit new high follow strong earning report
1030,MYL,nasdaq be dow jone industrial average ease just volume be tracking higher nasdaq nyse turnover be vs same time monday
1031,MYL,generic drug provider mylan myl be gapping earlier rival hospira hsp shot heavy volume beating analyst sale earning view
1032,MYL,boise idaho base chipmaker micron technology mu be stock be still share be work deep base relative price strength rating be
1033,MYL,retail sale rise january half forecast increase due unexpected drop auto sale sale exclude auto rise better expect
1034,MYL,rackspace gap new high report sale profit growth beat wall street forecast benchmark co raise stock rating buy hold lift month price target stifel nicolaus reiterate buy rating raise price target
1035,MYL,stock clear buy point feb flat base long handle cup be buy point midday tuesday
1036,MYL,valspar gap gain also hit new high minneapoli base operation report fiscal earning better expect revenue rise just well short view company raise full year ep guidance high side analyst forecast
1037,MYL,priceline com pcln climb very heavy trade add monday cup handle base online budget travel broker be now past buy point
1038,MYL,other big gainer include michael kor kor soar fiscal profit smash view strong sale north america europe stock have run sharply go public december
1039,MYL,virtual game maker zynga znga be ahead result be release close tuesday company social online game farmville word friend be host close ally facebook earlier month file plan go public stock edge mildly midday tuesday recoup loss follow mixed january retail sale cloud compute firm rackspace host rax paint maker valspar val hit new high follow strong earning report nasdaq be dow jone industrial average ease just volume be tracking higher nasdaq nyse turnover be vs same time monday generic drug provider mylan myl be gapping earlier rival hospira hsp shot heavy volume beating analyst sale earning view boise idaho base chipmaker micron technology mu be stock be still share be work deep base relative price strength rating be retail sale rise january half forecast increase due unexpected drop auto sale sale exclude auto rise better expect rackspace gap new high report sale profit growth beat wall street forecast benchmark co raise stock rating buy hold lift month price target stifel nicolaus reiterate buy rating raise price target stock clear buy point feb flat base long handle cup be buy point midday tuesday valspar gap gain also hit new high minneapoli base operation report fiscal earning better expect revenue rise just well short view company raise full year ep guidance high side analyst forecast priceline com pcln climb very heavy trade add monday cup handle base online budget travel broker be now past buy point other big gainer include michael kor kor soar fiscal profit smash view strong sale north america europe stock have run sharply go public december virtual game maker zynga znga be ahead result be release close tuesday company social online game farmville word friend be host close ally facebook earlier month file plan go public
1040,MYL,nothing prospect new revenue grab wall street attention look further recent stock run shire shpgy irish drugmaker specialize treatment attention deficit hyperactivity disorder adhd disease human genetic disorder feb company stock price climb food drug administration say
1041,MYL,stock continue slump mildly lower early afternoon trading tuesday recoup loss follow mixed january retail sale datum cloud compute firm rackspace host rax paint maker valspar val hit new high follow strong earning report nasdaq be dow jone industrial average volume be tracking
1042,MYL,stock be steady trimming initial loss weak trade midday
1043,MYL,dow jone industrial average be nasdaq narrow loss
1044,MYL,stock market today be not find glimmer progress political leader washington loss be mild institutional investor remain largely bench volume dim nasdaq sag lower nyse compare friday light trade
1045,MYL,almost stock be morning trade expedia expe fall more heavy action index biggest loss netflix nflx climb time average volume biggest gain
1046,MYL,loss continue be broad relatively shallow leader more ibd stock be trading lower mylan myl facebook fb qihoo technology qihu hold list worst loss
1047,MYL,whirlpool whr dive powerful selling longbow research say weak september shipment prevent company top expectation raise guidance appliance maker have be pull back high monday slip send share day line support heavy trade
1048,MYL,homebuilder stock be experience selling pressure ryland group ryl horton dhi pulte group phm lennar len stock be steady trimming initial loss weak trade midday dow jone industrial average be nasdaq narrow loss stock market today be not find glimmer progress political leader washington loss be mild institutional investor remain largely bench volume dim nasdaq sag lower nyse compare friday light trade almost stock be morning trade expedia expe fall more heavy action index biggest loss netflix nflx climb time average volume biggest gain loss continue be broad relatively shallow leader more ibd stock be trading lower mylan myl facebook fb qihoo technology qihu hold list worst loss whirlpool whr dive powerful selling longbow research say weak september shipment prevent company top expectation raise guidance appliance maker have be pull back high monday slip send share day line support heavy trade homebuilder stock be experience selling pressure ryland group ryl horton dhi pulte group phm lennar len
1049,MYL,investor trample stock wednesday avoid loom fiscal cliff go theoretical possible wake president obama re election meanwhile more protest greece parliament work pass new austerity plan secure fresh funding also rattle trader major index fall more volume surge nasdaq drop cut
1050,MYL,year mylan myl become third largest generic drug company world catapult acquisition totale
1051,MYL,late october watson pharmaceutical wpi overtake mylan buy swiss partner actavis deal value mylan drop
1052,MYL,so israel teva pharmaceutical teva swiss firm novartis nvs remain top generic drug firm worldwide
1053,MYL,mylan get bigger again
1054,MYL,management say have financial flexibility put much work make more acquisition
1055,MYL,be look right opportunity present take advantage say chief financial officer john phone interview week
1056,MYL,analyst say buy help offset expect drop number brand go patent banner year mute concern slow growth especially be see patent cliff
1057,MYL,fewer brand go patent generally mean fewer opportunity generic replace
1058,MYL,brand drug
1059,MYL,year be good year mylan also other generic manufacturer largest number brand drug come patent say morningstar analyst michael generic company have post good growth number
1060,MYL,mylan third quarter revenue jump prior year third quarter operate cash flow be highest history say
1061,MYL,management wouldn talk specific potential candidate other look globe put
1062,MYL,analyst believe re look generic drug company emerge market manufacturer injectable topical drug
1063,MYL,mylan get lion share sale generic drug be low cost copy brand drug sell more generic product
1064,MYL,also sell several brand drug specialty pharma business focus respiratory disease severe allergic reaction psychiatric disorder
1065,MYL,epipen product be top prescribe auto injector treat severe allergic reaction
1066,MYL,mylan epipen franchise be threaten potential generic entry teva
1067,MYL,mylan india base subsidiary mylan laboratory make wide range ingredient used drug manufacturing include generic antiretroviral treat hiv aids
1068,MYL,acquisition outside be view especially favorable
1069,MYL,mylan be heavily expose southern europe say add generic sale be vs only teva
1070,MYL,defend mylan high share be go be largest someplace want be largest say not sure europe be best place be largest
1071,MYL,say mylan be most expose europe generic drug company morningstar coverage
1072,MYL,second quarter year mylan european business show straight quarters negative growth however show gain revenue vs earlier year
1073,MYL,europe mylan be strongest france market share generic
1074,MYL,france other country austerity mind europe be now encourage higher use low cost generic drug say
1075,MYL,see europe long term growth driver generic utilization rate increase say
1076,MYL,rbc capital market analyst shibani malhotra agree be so much generic outside even europe ultimately generic be growth market say
1077,MYL,doesn expect mylan ink big deal still have lot debt balance sheet perhaps smaller one be pay debt acquisition long term debt be still
1078,MYL,mylan have spend german base merck kgaa unrelated base merck mrk more india base matrix rename mylan lab later pay rest
1079,MYL,merck kgaa give mylan more exposure europe other country
1080,MYL,matrix give mylan low cost manufacturing plant india china operation contribute mylan asia pacific revenue growth include negative impact foreign exchange translation
1081,MYL,strong earning
1082,MYL,long term debt be obviously big number say relation size company
1083,MYL,say vast majority acquisition be do borrow
1084,MYL,firm strong earning not mention assume earning target company enable borrow overleverage enterprise
1085,MYL,mylan earning grow prior year cent share analyst expect full year profit share revenue increase report thomson reuter
1086,MYL,analyst see profit slow single digit least
1087,MYL,mylan doesn see way
1088,MYL,see patent cliff affect generic company differently say example have product market have
1089,MYL,mylan be count get approval generic version glaxosmithkline gsk brand respiratory drug advair
1090,MYL,meanwhile mylan recently announce partnership japan pfizer pfe begin bearing fruit start year end
1091,MYL,mylan continue forecast double digit earning growth forecast share be just higher wall street forecast
1092,MYL,february management plan put new guidance year mylan myl become third largest generic drug company world catapult acquisition totale late october watson pharmaceutical wpi overtake mylan buy swiss partner actavis deal value mylan drop so israel teva pharmaceutical teva swiss firm novartis nvs remain top generic drug firm worldwide mylan get bigger again management say have financial flexibility put much work make more acquisition be look right opportunity present take advantage say chief financial officer john phone interview week analyst say buy help offset expect drop number brand go patent banner year mute concern slow growth especially be see patent cliff fewer brand go patent generally mean fewer opportunity generic replace brand drug year be good year mylan also other generic manufacturer largest number brand drug come patent say morningstar analyst michael generic company have post good growth number mylan third quarter revenue jump prior year third quarter operate cash flow be highest history say management wouldn talk specific potential candidate other look globe put analyst believe re look generic drug company emerge market manufacturer injectable topical drug mylan get lion share sale generic drug be low cost copy brand drug sell more generic product also sell several brand drug specialty pharma business focus respiratory disease severe allergic reaction psychiatric disorder epipen product be top prescribe auto injector treat severe allergic reaction mylan epipen franchise be threaten potential generic entry teva mylan india base subsidiary mylan laboratory make wide range ingredient used drug manufacturing include generic antiretroviral treat hiv aids acquisition outside be view especially favorable mylan be heavily expose southern europe say add generic sale be vs only teva defend mylan high share be go be largest someplace want be largest say not sure europe be best place be largest say mylan be most expose europe generic drug company morningstar coverage second quarter year mylan european business show straight quarters negative growth however show gain revenue vs earlier year europe mylan be strongest france market share generic france other country austerity mind europe be now encourage higher use low cost generic drug say see europe long term growth driver generic utilization rate increase say rbc capital market analyst shibani malhotra agree be so much generic outside even europe ultimately generic be growth market say doesn expect mylan ink big deal still have lot debt balance sheet perhaps smaller one be pay debt acquisition long term debt be still mylan have spend german base merck kgaa unrelated base merck mrk more india base matrix rename mylan lab later pay rest merck kgaa give mylan more exposure europe other country matrix give mylan low cost manufacturing plant india china operation contribute mylan asia pacific revenue growth include negative impact foreign exchange translation strong earningslong term debt be obviously big number say relation size company say vast majority acquisition be do borrow firm strong earning not mention assume earning target company enable borrow overleverage enterprise mylan earning grow prior year cent share analyst expect full year profit share revenue increase report thomson reuter analyst see profit slow single digit least mylan doesn see way see patent cliff affect generic company differently say example have product market have mylan be count get approval generic version glaxosmithkline gsk brand respiratory drug advair meanwhile mylan recently announce partnership japan pfizer pfe begin bearing fruit start year end mylan continue forecast double digit earning growth forecast share be just higher wall street forecast february management plan put new guidance
1093,MYL,investor show little love tuesday stock slunk lower slower expect january retail sale growth broad swathe company earning
1094,MYL,dow jone industrial average dip nasdaq give trading be quiet tracking lower exchange vs action same time monday third dow component trade lower nasdaq stock be mixed generic drug provider mylan myl chipmaker micron technology mu
1095,MYL,generic drug company hospira hsp lead gain top analyst sale earning view
1096,MYL,business continue increase inventory december post gain be november growth rate less expansion see analyst number add positive trend begin third quarter cautious company pare back inventory summer
1097,MYL,stock rackspace host rax gap gain easily knock new high cloud compute play report sale earning gain cent share number be analyst expectation benchmark co raise stock rating buy hold lift month price target stifel nicolaus reiterate buy rating raise price target
1098,MYL,stock clear buy point flat base long handle cup feb have climb buy point tuesday morning
1099,MYL,paint maker valspar val gap gain take new high minneapoli base operation report fiscal earning cent share vs analyst consensus view cent revenue climb well short expectation company raise full year ep guidance high side analyst forecast
1100,MYL,priceline com pcln climb very heavy trade add monday cup handle base online budget travel broker be now past buy point investor show little love tuesday stock slunk lower slower expect january retail sale growth broad swathe company earning dow jone industrial average dip nasdaq give trading be quiet tracking lower exchange vs action same time monday third dow component trade lower nasdaq stock be mixed generic drug provider mylan myl chipmaker micron technology mu generic drug company hospira hsp lead gain top analyst sale earning view business continue increase inventory december post gain be november growth rate less expansion see analyst number add positive trend begin third quarter cautious company pare back inventory summer stock rackspace host rax gap gain easily knock new high cloud compute play report sale earning gain cent share number be analyst expectation benchmark co raise stock rating buy hold lift month price target stifel nicolaus reiterate buy rating raise price target stock clear buy point flat base long handle cup feb have climb buy point tuesday morning paint maker valspar val gap gain take new high minneapoli base operation report fiscal earning cent share vs analyst consensus view cent revenue climb well short expectation company raise full year ep guidance high side analyst forecast priceline com pcln climb very heavy trade add monday cup handle base online budget travel broker be now past buy point
1101,MYL,big pharma win be get much bigger anytime soon
1102,MYL,many largest drugmaker top product start lose exclusive patent strong growth ve enjoy decade
1103,MYL,flow drug come market also win offset come patent cliff researcher say
1104,MYL,longer growth industry say leerink swann analyst seamus fernandez
1105,MYL,biggest ball drop late november pfizer pfe cholesterol fighter lipitor world top selling drug sale alone fall patent
1106,MYL,other blockbuster expire year eli lilly lly zyprexa glaxosmithkline gsk asthma drug advair diskus take respectively last year
1107,MYL,fall plavix bristol myer bmy france sanofi aventis sny sale astrazeneca azn lose seroquel crestor nexium
1108,MYL,other big name fade include merck mrk singulair forest laboratory frx lexapro
1109,MYL,global market share brand drug fall say im institute healthcare informatic spending brand drug drop
1110,MYL,call success penalty say michael kleinrock director research development im great medicine market last year
1111,MYL,generic be beautiful
1112,MYL,loss mean gain generic firm giant such teva teva mylan myl indian player ranbaxy lab sun pharmaceutical
1113,MYL,first file enjoy month market exclusivity other generic crowd cause price plunge ranbaxy file first generic version lipitor
1114,MYL,generic account global spending medicine vs im say
1115,MYL,share overall sale drug firm standing lose most patent loss next few year be astrazeneca lilly forest lab analyst say
1116,MYL,diversify health care firm abbott lab johnson johnson jnj be less affected last week say seek approval drug
1117,MYL,most drugmaker still generate lot cash yet trade steep discount due chiefly patent cliff soft product pipeline say morningstar analyst damien conover
1118,MYL,drug stock have be rise recently investor be realize valuation have fall too far say
1119,MYL,only look expensive go forward price earning ratio be forest lab fernandez say forest have enormous cash hoard debt so have tremendous financial flexibility
1120,MYL,health stock also be benefit defensive play current market slump
1121,MYL,drug firm be try offset loom lose revenue cost cut productivity program
1122,MYL,still profit growth be expect slow next few year health care reform pressure price even expand sale
1123,MYL,stock buyback prop earning share drug giant also be used takeover replenish drug pipeline seek growth emerge market
1124,MYL,patent loss loom blockbuster diabetes drug actos takeda pharmaceutical buy swiss nycomed give japan drugmaker shortcut emerge market
1125,MYL,promising brand drug be hit market work arrhythmia autoimmune disorder multiple sclerosis hepatitis diabetes
1126,MYL,still next batch be smaller last wave exception diabetes target smaller population
1127,MYL,argue low hang fruit have be picked degree fernandez say big pharma win be get much bigger anytime soon many largest drugmaker top product start lose exclusive patent strong growth ve enjoy decade flow drug come market also win offset come patent cliff researcher say longer growth industry say leerink swann analyst seamus fernandez biggest ball drop late november pfizer pfe cholesterol fighter lipitor world top selling drug sale alone fall patent other blockbuster expire year eli lilly lly zyprexa glaxosmithkline gsk asthma drug advair diskus take respectively last year fall plavix bristol myer bmy france sanofi aventis sny sale astrazeneca azn lose seroquel crestor nexium other big name fade include merck mrk singulair forest laboratory frx lexapro global market share brand drug fall say im institute healthcare informatic spending brand drug drop call success penalty say michael kleinrock director research development im great medicine market last year generic be loss mean gain generic firm giant such teva teva mylan myl indian player ranbaxy lab sun pharmaceutical first file enjoy month market exclusivity other generic crowd cause price plunge ranbaxy file first generic version lipitor generic account global spending medicine vs im say share overall sale drug firm standing lose most patent loss next few year be astrazeneca lilly forest lab analyst say diversify health care firm abbott lab johnson johnson jnj be less affected last week say seek approval drug most drugmaker still generate lot cash yet trade steep discount due chiefly patent cliff soft product pipeline say morningstar analyst damien conover drug stock have be rise recently investor be realize valuation have fall too far say only look expensive go forward price earning ratio be forest lab fernandez say forest have enormous cash hoard debt so have tremendous financial flexibility health stock also be benefit defensive play current market slump drug firm be try offset loom lose revenue cost cut productivity program still profit growth be expect slow next few year health care reform pressure price even expand sale stock buyback prop earning share drug giant also be used takeover replenish drug pipeline seek growth emerge market patent loss loom blockbuster diabetes drug actos takeda pharmaceutical buy swiss nycomed give japan drugmaker shortcut emerge market promising brand drug be hit market work arrhythmia autoimmune disorder multiple sclerosis hepatitis diabetes still next batch be smaller last wave exception diabetes target smaller population argue low hang fruit have be picked degree fernandez say
1128,MYL,strong earning help company move good great priceline pcln michael kor kor announce positive result past week be top ibd company move most last week list ibd be base superior earning strong stock price performance leadership industry
1129,MYL,several slice medical sector be top echelon ibd industry group top be medical biom biotech medical service group rank no go monday be week mutual fund be big buyer big beneficiary franklin dynatech be fund open stake latest disclosure period biom biotech group alexion pharmaceutical alxn more example fidelity select health care blackrock opportunity be fund start position sxc health solution sxci latest disclosure sxc be medical service other medical group post high ranking be base month price performance be medical supply jump medical system equipment be more medical group be top addition alexion sxc leader group be align technology algn medical supply bio reference lab brli medical service intuitive surgical isrg medical system equipment questor pharmaceutical qcor medical ethical drug watson pharmaceutical wpi medical generic drug individual growth story help explain variety leader several industry group say phil seligman analyst capital iq also investor have tilt health care stock general traditional safe haven volatile market such current say steven silver analyst capital iq room runalign technology be drive invisalign orthodontic system do not use ceramic metal bracket market share have room grow abroad especially china seligman say share be year sale rise past year share gap april day company say first quarter earning share rise cent beating view cent seligman also like outlook intuitive surgical fall april peak fall broad market pullback say quarterly sale ep growth have stay strong demand surgical system hold slow gdp growth analyst herman safta say watson have better fundamental outlook peer teva teva mylan myl mylan example be heavily reliant europe watson ep growth top estimate pricing pressure generic version cholesterol fighter lipitor hurt profit yet watson plan takeover actavis group boost earning much more price now reflect safta say still not leader have rosy prognosis alexion recently acquire enobia pharma be testing new drug report positive phase ii result alfa potential treatment rare bone disease value such treatment become clear silver see stock have limit upside potential
1130,MYL,major index remain positive week edge lower midday friday dwindle trade
1131,MYL,dow jone industrial average dip strong gain hewlett packard hpq dupont dd shed nasdaq hold loss
1132,MYL,trade weaken stock market today volume slip nasdaq nyse raft weak economic news dent optimism early session only industry group moved higher morning trade
1133,MYL,stock toyota motor tm defend gain follow second quarter report late thursday valueclick vclk continue hold morning worst loss report second quarter result
1134,MYL,ibd index head friday gain so far week lead stock continue strong performance
1135,MYL,mercadolibre meli surge cup base linkedin lnkd jump take new high yy yy tack gain add already extend run fifth straight week steep gain
1136,MYL,fleetcor technology flt ahead report late thursday second quarter revenue earning comfortably clear analyst view fleet fuel financing specialist raise full year earning guidance expectation offer revenue guidance line view
1137,MYL,big volume move hoist ibd stock more buy point flat base
1138,MYL,web com group wwww muscle heavy trade add second strong volume session ibd stock rebound day support design service provider turn better expect sale earning result
1139,MYL,ibd list drug maker mylan myl climb narrowly beating analyst sale earning forecast second quarter generic drugmaker be buy point base base pattern major index remain positive week edge lower midday friday dwindle trade dow jone industrial average dip strong gain hewlett packard hpq dupont dd shed nasdaq hold loss trade weaken stock market today volume slip nasdaq nyse raft weak economic news dent optimism early session only industry group moved higher morning trade stock toyota motor tm defend gain follow second quarter report late thursday valueclick vclk continue hold morning worst loss report second quarter result ibd index head friday gain so far week lead stock continue strong performance mercadolibre meli surge cup base linkedin lnkd jump take new high yy yy tack gain add already extend run fifth straight week steep gain fleetcor technology flt ahead report late thursday second quarter revenue earning comfortably clear analyst view fleet fuel financing specialist raise full year earning guidance expectation offer revenue guidance line view big volume move hoist ibd stock more buy point flat base web com group wwww muscle heavy trade add second strong volume session ibd stock rebound day support design service provider turn better expect sale earning result ibd list drug maker mylan myl climb narrowly beating analyst sale earning forecast second quarter generic drugmaker be buy point base base pattern
1140,MYL,stock waver modestly higher finish monday extend recent trend uncertain action nyse composite rise fifth straight gain rise tick fraction fourth gain techs lead monday nasdaq climb index have be much intraday close
1141,MYL,stock drive lower monday open hurt overseas uncertainty rise dollar nasdaq drop dow jone industrial average volume be nasdaq higher nyse compare same time friday new home sale jump more annualize rate
1142,MYL,leader have lag market late outperformed last week short trading week thank big gain several top stock ibd climb week vs gain nasdaq fall commvault system cvlt blast week putt back week line buy point maker storage software surge better expect fiscal result earning jump cent share be biggest gain quarters sale grow vs view grand canyon education lope surge year high easily beat view give upbeat guidance profit school operator earning jump cent help new enrollment sale grow marked fifth straight period acceleration grand canyon peg profit cent cent share vs view cent credit card firm mastercard rise first time week last week report mixed result company beat earning miss sale rival visa hit new high fiscal earning sale come expectation company also announce stock buyback raise dividend good quarterly result rosy outlook usually propel stock higher hasn always be case challenge environment cirrus logic crus take beating crush view give strong guidance stratasys ssys ellie mae elli have also sell same manner stratasys have fall more buy point low handle michael kor kor try break past flat base buy point friday reversed lower apparel firm report nov rentech nitrogen partner rnf also try break friday end slightly lower brighter note new name be enter ibd nordisk nvo be slightly day line still handle trigger danish drugmaker have deliver accelerate earning sale growth recent quarters mylan myl be best level more year retake week move average company recently unveil mixed quarterly result
1143,MYL,teva pharmaceutical teva shot monday heavy volume favorable court ruling stock still have work do israeli drugmaker have climb back downward slope week move average remain week line teva also appear be work new consolidation base right side need time
1144,MYL,stock remain modestly red late tuesday afternoon recoup loss follow mixed january retail sale datum facebook game developer zynga znga shot record high ahead first ever earning report nasdaq be dow jone industrial average volume be tracking higher nasdaq
1145,MYL,stock rebound recent loss score first gain day monday dow jone industrial average lead rise rise recoup most friday loss nasdaq lag gain still tech laden index close back level continue weakness biotech stock medical biom biotech industry group
1146,MYL,update stock finished small gain friday slew mixed economic datum
1147,MYL,nyse composite rise nasdaq dow inched fraction
1148,MYL,volume fall nasdaq rise nyse
1149,MYL,second estimate fourth quarter gdp come higher previously thought be view spending component be weaker expect
1150,MYL,chicago pmi unexpectedly rise sentiment housing datum come economist estimate
1151,MYL,stock dip week finished month side nasdaq jump dow nyse composite
1152,MYL,decker outdoors deck gap bolt month high clear buy point cup base late thursday footwear maker beat view rise earning gain sale
1153,MYL,warner chilcott wcrx rise heavy trading finished just penny day move average drugmaker report earning monday morning analyst see profit jump cent share revenue be expect surge october warner chilcott acquire procter gamble pg brand pharmaceutical business
1154,MYL,perfect world pwrd tack fast trade too finished just shy day line chinese gaming firm also report earning monday view be cent share sale perfect world be featured jan edition new america
1155,MYL,china agritech cagc erased earlier loss rally new record high thursday stock bounce back loss close chinese organic fertilizer producer have best earning share relative price strength rating chemical fertilizer group
1156,MYL,earning monday dress barn dbrn mindray medical mr perfect world pwrd warnaco wrc warner chilcott wcrx
1157,MYL,economic report ism manufacturing index construction spending personal income personal spending
1158,MYL,stock end seesaw session small gain
1159,MYL,vincent mao
1160,MYL,update stock vacillate modestly higher close friday
1161,MYL,nyse composite climb nasdaq dow eke fractional gain
1162,MYL,volume fall sharply board
1163,MYL,apparel maker transportation related group be friday top performer consult build related group be day worst
1164,MYL,stock pace lower weekly close
1165,MYL,vincent mao
1166,MYL,update stock be modestly higher late trading friday be pace close week small loss
1167,MYL,nyse composite gain nasdaq rise dow edge
1168,MYL,turnover continue track vastly lower exchange oil be gold close week high april contract settle ounce
1169,MYL,decker outdoors deck extend gain breaking cup base volume be huge late thursday footwear maker beat view rise earning gain sale
1170,MYL,group mate nike nke add month high stock clear week cup base nike have weak relative price strength rating
1171,MYL,stock edge afternoon trade
1172,MYL,vincent mao
1173,MYL,update stock firm slip mildly negative territory earlier trading have be rangebound slew economic datum
1174,MYL,nyse composite rise dow nasdaq tick volume be again tracking softer board
1175,MYL,dg fastchannel dgit rally brisk trade stock have be volatile recent session gain shortly clear week consolidation feb then give everything back next session dg fastchannel provide digital medium service advertising industry
1176,MYL,micrus endovascular mend erased earlier gain fall heavy trading stock also take back thursday gain micrus make implantable disposable medical device lose money past several year be expect turn profit cent share year
1177,MYL,stock shift neutral
1178,MYL,vincent mao
1179,MYL,update stock turn flat dollar pare loss vs rival
1180,MYL,nyse composite edge dow nasdaq hold fractional gain major index have be session peak turnover continue track vastly lower exchange
1181,MYL,trw automotive holding trw reversed morning loss rise month high stock clear month consolidation thursday auto part maker handily beat view profit share lose share year earlier period
1182,MYL,mylan myl also turn higher rise best level june stock clear week consolidation monday
1183,MYL,downside diamond food dmnd tumble fall day move average late thursday snack food maker beat view rise fiscal earning gain sale also raise low end profit forecast cent range share diamond also agree buy kettle food operation cash
1184,MYL,stock hold high
1185,MYL,vincent mao
1186,MYL,update stock hover session high dollar weaken euro yen
1187,MYL,nyse composite gain dow nasdaq rise
1188,MYL,volume continue track sharply lower exchange
1189,MYL,chinese stock show strength
1190,MYL,china biotic chbt gap gain month high company make supplement make probiotic beneficial bacterium china biotic earning growth range past quarters sale grow same period
1191,MYL,china agritech cagc erased earlier loss rally new record high thursday stock bounce back loss close chinese organic fertilizer producer have best earning share relative price strength rating chemical fertilizer group
1192,MYL,telestone technology tstc also stage comeback climb firm provide wireless communication service make telecom equipment telestone earning surge latest report period sale accelerate straight quarters last triple digit territory
1193,MYL,downside weight watcher international wtw gap day day move average dive heavy trading late thursday report earning view peg full year share vs view
1194,MYL,stock turn volume be still soft
1195,MYL,vincent mao
1196,MYL,update stock seesaw back positive territory new session high friday
1197,MYL,climb dow nasdaq nyse composite rise turnover be tracking sharply lower exchange
1198,MYL,decker outdoors deck gap rally follow stellar quarterly result late thursday clear week cup base ugg boot maker see full year earning rise vs analyst estimate drop
1199,MYL,gap gps gap gain month high late thursday apparel retailer beat view jump earning marked second straight quarter accelerate growth gap accumulation distribution rating have improve worst possible earlier month
1200,MYL,big lot big add month high jmp security start coverage close good retailer market outperform recently clear square box base
1201,MYL,earlier friday retail index hit month high
1202,MYL,elsewhere green plain renewable energy gpre reversed earlier loss gain stock drop thursday news secondary offer have already re-trace bulk thursday decline
1203,MYL,stock pressure mixed report
1204,MYL,vincent mao
1205,MYL,update stock fall early trading friday round mixed economic datum
1206,MYL,dow nasdaq nyse composite lose volume be tracking much lower board storm northeast be partly blame
1207,MYL,cke restaurant cke bolt agree be buy private equity firm thl partner cash cke run carl jr hardee chain now week high
1208,MYL,osi system osis gap rally upgrade morgan keegan raise stock outperform market perform composite rating however be only
1209,MYL,palm palm drop downgrade extend thursday dive friday morning kaufman bro cut share hold buy ub downgrade mobile device maker sell neutral stock touch lowest level nearly year
1210,MYL,economic news chicago pmi unexpectedly climb read february january figure be best read nearly year economist have expect read
1211,MYL,university michigan consumer sentiment index february come view sentiment index however do not always reflect actual consumer activity meanwhile exist home sale fall expect annualize rate unit january
1212,MYL,future signal mixed open
1213,MYL,vincent mao
1214,MYL,update stock future point narrow mixed open friday commerce department say economy grow faster pace previously thought
1215,MYL,future rise nearly vs fair value dow future gain point nasdaq future slip fraction
1216,MYL,economic front economy grow higher expect pace fourth quarter be prior estimate gain be due inventory reduction investment consumer spending component rise only prior read be still more revision gdp figure
1217,MYL,meanwhile pce deflator climb prior forecast core pce exclude food energy rise first read
1218,MYL,future have little reaction gdp report dollar gain yen be slightly lower euro
1219,MYL,university michigan consumer sentiment index exist home sale be shortly open
1220,MYL,corporate news american international group aig fall pre market trading hurt number charge item insurance giant say lose fourth quarter accord medium report aig plan repayment plan federal reserve government own stake aig
1221,MYL,future point flat open
1222,MYL,vance cariaga
1223,MYL,update stock future be mostly flat early friday ahead busy day economic datum future be unchanged pre market dow future fall point be fair value nasdaq future lose point
1224,MYL,commerce be schedule release second estimate fourth quarter gross domestic product economist expect report show annualize growth match advance estimate fourth quarter gdp
1225,MYL,also institute supply management new york release february index regional business activity ism issue chicago february index manufacturing activity midwest
1226,MYL,university michigan release final february consumer sentiment index economist expect read compare final january report
1227,MYL,national association realtor be slate release datum exist home sale january analyst expect total annualize unit vs prior month
1228,MYL,overseas japan nikkei stock average rise hong kong hang seng add afternoon trading britain ftse climb germany dax gain france cac advanced update stock finished small gain friday slew mixed economic datum nyse composite rise nasdaq dow inched fraction volume fall nasdaq rise nyse second estimate fourth quarter gdp come higher previously thought be view spending component be weaker expect chicago pmi unexpectedly rise sentiment housing datum come economist estimate stock dip week finished month side nasdaq jump dow nyse composite decker outdoors deck gap bolt month high clear buy point cup base late thursday footwear maker beat view rise earning gain sale warner chilcott wcrx rise heavy trading finished just penny day move average drugmaker report earning monday morning analyst see profit jump cent share revenue be expect surge october warner chilcott acquire procter gamble pg brand pharmaceutical business perfect world pwrd tack fast trade too finished just shy day line chinese gaming firm also report earning monday view be cent share sale perfect world be featured jan edition new america china agritech cagc erased earlier loss rally new record high thursday stock bounce back loss close chinese organic fertilizer producer have best earning share relative price strength rating chemical fertilizer group earning monday dress barn dbrn mindray medical mr perfect world pwrd warnaco wrc warner chilcott wcrx economic report ism manufacturing index construction spending personal income personal spending stock end seesaw session small gainsby vincent mao update stock vacillate modestly higher close friday nyse composite climb nasdaq dow eke fractional gain volume fall sharply board apparel maker transportation related group be friday top performer consult build related group be day worst stock pace lower weekly closeby vincent mao update stock be modestly higher late trading friday be pace close week small loss nyse composite gain nasdaq rise dow edge turnover continue track vastly lower exchange oil be gold close week high april contract settle ounce decker outdoors deck extend gain breaking cup base volume be huge late thursday footwear maker beat view rise earning gain sale group mate nike nke add month high stock clear week cup base nike have weak relative price strength rating stock edge afternoon tradeby vincent mao update stock firm slip mildly negative territory earlier trading have be rangebound slew economic datum nyse composite rise dow nasdaq tick volume be again tracking softer board dg fastchannel dgit rally brisk trade stock have be volatile recent session gain shortly clear week consolidation feb then give everything back next session dg fastchannel provide digital medium service advertising industry micrus endovascular mend erased earlier gain fall heavy trading stock also take back thursday gain micrus make implantable disposable medical device lose money past several year be expect turn profit cent share year stock shift neutralby vincent mao update stock turn flat dollar pare loss vs rival nyse composite edge dow nasdaq hold fractional gain major index have be session peak turnover continue track vastly lower exchange trw automotive holding trw reversed morning loss rise month high stock clear month consolidation thursday auto part maker handily beat view profit share lose share year earlier period mylan myl also turn higher rise best level june stock clear week consolidation monday downside diamond food dmnd tumble fall day move average late thursday snack food maker beat view rise fiscal earning gain sale also raise low end profit forecast cent range share diamond also agree buy kettle food operation cash stock hold highsby vincent mao update stock hover session high dollar weaken euro yen nyse composite gain dow nasdaq rise volume continue track sharply lower exchange chinese stock show strength china biotic chbt gap gain month high company make supplement make probiotic beneficial bacterium china biotic earning growth range past quarters sale grow same period china agritech cagc erased earlier loss rally new record high thursday stock bounce back loss close chinese organic fertilizer producer have best earning share relative price strength rating chemical fertilizer group telestone technology tstc also stage comeback climb firm provide wireless communication service make telecom equipment telestone earning surge latest report period sale accelerate straight quarters last triple digit territory downside weight watcher international wtw gap day day move average dive heavy trading late thursday report earning view peg full year share vs view stock turn volume be still softby vincent mao update stock seesaw back positive territory new session high friday climb dow nasdaq nyse composite rise turnover be tracking sharply lower exchange decker outdoors deck gap rally follow stellar quarterly result late thursday clear week cup base ugg boot maker see full year earning rise vs analyst estimate drop gap gps gap gain month high late thursday apparel retailer beat view jump earning marked second straight quarter accelerate growth gap accumulation distribution rating have improve worst possible earlier month big lot big add month high jmp security start coverage close good retailer market outperform recently clear square box base earlier friday retail index hit month high elsewhere green plain renewable energy gpre reversed earlier loss gain stock drop thursday news secondary offer have already re-trace bulk thursday decline stock pressure mixed reportsby vincent mao update stock fall early trading friday round mixed economic datum dow nasdaq nyse composite lose volume be tracking much lower board storm northeast be partly blame cke restaurant cke bolt agree be buy private equity firm thl partner cash cke run carl jr hardee chain now week high osi system osis gap rally upgrade morgan keegan raise stock outperform market perform composite rating however be only palm palm drop downgrade extend thursday dive friday morning kaufman bro cut share hold buy ub downgrade mobile device maker sell neutral stock touch lowest level nearly year economic news chicago pmi unexpectedly climb read february january figure be best read nearly year economist have expect read university michigan consumer sentiment index february come view sentiment index however do not always reflect actual consumer activity meanwhile exist home sale fall expect annualize rate unit january future signal mixed openby vincent mao update stock future point narrow mixed open friday commerce department say economy grow faster pace previously thought future rise nearly vs fair value dow future gain point nasdaq future slip fractionon economic front economy grow higher expect pace fourth quarter be prior estimate gain be due inventory reduction investment consumer spending component rise only prior read be still more revision gdp figure meanwhile pce deflator climb prior forecast core pce exclude food energy rise first read future have little reaction gdp report dollar gain yen be slightly lower euro university michigan consumer sentiment index exist home sale be shortly open corporate news american international group aig fall pre market trading hurt number charge item insurance giant say lose fourth quarter accord medium report aig plan repayment plan federal reserve government own stake aig future point flat openby vance cariaga update stock future be mostly flat early friday ahead busy day economic datum future be unchanged pre market dow future fall point be fair value nasdaq future lose point commerce be schedule release second estimate fourth quarter gross domestic product economist expect report show annualize growth match advance estimate fourth quarter gdp also institute supply management new york release february index regional business activity ism issue chicago february index manufacturing activity midwest university michigan release final february consumer sentiment index economist expect read compare final january report national association realtor be slate release datum exist home sale january analyst expect total annualize unit vs prior month overseas japan nikkei stock average rise hong kong hang seng add afternoon trading britain ftse climb germany dax gain france cac advanced
1229,MYL,update stock shrug worst expect job report friday close best level session
1230,MYL,equity be weak open news employer cut job december well economist expectation november payroll be revise show small gain
1231,MYL,nasdaq climb month close high amazon com amzn rise regain day move average google goog edge close back
1232,MYL,meanwhile nyse composite gain dow
1233,MYL,turnover fall board
1234,MYL,week nyse composite climb nasdaq dow
1235,MYL,chinese issue be again session best performer
1236,MYL,china agritech cagc jump new record high fast trade put stock buy point cup handle base november fertilizer producer report increase sale best performance year
1237,MYL,china automotive system caas erased early loss run new record high company make power steering system analyst see earning surge cent share
1238,MYL,asiainfo holding asia rally fast trade snap session lose streak
1239,MYL,elsewhere ulta salon ulta add trade highest more year stock clear buy point week tight pattern thursday
1240,MYL,downside valeant pharmaceutical vrx reversed multiyear high fall nearly twice average volume stock fall back buy point flat base
1241,MYL,earning monday alcoa aa allscript misys healthcare mdrx helen troy hele
1242,MYL,index close high
1243,MYL,vincent mao
1244,MYL,update stock battle back early weakness payroll datum end session high friday
1245,MYL,nasdaq rally nyse composite dow volume drop exchange accord preliminary figure
1246,MYL,farm equipment maker steel producer hospital operator be session top group cement maker retail chain school operator be worst group
1247,MYL,stock track weekly gain
1248,MYL,vincent mao
1249,MYL,update stock slightly weaken late trading friday be pace close week gain
1250,MYL,nasdaq be nyse composite dow fall volume be tracking higher board
1251,MYL,rue rue jump new high wednesday apparel retailer raise fourth quarter sale outlook stock go public november
1252,MYL,fuel system solution fsys be session high still stock be trading cup base buy point fuel system make alternative fuel component industrial transportation industry
1253,MYL,ulta salon ulta add trade highest more year lift put stock past buy point week tight pattern
1254,MYL,index improve afternoon trading
1255,MYL,vincent mao
1256,MYL,update stock strengthen afternoon trading most index now positive territory
1257,MYL,nasdaq rally nyse composite rise tick fraction dow fall drag loss coca cola ko boee ba
1258,MYL,volume be tracking lower exchange especially nyse
1259,MYL,tns tns come pressure fourth straight session share fall fast trade stock have meet resistance day move average recently accumulation distribution rating have weaken earlier month
1260,MYL,ross store rost gap fall fast trade oppenheimer co cut discount apparel retailer underperform perform oppenheimer also cut aeropostale aro tjx company tjx underperform
1261,MYL,upside home inn hotel management hmin rise best level more year stock be buy range recent bounce week move average home inn have deliver triple digit profit growth past quarters
1262,MYL,longtop financial technology lft erased earlier loss gain new record high put stock past buy point week tight pattern late thursday longtop agree buy banking solution provider giantstone information technology undisclosed sum deal be expect add earning fiscal
1263,MYL,index stay mixed early afternoon trade
1264,MYL,vincent mao
1265,MYL,update stock remain mixed early afternoon trading friday
1266,MYL,nasdaq climb lift big cap techs apple aapl amazon com amzn google goog bounce back
1267,MYL,nyse edge dow slip be break even point
1268,MYL,turnover be tracking sharply lower nyse tad lower nasdaq
1269,MYL,global payment gpn gap fall month low late thursday payment processor report rise fiscal earning beating view sale grow view friday morning barclay capital barrington research downgrade stock
1270,MYL,mylan laboratory myl gap day move average drop heavy trade goldman sachs cut drugmaker neutral buy mylan be session low
1271,MYL,valeant pharmaceutical vrx reversed multiyear high lose active trading stock fall back buy point flat base
1272,MYL,upside rino international rino erased earlier loss rise stock be wrapping sixth week cup base rino provide environmental protection service china steel industry analyst see sale growth accelerate next quarters
1273,MYL,major index hold steady midday
1274,MYL,jonah keri
1275,MYL,update investor continue take weak job report stride friday stock remain narrowly mixed midday nyse composite be dow lose upside nasdaq gain
1276,MYL,volume remain mixed fall nyse rise nasdaq compare same period thursday wall street have already price weak job report ahead friday session stock edge lower early session have remain narrowly mixed
1277,MYL,china agritech cagc surge more triple normal trade chinese fertilizer maker have surge nearly threefold close price ipo
1278,MYL,asiainfo holding update stock shrug worst expect job report friday close best level session equity be weak open news employer cut job december well economist expectation november payroll be revise show small gain nasdaq climb month close high amazon com amzn rise regain day move average google goog edge close back meanwhile nyse composite gain dow turnover fall board week nyse composite climb nasdaq dow chinese issue be again session best performer china agritech cagc jump new record high fast trade put stock buy point cup handle base november fertilizer producer report increase sale best performance year china automotive system caas erased early loss run new record high company make power steering system analyst see earning surge cent share asiainfo holding asia rally fast trade snap session lose streak elsewhere ulta salon ulta add trade highest more year stock clear buy point week tight pattern thursday downside valeant pharmaceutical vrx reversed multiyear high fall nearly twice average volume stock fall back buy point flat base earning monday alcoa aa allscript misys healthcare mdrx helen troy hele index close highsby vincent mao update stock battle back early weakness payroll datum end session high friday nasdaq rally nyse composite dow volume drop exchange accord preliminary figure farm equipment maker steel producer hospital operator be session top group cement maker retail chain school operator be worst group stock track weekly gainsby vincent mao update stock slightly weaken late trading friday be pace close week gain nasdaq be nyse composite dow fall volume be tracking higher board rue rue jump new high wednesday apparel retailer raise fourth quarter sale outlook stock go public november fuel system solution fsys be session high still stock be trading cup base buy point fuel system make alternative fuel component industrial transportation industry ulta salon ulta add trade highest more year lift put stock past buy point week tight pattern index improve afternoon tradingby vincent mao update stock strengthen afternoon trading most index now positive territory nasdaq rally nyse composite rise tick fraction dow fall drag loss coca cola ko boee ba volume be tracking lower exchange especially nyse tns tns come pressure fourth straight session share fall fast trade stock have meet resistance day move average recently accumulation distribution rating have weaken earlier month ross store rost gap fall fast trade oppenheimer co cut discount apparel retailer underperform perform oppenheimer also cut aeropostale aro tjx company tjx underperform upside home inn hotel management hmin rise best level more year stock be buy range recent bounce week move average home inn have deliver triple digit profit growth past quarters longtop financial technology lft erased earlier loss gain new record high put stock past buy point week tight pattern late thursday longtop agree buy banking solution provider giantstone information technology undisclosed sum deal be expect add earning fiscal index stay mixed early afternoon tradeby vincent mao update stock remain mixed early afternoon trading friday nasdaq climb lift big cap techs apple aapl amazon com amzn google goog bounce back nyse edge dow slip be break even point turnover be tracking sharply lower nyse tad lower nasdaq global payment gpn gap fall month low late thursday payment processor report rise fiscal earning beating view sale grow view friday morning barclay capital barrington research downgrade stock mylan laboratory myl gap day move average drop heavy trade goldman sachs cut drugmaker neutral buy mylan be session low valeant pharmaceutical vrx reversed multiyear high lose active trading stock fall back buy point flat base upside rino international rino erased earlier loss rise stock be wrapping sixth week cup base rino provide environmental protection service china steel industry analyst see sale growth accelerate next quarters major index hold steady middayby jonah keri update investor continue take weak job report stride friday stock remain narrowly mixed midday nyse composite be dow lose upside nasdaq gain volume remain mixed fall nyse rise nasdaq compare same period thursday wall street have already price weak job report ahead friday session stock edge lower early session have remain narrowly mixed china agritech cagc surge more triple normal trade chinese fertilizer maker have surge nearly threefold close price ipo asiainfo holding
1279,MYL,momenta pharmaceutical inc mnta free report report loss share cent quarter wider year loss cent revenue quarter come significantly year quarter quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be result lower sale due mylan myl free report entry copaxone market collaborative research development revenue come compare year quarter decrease be primarily due lower revenue recognize upfront payment mylan compare amount recognize period lower reimbursable expense complex generic program research development expense decrease year quarter due decrease external expense general administrative expense also decrease outlook expect operate expense exclude stock base compensation net collaborative revenue range operate expense second quarter be project momenta expect generate revenue mylan upfront payment quarterly basis pipeline updatesmomenta announce fda have finally approve sandoz abbreviated new drug application glatopa mg company earlier suffer setback fda issue warning letter pfizer pfe free report february be sandoz contract fill finish manufacturing partner glatopa nevertheless sandoz secure customer contract order glatopa mg ml have be ship meanwhile momenta continue progress biosimilar pipeline january momenta mylan announce plan initiate patient clinical trial propose biosimilar eylea first half biologic license application bla momenta biosimilar version humira be also ready be file fda however filing bla be dependent outcome company ongoing strategic review momenta suffer setback company partner mylan announce propose biosimilar orencia do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer hence momenta partner mylan continue evaluate next course action momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody momenta successfully complete phase single ascend dose study healthy volunteer january momenta report positive top line datum phase single ascend dose sad multiple ascend dose mad study normal human volunteer phase randomize double blind placebo controlled study evaluate safety tolerability pharmacokinetic pharmacodynamic consequently momenta be finalize development strategy be plan proof concept clinical trial second half pending regulatory feedback meanwhile momenta collaboration partner csl begin dose subject phase trial healthy volunteer evaluate safety tolerability study be expect be complete momenta be also track complete ind enable toxicology study year expect initiate trial second half takemomenta report wider year year loss first quarter fda approval glatopa mg relieve momenta competition limit market share gain note mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity momenta stock have gain last month industry decline follow announcement first quarter result share be meanwhile progress biosimilar pipeline be encourage zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1280,MYL,mylan myl free report be schedule report first quarter result market open mylan price consensus ep surprise mylan price consensus ep surprise mylan quote company performance have be mixed so far have top earning estimate miss other trail quarters company report average negative earning surprise say time frame last report quarter company beat earning estimate let see thing be shape announcement mylan stock have lose last month compare industry decline factor consider quartermylan expect revenue zack consensus estimate be mylan anticipate adjust ep zack consensus estimate be peg mylan have largest product portfolio generic pharmaceutical company challenge thing be look mylan company get major boost fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity company also receive fda approval ogiviri biosimilar version herceptin volatility market be expect persist yet approval position mylan better year ahead help combat decline epipen sale company have more submission plan launch generic version estrace cream be also underway meanwhile key anticipate approval include biosimilar version neulasta target action date june company expect launch biosimilar second half assume approval ema have also accept application biosimilar mylan partner momenta mnta free report initiate patient clinical trial propose biosimilar ophthalmology drug eylea first half trial be randomize double blind active control multus center study patient diabetic macular edema compare safety efficacy immunogenicity reference drug company be also look forward tentative approval generic restatis target action date july however sale epipen continue decline due increase competition impact launch authorize generic sale be expect decline further mount competition earning call expect investor focus performance epipen newly launch drug progress company biosimilar pipeline earning whispersour proven model doesn show mylan be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat earning be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank mylan currently carry zack rank rank be favorable company negative esp make surprise prediction difficult note caution sell rate stock never be consider go earning announcement especially company be see negative estimate revision stock considerhere be pharma company consider model show have right combination element deliver earning beat quarter gw pharmaceutical plc gwph free report be expect report quarterly result company have earning esp zack rank see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1281,MYL,teva pharmaceutical industry limit teva free report report first quarter earning cent share beat zack consensus estimate cent share however earning share decline year year revenue come also beat consensus estimate however sale decline year year exclude impact currency sale be hurt increase pricing erosion generic market rapid erosion sale teva key multiple sclerosis injection copaxone divesture core asset segment discussiona announce november last year teva longer report separate global group business generic specialty medicine instead report new segment base region north america europe growth market north america segment sale be year year due pricing erosion generic market lower sale copaxone divestiture core asset woman health business unite state revenue decline lead brand product copaxone post sale north america year year due generic competition mg well mg formulation glatopa generic version copaxone mg be be market momenta sandoz novartis nvs free report generic arm mylan myl free report launch version mg formulation october same month major blow teva mylan launch risk generic version mg thrice weekly formulation much earlier expect entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation glatopa be launch sandoz february year much earlier schedule launch april call teva say mylan introduction mg generic copaxone still command volume mg market however teva have decrease price copaxone increase rebate connection generic competition lower pricing help maintain volume share however teva expect tougher competition year progress exert further pressure pricing sale other brand product bendeka treanda proair qvar increase quarter newest product teva brand portfolio austedo record sale north america austedo sd be approve launch april treatment chorea associate huntington disease second indication dyskinesia unite state august generic product revenue decline quarter due lower volume price erosion significant competitive pricing pressure be hurt generic industry consolidation customer industry have increase ability negotiate lower price generic drug teva launch generic product first revenue be generate anda rise quarter august teva acquire allergan agn free report generic business actavis generic allergan anda inc fourth largest distributor generic pharmaceutical october europe segment record revenue year year however constant currency term sale decline due loss revenue closure distribution business hungary divestiture woman health business generic product include otc product revenue europe rise constant currency basis due new product launch volume growth otc partially offset price decline copaxone sale decline constant currency basis due price reduction follow entry generic growth market sale rise however constant currency term sale be flat segment higher sale israel japan russia be partially offset effect deconsolidation subsidiary venezuela loss revenue sale woman health business country generic product include otc revenue decline constant currency term copaxone sale decline other segment api manufacturing business certain contract manufacturing service record revenue year year due lower api sale third party profit declineadjust gross margin contract basis point bps quarter due lower profitability north america segment adjust research development expense decline year period due pipeline optimization selling marketing expenditure decline year level due cost cut re structuring activity adjust operate margin decline bps quarter lower cost outlook uppedteva raise sale earning guidance follow first quarter beat revenue outlook be raise range range earning guidance be raise band share share generic sale be expect decline roughly level approximately hurt ongoing price erosion cost be expect decline result company cost saving initiative free cash flow guidance be raise delay fda approval migraine candidatealong earning release company say do not expect get fda approval pipeline candidate fremanezumab prevention chronic episodic migraine pdufa date june say expect pre approval inspection take place soon teva expect fremanezumab be approve launch end year remind investor january teva partner celltrion receive fda warning letter facility south korea follow inspection fill finish side facility facility manufacture api fremanezumab eu regulatory application fremanezumab be review please note lilly amgen be also track launch new migraine treatment year taketeva beat expectation earning sale first quarter also raise full year outlook metric however teva stock decline more earning release teva share have decline year so far compare industry decline israel base generic drug maker have tough face significant challenge form accelerate generic competition copaxone new competition brand product pricing erosion generic business lower expect contribution generic launch massive debt load more mylan earlier expect launch first generic version mg strength copaxone be major setback teva teva divest core asset last year mainly woman health business cut significant debt load company also have new organizational structure place be close plant cut generic portfolio eliminate low value project aim cut global workforce more next year part restructure plan reveal december last year teva be progress well re structuring activity still expect save almost end initiative progress restructure activity fact financial position seem more stable believe teva have long way go gain stability teva pharmaceutical industry ltd price consensus ep surprise teva pharmaceutical industry ltd price consensus ep surprise teva pharmaceutical industry ltd quoteteva carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1282,MYL,teva pharmaceutical industry ltd teva free report report first quarter earning market open last report quarter company deliver positive earning surprise generic drug maker share have lose year so far compare industry decline teva earning surpass expectation only last quarters meet same miss expectation remain result average positive surprise teva pharmaceutical industry ltd price ep surprise teva pharmaceutical industry ltd price ep surprise teva pharmaceutical industry ltd quotelet see thing be shape announcement factor considerincreas pricing erosion volume decline generic unit rapid erosion sale copaxone decline sale several other product specialty segment be expect hurt teva top line first quarter significant competitive pricing pressure generic industry be hurt sale teva generic unit ongoing consolidation customer generic industry be result increase price erosion decrease volume accelerate fda approval additional generic version compete patent medicine increase competition largest product concerta authorize generic stringent government regulation be also hurt sale meanwhile specialty segment loss exclusivity key drug copaxone azilect nuvigil divesture core asset woman health business hurt sale sale blockbuster multiple sclerosis ms treatment copaxone be likely erode due lower volume mg mg formulation be face generic competition glatopa generic version copaxone mg be be market momenta sandoz novartis generic arm mylan myl free report launch version mg formulation october same month major blow teva mylan launch risk generic version mg thrice weekly formulation much earlier expect entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation glatopa be launch sandoz february year much earlier schedule launch april combat rapid decline sale december teva announce restructure plan see more company global workforce be layer next year majority expect update progress make so far restructure plan be also expect call earning whispersour proven model do not conclusively show teva be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand cent share zack consensus estimate be peg lower cent share uncover best stock buy sell re report earning esp filter zack rank teva have zack rank sell caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be drug biotech stock have right combination element beat earning time amag pharmaceutical inc amag free report have earning esp zack rank company be schedule release result celgene corporation celg free report have earning esp zack rank company be schedule release result see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1283,MYL,glaxosmithkline plc gsk free report report core earning cent american depositary share first quarter miss zack consensus estimate cent however earning be constant exchange rate cer compare year figure share glaxo be almost apr hour trading due lower expect result report quarter moreover stock have lose year time industry growth quarterly revenue rise cer drive strong performance vaccine segment top line however marginally miss zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market flip side sale europe be flat year year glaxo report financial figure segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug respiratory disease drug namely nucala ellipta portfolio upside be partly offset decline sale older respiratory product include seretide advair ventolin establish pharmaceutical hiv sale increase back growth unite state europe respectively international sale be also year year encourage number be drive continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due more severe generic competition particularly affect european market notably company latest product hiv portfolio be juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv drug be approve unite state last november generate first quarterly sale compare register previous quarter however last november gilead gild free report triple combination once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide be approve fda hiv infection treatment nod regulatory agency competitive threat juluca future quarters respiratory sale be flat cer year year international market sale increase metric decline unite state europe respectively quarter review sale rise ellipta portfolio nucala be offset fall sale older product seretide advair ventolin sale new respiratory portfolio grow include first quarterly contribution newly launch trelegy ellipta trelegy ellipta only once daily single inhaler triple therapy copd yielded sale unite state eu first quarter notably april gsk announce trelegy ellipta gain fda approval expand indication new indication be long term once daily maintenance treatment airflow obstruction patient copd include chronic bronchitis emphysema ellipta product record surge sale drive market share gain global roll continue however upside be offset weak sale seretide advair ventolin sale drop year year immuno inflammation drug benlysta rise quarter discussion new grouping establish pharmaceutical comprise previous establish product cardiovascular metabolic urology other pharma product establish pharmaceutical sale decrease quarter review sale consumer healthcare segment nudge slowdown market condition power brand particularly pain relief oral health category see sturdy performance quarter sale vaccine segment be impressive have increase year year primarily drive sale newly launch shingrix vaccine prevention shingle unite state shingrix record sale report quarter drive favorable recommendation center disease control prevention advisory committee immunization practice merck mrk free report zostavax moreover company state be rapidly build coverage shingrix vaccine presently more patient have access vaccine medicare commercial channel be important note shingrix be approve eu well japan last month give indication unite state vaccine sale soar europe international market metric decrease respectively sale meningitis vaccine bexsero increase unite state europe market menveo unite state post higher sale same be offset soft performance establish vaccine thank fierce competitive pressure infanrix pediarix europe company continue expect ep growth cer advair generic be launch further year however probable event advair generic be introduce market mid glaxo anticipate adjust ep be flat year year cer company namely mylan myl free report hikma pharmaceutical novartis try bring generic version advair market have receive complete response letter crl fda mylan hikma get crl last year novartis be forward same year delay entry generic market glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quote zack rankglaxo carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1284,MYL,expect allergan plc agn free report beat expectation report first quarter result apr market open last quarter company deliver positive earning surprise allergan share price have decline year so far compare industry decline allergan earning performance have be strong company beating expectation past quarters average positive earning surprise last quarters be allergan plc price ep surprise allergan plc price ep surprise allergan plc quotelet see thing be shape announcement factor consideron fourth quarter conference call company guide first quarter revenue earning share be expect be number indicate lowest revenue earning quarter year fourth quarter favorable timing physician rebate program benefit sale allergan facial aesthetic product benefit be absent first quarter hurt revenue such company expect first quarter revenue growth rate be somewhat lower annual growth rate also generic competition estrace namenda xr hurt sale sharply first quarter generic version namenda xr be launch indian company lupin february estrace cream be launch mylan myl free report january allergan expect generic version restasis second best selling drug be launch april july meanwhile generic version delzicol be expect be launch early second quarter investor focus call be management comment potential impact generic competition key growth driver restasis namenda xr zack consensus estimate restasis be nonetheless allergan establish product botox linzess loestrin juvderm collection filler new product juvderm collection filler support sale zack consensus estimate botox be fact recent label expansion botox fda approval forehead line treatment vraylar fda approval maintenance treatment schizophrenia avycaz fda approval habp vabp add sale drug meanwhile addition alloderm lifecell january coolsculpt body contour system zeltiq april acquisition continue support top line quarter however believe sale erosion aczone due generic pressure brand acne category loss exclusivity loe mainly asacol hd minastrin continue hurt top line remind investor call company have say do not expect significant activity allergan expect reevaluate strategy second half year once get loe update be expect upcoming conference call earning whispersour proven model show allergan be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank allergan have zack rank combination allergan zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be large cap health care stock worth consider model also have right combination element beat earning time bristol myer squibb company bmy free report have earning esp zack rank company be schedule report first quarter earning apr see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be also zack rank stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1285,MYL,mylan myl free report be partner fujifilm kyowa kirin biologic co ltd commercialize biosimilar abbvie abbv free report blockbuster arthritis drug humira adalimumab adalimumab be develop fujifilm kyowa kirin biologic mylan intend seek approval commercialize product europe european medicine agency ema accept marketing authorization application review propose biosimilar humira company expect receive ema decision second half agreement mylan have exclusive license commercialize biosimilar europe receive upfront fee fujifilm kyowa kirin company also be responsible sale activity product european country other hand fujifilm kyowa kirin biologic be eligible receive subsequent milestone payment sale royalty year share mylan increase compare industry fall humira be tnf inhibitor aim treat multiple chronic inflammatory condition be approve europe treatment rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis ankylose spondylitis crohn disease ulcerative colitis plaque psoriasis hidradenitis suppurativa uveitis note few day biogen inc biib free report partner samsung bioepis announce resolution ongoing patent dispute abbvie regard biogen biosimilar version imraldi abbvie humira eu settlement agreement biogen samsung bioepis plan launch imraldi europe oct also unite state samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan notably imraldi be second biosimilar version humira be launch eu biotechnology company amgen amgn free report be also expect launch biosimilar version humira eu come october year amjevita settlement abbvie notably amjevita be approve eu last march approve unite state september unite state settlement abbvie amjevita be likely be launch jan mylan price mylan price mylan quote zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1286,MYL,mylan myl free report announce have inked agreement israel base mapi pharma ltd company have team development ga depot long act glatiramer acetate product mylan also acquire global marketing right product note ga depot be propose once monthly injection treatment patient relapse remit multiple sclerosis ms rrm mapi pharma have complete open label phase ii trial company be also prepare commence phase iii trial support marketing application company be prepare submit investigational new drug application fda well other global health authority remind investor mylan already have experience glatiramer acetate market october mylan launch generic version teva teva free report copaxone mg ml be indicated treatment patient relapse form ms mylan partner europe synthon also receive marketing authorization approval europe glatiramer acetate injection mg ml estimate person worldwide basis be live ms nearly person be live ms unite state rrm account approximately initial ms diagnosis deal mapi pharma further strengthen company presence ms market mylan stock have gain last month industry decline mylan have largest product portfolio generic pharmaceutical company acquisition topical business mylan gain complementary portfolio approximately brand generic topical product include active pipeline approximately product well establish unite state sale marketing infrastructure target dermatologist topical business add mylan integrate manufacturing development platform lead topical focuse contract development manufacturing organization mylan be also explore world biosimilar company form partnership biocon also have collaboration agreement momenta pharmaceutical mnta free report company also receive fda approval biosimilar version roche holding rhhby free report herceptin zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1287,MYL,have be month last earning report mylan myl free report share have add time frame recent positive trend continue lead next earning release be myl due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst mylan earning surpass estimate revenue missmylan report mixed result fourth quarter epipen sale decline adjust earning share beat zack consensus estimate be report year quarter fourth quarter revenue miss zack consensus estimate be prior year period quarter company post result segment geographic basis namely north america europe rest world north america segment third party net sale come sale decline exist product result lower volume pricing partially offset contribution new product generic business north america experience higher price erosion previous quarters include impact loss market exclusivity olmesartan olmesartan hctz sale epipen auto injector plunge significantly decrease due effect launch authorize generic higher governmental rebate third party net sale europe be be propel new product introduction region combine volume expansion pricing exist product favorable foreign currency translation have impact continent rest world segment third party net sale be drive new product increase net sale retroviral franchise higher sale emerge market favourable foreign currency translation have impact adjust gross margin contract year quarter due lower gross profit sale exist product north america include epipen auto injector partially offset contribution new product mylan repurchase approximately share approximately previously approve share repurchase program january mylan buy back additional ordinary share worth approximately complete share buyback program resultsrevenue come however top line miss zack consensus estimate adjust ep be surpass consensus mark outlookmylan expect revenue zack consensus estimate be well wit hin guidance provide company mylan anticipate adjust ep zack consensus estimate be peg have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter mylan price consensus mylan price consensus mylan quotevgm scoresat time myl have subpar growth score grade same score momentum front stock be allocate grade value side putt top quintile investment strategy overall stock have aggregte vgm score aren focuse strategy score be be interested company stock be suitable solely value base style score outlookestimate have be trend upward stock magnitude revision indicate downward shift notably myl have zack rank hold expect line return stock next few month
1288,MYL,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put mylan myl free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front mylan have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend mylan current pe level put midpoint past year number have rise rapidly past few month further stock pe be also slightly undervalue zack medical generic drug industry trail month pe ratio also point mylan have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead mylan stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now mylan have ratio be bit lower average come right now also see chart be well high stock particular past few year anything myl be lower end range time period metric suggest level undervalue trading least compare historical norm broad value outlookin aggregate mylan currently have value score putt top stock cover look make mylan solid choice value investor other key metric make pretty clear too example cf ratio great indicator value come be far better industry average clearly myl be solid choice value front multiple angle stock overall mylan be good choice value investor be plenty other factor consider investing name particular be worth note company have growth score momentum score give myl zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be mixed best current quarter have see estimate go higher past day compare lower full year estimate have see same time period have have significant impact consensus estimate current quarter consensus estimate have fall past month full year estimate have inched see consensus estimate trend recent price action stock chart mylan price consensus mylan price consensus mylan somewhat mixed trend be stock have just zack rank hold be look line performance company term bottom linemylan be inspire choice value investor be hard beat incredible lineup statistic front however sluggish industry rank bottom more industry zack rank be hard get too excited company overall fact past year industry have clearly underperform broader market see so value investor want estimate analyst sentiment broader factor turn name first once happen stock be compelling pick hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1289,MYL,share mylan myl free report have gain last month industry decline mylan fourth quarter result be mixed bottom line exceed expectation top line lag same due weak epipen sale generic business unite state continue experience pricing pressure year be challenge mylan give ongoing pricing pressure unite state uncertain regulatory environment moreover company effort get advair generic approve face jolt fda issue complete response letter abbreviated new drug application anda generic advair diskus however thing be look mylan note mylan get major boost fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity company also receive fda approval biosimilar version roche holding rhhby free report herceptin volatility market be expect persist yet approval position mylan better year ahead help combat decline epipen sale company have more submission plan launch generic version estrace cream be also offing meanwhile key anticipate approval include biosimilar version neulasta target action date june company expect launch biosimilar second half assume approval ema have also accept application biosimilar meanwhile mylan partner momenta mnta free report announce company initiate patient clinical trial propose biosimilar eylea first half trial be randomize double blind active control multus center study patient diabetic macular edema compare safety efficacy immunogenicity reference drug note eylea vascular endothelial growth factor vegf inhibitor have be approve treatment neovascular wet age related macular degeneration macular edema follow retinal vein occlusion diabetic macular edema diabetic retinopathy patient diabetic macular edema company be also look forward tentative approval generic restatis target action date july zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1290,MYL,buy hold value investing example successful long term retail investor buy hold strategy tracey top stock pick episode roundup deo myl sne abbv wbawelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick do want be buy hold investor just don know start buy hold investing be toughest type investing do call go human nature instant big payout do play lottery love idea become millionaire overnight buy hold investing be slow slog payout not come several decade have gut stick long investor do have gut buy hold investing pay big return strategy buy hold investing start young longer have invest more ll reap reward compound diversify don just buy stock even be bear stearn spread risk don get fancy don need latest fad stock biotech wonder stick basic buy company have solid fundamental strong brand stock buy buy hold portfolio todaywhen read successful buy hold investor re almost always invest company ve hear therefore tracey screen big cap company zack rank strong buy buy hold also have value component average be diageo plc deo free report isn technically value stock have forward expect grow earning fiscal maker guinness bailey johnnie walker also pay dividend currently yielding healthy mylan myl free report be dirt cheap drug company trade forward just also have earning growth be expect be sony sne free report be big entertainment be also move self drive car market work sensor value stock forward sony also pay dividend currently yielding abbvie abbv free report be rare growth value stock have forward yet be expect grow earning extra bonus shareholder also get dividend yielding walgreen boot wba free report have pull back high so cheaper january trade forward close rite aid deal add store earning be expect rise fiscal else know be buy hold investor find week podcast breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1291,MYL,buy hold value investing example successful long term retail investor buy hold strategy tracey top stock pick episode roundup deo myl sne abbv wbawelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick do want be buy hold investor just don know start buy hold investing be toughest type investing do call go human nature instant big payout do play lottery love idea become millionaire overnight buy hold investing be slow slog payout not come several decade have gut stick long investor do have gut buy hold investing pay big return strategy buy hold investing start young longer have invest more ll reap reward compound diversify don just buy stock even be bear stearn spread risk don get fancy don need latest fad stock biotech wonder stick basic buy company have solid fundamental strong brand stock buy buy hold portfolio todaywhen read successful buy hold investor re almost always invest company ve hear therefore tracey screen big cap company zack rank strong buy buy hold also have value component average be diageo plc deo free report isn technically value stock have forward expect grow earning fiscal maker guinness bailey johnnie walker also pay dividend currently yielding healthy mylan myl free report be dirt cheap drug company trade forward just also have earning growth be expect be sony sne free report be big entertainment be also move self drive car market work sensor value stock forward sony also pay dividend currently yielding abbvie abbv free report be rare growth value stock have forward yet be expect grow earning extra bonus shareholder also get dividend yielding walgreen boot wba free report have pull back high so cheaper january trade forward close rite aid deal add store earning be expect rise fiscal else know be buy hold investor find week podcast breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1292,MYL,biotech major amgen inc amgn free report announce committee medicinal product human use chmp european medicine agency ema have grant positive opinion update label neulasta include neulasta onpro kit innovative delivery system neulasta onpro kit combine pre filled syringe single dose neulasta single use body injector obi delivery system neulasta be used prevent chance infection patient myeloid cancer receive cancer therapy neulasta onpro kit be improve administration option patient provide opportunity administer recommend dose neulasta home day chemotherapy thereby save trip back doctor kit have be available unite state command market share unite state neulasta sale neulasta revenue decline year period due lower demand increase competition pd other new cancer therapy be hurt demand neulasta biosimilar be already hurt sale neulasta eu start face biosimilar competition unite state year many company be look get approval biosimilar version neulasta however biocon mylan myl free report coherus bioscience inc chrs free report novartis nvs free report generic arm sandoz have receive complete response letter fda application market generic version neulasta hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1293,MYL,mylan myl free report report mixed result fourth quarter epipen sale decline adjust earning share beat zack consensus estimate be report year quarter mylan price consensus mylan price consensus mylan quote fourth quarter revenue miss zack consensus estimate be prior year period mylan stock have lose year better industry decline quarter company post result segment geographic basis namely north america europe rest world north america segment third party net sale come sale decline exist product result lower volume pricing partially offset contribution new product generic business north america experience higher price erosion previous quarters include impact loss market exclusivity olmesartan olmesartan hctz sale epipen auto injector plunge significantly decrease due effect launch authorize generic higher governmental rebate third party net sale europe be be propel new product introduction region combine volume expansion pricing exist product favorable foreign currency translation have impact continent rest world segment third party net sale be drive new product increase net sale retroviral franchise higher sale emerge market favourable foreign currency translation have impact adjust gross margin contract year quarter due lower gross profit sale exist product north america include epipen auto injector partially offset contribution new product mylan repurchase approximately share approximately previously approve share repurchase program january mylan buy back additional ordinary share worth approximately complete share buyback program resultsrevenue come however top line miss zack consensus estimate adjust ep be surpass consensus mark outlookmylan expect revenue zack consensus estimate be well guidance provide company mylan anticipate adjust ep zack consensus estimate be peg takemylan fourth quarter result be mixed bottom line exceed expectation sale lag same due weak epipen sale generic business unite state continue experience pricing pressure note mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda abbreviated new drug application glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity company also receive fda approval biosimilar version roche holding rhhby free report herceptin volatility market be expect continue yet regulatory body approval position mylan better year ahead help combat decline epipen sale meanwhile company receive complete response letter fda regard anda generic version glaxosmithkline plc gsk free report asthma drug advair diskus be work address issue zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1294,MYL,mylan myl free report just release latest quarterly financial result post adjust earning share revenue currently myl be zack rank hold change base today result stock be currently share hour trading shortly earning report be release mylan beat earning estimate company post adjust earning share beating zack consensus estimate share miss revenue estimate company see revenue figure beating consensus estimate total revenue be prior year quarter north american third party net sale be exclude decrease sale epipen segment slump europe segment third party net sale be mylan business continue deliver solid result be pleased once again provide strong outlook growth especially give environment say ceo heather bresch performance be testament strength diversification resilience unique global platform demonstrate mylan truly be build last mylan say expect full year revenue fall range current consensus estimate be call revenue year here graph look mylan recent earning performance mylan price consensus ep surprise mylan price consensus ep surprise mylan quotemylan nv be pharmaceutical company company develop license manufacture market distribute generic specialty pharmaceutical check back later full analysis myl earning report want more analysis author make sure follow ryan_mcqueeney twitter wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1295,MYL,theravance biopharma tbph free report report fourth quarter loss share wider zack consensus estimate loss year loss total revenue quarter plunge year year compare prior year figure downside mainly be attribute lower sale company sole market product vibativ telavancin however top line surpass zack consensus estimate theravance share be more feb hour trading follow earning release report wider loss moreover share have underperform industry year time stock have lose versus industry increase quarterly detailsvibativ generate revenue fourth quarter year period sale decrease mainly due impact generic competition unite state revenue collaboration be compare year earlier quarter research development expense be year period mainly due increase employee related cost advancement company priority pipeline program partially offset reduction external expense selling general administrative expense rise primarily higher employee related cost resultsfull year sale slump year year however number beat zack consensus estimate full year loss share be wider year tally loss be also wider consensus mark loss pipeline other updatesearlier february theravance enter global collaboration agreement janssen subsidiary johnson johnson jnj free report jointly develop commercialize pan janus kinase inhibitor td treatment inflammatory intestinal disease pursuant mentioned contract theravance be entitle receive upfront payment be also eligible get potential payment remain collaboration completion phase ii activity also january theravance partner mylan myl free report announce new drug application nda pipeline candidate revefenacin td have be accept fda treatment adult chronic obstructive pulmonary disease response regulatory body be expect nov nda acceptance be support positive datum replicate pivotal phase iii efficacy study single month open label active comparator safety trial october company report positive datum phase iii evaluation project operate loss range theravance biopharma inc price consensus ep surprise theravance biopharma inc price consensus ep surprise theravance biopharma inc quote zack rank key picktheravance carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1296,MYL,mylan myl free report be schedule report fourth quarter result feb market close company performance have be mixed so far have top earning estimate miss other trail quarters company report average negative earning surprise say time frame mylan price consensus mylan price consensus mylan quote last quarter company miss earning estimate let see thing be shape announcement mylan stock have return last month industry decline approval generic copaxone mg provide boost stock factor consider company third quarter result be dismal due lower epipen sale nevertheless mylan raise lower end sale guidance banking launch generic version copaxone mylan win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity accord quintilesim sale copaxone mg ml dose be approximately mg ml dose be month period end july company now expect revenue earlier projection zack consensus estimate revenue be company now project earning share range zack consensus estimate same be approval come silver line distraught mylan give ongoing challenge unite state uncertain regulatory environment mylan specialty segment epipen be most significant product continue be weak sale epipen auto injector be anticipate continue decline current quarter result increase competition impact authorize generic launch meanwhile company effort get advair generic approve face jolt fda issue complete response letter anda generic advair diskus nevertheless newly launch product be likely perform well drive top line acquisition meda renaissance topical business be also expect boost top line generic segment fda recently approve ogiviri biosimilar version roche holding rhhby free report herceptin mylan recently obtain tentative fda approval president emergency plan aids relief pepfar new drug application dolutegravir emtricitabine tenofovir alafenamide tablet mg mg mg earning call expect investor focus performance epipen newly launch drug progress company biosimilar pipeline earning whispersour proven model doesn conclusively show mylan be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat earning be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filterzack rank mylan currently carry zack rank rank be favorable company negative esp make surprise prediction difficult note caution sell rate stock never be consider go earning announcement especially company be see negative estimate revision stock considerhere be health care stock consider model show have right combination element post earning beat quarter exelixis exel free report be schedule release fourth quarter result feb market close company have earning esp zack rank see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1297,MYL,follow announcement fourth quarter result share momenta pharmaceutical inc mnta free report moved company report earning share cent quarter beating zack consensus estimate cent figure however be cent earn year quarter momenta pharmaceutical inc price consensus momenta pharmaceutical inc price consensus momenta pharmaceutical inc quote revenue quarter come top zack consensus estimate be year quarter momenta stock have gain last month industry decline quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be primarily due inventory price adjustment owing mylan myl free report entry copaxone market deduction reimburse company share glatopa related legal expense sandoz collaborative research development revenue come year quarter increase be due revenue recognition upfront payment csl fourth quarter research development expense be year quarter general administrative expense decrease outlookmomenta expect operate expense exclude stock base compensation net collaborative revenue range operate expense first quarter be project momenta expect generate revenue mylan upfront payment quarterly basis pipeline updatesmomenta announce fda have finally approve sandoz abbreviated new drug application glatopa mg company suffer setback fda issue warning letter pfizer pfe free report february be sandoz contract fill finish manufacturing partner glatopa meanwhile momenta continue progress other pipeline candidate january momenta mylan announce plan initiate patient clinical trial propose biosimilar eylea first half investigational new drug ind application have be accept regulatory body biologic license application bla momenta biosimilar version humira be also ready be file fda company be look collaboration partner same momenta suffer setback company partner mylan announce propose biosimilar orencia do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer hence momenta partner mylan continue evaluate next course action momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody momenta successfully complete phase single ascend dose study healthy volunteer january momenta report positive top line datum phase single ascend dose sad multiple ascend dose mad study normal human volunteer phase randomize double blind placebo controlled study evaluate safety tolerability pharmacokinetic pharmacodynamic candidate do not exhibit adverse event be well tolerate decrease circulate igg level mean reduction day mad study addition sad portion study enrolled cohort total healthy adult volunteer show single dose achieve reduction circulate igg antibody takemomenta fourth quarter result be better expect drive receipt upfront payment be challenge company face approval delay glatopa mg report disappointing result biosimilar candidate fda approval glatopa mg relieve momenta competition limit market share gain note mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity hence expect company face challenge market meanwhile progress biosimilar pipeline be encourage zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1298,MYL,johnson johnson jnj free report partner glaxosmithkline gsk free report recently announce fda approval juluca combination glaxo tivicay rilpivirine edurant dolutegravir single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen approval juluca have shift investor focus hiv disease space let see company be try tap huge market note hivhiv stand human virus weaken immune system destroy cell fight disease infection eventually lead aids acquire syndrome medicine treatment hiv be call antiretroviral therapy art slow put check progression virus globally person be live hiv aids end total be child less year old improve medical understand hiv prevention treatment well significant effort make lead government medical body hiv aids still have cure notably person die aids related illness reach total number start epidemic company develop hiv drugsmarkete therapy hivseveral pharmaceutical company be marketing drug therapy treat hiv gilead gild free report be dominant player hiv market impressive portfolio company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya be bestseller surpass truvada atripla fourth quarter company glaxosmithkline have long standing commitment hiv infectious disease company have develop widely used antibiotic amoxycillin year develop first medicine approve treat hiv azt company other market hiv drug include triumeq tivicay other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress pharmaceutical company mylan myl free report have receive tentative approval fda combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate treat hiv pipeline company be work develop new drug treat prevent possibly cure hiv scientist be explore new treatment paradigm drug regimen make therapy drug improve safety profile new mechanism action gilead str bictegravir hiv treatment be priority review unite state fda be expect announce decision next february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone merck be develop investigational nucleoside reverse transcriptase inhibitor mk doravirine hiv infection plan tofile regulatory application fix dose combination same single entity tablet fix dose combination tabletconsist fix dose combination doravirine dor lamivudine tc tenofovir disoproxil fumarate tdf late glaxo be also develop drug regimen be dolutegravir cabotegravir rilpivirine increase number company be develop drug treat life threaten disease competition have intensified manifold space meanwhile be be see juluca fare market be reissue article correct mistake original article issue tuesday nov longer be rely
1299,MYL,accord israeli newspaper teva pharmaceutical industry ltd teva free report be expect reduce workforce consequently share company be more pre market trading nov however so far year stock have be compare industry decline daily teva be also plan lay current president global research development chief scientific officer michael hayden meanwhile company be face significant challenge form generic competition copaxone new competition brand product pricing erosion generic business lower expect contribution new generic launch massive debt load generic industry be also confront significant competitive pricing pressure thereby affect company top line performance also increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure industry challenge generic market be expect continue year probably next well company lead brand drug copaxone be witness decline sale quite time now october mylan myl free report launch risk generic version mg formulation much earlier expect be major blow teva glatopa generic version copaxone mg be already be market momenta novartis nvs free report generic arm sandoz mylan myl free report launch version mg formulation october additionally company profitability be hurt huge debt burden accrue result teva acquisition allergan agn free report generic unit allergan generic order combat challenge teva have divest core asset cut significant debt load rumor workforce reduction plan probably cheer investor save cost company remain see effort be enough revive company fortune challenge scenario especially face erosion largest product copaxone zack rank teva have zack rank strong sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1300,MYL,theravance biopharma inc tbph free report share rise almost thursday follow approval glaxosmithkline plc gsk free report chronic obstructive pulmonary disease copd therapy trelegy ellipta europe investor cheer approval theravance have economic interest royalty glaxo pay partner innoviva inc global sale trelegy ellipta note innoviva spun operation june subsidiary call theravance biopharma part spin agreement entity theravance be eligible receive future payment paid glaxo connection gsk partner respiratory program moreover glaxo be expect pay innoviva royalty range global sale trelegy elipta theravance receive cash flow amount approximately worldwide net sale drug however theravance share be so far year underperform industry decline trelegy ellipta triple combination therapy be grant marketing authorization eu maintenance therapy treatment patient copd nov be approve unite state september year product be expect bring blockbuster sale meanwhile earlier week theravance submit new drug application fda copd candidate revefenacin have be develop partnership mylan myl free report revefenacin be nebulized long act muscarinic antagonist lama approval be huge boost patient prefer nebulized therapy have access nebulized lama theravance have zack rank hold see complete list today zack rank strong buy stock here theravance biopharma inc price theravance biopharma inc price theravance biopharma inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1301,MYL,theravance biopharma inc tbph free report partner mylan myl free report announce new drug application combine entity key pipeline candidate revefenacin td have be submit fda treatment adult chronic obstructive pulmonary disease copd notably revefenacin be experimental once daily nebulized long act muscarinic antagonist lama treat copd remind investor theravance mylan enter development agreement revefenacin february term agreement company codevelop revefenacin copd other respiratory disease theravance lead registration development program mylan be responsible product commercial manufacture share theravance have underperform industry so far year stock have lose broader industry have remain flat period nda submission be support positive datum replicate pivotal phase iii efficacy study single month open label active comparator safety trial october company report positive datum phase iii study program meet primary endpoint demonstrate statistically significant improvement placebo week dose dose revefenacin comprise mcg once daily mcg once daily respectively earlier july company have announce positive datum month safety study finding study demonstrated dose revefenacin be generally well tolerate low rate adverse event serious adverse event respectively significantly company initiate phase iiib study evaluate revefenacin patient low peak inspiratory flow rate march datum study be expect early company press release copd be third lead cause death unite state grim picture suggest american be diagnosed disease almost equal number patient remain undiagnosed approval be huge boost patient prefer nebulized therapy have access nebulized lama hence be large commercial countrywide opportunity revefenacin copd area theravance biopharma inc price theravance biopharma inc price theravance biopharma inc quotezack rank key pickstheravance carry zack rank hold few better rank stock health care sector include ligand pharmaceutical inc lgnd free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have surge year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1302,MYL,third quarter report cycle be draw close quarterly result have be strong overall beat percentage be line recent quarters growth rate have be particularly impressive also estimate revision trend have be mostly favorable nov member accounting index total market capitalization have report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning big biotech pharma company report week generic maker mylan myl free report miss estimate earning sale due lower epipen sale one report last week pfizer pfe free report allergan agn free report beat earning expectation revenue come line zoetis zts free report beat expectation earning sale pfizer zoetis raise earning guidance allergan increase only upper end earning outlook here have small biotech pharma company be set report third quarter result nov let see thing be shape quarter puma biotechnology inc pbyi free report puma biotech be schedule release earning market close deliver positive surprise last quarter company earning track record have be good so far have deliver average positive surprise last quarters quarter puma have earning esp zack rank hold indicate likely positive surprise zack consensus estimate be peg loss share uncover best stock buy sell re report earning esp filter puma biotechnology only market product nerlynx neratinib be launch treatment positive breast cancer august so be first quarter puma record sale nerlynx read more puma earning surpass estimate again intrexon corporation xon free report intrexon be also schedule announce result market close last quarter company deliver positive earning surprise trail quarters miss expectation twice surpass estimate once meeting same other result average negative surprise company have earning esp zack rank sell zack consensus estimate be peg loss cent share investor focus be expect be intrexon pipeline conference call company be develop several candidate partnership other company read more store intrexon earning season ligand pharmaceutical inc lgnd free report ligand be expect report market close ligand earning history have be mixed bag company surpass estimate last quarters miss same other also deliver trail quarter average positive surprise last quarter company come positive earning surprise company have earning esp zack rank strong buy see complete list today zack rank stock here zack consensus estimate earning be peg cent share expect investor focus remain company update regard partnership major pipeline asset third quarter conference call read more store ligand earning season wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1303,MYL,mylan myl free report report disappointing third quarter result earning sale miss estimate due lower epipen sale company report earning share miss zack consensus estimate be report year quarter third quarter revenue miss zack consensus estimate be year quarter mylan stock have tumble year date compare industry decline quarter company report result segment geographic basis north america europe rest world north america segment third party net sale come due decline sale exist product result lower volume pricing partially offset contribution new product generic business north america experience higher price erosion previous quarters include impact loss market exclusivity armodafinil sale epipen auto injector plunge significantly decline result impact launch authorize generic higher governmental rebate third party net sale europe be propel acquisition meda new product introduction favorable volume pricing exist product favorable foreign currency translation have impact europe rest world segment third party net sale be fuel meda acquisition sale also benefit new product increase net sale emerge market be drive primarily higher volume be partially offset lower pricing volume exist product retroviral franchise include active pharmaceutical ingredient foreign currency translation have favorable impact adjust gross margin decline year quarter due lower gross profit sale exist product north america include epipen auto injector partially offset contribution acquire business mylan price consensus mylan price consensus mylan quote outlook updatedmylan raise lower end sale guidance due launch generic version copaxone company now expect revenue earlier projection company now project earning share range previous project range note mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity takemylan third quarter result be dismal company miss earning sale estimate due challenge north america quarter experience accelerate decline epipen sale due launch authorize generic well contraction overall epinephrine auto injector market company earlier suffer few setback mylan receive complete response letter fda regard abbreviated new drug application anda generic version glaxosmithkline plc gsk asthma drug advair diskus be work address issue fda oncologic drug advisory committee unanimously recommend approval biosimilar version roche holding rhhby free report herceptin however anticipate fda goal date set biosimilar user fee act be defer december september zack rankmylan currently carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1304,MYL,ve get busy week store more earning economic datum republican congress get busy work detail massive tax reform program arrest saudi arabia man know warren buffett middle east be grab headline morning also see appear be hostile bid broadcom avgo free report take qualcomm qcom free report share include cash qualcomm debt merger deal be accept be largest pure tech deal history be accretive broadcom first year merge odd be very good qualcomm reject proposal company have acknowledge have receive offer give indication board find term favorable consider qualcomm recent difficulty supplier apple aapl free report product see broadcom move very advantageous time report morning be qualcomm official be openly question initial ask price well antitrust issue be understood be initially negative reaction apple involvement scene perhaps somehow manage facilitate deal road way put qualcomm issue apple thing be sure be discussion just warm expect hear much more propose deal rest week prince al walee bin talal reportedly face money launder charge follow corruption purge saudi crown prince mohammad bin salman cause ripple market morning especially al walee major holding citigroup free report twitter twtr free report question regard middle eastern country surround necessarily affected crown prince move such rival major power region iran lebanon have have own issue stability top recess government future market be so far shake be green again morning follow straight week market ve discuss here elsewhere least positive sentiment be result hopefulness corporate tax cut create new windfall company shareholder perhaps even year be earning updatecvs pharmacy cvs free report beat estimate penny share morning line quarterly sale earning be year year revenue be cvs also up earning guidance full year michael kor kor free report well outperformed expectation today open bell earning share easily surpass cent zack consensus year year fiscal sale top have be expect guidance fiscal full year top bottom line be also raise mylan pharma myl free report however miss expectation earning revenue share short be look sale zack consensus estimate weaker expect performance north america underscored fall epipen sale quarter be cite company report
1305,MYL,monday november ve get busy week store more earning economic datum republican congress get busy work detail massive tax reform program arrest saudi arabia man know warren buffett middle east be grab headline morning also see appear be hostile bid broadcom avgo free report take qualcomm qcom free report share include cash qualcomm debt merger deal be accept be largest pure tech deal history be accretive broadcom first year merge odd be very good qualcomm reject proposal company have acknowledge have receive offer give indication board find term favorable consider qualcomm recent difficulty supplier apple aapl free report product see broadcom move very advantageous time report morning be qualcomm official be openly question initial ask price well antitrust issue be understood be initially negative reaction apple involvement scene perhaps somehow manage facilitate deal road way put qualcomm issue apple thing be sure be discussion just warm expect hear much more propose deal rest week prince al walee bin talal reportedly face money launder charge follow corruption purge saudi crown prince mohammad bin salman cause ripple market morning especially al walee major holding citigroup free report twitter twtr free report question regard middle eastern country surround necessarily affected crown prince move such rival major power region iran lebanon have have own issue stability top recess government future market be so far shake be green again morning follow straight week market ve discuss here elsewhere least positive sentiment be result hopefulness corporate tax cut create new windfall company shareholder perhaps even year be earning updatecvs pharmacy cvs free report beat estimate penny share morning line quarterly sale earning be year year revenue be cvs also up earning guidance full year michael kor kor free report well outperformed expectation today open bell earning share easily surpass cent zack consensus year year fiscal sale top have be expect guidance fiscal full year top bottom line be also raise mylan pharma myl free report however miss expectation earning revenue share short be look sale zack consensus estimate weaker expect performance north america underscored fall epipen sale quarter be cite company report mark vickerysenior editorquestion comment article author click here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1306,MYL,mylan myl free report be global pharmaceutical company well establish generic business well presence specialty pharmaceutical company business model include development manufacturing marketing brand generic drug well active pharmaceutical ingredient apis north america europe rest world notably mylan have world largest api operation mylan have be make prudent acquisition inking strategic deal drive long term growth feb company acquire abbott laboratory develop market specialty brand generic business further nov acquire certain female health care business famy care however mylan have be immense pressure aug company face criticism price increase epipen acquisition drug lawmaker consumer common person alike mylan performance have be mixed so far have beaten earning estimate trail quarters miss other overall have deliver average negative surprise currently mylan have zack rank buy definitely change follow company earning report be just release have highlighted key stat just reveal announcement mylan price consensus ep surprise mylan price consensus ep surprise mylan quoteearning mylan miss earning consensus call ep company report ep revenue revenue too miss expectation mylan post revenue compare consensus estimate key stat challenge north america continue impact performance quarter company also witness accelerate deceleration epipen sale launch authorize generic well contraction overall epinephrine auto injector market pre market trading share be trading pre market trading check back later full mylan earning report later wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1307,MYL,horizon pharma plc hznp free report be schedule report third quarter result open bell nov last quarter company miss expectation let see thing be shape quarter horizon pharma share have decline year so far underperform industry gain factor likely impact second quarter earning company raise outlook now expect sale range compare earlier estimate horizon pharma be significantly increase investment key growth driver krystexxa project peak sale drive higher demand guidance include assumption lower net average net realize price government health resource service administration final rule drug ceiling price implementation schedule oct company expect continue double digit net sale growth ravicti room additional uptake due recent label expansion drug be also expect be launch europe second half however sale procysbi decline due divestiture european right sale actimmune be project grow low single digit drive year year growth second half meanwhile horizon pharma primary care business be pressure due implementation new commercial model company be team pharmacy benefit manager payer help patient obtain access medicine third quarter earning call focus be performance business unit product actimmune krystexxa earning whispersour proven model do not conclusively show horizon pharma be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be cent zack consensus estimate be currently peg cent uncover best stock buy sell re report earning esp filter zack rank horizon pharma currently carry zack rank sell be sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision horizon pharma plc price ep surprise horizon pharma plc price ep surprise horizon pharma plc quotestock considerhere be health care stock want consider model show have right combination element post earning beat quarter inc agen free report have earning esp zack rank company be schedule release third quarter result nov see complete list today zack rank stock here acadium pharmaceutical inc acad free report have earning esp currently carry zack rank company be expect release third quarter result nov mylan myl free report have earning esp currently carry zack rank company be expect release third quarter result nov note be republish article correct mistake original version publish earlier today thursday november longer be rely zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1308,MYL,quanta service inc pwr free report be slate report third quarter result open bell nov quanta service have have dismal earning surprise history miss line earning trail quarters average negative surprise last quarter company earning miss zack consensus estimate however expect quanta service score earning beat be report quarter likely positive surprise proven model show quanta service have right combination key ingredient stock need have positive earning esp zack rank strong buy buy least hold happen be perfectly case here see zack esp quanta service have earning esp most accurate estimate cent be peg zack consensus estimate cent uncover best stock buy sell re report earning esp filter zack rank company carry zack rank combine positive esp make reasonably confident earning beat conversely caution stock zack rank sell rate go earning announcement especially company be witness negative estimate revision factor drive better expect resultsquanta service have be derive sturdy benefit company diligent prong growth strategy strategy focus timely delivery project leverage core business area expand complementary service line venture new service line well quanta service thrive engineering project management service be anticipate bolster revenue soon be report quarter late company have be witness solid rebound end market back key growth driver age grid shift generation mix implementation clean energy initiative factor likely boost segment top line moreover company be currently pursue several high voltage electric transmission award opportunity substantial bidding activity australia canada unite state reflect upcoming quarterly result quanta service inc price consensus ep surprise quanta service inc price consensus ep surprise quanta service inc quotequanta service raise earning revenue guidance last quarter believe optimism stem healthy backlog level be anticipate benefit result be report quarter upbeat industry trend act major growth catalyst quarter be report apart company be likely benefit directly increase production liquid fuel also quanta service win more construction engineering contract performance production level energy sector increase robust pipeline project oil gas sector support active bidding negotiating environment also act huge profit churner top line third quarter addition quanta service previously complete acquisition be likely contribute significantly electric power infrastructure service segment top line particularly recent stronghold acquisition drive company revenue increase penetration downstream midstream petrochemical market turn be beneficial quarter review stock warrant lookhere be company want consider model show have right combination element post earning beat quarter take interactive software inc free report earning esp zack rank be expect release quarterly number nov see complete list today zack rank stock here mylan myl free report earning esp zack rank be slate report result nov match group inc mtch free report have earning esp zack rank company be likely release earning nov more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1309,MYL,premier waste management firm republic service inc rsg free report be schedule report third quarter result close bell nov company be likely report higher revenue collection segment account more total revenue due improve demand product lead higher earning quarter remain be see top line service have significantly expand product offering commerce platform address evolve need customer low cost sale channel be likely aid company quarter addition company improve capability functionality customer portal mobile app value drive interactive feature be likely lead incremental order higher revenue be report quarter same time republic service be focuse increase operational efficiency convert fleet compress natural gas collection vehicle modify rear load truck automate side loader reduce cost improve profitability company be realign field support function combine organizational layer expect initiative contribute approximately annual cost saving part realignment program company centralize management structure recycling operation new organizational structure be likely ensure clear ownership recycling process market vertical republic service be also transition fee base recycling process model cover process cost generate healthy return investment zack consensus estimate collection segment revenue be currently peg report year quarter revenue landfill segment be expect be compare report revenue year earlier quarter revenue transfer disposal service segment be anticipate be report year quarter other key factorshowever margin pressure remain bottleneck company margin be expect remain constrain impending quarter republic service have more exposure collection service less disposal service typically disposal service generate highest margin collection service generate lowest company performance be also likely be hurt protracted weakness special waste industrial volume tight municipal budget addition increase competitive pressure remain concern company proven model do not conclusively show republic service be likely beat earning quarter do not possess key component stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter republic service inc price ep surprise republic service inc price ep surprise republic service inc quotezack rank republic service have zack rank sell note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision momentum stock considerhere be company want consider model show have right combination element post earning beat quarter kemet corporation kem free report have earning esp zack rank see complete list today zack rank stock here mylan myl free report have earning esp zack rank telus corporation tu free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1310,MYL,information technology service provider gartner inc free report be schedule report third quarter result open bell nov company be likely report higher revenue research segment account more total revenue due improve demand product result higher earning quarter remain be see top line diligent execution operational plan gartner have record double digit growth key metric more decade addition performance drive firm have strong cash flow healthy balance sheet position have vast untapped market opportunity worth estimate acquisition ceb industry leader provide best practice talent management insight further reinforce gartner market strength combination analyst drive syndicate research advisory service ceb expertise be likely provide comprehensive differentiate suite service portfolio globe gartner have recur revenue stream total revenue generate subscription long term contract addition company have large diverse addressable market low customer concentration mitigate operate risk operate industry low barrier entry gartner have integrate research consult team design best serve client need enable have competitive advantage rival leverage intellectual capital gartner create distribute proprietary research content broadly possible publish report interactive tool facilitate peer networking briefing consult advisory service event facilitate steadily improvement company revenue stream zack consensus estimate research segment revenue be currently peg report year quarter revenue event segment be expect be compare report revenue year earlier quarter however revenue consult segment be anticipate be report year quarter other key factorsgartner be relatively immune vagary market due secular growth information technology spend increase market penetration rate however service be cyclically sensitive addition revenue federal government business be expose lengthy approval time other austerity measure often increase operate risk factor undermine long term growth potential company extent proven model do not conclusively show gartner be likely beat earning quarter do not possess key component stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter gartner inc price ep surprise gartner inc price ep surprise gartner inc quotezack rank gartner have zack rank increase predictive power esp need have positive esp be confident earning surprise note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision momentum stock considerhere be company want consider model show have right combination element post earning beat quarter kemet corporation kem free report have earning esp zack rank see complete list today zack rank stock here mylan myl free report have earning esp zack rank telus corporation tu free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1311,MYL,major pharma company eli lilly lly free report bristol myer squibb bmy free report glaxosmithkline plc gsk free report novartis read more novartis earning sale top new drug strength report third quarter result week be beat raise quarter lilly bristol myer result be mixed recap week most important storieslilly top expectation mull option animal health segment lilly third quarter result be better expect company beating top bottom line raise outlook year reflect uptake trend new pharmaceutical product company also announce be explore strategic alternative animal health business elanco animal health update expect mid company be weigh option initial public offer merger sale retention business segment bring revenue so far read more lilly beat earning explore sale elanco lilly be zack rank buy stock see complete list today zack rank strong buy stock here mixed quarter bmy be mixed quarter bristol myer company miss earning surpass revenue expectation opdivo performance remain strong presence increase competition sale grow eliquis also perform well company say business development remain top priority expect buy back share worth additional year end read more bristol myer miss earning opdivo focus company have gain year date compare rally industry belong sanofi file patent infringement lawsuit mylan lantus french drugmaker sanofi sny free report have file patent infringement suit mylan myl free report lantus lantus solostar lawsuit file unite state district court district new jersey allege infringement patent sanofi diabetes product sale be immense pressure lantus franchise remain major contributor top line earlier year august sanofi have file patent infringement suit merck allege infringement patent related lantus product interest increase pfizer consumer healthcare business ever pfizer pfe free report announce be explore strategic option consumer healthcare business include full partial separation spin sale quite few company have be rumore be interested striking deal week british pharma major glaxo be ask third quarter call interest acquire pfizer consumer healthcare business glaxo own consumer segment have be witness material slowdown global growth key category factor pricing pressure increase competition tougher emerge market weigh performance read more glaxo earning beat revenue line share meanwhile accord reuter article pfizer expect start auction process consumer healthcare business november accord source possible bidder apart glaxo reckitt benckiser include name procter gamble sanofi johnson johnson nestle nyse arca pharmaceutical index decline week major stock glaxo decline mainly reflect concern company dividend payout especially strike deal pfizer consumer healthcare business last month be see last pharma stock roundup here beat raise quarter allergan hit restasis ruling next pharma world watch earning result company merck mrk free report pfizer wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1312,MYL,glaxosmithkline plc gsk free report report core earning cent american depositary share third quarter surpass zack consensus estimate cent bottom line be however flat constant exchange rate cer glaxo share drop more hour trading third quarter conference call glaxo show interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout so far year stock have lose industry increase quarterly revenue be cer back strong performance mainly pharmaceutical segment however revenue be line zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market other hand sale europe register decrease sale new pharmaceutical vaccine product surge drive hiv drug tivicay triumeq respiratory drug ellipta product nucala vaccine prevent meningitis bexsero menveo glaxo report result segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug tivicay triumeq respiratory disease drug relvar breo nucala upside be partly offset impact recent divestment hiv sale rally back growth unite state international sale europe sale be however year year otherwise encourage number come back continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due increase generic competition particularly affect european market respiratory sale be flat cer unite state europe sale dip however international market same increase downside be mainly due continue transition newer product portfolio sale new respiratory product relvar breo ellipta anoro ellipta arnuity ellipta nucala be offset lower sale seretide advair sale flixotide flovent ventolin sale decrease respectively ellipta product record surge sale drive market share gain global roll continue immuno inflammation drug include benlysta rise quarter new grouping establish pharmaceutical include previous establish product cardiovascular metabolic urology cvmu other pharma product establish pharmaceutical sale decline quarter sale consumer healthcare segment go slowdown market condition power brand particularly pain relief oral health category see strong performance quarter sale vaccine segment be flat cer geographically unite state europe be international market drop meningitis vaccine bexsero unite state europe menveo unite state see higher sale same be offset weak performance establish vaccine drive increase competitive pressure infanrix pediarix unite state europe notably october glaxo announce fda have grant approval vaccine shingrix prevention shingle herpes zoster subsequently same month center disease control prevention advisory committee immunization practice acip vote favor recommendation use shingrix vaccine be prefer merck mrk free report zostavax company expect face generic competition advair unite state next year affect top line however be uncertainty regard timing launch generic version drug generic version advair expect be unveil company continue expect core earning growth range cer remind investor mylan myl free report effort bring generic version advair market suffer blow fda issue complete response letter abbreviated new drug application anda advair april thereby delay entry generic hikma pharmaceutical plc generic version advair be also deny approval fda drug generic version be therefore not likely be approve year glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quotezack rankglaxo currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1313,MYL,allergan plc agn free report announce texas federal district court invalidate patent cover restasis allergan second bestselling drug potentially open door early generic competition share company fall almost response monday company be disappoint court ruling be plan appeal however ruling be upheld even appeal negatively impact restasis sale invalidate patent be list orange book be set expire aug restasis be approve treatment chronic dry eye allegan share have outperformed industry so far year company stock fall industry be period allergan have file patent infringement lawsuit group generic drug manufacturer include teva pharma teva free report mylan myl free report other company be seek approval generic version restasis unite state meanwhile last week allergan settle innopharma grant latter right market generic restasis begin feb moreover bid dismiss parte review restasis allergan sign agreement last month saint regis mohawk tribe gain sovereign immunity however court litigation be purview sovereign immunity unconventional move company have be question many lawmaker be criticize generic manufacturer such deal gain sovereign immunity make launch generic lengthy complex legal process curb competition restasis generate sale worldwide first month fda approval shire plc shpg free report xiidra last year have already increase competition drug earlier expect generic entry follow invalidation patent further increase competition allergan plc price consensus allergan plc price consensus allergan plc quoteallergan carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1314,MYL,voyager therapeutic inc vygr free report be big mover last session company see share rise nearly day move come solid volume too far more share change hand normal session continue recent uptrend company company stock be now past month time frame company have see negative estimate revision past few month zack consensus estimate current quarter have also moved lower past few month suggest be trouble road so make sure keep eye stock go forward see recent move higher last voyager therapeutic currently have zack rank hold earning esp be voyager therapeutic inc price voyager therapeutic inc price voyager therapeutic inc quotea better rank stock medical sector be mylan myl free report currently carry zack rank buy see complete list today zack strong buy rank stock here be hstm go predict see other think stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1315,MYL,mylan myl free report suffer setback follow fda complete response letter crl company biologic license application bla myl propose biosimilar amgen inc amgn free report neulasta crl relate pending update bla certain cmc datum facility requalification activity post recent plant modification however crl do not raise question biosimilarity pharmacokinetic pharmacodynamic datum clinical datum immunogenicity mylan be explore world biosimilar market have potential grow partnership biocon additional collaboration have help mylan develop wide portfolio biosimilar insulin analog generic product represent total brand market value more worldwide sale earlier fda notified mylan partner biocon target action date biosimilar version roche hold ag rhhby free report herceptin trastuzumab have be extend dec decision fda be expect sep review period be extend due clarificatory information be need be submit agency part process last week fda approve generic version teva pharmaceutical industry limit teva free report multiple sclerosis drug copaxone glatiramer acetate mg ml thrice weekly news boost investor sentiment company share surge same mylan stock have increase last month compare industry decline notably be first generic copaxone have be approve fda also approve generic copaxone mg ml once daily mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity accord quintilesim sale copaxone mg ml dose be approximately mg ml dose month period end july hence generic approval be expect provide significant boost mylan zack rankmylan currently carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1316,MYL,johnson johnson jnj free report subsidiary janssen biotech announce fda have approve new drug application nda apalutamide treatment man metastatic castration resistant prostate cancer nmcrpc apalutamide next generation oral androgen receptor ar inhibitor be market trade name erleada fda decision come much earlier expect please note december last year nda be grant priority review fda fda grant priority review response be expect april erleada nda submission be base positive datum phase iii spartan study last week present positive datum spartan study american society clinical oncology genitourinary cancer symposium meeting datum study show erleada apalutamide significantly reduce risk metastatis death increase median metastatis free survival more year patient nmcrpc stock have return past year compare favorably gain record industry give be fda approve treatment available patient population erleada approval be significant boost company cancer portfolio also erleada approval have strengthen prostate cancer franchise especially key drug zytiga approve treat metastatic crpc face patent challenge several company amneal apotex dr reddy rdy free report mylan myl free report teva teva free report other be look fda approval generic version zytiga last month announce pto issue final written decision party review ipr generic manufacturer invalidate patent zytiga zytiga be key driver revenue growth last year zytiga sale rise due improve market share grow metastatic castration resistant prostate cancer market do not expect biosimilar entrant zytiga year be confident guidance organic sale growth absorb impact potential zytiga headwind such earlier expect generic launch addition erleada early approval somewhat make lose sale zytiga case generic be launch year apalutamide be add portfolio august aragon acquisition carry zack rank hold johnson johnson price consensus johnson johnson price consensus johnson johnson quote be reissue article correct mistake original article issue thursday february longer be rely wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1317,MYL,johnson johnson jnj free report subsidiary janssen biotech announce fda have approve new drug application nda apalutamide treatment man metastatic castration resistant prostate cancer nmcrpc apalutamide next generation oral androgen receptor ar inhibitor be market trade name erleada fda decision come much earlier expect please note december last year nda be grant priority review fda fda grant priority review response be expect april erleada nda submission be base positive datum phase iii spartan study last week present positive datum spartan study american society clinical oncology genitourinary cancer symposium meeting datum study show erleada apalutamide significantly reduce risk metastatis death increase median metastatis free survival more year patient nmcrpc stock have return past year compare favorably gain record industry give be fda approve treatment available patient population erleada approval be significant boost company cancer portfolio also erleada approval have strengthen prostate cancer franchise especially key drug zytiga approve treat metastatic crpc face patent challenge several company amneal apotex dr reddy rdy free report mylan myl free report teva teva free report other be look fda approval generic version zytiga last month announce pto issue final written decision party review ipr generic manufacturer invalidate patent zytigazytiga be key driver revenue growth last year zytiga sale rise due improve market share grow metastatic castration resistant prostate cancer market do not expect biosimilar entrant zytiga year be confident guidance organic sale growth absorb impact potential zytiga headwind such earlier expect generic launch addition erleada early approval somewhat make lose sale zytiga case generic be launch year apalutamide be add portfolio august aragon acquisition carry zack rank hold hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1318,MYL,share teva pharmaceutical industry limit teva free report be tuesday generic version blockbuster multiple sclerosis injection copaxone be launch earlier expect sandoz novartis nvs free report generic arm announce fda approval launch glatopa mg ml generic version mg formulation copaxone be second generic version mg formulation copaxone launch come much earlier expect teva fourth quarter conference call hold last week have say second generic version mg formulation be likely be launch april year first generic version copaxone mg be launch mylan myl free report october last year also much earlier expect dealt major blow teva also same time mylan launch second biosimilar version mg formulation please note first generic version copaxone mg have be market momenta mnta free report sandoz entry generic version mg formulation entry second generic version mg formulation copaxone sale witness rapid erosion now launch second generic version mg formulation sale be expect decline further copaxone sale totale almost level teva estimate copaxone sale fall copaxone franchise continue erode fact teva issue weak outlook expect sale profit decline further year israel base generic drugmaker have tough face significant challenge form accelerate generic competition copaxone new competition brand product pricing erosion generic business lower expect contribution generic launch massive debt load more mylan earlier expect launch first generic version mg strength copaxone be major setback teva teva divest core asset mainly woman health business cut significant debt load company also have new organizational structure place be close plant cut generic portfolio eliminate low value project aim cut global workforce more next year part restructure plan reveal december company expect save almost end restructure initiative clear path growth be not visible effort not be enough revive company fortune challenge period especially face erosion largest product copaxone other divesture pricing pressure generic business continue hurt top line teva share have slump past year compare industry sdecline teva carry zack rank sell see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1319,MYL,teva pharmaceutical teva free report report disappointing quarter last week fourth quarter earning decline year year sale be israel base company product sale be hurt increase pricing erosion volume decline generic unit rapid erosion sale copaxone teva blockbuster multiple sclerosis injection specialty segment mylan myl free report earlier expect launch first generic version mg strength copaxone be major setback teva company be also bog new competition brand product huge debt burden fourth quarter call teva provide weak guidance expect sale profit decline further year teva expect revenue range earning be expect band share number fall investor expectation however teva have undertake strategic restructure effort include divestiture core asset closure plant trimming generic portfolio termination low value project plan reduce workforce more quarter next year company expect save almost end restructure initiative clear path growth be not visible face erosion largest product copaxone other loss sale due divesture pricing pressure generic business continue hurt top line fact price erosion several other challenge cast shadow whole generic drug industry generic drug industry doldrumsgeneric drug have zack industry rank bottom zack industry industry have decline past year underperform increase broader drug industry generic industry unite state face significant competitive pricing pressure trend be expect continue moreover customer industry be consolidate thereby increase scope negotiating lower price generic drug be lead increase price erosion decrease volume sharp decline generic drug price be prove be major challenge generic drugmaker well drug distributor moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume stock generic pricing erosion expect continue year recommend investor dump company industry include teva tevateva have zack rank sell follow unimpressive fourth quarter result trim view zack consensus estimate earning decline last day teva have lose value past year dr reddy laboratory rdy free report india base generic drugmaker have zack rank strong sell larger peer dr reddy also suffer drug price erosion fierce competitive pressure lower contribution product launch unite state addition implementation general sale tax gst india be also hurt top line extent however company have launch several generic various drug include sanofi dollar drug renvela launch have favorable impact company generic sale have register sequential growth quarter end december dr reddy earning estimate have decline almost past day stock have decline past year teligent tlgt free report teligent be small pharmaceutical company generic brand product portfolio company have also suffer due generic market headwind moreover product launch have not be able make loss due pricing pressure company lead product zack consensus estimate sale earning be expect decline respectively fourth quarter teligent also carry zack rank share company have tumble past year company large be see decline sale profit due price erosion however be few exception mylan be mylan stock decline first half share rebound august outperform industry stock have gain august mylan have zack rank hold earning estimate have rise past day see complete list today zack rank strong buy stock here mylan turnaround be drive launch generic version several drug include blockbuster drug novartis nvs free report gleevec teva copaxone second half moreover patent trademark appeal board instituted parte review proceedings ontwo patent related sanofi lantus favorable ruling boost mylan prospect lantus be blockbuster drug sale first month potential launch generic version mylan significantly boost top line hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1320,MYL,teva pharmaceutical industry limit teva free report report fourth quarter earning cent share beat zack consensus estimate cent share come ahead guide range cent cent however earning share decline year year revenue be marginally beat consensus estimate however sale decline year year exclude impact currency sale be hurt increase pricing erosion volume decline generic unit rapid erosion sale copaxone teva blockbuster multiple sclerosis injection specialty segment segment discussionteva revise segment structure follow actavis acquisition generic segment now include revenue otc business well api business generic medicine segment revenue be year year revenue generic business decline due significant competitive pricing pressure generic industry ongoing consolidation customer generic industry lead increase price erosion decrease volume consolidation industry have increase ability negotiate lower price generic drug accelerate fda approval additional generic version compete patent medicine increase competition concerta authorize generic stringent government regulation also hurt sale european generic revenue be flat year year however sale decline local currency term year period mainly due absence revenue generic business actavis unite kingdom be divest january rest world row generic revenue decline quarter local currency basis sale rise mainly due higher sale russia israel api revenue be flat otc revenue be local currency term specialty medicine revenue be year period due lower sale central nervous system cns product divesture core asset woman health business teva various therapeutic area cns sale decline due lower sale copaxone sale respiratory product decline oncology product sale rise woman health business record decrease revenue other specialty revenue decline worldwide revenue copaxone decline mainly due lower sale unite state sale decline unite state mainly due generic competition result higher rebate lower volume glatopa generic version copaxone mg be be market momenta mnta free report sandoz novartis generic arm mylan myl free report launch version mg formulation october same month major blow teva mylan launch risk generic version mg thrice weekly formulation much earlier expect entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation be expect be launch april year ex sale copaxone be flat local currency basis other product azilect sale decline generic version drug be launch unite state proair decline qvar decline hurt negative net pricing effect combine treanda bendeka revenue rise millionthe other segment distribution other activity record revenue year year company sell distribution business profit declineadjust gross margin contract basis point bps quarter research development expense decline almost year period selling marketing expenditure decline year level adjust operate income decline quarter lower cost resultsfull year sale beat zack consensus estimate also come ahead guide range sale rise year year gain inclusion actavis generic revenue teva acquire allergan agn free report generic segment actavis generic also generic distribution business anda adjust earning be share beat zack consensus estimate share exceed guide range share earning decline year year outlook expect revenue range fall short current zack consensus estimate company expect earning band share also short current zack consensus estimate share teva expect copaxone generate sale globally significantly lower franchise continue erode generic sale be expect decline roughly level approximately hurt ongoing price erosion generic concerta also proair franchise be expect see generic competition second half cost be expect decline teva beat expectation earning sale fourth quarter stock crash more thursday company issue weak outlook expect sale profit decline further year teva share have slump past year compare industry decline israel base generic drug maker have tough face significant challenge form accelerate generic competition copaxone new competition brand product pricing erosion generic business lower expect contribution generic launch massive debt load more mylan earlier expect launch first generic version mg strength copaxone be major setback teva teva divest core asset mainly woman health business cut significant debt load company also have new organizational structure place be close plant cut generic portfolio eliminate low value project aim cut global workforce more next year part restructure plan reveal december company expect save almost end restructure initiative clear path growth be not visible effort not be enough revive company fortune challenge period especially face erosion largest product copaxone other divesture pricing pressure generic business continue hurt top line teva carry zack rank sell teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1321,MYL,glaxosmithkline plc gsk free report report core earning cent american depositary share fourth quarter surpass zack consensus estimate cent bottom line be constant exchange rate cer compare year figure glaxo share have lose year time industry increase quarterly revenue rise cer drive strong segmental performance consumer healthcare pharmaceutical vaccine top line also outpaced zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be unite state international market flip side sale europe be flat year year sale new pharmaceutical vaccine product surge drive hiv drug tivicay triumeq respiratory drug ellipta product nucala meningitis preventive vaccine bexsero menveo glaxo report financial figure segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug tivicay triumeq respiratory disease drug relvar breo nucala upside be partly offset impact recent divestment sale decrease older respiratory product include seretide advair establish pharmaceutical hiv sale increase back growth unite state international sale respectively europe sale be also year year encourage number be drive continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due increase generic competition particularly affect european market notably company latest product hiv portfolio be juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv be approve unite state november drug generate initial sale quarter however week gilead science gild free report have announce fda approval triple combination once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide hiv infection treatment approval competitive threat juluca come quarters respiratory sale be cer eu international market sale increase respectively however unite state metric be flat year year sale improvement be mainly drive new respiratory product sale growth partially offset sale decline older product seretide advair flovent ventolin notably recently launch respiratory product trelegy ellipta only once daily single inhaler triple therapy copd have generate initial sale unite state eu report quarter ellipta product record surge sale drive market share gain global roll continue however upside be offset lower sale seretide advair flixotide flovent ventolin sale decrease respectively immuno inflammation drug include benlysta rise quarter new grouping establish pharmaceutical comprise previous establish product cardiovascular metabolic urology cvmu other pharma product establish pharmaceutical sale decline quarter review sale consumer healthcare segment climb slowdown market condition power brand particularly pain relief oral health category see sturdy performance quarter sale vaccine segment be impressive have increase year year geographically unite state europe international market increase respectively meningitis vaccine bexsero decrease unite state same increase europe market menveo unite state post higher sale same be offset weak performance establish vaccine due increase competitive pressure infanrix pediarix unite state europe be important note october fda grant approval glaxo shingle vaccine shingrix later same month center disease control prevention advisory committee immunization practice vote favor recommendation use shingrix vaccine be prefer merck mrk free report zostavax owing favorable recommendation shingrix generate initial sale unite state period discussion resultsfull year sale gain year year however metric marginally miss zack consensus estimate earning share be line zack consensus estimate full year bottom line reflect growth compare year figure moreover report earning match previously announce guidance company state ep growth be uncertain due timing entry advair generic market hence issue set guidance company expect ep growth cer advair generic be launch further year however probable event introduce advair generic market mid glaxo anticipate adjust ep be flat year year cer company mylan myl free report hikma pharmaceutical novartis be try bring generic version advair market receive complete response letter crl fda mylan hikma receive crl last year novartis receive same week delay entry generic market long term company project ep witness cagr mid high single digit range vaccine segment be estimate register mid high single digit growth competition pediatric flu vaccine consumer healthcare segment be expect deliver low mid single digit top line cagr glaxosmithkline plc price consensus ep surprise glaxosmithkline plc price consensus ep surprise glaxosmithkline plc quote zack rankglaxo carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1322,MYL,allergan plc agn free report fourth quarter earning come share beating zack consensus estimate earning rise year year drive higher revenue lower cost revenue come beat zack consensus estimate revenue rise year period key product botox juvderm collection filler new product vraylar viberzi namzaric do well quarter however sale erosion namenda xr aczone loss exclusivity mainly asacol hd minastrin hurt top line fourth quarter revenue also benefit addition alloderm lifecell january coolsculpt body contour system zeltiq april company report revenue segment general medicine specialize therapeutic international specialize therapeutic net revenue increase drive continue strong performance facial aesthetic product botox juvderm collection filler botox cosmetic rake sale botox therapeutic revenue be addition juvderm collection filler rise eye care ozurdex sale increase blockbuster dry eye drug restasis sale rise plastic surgery breast implant sale increase contribute upside medical dermatology aczone sale decline quarter lifecell alloderm add zeltiq coolsculpt business add sale fourth quarter general medicine net revenue be flat report quarter sale decline diversify brand woman health franchise infective sale rise rise central nervous system sale rise establish product linzess loestrin well new product namzaric viberzi vraylar do well quarter linzess sale rise quarter drive strong demand loestrin sale rise backed strong demand trend higher selling price newer product namzaric once daily fix dose combination namenda xr record sale almost flat previous quarter viberzi record sale drive higher selling price namenda xr sale decline quarter due lower demand generic pressure asacol delzicol sale decline due reduction demand ascaol hd follow launch authorize generic august well lower demand delzicol woman health segment minastrin revenue decline quarter due loss exclusivity march last year international segment record net revenue year period drive growth facial aesthetic botox therapeutic eye care addition coolsculpt sg cost rise declinessel general administrative sg expense rise quarter primarily due cost related acquisition expense decline due cost control program resultsfull year sale beat zack consensus estimate revenue be guidance sale rise year year adjust earning be share beat zack consensus estimate share be guide range earning rise year year outlookallergan maintain previously issue total sale guidance range approximately meanwhile company say expect adjust earning range share last month allergan have say expect earning least share adjust tax rate be expect be approximately migraine candidate succeed phase iii studyallergan announce phase iii study evaluate migraine candidate ubrogepant meet co primary endpoint achieve study evaluate efficacy safety orally administer ubrogepant treat single migraine attack moderate severe headache intensity study datum demonstrated significant greater percentage patient treat ubrogepant dose mg mg be free pain hour initial dose compare treat placebo also statistically significant greater percentage ubrogepant patient experience absence most bothersome migraine associate symptom hour initial dose compare treat placebo takeallergan fourth quarter result be strong beat expectation earning revenue strong demand key drug botox addition positive top line datum ubrogepant study push share price pre market trading however past year allergan share price have decline compare industry decline allergan be face potential loss exclusivity several key product include namenda xr restasis generic version namenda xr be expect be launch early first quarter generic version restasis allergan second best selling drug be expect be launch second quarter also december mylan myl free report launch first generic version estrace cream generic version ulcerative colitis drug delzicol be expect be launch early second quarter meanwhile new competition key growth driver botox restasis linzess be investor concern december revance therapeutic next generation neuromodulator rt demonstrated substantial reduction severity glabellar line phase iii study longer duration efficacy compare currently market neuromodulator include botox product be be consider potential threat botox be market same indication shire shpg free report dry eye disease drug xiidra launch last year be pose strong competition restasis meanwhile synergy pharmaceutical inc sgyp free report trulance plecanatide be launch chronic idiopathic constipation competition linzess nonetheless allergan product botox linzess new product such viberzi vraylar support sale growth also boast strong brand pipeline biosimilar also represent significant opportunity also last month allergan announce cost save restructure program allergan be layer employee protect potential revenue decline allergan carry zack rank sell allergan plc price consensus ep surprise allergan plc price consensus ep surprise allergan plc see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1323,MYL,teva pharmaceutical industry ltd teva free report report fourth quarter full year earning feb market open last quarter company deliver negative earning surprise generic drug maker share have lose past year industry witness decrease teva earning have surpass expectation only last quarters meet same miss expectation remain result average negative surprise teva pharmaceutical industry limit price ep surprise teva pharmaceutical industry limit price ep surprise teva pharmaceutical industry limit quotelet see thing be shape announcement factor considerincreas pricing erosion volume decline teva generic unit ongoing political turmoil venezuela loss exclusivity specialty segment be hurt company top line do not expect improve trend fourth quarter generic industry be witness significant competitive pricing pressure thereby affect company top line performance increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure industry drug price erosion be third quarter management have warn call erosion accelerate fourth quarter moreover accelerate fda approval additional generic version compete patent medicine lower expect contribution new generic launch increase competition largest product concerta authorize generic also continue hurt sale generic unit meanwhile specialty segment loss exclusivity key drug copaxone azilect nuvigil hurt sale sale teva blockbuster multiple sclerosis ms treatment copaxone continue erode due generic competition glatopa generic version copaxone mg have be market june october major blow teva mylan myl free report launch risk generic version mg formulation much earlier expect mylan also launch version mg formulation october entry generic version mg formulation entry second generic version mg formulation copaxone sale be expect erode rapidly teva have previously estimate negative impact least cent share fourth quarter earning meanwhile generic version azilect be launch unite state january sale have start decline sharply proair also lose exclusivity unite state fourth quarter sale be likely be lower combat rapid decline sale last month teva announce restructure plan see more company global workforce be layer next year majority expect management then provide quite few detail plan be execute expect update upcoming conference call also november teva have announce new organizational leadership structure save cost increase productivity include departure head division company have also say then longer have separate global group business generic specialty medicine instead teva now operate region north america europe growth market include generic specialty counter otc medicine update progress make new strategy so far be expect call earning whispersour proven model do not conclusively show teva be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand cent share zack consensus estimate be peg higher cent share uncover best stock buy sell re report earning esp filter zack rank teva have zack rank sell caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be other drug biotech stock have right combination element beat earning time alexion pharmaceutical inc alxn free report earning esp zack rank company be schedule release result feb puma biotechnology inc pbyi free report earning esp zack rank company be expect release result later month see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1324,MYL,teva pharmaceutical industry ltd teva free report announce have complete divestment global woman health business privately hold private equity firm cvc capital partner deal be close cash divest portfolio include product contraception fertility menopause osteoporosis category drug portfolio include ovaleap zoely seasonique colpotrophine actonel be sell outside unite state product now be sell theramex woman health unit previously hold teva sale be part teva plan divestment specialty product woman health remind investor teva have sign definitive agreement sale cvc capital partner september moreover company also sign definitive agreement foundation consumer healthcare sale plan step brand emergency contraception cvc capital partner have appoint anish mehta former head international business development allergan agn free report theramex chief executive officer separate sec filing teva report have enter settlement agreement allergan jointly dismiss work capital dispute arbitration allergan pay teva part settlement teva share rise feb follow news however share company have decline past year underperform industry decline teva decline be attribute industry pressure generic competition blockbuster drug copaxone massive debt load teva also suffer setback october mylan myl free report launch generic version mg formulation copaxone much earlier expect order combat challenge teva have divest core asset cut significant debt load aim cut global workforce more next year teva pharmaceutical industry limit price teva pharmaceutical industry limit price teva pharmaceutical industry limit quotezack rank stock considerteva carry zack rank sell zoetis inc zts free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here zoetis earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1325,MYL,momenta pharmaceutical inc mnta free report announce fda classify outcome fourth quarter reinspection pfizer inc pfe free report mcpherson facility voluntary action indicated vai glatopa mg ml be approve fda glatopa mg ml be first ap rate substitutable generic equivalent once daily copaxone generic be develop be be commercialize collaboration sandoz ag sandoz generic arm novartis pharma ag nvs free report collaboration agreement sandoz be responsible glatopa mg ml momenta earn contractually defined profit drug sale sandoz abbreviated new drug application anda mg thrice weekly formulation copaxone glatopa mg be fda review however momenta suffer setback fda issue warning letter pfizer february be sandoz contract fill finish manufacturing partner glatopa anda glatopa remain regulatory review momenta believe application review be complete time connection change vai status news bring breath fresh air investor company share go momenta stock have lose year underperform industry rally nevertheless announce change compliance status mcpherson kansa facility amend vai momenta expect gain marketing approval subsequently launch glatopa mg first half momenta have have rough time mylan nv myl free report obtain fda approval generic version copaxone mg make first generic be approve be huge setback momenta mylan launch copaxone mg copaxone mg product company expect revenue glatopa be adversely impact due decline price volume moreover be additional pressure market customer switch mg product mg product company also suffer blow regard development biosimilar candidate candidate do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity reference drug orencia normal healthy volunteer hence momenta partner mylan evaluate next course action zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1326,MYL,teva pharmaceutical industry limit teva free report announce phase iii study evaluate subcutaneous formulation asthma injection cinqair reslizumab do not meet primary endpoint cinqair be already available market intravenous formulation treat patient severe asthma elevated blood eosinophil phase iii registration study evaluate subcutaneously administer reslizumab fix dose mg pre filled syringe patient uncontrolled asthma elevated blood eosinophil top line result study show reslizumab be unsuccessful significantly reduce frequency clinical asthma exacerbation caes thereby fail meet primary endpoint other phase iii claim support study evaluate subcutaneous dose option patient oral corticosteroid ocs dependent asthma here too reslizumab fail meet primary endpoint reduction daily ocs dose teva state determine subsequent course action full review datum teva share have slump past year compare industry decline teva be face significant challenge form generic competition largest brand drug copaxone new competition brand product pricing erosion generic business lower expect contribution generic launch massive debt load generic industry be face significant competitive pricing pressure be hurt company top line teva blockbuster multiple sclerosis drug copaxone sale have be decline quite time now october major blow teva mylan myl free report launch risk generic version mg formulation much earlier expect meanwhile glatopa generic version copaxone mg be market momenta sandoz novartis nvs free report generic arm mylan also launch version mg formulation october entry generic version mg formulation second generic version mg formulation copaxone sale be expect erode rapidly additionally company debt burden increase result acquisition allergan agn free report generic unit allergan generic nearly debt company borrow cost have increase significantly be hurt profit order combat challenge teva have divest core asset cut significant debt load aim cut global workforce more next year however clear path growth be not visible effort not prove enough revive company fortune challenge period especially face erosion largest product copaxone teva carry zack rank sell see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1327,MYL,teva pharmaceutical industry ltd teva free report announce fda have approve label expansion trisenox injection include first line treatment acute promyelocytic leukemia apl patient combination tretinoin eligible apl patient have translocation pml rar alpha gene expression trisenox be currently approve similar indication patient be refractory relapse retinoid anthracycline chemotherapy drug be already approve eu first line second line treatment indication teva share have decline past year underperform industry decline period accord company trisenox combination retinoic acid increase survival rate dramatically reduce risk relapse help avoid chemotherapy related side effect low intermediate risk apl patient have be see clinical study trisenox combination retinoic acid lead overall survival rate almost relapse more year month median follow teva oncology portfolio include drug perform well third quarter register year year growth reach label expansion trisenox be expect further boost portfolio performance come quarters however teva be face headwind due pricing pressure generic industry also approval mylan myl free report generic version key drug copaxone october last year have negative impact fourth quarter revenue guidance moreover israeli firm be also face huge debt load swell acquisition allergan agn free report generic division bid get rid problem company bring new chief executive officer ceo kare schultz have play instrumental role turnaround denmark lundbeck be struggle string loss also work chief operate officer denmark base drug giant nordisk nvo free report new ceo announce restructure plan december order reduce cost improve business performance profitability cash flow generation productivity teva have announce cut job cut more company global workforce next year majority expect company also shut many office facility globe divest asset move be expect reduce cost base estimate end teva pharmaceutical industry limit price teva pharmaceutical industry limit price teva pharmaceutical industry limit quotezack rankteva carry zack rank sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1328,MYL,allergan plc agn free report announce weaker expect sale outlook face potential loss exclusivity key product allergan expect total sale range approximately fall short zack consensus estimate meanwhile company say expect adjust earning least share not directly comparable earning projection also appear short zack consensus estimate share allergan be face potential loss exclusivity several key product include alzheimer treatment namenda xr blockbuster dry eye drug restasis latest press release company say expect generic version namenda xr be launch early first quarter restasis allergan second best selling drug be not expect be launch prior second quarter remind investor october texas federal district court invalidate patent cover restasis patent loss open door early generic competition restasis patent be schedule expire august please note generic version restasis have be approve yet also remind investor third quarter earning call allergan have say generic version restasis be launch mid adjust earning share be less also company say generic enter market jan adjust earning share be more share also year allergan face loss patent exclusivity estrace vaginal cream ulcerative colitis drug delzicol december last year mylan myl free report launch first generic version estrace cream generic version delzicol be expect be launch early second quarter last week allergan regulatory filing announce be layer employee part cost save restructure program latest press release allergan say cost reduction effort reduce operate expense also new competition key growth driver restasis linzess be investor concern shire shpg free report dry eye disease drug xiidra launch last year be pose strong competition restasis meanwhile synergy pharmaceutical inc sgyp free report trulance plecanatide be launch last year chronic idiopathic constipation competition allergan linzess past year allergan share have decline compare industry sdecline allergan also provide other update issue outlook company say impact tax reform be broadly neutral adjust effective tax rate time moderate increase rate level allergan guide adjust tax rate approximately new share buyback plan announce september last year allergan say have already buy back approximately authorize amount month end december also company say plan sell remain stake teva security year allergan carry zack rank sell seethe complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1329,MYL,momenta pharmaceutical inc mnta free report report positive top line datum pipeline candidate phase single ascend dose sad multiple ascend dose mad study normal human volunteer phase randomize double blind placebo controlled study evaluate safety tolerability pharmacokinetic pharmacodynamic be fully human neonatal fc receptor fcrn aglycosylate immunoglobulin igg monoclonal antibody engineer reduce circulate pathogenic igg antibody excess achieve current treatment completely block endogenous igg recycling fcrn candidate do not exhibit adverse event be well tolerate decrease circulate igg level mean reduction day mad study addition sad portion study enrolled cohort total healthy adult volunteer show single dose achieve reduction circulate igg antibody remind investor momenta plan present top line result future conference momenta novel therapeutic portfolio have pipeline candidate meanwhile company be also try hard bring biosimilar market last week momenta partner mylan myl free report announce company initiate patient clinical trial propose biosimilar regeneron pharmaceutical regn free report eylea first half commercial opportunity be significant company have collaborate mylan develop manufacture commercialize current biosimilar candidate momenta mylan have enter agreement develop manufacture commercialize momenta biosimilar candidate include propose biosimilar orencia concurrent third quarter earning momenta announce do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer momenta stock have increase last month industry loss momenta have have rough ride late company suffer setback mylan win fda approval generic version teva pharmaceutical teva copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity other hand momenta anda approval be contingent satisfactory resolution compliance observation state warning letter issue fda result delay approval zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1330,MYL,biosimilar space be focus key fda approval biosimilar contain version active substance already approve original biological drug development biosimilar be technically more challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same be highly lucrative acceleration approval biosimilar market have thus attract lot many player be witness rapid growth here go progress report merck co inc mrk free report launch reneflexis biosimilar version remicade infliximab unite state july approval april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold see complete list today zack rank strong buy stock here remicade have be see intense competition biosimilar space late note pfizer inc pfe free report supply inflectra biosimilar version remicade pfizer be strong player biosimilar market december pfizer get fda approval remicade biosimilar ixifi treatment rheumatoid arthritis crohn disease pediatric crohn disease ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis company have portfolio market biosimilar medicine outside unite state include inflectra retacrit epoetin zeta nivestim filgrastim strong pipeline distinct biosimilar molecule various stage development pfizer currently carry zack rank generic leader mylan nv myl free report be also explore biosimilar market have potential grow early last december mylan partner biocon ltd announce fda approval ogivri trastuzumab dkst biosimilar version herceptin trastuzumab ogivri have be approve indication include label reference product herceptin include treatment overexpressing breast cancer metastatic stomach cancer ogivri be first fda approve biosimilar herceptin first biosimilar mylan biocon joint portfolio mylan currently carry zack rank meanwhile amgen inc amgn free report allergan plc agn free report win fda approval biosimilar version avastin september treatment multiple type cancer note mvasi be first biosimilar approve unite state treatment cancer amgen biosimilar version humir amjevita be already approve fda be launch unite state jan company resolve litigation abbvie inc abbv free report company have also submit bla fda abp biosimilar candidate herceptin july note company be collaborate oncology biosimilar include abp be second be submit fda approval company also submit marketing authorization application european medicine agency candidate note amgen have total biosimilar pipeline have be approve fda amgen currently carry zack rank boehringer ingelheim cyltezo adalimumab adbm biosimilar humira be also approve fda august medical generic drug industry yr return medical generic drug industry yr slew fda approval expect investor remain focuse space future zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1331,MYL,week have be pretty slow key announcement include allergan agn free report job cut announcement pfizer pfe free report collaboration agreement company sangamo arvina recap week most important storiesallergan announce job cut time announce third quarter result november allergan have say have look cost reduction order deal impact loss exclusivity loe key product include restasis week company announce cost cut restructure program lead elimination more currently filled position primarily commercial other function open position also be eliminate restructure cost primarily due severance be record mostly fourth quarter overall operate expense saving expect range compare company expect achieve additional cost reduction headcount spending rationalization read more allergan cut job loss exclusivity key drug pfizer protein degradation deal arvina pfizer have agree shell private biotech company arvina be focuse create new class drug base protein degradation company announce research collaboration license agreement discovery development drug candidate used arvina proprietary protac proteolysis target chimera platform novel technology be used creation small molecule therapeutic aim degrading disease cause cellular protein multus year agreement cover different therapeutic area see arvina drive discovery effort pfizer be responsible clinical development product result collaboration cover upfront milestone payment depend achievement specify preclinical clinical commercial milestone deal term include tiered royalty well protein degradation be area have be attract interest large cap company arvina have agreement roche rhhby free report well pfizer sangamo sign collaboration agreement pfizer have sign collaboration agreement sangamo development potential gene therapy used zinc finger protein transcription factor zfp tfs treatment amyotrophic lateral sclerosis al frontotemporal lobar degeneration ftld link mutation orf gene agreement see pfizer shell upfront payment well milestone payment worth tiered royalty net sale sangamo be responsible development zfp tf candidate pfizer be operationally financially responsible subsequent research development manufacturing orf zfp tf program other result product sangamo pfizer already have collaboration agreement be announce last year development gene therapy product hemophilia include sb read more pfizer collaborate sangamo gene therapy pfizer be zack rank hold stock see complete list today zack rank strong buy stock here company stock be last year compare rally industry belong roche macrogenic ink deal roche clinical stage biopharma company macrogenic be collaborate discovery development innovative monoclonal antibody base therapeutic treatment cancer well several autoimmune disorder infectious disease company respective platform include macrogenic dart platform roche crossmab dutafab technology be used selection bispecific format lead pipeline candidate roche be responsible further development such pipeline candidate deal see roche make upfront payment achievement milestone royalty future sale mylan partner start eylea biosimilar study mylan myl free report partner momenta announce intend start pivotal study propose biosimilar regeneron blockbuster eye drug eylea vascular endothelial growth factor vegf inhibitor eylea be indicated treatment neovascular wet age related macular degeneration macular edema follow retinal vein occlusion diabetic macular edema diabetic retinopathy patient diabetic macular edema study be schedule commence first half patient diabetic macular edema eylea be flagship product regeneron global sale come first month read more momenta mylan initiate trial biosimilar eylea cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock astrazeneca azn free report be last month pfizer be glaxosmithkline gsk free report decline see last pharma stock roundup here roche mnk announce acquisition agreement regulatory update novartis next pharma world watch update outlook be provide several company next week annual morgan healthcare conference zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1332,MYL,allergan plc agn free report regulatory filing announce be layer employee part cost save restructure program protect potential revenue decline allergan say job cut impact employee commercial function revolve product category already face face loss exclusivity allergan also say plan eliminate additional open position company estimate incur cost approximately job cut other cost saving measure be expect save operate cost year also majority cost primarily due severance be record fourth quarter allergan currently employ more person job cut come time allergan be face potential loss exclusivity several key product include alzheimer treatment namenda xr blockbuster dry eye drug restasis be expect hurt sale allergan be adopt different way protect restasis second best selling drug generic competition restasis record sale first month allergan come fire enter agreement saint regis mohawk tribe latter obtain right patent cover restasis allergan be grant exclusive license restasis product lawmaker question unconventional move adopt company protect restasis generic competition deal tribe have raise concern curb generic competition pharmaceutical industry discourage generic drug maker make cheaper version expensive drug however october texas federal district court invalidate patent cover restasis potentially open door early generic competition restasis patent be schedule expire august generic version be launch early mid also year allergan face loss patent exclusivity estrace vaginal cream ulcerative colitis drug delzicol last week mylan myl free report launch first generic version estrace cream also new competition key growth driver restasis linzess be investor concern shire shpg free report dry eye disease drug xiidra launch last year be pose strong competition restasis meanwhile synergy pharmaceutical inc sgyp free report trulance plecanatide be launch last chronic idiopathic constipation competition allergan linzess past year allergan share have decline compare industry decline job cut be aim save dollar time allergan be face competitive generic pressure related highest revenue generate product allergan carry zack rank sell seethe complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1333,MYL,momenta pharmaceutical inc mnta free report mylan myl free report have announce company initiate patient clinical trial propose biosimilar regeneron pharmaceutical regn free report eylea first half trial be randomize double blind active control multus center study patient diabetic macular edema compare safety efficacy immunogenicity reference drug note eylea vascular endothelial growth factor vegf inhibitor have be approve treatment neovascular wet age related macular degeneration macular edema follow retinal vein occlusion diabetic macular edema diabetic retinopathy patient diabetic macular edema sale drug come momenta mylan have enter agreement develop manufacture commercialize momenta biosimilar candidate include propose biosimilar orencia concurrent third quarter earning momenta announce do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer meanwhile potential entry biosimilar impact eylea sale drug be regeneron growth driver share momenta have decline past year compare industry rally momenta have have rough ride late company suffer setback mylan win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity other hand momenta anda approval be contingent satisfactory resolution compliance observation state warning letter issue fda result delay approval currently momenta biosimilar version humira be be evaluate phase iii study patient suffering moderate severe chronic plaque psoriasis zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1334,MYL,teva pharmaceutical industry limit teva free report announce fda have accept biologic license application bla seek approval monoclonal antibody candidate fremanezumab preventive treatment migraine fda grant priority review designation bla decision fda be expect mid teva look launch fremanezumab next year bla submission be support positive datum phase iii study halo program evaluate candidate patient episodic migraine chronic migraine cm fremanezumab be also be evaluate late stage study enforce prevention chronic episodic cluster headache latest press release company also say fda have grant fast track designation fremanezumab prevention cluster headache addition recently phase ii clinical program post traumatic headache have also be initiate meanwhile teva restructure plan announce last week aim lay more global workforce shut plant have result massive protest strike israel employee well country main public sector labor union strike briefly shut ben gurion airport bank stock exchange government office sunday teva be israel biggest employer last month teva new chief executive officer kare schultz announce new organizational leadership structure save cost increase productivity organizational change include departure head division teva share have slump so far year compare industry decline teva be face significant challenge form generic competition largest brand drug copaxone new competition brand product pricing erosion generic business lower expect contribution new generic launch massive debt load generic industry be face significant competitive pricing pressure be hurt company topline meanwhile teva blockbuster multiple sclerosis drug copaxone sale have be decline quite time now october major blow teva mylan myl free report launch risk generic version mg formulation much earlier expect meanwhile glatopa generic version copaxone mg be market momenta sandoz novartis nvs free report generic arm mylan also launch version mg formulation october entry generic version mg formulation entry second generic version mg formulation copaxone sale be expect erode rapidly additionally company debt burden increase result acquisition allergan agn free report generic unit allergan generic nearly debt company borrow cost have increase significantly be hurt profit order combat challenge teva have divest core asset cut significant debt load remain see latest corporate shake plan layoff divesture be enough revive company fortune challenge period especially face erosion largest product copaxone teva carry zack rank sell see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1335,MYL,mylan myl free report announce patent trademark appeal board ptab have instituted parte review ipr proceedings claim orange book list patent patent no respectively patent be own sanofi sny free report lantus insulin glargine injection unit ml remind investor mylan new drug application nda insulin glargine vial pen dosage form be active review fda october sanofi initiate patent infringement litigation mylan nda unite state district court district new jersey allege violation patent suit inclusive lantus patent lantus lantus solostar be approve improve glycemic control adult patient diabetes mellitus sanofi diabetes franchise seem highly weigh key product lantus face tremendous competitive pressure payor level well other biosimilar several european market japan moreover biosimilar version lantus have hit market last december meanwhile share mylan have rally so far year outperform industry decline period mylan be lead generic drug company term total new prescription company pursuit first file opportunity help maintain strong position global generic market mylan be also explore world biosimilar market potential grow partnership biocon collaboration momenta pharmaceutical inc mnta free report mabion have aid company develop portfolio biosimilar insulin analog generic product however mylan performance continue be affected ongoing challenge north america third quarter witness fast decline epipen sale thank launch authorize generic well contraction overall epinephrine auto injector market major boost mylan also receive fda approval generic version copaxone mg first filer company enjoy day exclusivity recent fda approval mylan biosimilar version roche holding rhhby free report herceptin also boost company biosimilar portfolio zack rank mylan carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1336,MYL,week company nordisk nvo free report eli lilly company lly free report be news provide regulatory update nordisk gain approval new type ii diabetes drug fda expand label lilly taltz recap week most important storiesnovo nordisk diabetes drug get fda nod nordisk get major boost fda approve company new type ii diabetes drug ozempic ozempic once weekly glp agonist be approve use adjunct diet exercise improve glycemic control adult type ii diabetes mellitus approval come shortly fda advisory panel have vote favor approve drug ozempic enter highly crowd market have be show lead clinically meaningful statistically significant reduction hba compare placebo januvia sitagliptin bydureon exenatide extend release lantus insulin glargine ozempic be also associate weight loss ozempic be expect enter market early represent blockbuster potential read more nordisk semaglutide get fda approval diabetes positive datum abbvie imbruvica rituxan combo wm johnson johnson jnj free report partner abbvie present datum combination btk inhibitor imbruvica rituxan treatment newly previously treat patient waldenstrm wm primary endpoint progression free survival pfs be achieve late stage study imbruvica be approve different indication include chronic lymphocytic leukemia previously treat mantle cell lymphoma wm well chronic graft versus host disease read more abbvie imbruvica succeed combo study rituxan be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong sanofi present toujeo head head datum end vaccine development sanofi sny free report present positive datum toujeo head head study versus insulin degludec effect toujeo blood sugar level be find be similar insulin degludec read more sanofi toujeo meet key objective head head study sanofi also announce have decide end development clostridium vaccine base plan interim analysis show chance vaccine meeting primary endpoint late stage study be low be latest blow company vaccine segment be face issue dengue vaccine dengvaxia due safety concern earlier week philippine fda ask company suspend sale distribution marketing dengvaxia withdraw market pending compliance directive agency second indication approve lilly taltz lilly taltz ixekizumab gain fda approval second indication agency give nod use drug treatment adult active psoriatic arthritis psa taltz be initially approve treatment adult patient moderate severe plaque psoriasis be candidate systemic therapy phototherapy taltz work specifically target il protein play role drive underlie inflammation psoriasis read more lilly taltz get approval label expansion fda nod first herceptin biosimilar fda grant approval mylan myl free report biocon biosimilar version roche rhhby free report blockbuster cancer drug herceptin trastuzumab remind investor earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar ogivri have be approve indication reference product herceptin include treatment positive breast gastric cancer cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock lilly be bristol myer decline last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here pfizer merck kgaa drug fail study teva ceo announce change next pharma world watch regulatory pipeline news pharma stock several company be present annual meeting american society hematology ash december datum approve pipeline drug wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1337,MYL,mylan myl free report india base partner biocon announce fda have approve biosimilar version roche rhhby free report herceptin trastuzumab biosimilar be available tradename ogivri include indication herceptin label include positive breast cancer metastatic stomach cancer mylan be also seek approval herceptin biosimilar europe company announce acceptance marketing authorization application maa biosimilar friday european medicine agency ema maa be look get approval biosimilar amgen inc amgn free report neutropenia drug neulasta however fda have issue complete response letter biologic license application seek approval biosimilar version neulasta unite state meanwhile amazon be explore option pharmaceutical segment report cnbc amazon first focus distribute generic be reportedly preliminary talk generic maker mylan sandoz novartis nvs free report generic arm mylan share be friday rumour amazon plan enter pharmacy segment meanwhile share company have decline so far year outperform industry fall period ogivri be first approve biosimilar herceptin unite state earlier march mylan receive global license trastuzumab product roche allow commercialize biosimilar worldwide mylan be already lead supplier cancer medication company supply network help ogivri reach patient quickly boost prospect potential approval europe provide further boost separate press release mylan announce fda have approve generic version blood thinner heparin mylan be focuse develop generic biosimilar popular drug biosimilar portfolio press release mylan currently have abbreviated new drug application review represent annual brand sale mylan price mylan price mylan quotemylan carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1338,MYL,week speculation cvs health cvs free report announce decision acquire aetna aet free report nation lead diversify health care benefit company cash stock deal see aetna shareholder receive share cash cvs health share aetna share aetna be value approximately share include assumption aetna debt news possible merger pharmacy giant health insurer have surface late october wall street journal report company be talk cvs propose pay more share acquisition deal slate go second half company be look change healthcare landscape announcement come time insurer be pressure cut medical cost company cvs be face prospect fierce competition especially give rumor tech giant amazon com amzn free report plan entry space low visibility amazon expect enter market potential entry pose major threat retail pharmacy chain cvs merge aetna cvs be able strengthen position pharmacy benefit management pbm business wider coverage pharmacy benefit manager pbms provide wide range service include formulary management medicare part service mail order specialty pharmacy infusion service retail pharmacy network management service prescription management system clinical service disease management service medical spend management key responsibility be negotiation price drugmaker look additional rebate discount so lower pocket cost consumer formulary coverage exclusion list be issue pbms keep consumer aware drug be cover extra pocket cost be incur client include insurance company focus be provide drug be beneficial well cost effective merge aetna cvs be able expand coverage full ambit healthcare include medical benefit space combine company be also expect be better position negotiate discount drug manufacturer moreover aetna insurance plan help boost coverage diversify cvs business combine company be well position meet health need many more person especially american chronic condition account more health care cost moreover cvs pharmacy location add additional product service include space wellness clinical pharmacy service vision hearing nutrition beauty medical equipment post merger cvs find positon integrate retailer pharmacy benefit manager health plan provider next late insurer pbms have be come together especially keep mind unitedhealth optumrx combination give change healthcare scenario demand more transparency drug pricing be concern be more such merger round corner meanwhile eye be focuse amazon plan enter healthcare sector just last week cnbc report say amazon be preliminary discussion generic drugmaker include mylan myl free report novartis generic arm sandoz enter pharmacy market have also be news amazon have obtain wholesale distribution license pharmaceutical board certain state not much information be available be lot speculation discussion industry watcher way tech giant be plan enter market drug wholesaler retailer cvs aetna be zack rank hold stock see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1339,MYL,year world aids day be celebrate dec raise public awareness acquire immuno deficiency syndrome popularly know aids day be observed make person aware proper cure prevention disease regard year theme day year be right health day also commemorate have die aids related illness world aids day be official global public health campaign marked world health organization accord globally person be suffering hiv aids end total be child less year old aids be pandemic disease cause due infection human virus hiv virus weaken immune system destroy cell fight disease infection eventually lead aids medicine treatment hiv be call antiretroviral therapy art slow put check progression virus currently company be investigate new medicine treat prevent ultimately cure hiv scientist also be explore new treatment paradigm drug regimen make therapy drug drug improve long term safety profile new mechanism action improve medical understand hiv significant effort make lead government medical body prevent treat hiv aids disease still have limit treatment option person die aids related illness totale start epidemic base statistic be not surprising several healthcare company be investing significant amount expenditure develop treatment device hiv aids stock watch world aids day here be key pharma company hiv market investor rely glaxosmithkline gsk free report have long standing commitment hiv aids company have develop widely used antibiotic amoxycillin year be first medicine approve treat hiv sale older hiv product epzicom selzentry have be decline however newer hiv drug triumeq tivicay be witness consistent increase sale gain market share meanwhile significant portion expenditure be be used develop hiv medicine treat prevent hiv last week glaxo partner johnson johnson announce fda approval juluca combination glaxo edurant dolutegravir tivicay rilpivirine single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen week viiv healthcare hiv company majorly own glaxo pfizer pfe free report announce start large late stage african study evaluate long act prevention hiv sexually active woman approve cabotegravir injection be administer month opposed presently available oral retroviral medication need be take day already viiv healthcare have start conduct hptn study cabotegravirin hiv uninfected man transgender woman have sex man co funding national institute allergy infectious disease niaid meanwhile cabotegraviris also be evaluate late stage study drug regimen withedurant third study initiation announce earlier week furthermore glaxo be develop drug regimen ofdolutegravir lamivudine gilead gild free report be dominant player hiv market impressive portfolio fact gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya happen be bestseller surpass truvada atripla fourth quarter currently gilead bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be also review eu company work develop hiv drug be johnson johnson jnj free report company partner glaxo recently receive fda approval first drug regimen juluca discuss further company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine be safe be able reduce incidence hiv infection woman sub saharan africa hiv have significant unmet need woman girl account person live hiv eastern southern africa otherssome other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress mylan myl free report also recently receive tentative fda approval combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate meanwhile merck be develop investigational nucleoside reverse transcriptase inhibitor doravirine single entity tablet combination fix dose tablet other antiretroviral agent lamivudine tenofovir disoproxil fumarate tdf company plan file regulatory application same end conclusionaid hiv be life threaten disease have limit medical cure however be numerous company be develop drug treatment care person suffering hiv be risk become infected hiv thereby make space competitive johnson johnson sport zack rank strong buy glaxo gilead carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1340,MYL,be major news cancer space week failure pfizer inc pfe free report bavencio gastric cancer study setback eisai co ltd esaly free report national institute health care excellence nice do not recommend approval breast cancer drug halaven use second line set uk meanwhile astrazeneca azn free report filing label expansion tagrisso first line set treat lung cancer be accept european medicine agency ema apart bristol myer bmy free report blockbuster drug opdivo again prove worth achieve superior overall survival os phase iii lung cancer study moreover celldex therapeutic inc cldx free report also announce initiation phase study new oncology candidate cdx solid tumor recap week most important storiespfizer bavencio fail gastric cancer study pfizer germany base partner merck kgaa announce failure phase iii study evaluate key pipeline candidate bavencio avelumab treatment gastric cancer third line set study javelin gastric evaluate bavencio monotherapy patient unresectable recurrent metastatic gastric junction adenocarcinoma disease have progressed follow prior therapeutic regimen however study javelin gastric continue evaluate drug first line switch maintenance set read more pfizer merck kgaa bavencio fail gastric cancer study pfizer inc price pfizer inc price pfizer inc quoteeisai halaven suffer setback uk eisai announce nice do not recommend approval halaven uk second line set treat locally advanced metastatic breast cancer have receive chemotherapy approval have give competitive advantage drug drug be already approve uk third later line set same indication eisai co price eisai co price eisai co quotebristol myer opdivo superior lung cancer study bristol myer pd immune checkpoint inhibitor opdivo achieve superior os compare docetaxel phase iii study study checkmate evaluate drug previously treat advanced metastatic small cell lung cancer study be conduct mainly chinese patient achieve primary endpoint os earlier expect company biologic license application file basis positive result study have be accept china food drug administration bristol myer squibb company price bristol myer squibb company price bristol myer squibb company week ema accept mylan myl free report marketing authorization application biosimilar roche rhhby free report breast gastric cancer drug herceptin amgen neutropenia drug neulasta medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1341,MYL,report tech giant amazon meeting generic drugmaker make round company pfizer pfe free report teva pharmaceutical industry ltd teva free report be news former report late stage datum latter announce leadership organizational change recap week most important storiesis amazon talk generic drugmaker accord cnbc report tech giant amazon be preliminary discussion generic drugmaker include mylan myl free report novartis generic arm sandoz enter pharmacy market not much information be available be lot speculation discussion industry watcher way tech giant be plan enter market drug wholesaler retailer pfizer merck kgaa bavencio fail late stage study pfizer merck kgaa suffer setback effort expand label checkpoint inhibitor bavencio avelumab therapy fail meet primary endpoint superior overall survival os compare physician choice chemotherapy late stage study be be conduct evaluate bavencio third line treatment unresectable recurrent metastatic gastric junction gej adenocarcinoma patient disease progressed follow prior therapeutic regimen regardless pd expression company continue evaluate bavencio first line switch maintenance set gastric cancer accord information provide company gastric cancer be fifth most common cancer world third most common cause cancer death survival advanced disease be poor usually less year third line set be difficult treat population read more pfizer merck kgaa bavencio fail gastric cancer study leadership organizational change teva teva new ceo have announce change organization well leadership structure company key change be generic specialty medicine segment now operate single segment region north america europe growth market generic specialty organization also be merged global group newly form marketing portfolio function be set change dr michael hayden dr rob koreman dipankar bhattacharjee be exit teva effective dec several new appointment be also announce detailed restructure plan be unveil mid december teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track generic competition copaxone mg be major setback stock teva have lose value year date versus decline record industry mylan biosimilar eu review mylan partner biocon say european medicine agency ema have accept marketing application biosimilar version roche herceptin trastuzumab amgen neulasta pegfilgrastim herceptin be used treatment certain positive breast gastric cancer neulasta be used reduction duration neutropenia low count neutrophil type white blood cell incidence fever associate neutropenia adult patient treat chemotherapy certain type cancer marketing application have be withdraw earlier follow audit be conduct european inspect authority biocon drug product facility biocon say have complete corrective preventive action capas base audit be verify inspection part regulatory review process meanwhile company get response fda regulatory application biosimilar version herceptin december earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar fda be not require do so usually follow recommendation advisory panel partner commence hiv vaccine efficacy study focus world aids day today johnson johnson jnj free report bill melinda gate foundation national institutes health have initiate first efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine efficacy safety reduce incidence hiv infection woman sub saharan africa be significant unmet need vaccine hiv lot progress have be make treat manage disease almost person become infected year develop vaccine hiv have prove be challenge due unique property virus include ability mutate rapidly moreover genetic diversity multiple strain subtype prevalent different part world be additional hurdle note efficacy study evaluate different vaccine candidate be be conduct south africa be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong viiv start late stage study hiv prevention viiv healthcare global specialist hiv company majority own glaxosmithkline gsk free report pfizer shionogi limit shareholder have commence late stage study long act cabotegravir prevention hiv infection sexually active woman study compare cabotegravir injection give month daily oral pre exposure prophylaxis prep emtricitabine tenofovir disoproxil fumarate cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock bristol myer bmy free report be astrazeneca decline last month bristol myer be glaxo decline see last pharma stock roundup here fda approve glaxo hiv drug roche present datum next pharma world watch regulatory pipeline news pharma stock response fda regard approval status mylan biocon biosimilar version roche blockbuster cancer drug herceptin trastuzumab be december nordisk nvo free report key player diabetes market also get know approval status latest type ii diabetes product offer semaglutide month medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1342,MYL,glaxosmithkline plc gsk free report share have decline year so far underperform increase witness industry british pharma consumer giant stock be rise trajectory announcement third quarter result oct call glaxo expressed interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout share decline sharply thereafter earning release share glaxo have decline earning estimate also witness decline past day meanwhile persistent challenge stiff competition genericization pricing pressure slow growth emerge market have be hurt sale pricing pressure competitive dynamic be hurt sale glaxo respiratory franchise particularly older product meanwhile top selling product advair be also expect face generic competition unite state next year further hurt sale mylan myl free report hikma pharmaceutical be look bring generic version advair unite staressale advair be already be adversely impact pricing competitive pressure unite state generic competition europe slowdown sale consumer healthcare segment year due slowdown global growth key consumer category be also concern however not everything be go wrong glaxo newer respiratory hiv drug vaccine be do well continue boost revenue new product generate glaxo pharmaceutical vaccine sale first month go ahead glaxo expect new pharmaceutical vaccine product include contribution shingrix deliver sale annum meanwhile glaxo have make significant progress late stage pipeline think glaxo possess stronger late stage pipeline large cap pharma company be focuse oncology immuno inflammation hiv respiratory therapeutic area company plan terminate partner divest pre clinical clinical program instead allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation recent back back approval new product trelegy ellipta only once daily single inhaler triple therapy copd shingrix vaccine prevention shingle juluca first dual treatment hiv have strengthen glaxo competitive position see glaxo strong pipeline consistent outperformance new hiv drug vaccine new product cost cut bring back track next year glaxo have zack rank hold see complete list today zack rank strong buy stock here large cap pharma stock have decline year be merck co inc mrk free report due several notable pipeline setback year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1343,MYL,have be pretty good year pharma biotech stock fda decision be concern regulatory body have approve novel drug so far easily surpass last year total tally be quite few landmark approval year include approval couple gene base therapy cancer novartis nvs free report kymriah treatment certain pediatric young adult patient form acute lymphoblastic leukemia gilead science gild free report yescarta cell base gene therapy treatment adult patient certain type large cell lymphoma have not respond have relapse least other kind treatment therapy have potential change way look cancer treatment other key approval year include lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month december cardiovascular outcome datum be part amgen pcsk inhibitor label amgen amgn free report be look add cardiovascular outcome datum label pcsk inhibitor repatha fda grant priority review company regulatory application response be december cardiovascular disease be lead cause death world addition datum repatha label boost product sale sale pcsk inhibitor be once consider be worth multus dollar be yet ramp significantly repatha sale first month be amgen continue work payer improve patient access repatha fda allow addition cardiovascular outcome datum label company be position promote repatha ability reduce risk cardiovascular event heart attack stroke amgen share be year date substantially outperform gain record industry belong amgen be zack rank hold stock see complete list today zack rank strong buy stock here fda approve mylan herceptin biosimilar mylan myl free report partner biocon also get response fda biosimilar version roche blockbuster cancer drug herceptin trastuzumab month fda have previously extend target action date biosimilar order review clarificatory information provide company be expect give response december remind investor earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar fda be not require do so usually follow recommendation advisory panel mylan share be year date compare decline record industry belong fda follow advisory panel recommendation nvo diabetes drug nordisk nvo free report key player diabetes market get know approval status latest diabetes product offer semaglutide month once weekly semaglutide be fda review improvement glycemic control adult type ii diabetes fda advisory panel voting favor approval chance gain approval look high nordisk share be year date substantially outperform gain record industry belong christmas cheer aclaris aclaris therapeutic acrs free report be focuse address significant unmet need medical aesthetic dermatology be seek fda approval lead pipeline candidate topical treatment seborrheic keratosis sk accord information provide company person unite state be affected sk common malignant skin tumor current treatment cryosurgery curettage excision be painful invasive timely approval make first fda approve medication treatment sk fda action date be december aclaris share be year date compare rally industry belong valeant eye drop ocular redness review valeant pharmaceutical international inc vrx free report new drug application nda luminesse brimonidine tartrate ophthalmic solution be fda review pdufa action date december topical vasoconstrictor formulation have be develop relieve redness eye due minor eye irritation approve eye drop be first counter otc product be develop brimonidine tartrate treatment ocular redness valeant share be year date compare rally industry belong hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1344,MYL,teva pharmaceutical industry limit teva free report new chief executive officer kare schultz announce new organizational leadership structure save cost increase productivity organizational change include departure head division be effective immediately share teva rise monday however share have slump so far year compare industry decline israeli drugmaker longer have separate global group business generic specialty medicine instead teva now operate region north america europe growth market include generic specialty counter otc medicine generic specialty organization be combine consolidated global unit be head dr hafrun fridriksdottir be now serve president global generic marketing portfolio function have be form take care interface region operation however schultz joined teva nov make mention workforce reduction rumor have be do round lately last week israeli newspaper publish report state teva cut workforce ten percent israeli workforce however company do say be work detailed restructure plan detail be share next month israeli newspaper report also say current head chief scientific officer michael hayden be remove latest press release teva confirm rumor state hayden retire end year dr rob koreman dipankar bhattacharjee head specialty medicine generic medicine group respectively teva also announce top leadership change include michael mcclellan executive vice president chief financial officer effective immediately teva be face significant challenge form generic competition largest brand drug copaxone new competition brand product pricing erosion generic business lower expect contribution new generic launch massive debt load generic industry be face significant competitive pricing pressure affect company top line performance increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure industry challenge generic market be expect continue rest year probably next teva blockbuster multiple sclerosis drug copaxone sale have be decline quite time now last month major blow teva mylan myl free report launch risk generic version mg formulation much earlier expect meanwhile glatopa generic version copaxone mg be market momenta sandoz novartis nvs free report generic arm mylan launch version mg formulation last month entry generic version mg formulation entry second generic version mg formulation copaxone sale be expect erode rapidly additionally company debt burden accrue result acquisition allergan agn free report generic unit allergan generic nearly debt company borrow cost have increase significantly be hurt profit order combat challenge teva have divest core asset cut significant debt load remain see latest corporate shake rumore layoff divesture be enough revive company fortune challenge period especially face erosion largest product copaxone teva carry zack rank strong sell see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1345,MYL,teva pharmaceutical industry limit teva free report report third quarter earning share miss zack consensus estimate share decline year year revenue be line zack consensus estimate sale increase year year exclude impact currency mainly due inclusion extra month revenue actavis acquisition compare third quarter last year teva acquire allergan agn free report generic segment actavis generic also generic distribution business anda inc last year exclude benefit actavis generic acquisition core sale performance be expectation sale quarter be hurt increase pricing erosion volume decline generic unit ongoing political turmoil venezuela loss exclusivity specialty segment quarter segment fourth quarter teva revise segment structure follow actavis acquisition generic segment now include revenue otc business well api business generic medicine segment revenue be year year revenue generic business decline due significant competitive pricing pressure generic industry ongoing consolidation customer generic industry have lead increase price erosion decrease volume consolidation industry have increase ability negotiate lower price generic drug moreover accelerate fda approval additional generic version compete patent medicine increase competition concerta authorize generic also hurt sale european generic revenue be local currency year period be due inclusion month revenue generic business actavis versus month year quarter rest world row generic revenue decline quarter local currency basis sale rise mainly due inclusion revenue actavis api revenue decline otc revenue be local currency term specialty medicine revenue be year period due lower sale central nervous system cns product teva various therapeutic area cns sale decline due lower sale multiple sclerosis drug copaxone teva lead brand product sale respiratory product rise oncology product sale rise woman health business record increase revenue other specialty revenue rise worldwide revenue copaxone decline mainly due lower sale unite state sale decline unite state due lower volume mg formulation negative net pricing effect price increase take january glatopa generic version copaxone mg be be market momenta sandoz novartis nvs free report generic arm mylan myl free report launch version mg formulation last month major blow teva last month mylan also launch generic version mg thrice weekly tw time week formulation much earlier expect mg formulation copaxone account more total copaxone scrip unite state end report quarter ex sale copaxone decline other product azilect sale decline generic version drug be launch unite state year proair rise combine treanda bendeka revenue decline qvar decline other segment distribution other activity record revenue year year segment mainly gain inclusion distribution revenue anda profit declineadjust gross margin contract basis point bps quarter due addition low margin anda distribution business low margin generic medicine specialty medicine segment research development expense decline year period selling marketing expenditure decline year level adjust operate margin decline bps quarter lower cost outlook slashedteva lower sale earning outlook second time year teva now expect revenue range compare expect previously company expect earning band share significantly lower share expect price erosion volume decline generic market lower expect contribution new generic launch unite state accelerate erosion copaxone sale follow earlier expect launch mg generic result guidance cut entry generic version mg formulation second generic version mg formulation teva estimate negative impact least cent share fourth quarter earning higher teva previous assumption cent meanwhile many other filer include momenta be also look get approval generic version mg formulation approve erode sale further teva now expect new product launch contribute revenue compare expect previously takeamid already lower expectation teva disappointing third quarter result slash outlook lead sharp decline share price share decline almost thursday hit week low fact share have slump so far year compare industry decline teva brand drug pipeline be progress decently have also divest core asset mainly woman health business include paragard plan step contraceptive cut significant debt load however not be enough revive company fortune challenge period particularly face erosion largest product copaxone be interesting see new chief executive officer kre schultz guide israel base generic drug maker post turnaround teva carry zack rank strong sell teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1346,MYL,match group inc mtch free report be set report third quarter earning result nov company go public november first earning announcement publicly trade company match group have miss earning estimate succeed quarters prove be slightly better company earning beat estimate twice many miss trail quarters modest average positive surprise last quarter miss estimate however anticipate match group score earning beat be report quarter likely positive surprise proven model show match group have right combination key ingredient stock need have positive earning esp zack rank strong buy buy least hold happen be perfectly case here see zack esp match group have earning esp most accurate estimate cent be peg zack consensus estimate cent uncover best stock buy sell re report earning esp filter zack rank company carry zack rank combine positive esp make reasonably confident earning beat conversely caution stock zack rank sell rate go earning announcement especially company be witness negative estimate revision factor drive better expect resultsmatch group be world foremost provider date product operate portfolio more brand biggest best know brand be match com okcupid tinder company reputation establish user base size be anticipate prove be favorable upcoming earning company revenue come directly user date service north america mostly form membership subscription online date have be expand user more demographic join fray most match group user connect mobile device conversion paid member be also higher last quarter average pmc paid member count rise year year drive solid contribution tinder plentyoffish pair okcupid momentum bode well company top line growth quarter review match group have be reap profit past year record top line growth well company be currently enjoy strong growth drive robust growth momentum tinder solid performance meetic match well recently acquire plentyoffish match group inc price consensus ep surprise match group inc price consensus ep surprise match group inc quotematch group recently rolled tinder gold subscription package be anticipate drive incremental arppu well incremental pmc early result service be very promising benefit result quarter review last quarterly report match group have give revenue projection third quarter range reflect year year growth mid point adjust ebitda quarter however slight delay launch tinder gold globally weaker expect ad revenue growth trend dent company top line quarter further profit be impact due higher investment tinder be also drive higher expect datum cost stock warrant lookhere be company want consider model show have right combination element post earning beat quarter take interactive software inc free report earning esp zack rank be expect release quarterly number nov see complete list today zack rank stock here mylan myl free report earning esp zack rank be slate report result nov caredx inc cdna free report have earning esp zack rank company be likely release earning nov look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1347,MYL,regeneron pharmaceutical inc regn free report be schedule release third quarter result nov open bell last quarter regeneron pharma beat earning expectation company performance have be mixed so far last quarters surpass earning estimate occasion miss overall company have record average positive earning surprise let see thing be shape quarter regeneron stock have lose year date compare industry decline factor influence pharma key growth driver eylea be likely continue contribute company top line growth base strong first half company raise sale guidance eylea regeneron pharma expect eylea net sale grow earlier guidance growth single digit unite state zack consensus estimate drug sale worldwide basis be currently quarter note regeneron pharma have global development agreement bayer ag bayry free report outside unite state eylea product revenue ex eylea sale be record bayer meanwhile regeneron pharma be work expand eylea label additional indication phase iii study panorama be evaluate eylea treatment moderately severe severe proliferative diabetic retinopathy patient dme phase iii study japan be evaluate neovascular glaucoma apart eylea investor remain focuse uptake new drug kevzara dupixent kevzara sarilumab interleukin il receptor monoclonal antibody be approve canada treatment adult patient moderately severely active rheumatoid arthritis have inadequate response intolerance more biologic biologic disease modify rheumatic drug be approve fda fda also approve dupixent dupilumab injection treatment adult moderate severe atopic dermatitis ad initial uptake drug be encourage drug be approve europe also company be also evaluate drug treat asthma adult liberty asthma quest study phase iii study dupixent pediatric patient year age uncontrolled persistent asthma be initiate second quarter hence focus be company performance particularly eylea dupixient uptake third quarter earning call investor be also expect await update company pipeline meanwhile regeneron pharma partner sanofi sny free report be allow continue sell pcsk inhibitor praluent unite state court appeal federal circuit follow favorable ruling bode well expect management throw more light upside however sale drug have fail impress so far earning whispersour proven model do not conclusively show regeneron pharma be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank regeneron pharma currently carry zack rank sell note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc quotestock warrant lookhere be health care stock want consider instead model show have right combination element post earning beat quarter mylan myl free report have earning esp currently carry zack rank company be expect release third quarter result nov see complete list today zack rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1348,MYL,be approach tail end third quarter report cycle result have be strong overall accelerate revenue growth have be particularly impressive number company come positive surprise have be significantly higher revenue surprise trend historical average also estimate revision trend have be mostly favorable nov member accounting index total market capitalization have report result accord earning outlook total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue meanwhile earning growth be currently expect be please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning big biotech pharma company report week pfizer pfe free report allergan agn free report beat earning expectation revenue come line zoetis zts free report beat expectation earning sale pfizer zoetis raise earning guidance allergan increase only upper end earning outlook here have biotech pharma company be set report third quarter result nov let see thing be shape quarter mylan myl free report mylan be schedule release earning market open deliver negative earning surprise last quarter mylan earning have be mixed so far company top earning estimate trail quarters miss same other company deliver average negative earning surprise trail quarters quarter mylan have earning esp zack rank buy indicate likely positive surprise zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter newly launch product acquisition meda renaissance topical business be likely aid top line however sale epipen auto injector be anticipate decline current quarter result increase competition impact authorize generic launch read more be beat card mylan earning season horizon pharma public limit company hznp free report horizon pharma be also schedule announce result open bell earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be last quarter company deliver positive earning surprise company have earning esp zack rank sell zack consensus estimate be peg cent share company expect continue double digit net sale growth ravicti meanwhile horizon pharma primary care business be pressure due implementation new commercial model read more horizon pharma earning disappointment store keryx inc kerx free report keryx be expect report market close last quarter company deliver negative earning surprise keryx performance last quarters have be disappointing company report wider expect loss trail quarters average negative surprise company have earning esp zack rank see complete list today zack rank strong buy stock here zack consensus estimate be peg loss cent share apart license fee keryx top line comprise revenue generate only market product auryxia be approve treat patient suffering chronic kidney disease ckd dialysis company believe recent formulary addition major part provider boost aurexia sale read more expect keryx earning season look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1349,MYL,investor be always look stock be poise beat earning season mylan myl free report be such company firm have earning come pretty soon event be shape quite nicely report be mylan be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface myl report analyst have very recently bump estimate myl give stock zack earning esp head earning season mylan price ep surprise mylan price ep surprise mylan quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give myl have zack rank buy esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead mylan beat be card upcoming report look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1350,MYL,share momenta pharmaceutical inc mnta free report be company report disappointing result phase study be conduct partner mylan myl free report propose biosimilar orencia company also report loss cent share third quarter narrower zack consensus estimate cent report loss be however wider year loss cent mylan price ep surprise mylan price ep surprise mylan quoterevenue quarter come top zack consensus estimate loss however revenue be year quarter momenta stock have decrease year date compare industry rally quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be primarily due higher sale deduction inventory price adjustment owing mylan entry copaxone market deduction reimburse company share glatopa related legal expense sandoz collaborative research development revenue come year quarter increase be due commercial milestone payment earn connection glatopa mg ml however upside sale be partially offset less revenue due termination baxalta collaboration agreement effective dec research development expense be general administrative expense increase outlook updatedmomenta now expect operate expense exclude stock base compensation net collaborative revenue range compare previous guidance guidance also include approximately capital expenditure operate expense third quarter be project momenta expect generate revenue mylan upfront payment quarterly basis pipeline updatesandoz abbreviated new drug application anda mg thrice weekly formulation copaxone glatopa mg be fda review however momenta suffer setback fda issue warning letter pfizer inc pfe free report february be sandoz contract fill finish manufacturing partner glatopa pfizer have submit comprehensive response observation cite warning letter anda approval be now contingent satisfactory resolution compliance observation state warning letter issue pfizer meanwhile momenta continue progress other pipeline candidate currently momenta biosimilar version abbvie inc abbv humira be be evaluate phase iii study patient suffering moderate severe chronic plaque psoriasis move ahead company plan submit candidate approval regulatory body however momenta announce do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer hence momenta partner mylan evaluate next course action furthermore momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody momenta successfully complete phase single ascend dose study healthy volunteer multiple ascend dose portion study be initiate january complete august top line datum be expect fourth quarter takemomenta third quarter result be overshadowed disappointing result phase study propose biosimilar verison orencia momenta have already suffer blow note mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity other hand momenta anda approval glatopa be contingent satisfactory resolution compliance observation state warning letter issue fda result delay approval zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1351,MYL,horizon pharma plc hznp free report be schedule report third quarter result open bell nov last quarter company miss expectation let see thing be shape quarter horizon pharma share have decline year so far underperform industry gain factor likely impact second quarter earning company raise outlook now expect sale range compare earlier estimate horizon pharma be significantly increase investment key growth driver krystexxa project peak sale drive higher demand guidance include assumption lower net average net realize price government health resource service administration final rule drug ceiling price implementation schedule oct company expect continue double digit net sale growth ravicti room additional uptake due recent label expansion drug be also expect be launch europe second half however sale procysbi decline due divestiture european right sale actimmune be project grow low single digit drive year year growth second half meanwhile horizon pharma primary care business be pressure due implementation new commercial model company be team pharmacy benefit manager payer help patient obtain access medicine third quarter earning call focus be performance business unit product actimmune krystexxa earning whispersour proven model do not conclusively show horizon pharma be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be cent zack consensus estimate be currently peg cent uncover best stock buy sell re report earning esp filter zack rank horizon pharma currently carry zack rank sell be sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision horizon pharma plc price ep surprise horizon pharma plc price ep surprise horizon pharma plc quotestock considerhere be health care stock want consider model show have right combination element post earning beat quarter inc agen free report have earning esp zack rank company be schedule release third quarter result nov see complete list today zack rank stock here acadium pharmaceutical inc acad free report have earning esp currently carry zack rank company be expect release third quarter result nov mylan myl free report have earning esp currently carry zack rank company be expect release third quarter result nov note be republish article correct mistake original version publish earlier today thursday november longer be rely zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1352,MYL,sucampo pharmaceutical inc report adjust earning cent share third quarter beating zack consensus estimate cent however report earning be year figure cent total revenue come year quarter surpass zack consensus estimate drive higher amitiza sale unite state japan sucampo have license supply agreement mylan myl free report marketing amitiza japan sucampo share price have decrease year date industry lose quarter detailproduct sale be year year product royalty revenue be year year sale amitiza report takeda pharmaceutical royalty calculation purpose unite state be due strong marketing selling well growth brand market takeda hold global marketing right amitiza outside japan china pay royalty sucampo report mylan amitizia sale increase japan unit volume increase company operational expense ga increase year period due inclusion research development expense related vtesse developmentsin july company file supplemental new drug application snda fda label expansion amitizia include pediatric patient year age suffering functional constipation snda be grant priority review decision expect jan moreover quarter fda grant fast track status cpp sulindac be be develop adult familial adenomatous polyposis guidance raisedsucampo raise guidance full year company now expect total revenue range previously zack consensus estimate be company increase adjust net income guidance range previously adjust earning range previously sucampo pharmaceutical inc price consensus ep surprise sucampo pharmaceutical inc price consensus ep surprise sucampo pharmaceutical inc quotezack rank key pickssucampo carry zack rank hold stock couple better rank stock pharma sector include inc agen free report exelixis inc exel free report stock carry zack rank buy see complete list today zack rank strong buy stock here loss estimate remain stable narrow last day company deliver positive earning surprise trail quarters average beat exelixis earning share estimate remain stable cent increase cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1353,MYL,israel base generic drug maker teva pharmaceutical industry limit teva free report see share decline last week company suffering fresh setback form fda approval generic version company top selling brand drug copaxone multiple sclerosis mylan nv myl free report gain fda approval generic version mg thrice weekly dosage well once daily mg formulation copaxone mylan be first applicant challenge mg patent company enjoy day exclusivity mylan have launch product mylan also gain approval mg dose eu fda approval generic copaxone be major blow teva be currently face whole lot challenge teva issue statement say launch mg formulation final resolution pending patent infringement lawsuit mylan be treat risk launch mean mylan have pay significant damage court uphold patent protect drug copaxone bring total sale first half end second quarter copaxone mg account more total copaxone prescription unite state entry mg formulation entry second generic version mg formulation sandoz momenta have be market quite glatopa generic version mg dose be expect cut teva earning least cent share additional detail be company announce third quarter result november entry generic copaxone just add exist list problem be face teva generic pricing erosion remain huge issue generic company teva sharp decline generic drug price blessing patient be prove be major challenge generic drugmaker well drug distributor consolidation industry have increase ability negotiate lower price generic drug lead increase price erosion decrease volume moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume teva say price erosion be second quarter be expect increase high single digit remainder year headwind persist generic unit future result lower revenue profit segment potentially meanwhile company say do not expect earning contribution business venezuela give significant devaluation venezuelan currency teva also cut dividend teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track company have be work address issue recently announce appointment new ceo read more do teva pharmaceutical stock soar today teva have also make significant progress divestment core business however entry copaxone mg be major setback company well be teva be able get back track teva be zack rank sell stock company have see zack consensus estimate current year earning be revise downward last day zack consensus estimate have be revise downward last day teva have lose value year date versus decline industry teva deal challenge here be look drug company sport strong zack rank look well position celgene corporation celg free report celgene be focuse discovery development innovative therapy treatment cancer inflammatory disease company have several blockbuster product portfolio include revlimid pomalyst otezla celgene have rich promising pipeline well key datum readout line next year celgene zack rank buy stock have gain year date outperform rally industry belong company also have vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential see complete list today zack rank strong buy stock here pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product first half year company paid dividend share buyback shareholder include accelerate share repurchase program pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score amgen amgn free report amgen most well know name biotech industry have presence oncology hematology inflammation nephrology bone health cardiovascular disease market key product include enbrel neulasta aranesp prolium xgeva epogen kyproli repatha blincyto other most product be blockbuster have blockbuster potential amgen have deep pipeline company work bring new product market combat impact potential biosimilar competition mature product franchise company have be return value shareholder form share buyback dividend amgen be also zack rank stock vgm score stock have gain year date outperform rally industry belong vertex pharmaceutical vrtx free report vertex be key player cystic fibrosis cf market company hold strong position market market product orkambi kalydeco vertex be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong ligand pharmaceutical incorporate lgnd free report ligand business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure company be focuse development licensing asset ligand captisol formulation technology have allow enter several licensing deal generate royalty company partner include big name amgen novartis other ligand also have licensing deal base omniab technology ligand recent decision acquire crystal bioscience leader avian genetic generation fully human therapeutic antibody be expect boost company revenue least earning least cent share ligand zack rank stock have gain year date substantially outperform rally industry belong look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1354,MYL,week company allergan agn free report teva teva free report mylan myl free report be limelight mylan teva be news related fda approval mylan generic version teva top selling brand drug copaxone allergan be fire agreement saint regis mohawk tribe restasis recap week most important storiesallergan restasis deal fire allergan deal saint regis mohawk tribe announce early september have come fire lawmaker question unconventional move adopt company protect blockbuster eye drug restasis generic competition term deal allergan transfer patent related restasis tribe be grant exclusive license patent return allergan pay execution agreement well annual royalty restasis be allergan second best selling drug bring sale almost original patent drug active ingredient be set expire allergan file additional patent extend protection lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent fact tribe be filing dismiss ongoing parte review ipr restasis patent base sovereign immunity ipr challenge deal have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug allergan have be ask committee oversight government reform provide certain document information deal oct mylan gain teva loss major development mylan gain fda approval generic version teva top selling brand drug copaxone multiple sclerosis mylan gain approval mg thrice weekly dosage well once daily mg formulation mylan be first applicant challenge mg patent company therefore enjoy day exclusivity formal communication fda regard same be yet come mylan have launch product accord quintilesim brand sale mg mg dose be approximately respectively month end jul mylan also gain approval mg dose eu fda approval generic copaxone be big boost mylan be major blow teva be currently face whole lot challenge teva issue statement say launch mg formulation final resolution pending patent infringement lawsuit mylan be treat risk launch mean mylan have pay significant damage court uphold patent protect drug entry mg formulation entry second generic version mg formulation sandoz momenta have be market quite glatopa generic version mg dose be expect cut teva earning least cent share additional detail be company announce third quarter result november entry generic copaxone just add exist list problem be face teva read more teva share plummet mylan copaxone generic get fda approval nordisk get fda approval fiasp nordisk nvo free report have strong presence diabetes market provide regulatory update diabetes franchise company gain fda approval fiasp fast act mealtime insulin treatment adult diabetes approval process be not exactly company receive complete response letter last year agency have ask additional information related assay immunogenicity clinical pharmacology datum read more nordisk fiasp get fda nod diabetes adult meanwhile european medicine agency ema committee medicinal product human use chmp endorse company plan update eu label tresiba include result devote study show significant reduction risk severe hypoglycemia nordisk be zack rank buy stock see complete list today zack rank strong buy stock here sanofi regeneron score pcsk inhibitor litigation sanofi sny free report partner regeneron get major boost court appeal federal circuit order new trial related amgen claim regard patent pcsk inhibitor court also vacated permanent injunction lawsuit mean sanofi regeneron continue selling pcsk inhibitor praluent unite state favorable court ruling lilly company get positive ruling patent front be eli lilly company lly free report company say patent trial appeal board patent trademark office pto rule favor regard vitamin regimen patent cancer therapy alimta pemetrexed injection patent be upheld alimta be safe generic competition decision have remove overhang share alimta bring sale more dollar first half week lilly also gain fda approval new cancer treatment verzenio use woman hr advanced breast cancer lilly have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain so far week major stock lilly be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here drug get crl label expansion merck bmy drug next pharma world watch usual pipeline regulatory update stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1355,MYL,share teva pharmaceutical industry limit teva free report decline almost wednesday mylan myl free report hour tuesday announce fda approval generic version mg thrice weekly formulation former blockbuster multiple sclerosis drug copaxone fda also approve mylan generic copaxone mg formulation once daily mylan confirm launch mg mg formulation unite state wednesday mylan share be wednesday notably be first generic copaxone mg version have be approve mylan other filer be eligible enjoy exclusivity day generic version mg formulation copaxone glatopa have be market novartis ag nvs free report generic arm sandoz partner momenta pharmaceutical inc mnta free report response launch mylan teva issue press release wednesday say launch mylan resolution various patent appeal be consider risk launch result substantial damage latter remind investor january year district court district delaware invalidate orange book patent copaxone mg teva have appealed decision court appeal federal circuit teva have also appealed same court december parte review decision patent trial appeal board find claim copaxone patent be unpatentable mg thrice weekly formulation copaxone account more total copaxone scrip unite state end second quarter copaxone generate almost worldwide sale first half earlier expect entry generic version copaxone be major setback company second quarter conference call teva have say do not expect generic competition copaxone mg year however company have also mentioned time case more generic version be launch full quarter year hurt earning cent cent share earlier expect launch mylan generic version teva estimate negative impact least cent share fourth quarter earning addition mylan momenta be also look get approval generic version mg thrice weekly formulation copaxone fda approval momenta generic version copaxone have be delay owing manufacturing issue momenta share be almost wednesday be teva have be face tough time be zack rank sell stock year date ytd teva have lose value compare decline industry challenge environment generic business continue deterioration venezuela have be hurt teva sale generic industry be face significant competitive pricing pressure have be affect company top line performance higher fda generic drug approval ongoing customer consolidation have increase competitive pressure industry challenge generic market be expect continue year meanwhile delay launch new generic drug increase competition other be also hurt segment sale new competition brand product high cost base debt load be other wo august teva announce cut dividend see complete list today zack rank strong buy stock here stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1356,MYL,share pepsico inc pep free report gain report third quarter earning share surpass zack consensus estimate mattel inc mat free report share surge company announce joseph euteneuer new chief financial officershare mylan myl free report rally company announce have receive approval food drug administration generic version multiple sclerosis treatment drug copaxone make teva pharmaceutical industry ltd teva office depot inc odp free report share plummet company lower revenue guidance initially
1357,MYL,mylan myl free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session break recent trend company stock be now trading volatile price range past month time frame upside come company win regulator approval generic version teva pharmaceutical multiple sclerosis drug copaxone company have not see estimate revision past month zack consensus estimate current quarter also remain unchanged recent price action be encourage so make sure keep close watch firm future mylan currently have zack rank strong sell earning esp be negative mylan price mylan price mylan quotea better rank stock medical generic drug industry be axogen inc axgn free report currently carry zack rank buy see complete list today zack rank strong buy stock here be myl go predict see other think stock watch massive equifax hack cybersecurity stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1358,MYL,share teva pharmaceutical teva free report open more lower wednesday plunge close week low process struggle israeli pharma firm have face significant pressure reduce debt load be slide once again time brand new competitor indeed big news rocking pharmaceutical world today be mylan myl free report major drugmaker wrapped own chaos past year so have receive fda approval sell generic version teva multiple sclerosis drug copaxone mylan say want quickly introduce slew new generic market effort curb rise drug cost today approval certainly help company top line also be first step new plan contribute mylan ongoing effort regain public trust be embroil epipen price hike scandal share mylan open higher touch nearly month high teva other hand plummet share be now more year mylan have miss approval copaxone generic twice year company management be recently force lower earning forecast due delay launch key drug note morning well fargo analyst say new generic add cent share mylan quarterly earning so long fda grant company day exclusivity period teva new competition have serious consequence copaxone generate more sale second quarter alone ongoing challenge generic business fda approval mylan generic copaxone earning cash flow be likely affected jeffery analyst david steinberg write note copaxone have be strong contributor cash flow last decade grow generic competition franchise have be overhang teva share recent year fresh generic competition mylan only add teva grow list problem past few month israeli firm have be desperately scramble ramp asset effort preserve credit rating cut mount debt complete deal buy allergan agn free report generic division last year teva debt pile swell whopping august same day company report lackluster earning slash full year outlook cut dividend teva ceo yitzhak peterburg say asset sale likely generate least well level be previously forecast now teva remain zack rank hold however company need improve performance own generic unit pare debt quickly want lift share price anytime soon want more stock market analysis author make sure follow ryan_mcqueeney twitter hacker put money portfolio just last month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1359,MYL,mylan myl free report announce fda have approve abbreviated new drug application anda generic version teva pharmaceutical industry limit teva free report multiple sclerosis ms drug copaxone glatiramer acetate mg ml thrice weekly notably be first generic copaxone have be approve fda also approve generic copaxone mg ml once daily mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity accord quintilesim sale copaxone mg ml dose be approximately mg ml dose month period end july hence generic approval be expect provide significant boost mylan moreover approximately individual unite state suffer ms relapse ms news be expect relieve investor mylan stock have fall last month compare industry decline mylan continue face challenge north america uncertain regulatory environment region have lead company defer major launch unite state mylan currently have anda pending fda approval pending anda be potential first file opportunity however company suffer blow fda issue complete response letter anda generic version glaxosmithkline plc gsk free report asthma drug advair diskus advair record sale company believe approval delay persist thereby impact business further company believe increase competition result fda focus accelerate approval third fourth fifth generic also impact sale meanwhile momenta pharmaceutical inc mnta free report sandoz be look get approval generic version glatopa mg mg thrice weekly formulation copaxone momenta sale glatopa mg continue do well have already capture approximately market unite state zack rankmylan currently carry zack rank strong sell see complete list today zack rank strong buy stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1360,MYL,teva pharmaceutical industry ltd teva free report announce reintroduction generic equivalent depo prover contraceptive injection acetate injectable suspension usp mg ml unite state indicated prevention pregnancy reintroduction patient get access additional product market acetate injectable suspension usp mg ml have annual sale approximately unite state accord im datum july notably teva be world largest generic drug company term total new prescription company also enjoy lead position unite state be world largest generic market market share post actavis deal meanwhile global generic market teva command share follow actavis generic acquisition teva have more abbreviated new drug application anda pending fda approval include more first file ftf opportunity exclude unite state company have estimate regulatory filing pending europe growth market go forward teva be plan generic launch globally more sale unite state product launch additionally company intend pursue ftf first market opportunity seek approval complex generic be likely face less competition help company maintain strong position global generic market teva project generate approximately new product however generic market be highly crowd teva face competition player mylan myl free report dr reddy rdy free report sandoz generic arm novartis nvs free report other also pricing erosion generic business continue deterioration venezuela be hurt sale teva lead guidance dividend cut august stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1361,MYL,share mylan myl free report have decline last month compare industry loss here analyze factor lead mylan be global pharmaceutical company well establish generic business well presence specialty pharmaceutical however company continue face challenge due volatility uncertainty world largest pharmaceutical market unite state due pressure accelerate new approval company exist generic product continue consolidation customer base contribution new product launch unite state be lowest second quarter sale epipen continue decline due increase competition impact launch authorize generic recently meridian medical technology pfizer inc pfe free report company manufacture epipen auto injector epipen jr auto injector authorize generic epipen auto injector epipen jr auto injector receive warning letter fda mylan be also explore world biosimilar market have potential grow partnership biocon collaboration momenta mabion have help mylan develop wide portfolio biosimilar insulin analog generic product represent total brand market value more worldwide sale biocon partnership include biosimilar version herceptin neulasta humira avastin enbrel neupogen insulin analog lantus humalog novolog however fda recently notified mylan partner biocon target action date biosimilar version roche holding rhhby free report herceptin trastuzumab have be extend dec decision fda be expect sep fda extend period due review clarificatory information submit agency part application review process meanwhile company effort get advair generic approve suffer blow fda issue complete response letter crl anda generic advair diskus advair record sale thereby represent great potential company do not mention content crl such setback be likely weigh company share moreover fda recently accept novartis ag nvs free report sandoz anda advair potential approval give sandoz edge mylan moreover company believe approval delay persist thereby impact business further company believe increase competition result fda focus accelerate approval third fourth fifth generic impact sale hence expect company face challenge condition ahead zack rankmylan currently carry zack rank strong sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1362,MYL,biosimilar space remain spotlight number regulatory decision be pending generic drug be follow version chemically synthesize molecule biosimilar contain version active substance already approve original biological drug development biosimilar be technically challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same remain highly lucrative acceleration approval biosimilar market have thus attract lot player be witness rapid growth here be few latest development space lead biosimilar space be novartis ag nvs free report generic arm sandoz be strong player biosimilar market market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state company plan launch major oncology immunology biosimilar include biosimilar version rituxan rituximab be approve european commission june market rixathon recently fda accept biologic license application bla propose biosimilar version rituxan august sandoz erelzi biosimilar version amgen inc amgn free report blockbuster drug enbrel gain approval unite state indication erelzi be also approve european commission european medicine agency also accept company marketing authorization application biosimilar version humira adalimumab remicade infliximab review novartis currently carry zack rank hold see complete list today zack rank strong buy stock here generic leader mylan nv myl free report be also explore world biosimilar market have potential grow fda recently notified mylan partner biocon target action date biosimilar version herceptin trastuzumab have be extend dec decision fda be expect sep fda extend review period due review clarificatory information submit agency part application review process note biocon partnership include biosimilar program such biosimilar version herceptin neulasta humira avastin enbrel neupogen insulin analog lantus humalog novolog mylan have collaboration agreement momenta pharmaceutical inc mnta free report develop manufacture commercialize momenta current biosimilar candidate include momenta biosimilar candidate orencia mylan currently carry zack rank strong sell meanwhile amgen allergan plc agn free report have also submit bla fda abp biosimilar candidate herceptin jul note company be collaborate oncology biosimilar include abp be second be submit fda approval company have also submit marketing authorization application european medicine agency candidate earlier note amgen have total biosimilar pipeline have be approve fda march european commission grant marketing authorization amgevita biosimilar version humira available indication company have important event line fda be expect give decision approval abp biosimilar version avastin shortly amgen currently carry zack rank hold last month biotech major biogen inc biib free report announce european commission grant marketing authorization imraldi biosimilar version humira be third tnf biosimilar biogen receive marketing authorization european union follow approval benepali biosimilar enbrel flixabi infliximab biosimilar version remicade biogen currently carry zack rank hold july merck co inc mrk free report launch reneflexis biosimilar version remicade unite state be approve fda april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold medical sector yr return medical sector yr give fact so much be happen space expect investor focus upcoming approval date trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1363,MYL,teva pharmaceutical industry limit teva free report monday announce have hire lundbeck hluyy free report chief kre schultz new ceo appointment end teva more month long search permanent ceo erez vigodman step february year israel base teva have be face tough time challenge environment generic business continue deterioration venezuela have be hurt sale meanwhile delay launch new generic drug fierce competition other be also hurt generic segment sale teva be also face several other challenge form generic competition brand multiple sclerosis drug copaxone key revenue generator new competition brand product high cost base debt load remain be see schultz use year extensive global pharmaceutical experience help world largest generic drugmaker regain lose ground schultz be tasked increase sale reduce debt generic drugmaker be worth mention here schultz joined lundbeck company be struggle due loss patent key drug help company turn backed significant restructure initiative meanwhile huge development teva have once again shift focus generic drug industry be presently face several drug industry generic drug industry have zack industry rank bottom zack industry industry have decline year date ytd significantly less return generic industry be face significant competitive pricing pressure ongoing consolidation customer industry have lead increase price erosion decrease volume consolidation industry have increase ability negotiate lower price generic drug sharp decline generic drug price be prove be major challenge generic drugmaker well drug distributor moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume stock generic pricing erosion expect continue year recommend investor dump biggest name industry include teva tevateva have zack rank strong sell see complete list today zack rank strong buy stock here follow disappointing second quarter result trim view august zack consensus estimate earning decline respectively last day ytd basis teva have lose value compare decline industry mylan myl free report mylan second quarter result be dismal company miss earning sale estimate due challenge generic drug industry cut annual guidance be also disappointing contribution new product launch unite state be lowest second quarter generic maker also see increase competitive pressure exist generic product fda approve more generic accelerate approval ongoing challenge unite state uncertain regulatory environment region have lead company defer major launch include generic advair generic copaxone meanwhile sale mylan key brand product epipen continue decline due increase competition impact launch authorize generic note mylan have be immense pressure august last year company come spotlight increase epipen price draw immense criticism lawmaker consumer common person alike mylan be also rank stock mylan stock have decline year so far earning estimate have decline respectively past day dr reddy laboratory limit rdy free report indian generic drugmaker have zack rank larger peer dr reddy also suffer drug price erosion fierce competitive pressure lower contribution new product launch unite state addition implementation general sale tax gst india be also hurt topline extent dr reddy earning estimate have decline almost respectively past day dr reddy stock have decline year so far conclusionwhile teva share be close monday mylan dr reddy also share positive momentum share rise almost respectively positive share price movement come long time generic maker however relief be probably temporary company have daunting task ahead counter broader market challenge more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1364,MYL,share much malign drugmaker mylan nv myl free report climb thursday justice department announce officially reach settlement company regard epipen lawsuit justice department announce mylan have pay settlement fee medicaid program state end nearly year long lawsuit accuse pharmaceutical company knowingly misclassify epipen product generic order avoid medicaid rebate payment accord lawsuit mylan knowingly bypass medicaid drug rebate program be put place prevent drug maker price gouge brand name single source drug law force pharmaceutical company have complete control drug pay much higher rebate price generic drug come more manufacturer pay much lower rebate fee lawsuit state mylan simply classify epipen product inject epinephrine help treat emergency allergic reaction generic weren fda approve drug equivalent epipen real kicker be lawsuit contend mylan up price epipen product roughly charge much treatment mylan previously confirm company have reach settlement justice department nearly month attorney office massachusett do not make official thursday mylan misclassify brand name drug epipen profit expense medicaid program attorney william weinreb say statement continue root fraud abuse protect integrity medicaid ensure level play field pharmaceutical company pharmaceutical company be also force year corporate integrity agreement see mylan much heavier scrutiny however epipen maker do not confess wrongdoing part settlement say announce settlement last year bring closure matter be right course action mylan stakeholder allow move forward mylan ceo heather bresch say statement course last year have take significant step enhance access epinephrine auto injector include bring solution fast change healthcare landscape launch authorize generic version less half wholesale acquisition cost brand meaningfully expand patient access program member party congress have say settlement be far too low lenient share mylan rise much thursday morning stock still sit only slightly week low share mylan be currently zack rank strong sell seem least investor company be relieve have lawsuit officially simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1365,MYL,wednesday august straight day dow close include straight time high investor be forgive robust bull market heel successful earning season have momentum power anything then cold go everyone president trump retort new threat attack north korea fire fury world have never see market sank negative territory first time almost week likely re look mere idle rhetoric here re not regardless investor foreign policy belief background be yesterday episode be instructional market bull run be completely bullet proof nuke proof also help give insight person fed president be constantly lookout event capable unsettling steady growth ve see quite time serve convenient reminder always be pitfall lurk even seemingly strongest market eye caution always be warrant productivity labor costseconomic datum meanwhile continue muted march positive morning case productivity labor cost report more accommodative result expect preliminary farm business productivity reach growth expect unit labor cost be lower anticipate have be expect analyst revision figure rise today latest account productivity go modestly unch previous quarter read labor cost other hand balloon revision last time morning version result be more datum tracking overall inflation metric consider quarterly labor cost go early be something charge create policy be circle red marker morning earning continuezack rank buy rate wendy co wen free report top earning estimate morning cent cent share quarterly sale soar past expect restaurant comp north america grow more quarter share be trading nearly today pre market generic pharma major mylan myl free report miss expectation top bottom line morning share miss zack consensus revenue come just short have be look yesterday bell disney free report mixed fiscal earning result company beat cent share revenue slightly expect be eclipse announcement entertainment giant be end distribution agreement stream major netflix nflx free report disney plan create own stream service disney pixar film be stream own subscription service include sport content espn franchise novel approach disney shore content future term market doesn share be nearly today pre market longer term perhaps netflix amazon amzn free report other stream model be right way go company mark vickerysenior editorquestion comment article author click here
1366,MYL,mylan myl free report be global pharmaceutical company well establish generic business well presence specialty pharmaceutical company business model include development manufacturing marketing brand generic drug well active pharmaceutical ingredient apis north america europe rest world notably mylan have world largest api operation mylan have be make prudent acquisition inking strategic deal drive long term growth feb company acquire abbott laboratory develop market specialty brand generic business further nov acquire certain female health care business famy care however mylan have be immense pressure aug company face criticism price increase epipen acquisition drug lawmaker consumer common person alike mylan performance have be decent so far have beaten earning estimate trail quarters miss once overall have deliver average positive surprise currently mylan have zack rank sell definitely change follow company earning report be just release have highlighted key stat just reveal announcement mylan price ep surprise mylan price ep surprise mylan quote earning mylan miss earning consensus call ep company report ep revenue revenue too miss expectation mylan post revenue compare consensus estimate key stat challenge north america continue impact performance company also lower guidance pre market trading share be trading disappointing result check back later full mylan earning report later more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1367,MYL,investor be always look stock be poise beat earning season mylan myl free report be such company firm have earning come pretty soon event be shape quite nicely report be mylan be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface myl report fact most accurate estimate current quarter be currently share myl compare broader zack consensus estimate share suggest analyst have very recently bump estimate myl give stock zack earning esp head earning season mylan price ep surprise mylan price ep surprise mylan quote be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give myl have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead mylan beat be card upcoming report look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1368,MYL,be tough week generic drugmaker see share tumble follow release disappointing second quarter result israel base teva pharmaceutical industry limit teva free report teva not only miss earning revenue expectation company also slash outlook announce cut dividend teva share plunge trading session follow release second quarter result reflect concern company business debt burden trigger few analyst downgrade year date ytd teva have lose value versus decline generic pricing environmenta key reason teva dismal performance be generic pricing erosion sharp decline generic drug price blessing patient be prove be major challenge generic drugmaker well drug distributor second quarter conference call teva say ongoing consolidation customer have lead increase price erosion decrease volume consolidation industry have increase ability negotiate lower price generic drug moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume generic drug be basically cheaper version brand drug have go patent teva say price erosion be second quarter be expect increase high single digit remainder year not just teva be affected tough generic pricing environment corporation abc free report report mixed quarter see share decline trading session follow release third quarter fiscal result company mentioned generic deflation remain headwind be yet ease high single digit be quarters generic deflation be expect remain headwind remainder fiscal range situation continue fiscal well cardinal health inc cah free report too mentioned generic drug pricing be material headwind company pharma distribution business fourth quarter fiscal company expect generic deflation mid single digit fiscal stock focusfollow release teva second quarter result company presence generic market see share decline concern company too be affected generic drug pricing environment company mylan nv myl free report lannett company inc lci free report perrigo company plc prgo free report impax laboratory inc be last trading session week investor be focuse mylan second quarter result include company take generic pricing situation impax perrigo also be report result week mylan perrigo impax be zack rank hold stock lannett be zack rank buy stock see complete list today zack rank strong buy stock here medical generic drug industry yr return medical generic drug industry yr returnin view generic price erosion remain headwind remainder year affect margin generic player fda focuse speeding generic drug approval process market continue witness additional competition escalate generic price erosion trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1369,MYL,teva pharmaceutical industry limit teva free report report second quarter earning cent share include equity compensation expense miss zack consensus estimate share year adjust earning be share revenue miss zack consensus estimate sale however increase year year exclude impact currency mainly due inclusion revenue allergan plc agn free report generic segment actavis generic include andateva acquire actavis generic aug also allegan generic distribution business anda inc oct exclude benefit actavis generic acquisition core sale performance be expectation sale quarter be hurt increase pricing erosion generic unit ongoing political turmoil venezuela loss exclusivity specialty segment quarter segment discussionbegin fourth quarter teva revise segment structure follow actavis acquisition generic segment now include revenue otc business well api business generic medicine segment revenue rise mainly attributable inclusion revenue actavis generic business revenue generic business rise due inclusion revenue generic business actavis european generic revenue be local currency year period be due inclusion revenue generic business actavis rest world row generic revenue decline quarter local currency basis sale rise mainly due inclusion revenue actavis api revenue decline otc revenue rise local currency term exclude benefit actavis generic acquisition core sale performance segment be poor due accelerate generic drug price erosion decrease volume meanwhile delay launch new generic drug increase competition other also hurt sale segment generic industry be face significant competitive pricing pressure increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure generic industry drug price erosion be expect accelerate second half year teva say price erosion generic business be expect be high single digit range specialty medicine revenue decline year period due lower sale central nervous system cns oncology product teva various therapeutic area cns sale decline due lower sale multiple sclerosis drug copaxone teva lead brand product sale respiratory product rise oncology product sale decline woman health business record decline revenue other specialty revenue rise worldwide revenue copaxone decline sale decline due lower volume mg formulation be face generic competition negative net pricing effect price increase take january jun novartis ag nvs free report generic arm sandoz launch glatopa once daily generic version mg formulation copaxone ex sale copaxone decline mg thrice weekly tw time week formulation copaxone account more total copaxone scrip end report quarter note teva be face patent challenge mg formulation company mylan myl free report momenta pharmaceutical be look get approval generic version mg thrice weekly formulation copaxone late january teva suffer major setback district court district delaware invalidate orange book patent protect copaxone mg teva intend appeal decision however generic version mg formulation have not be launch yet fda approval momenta generic version copaxone have be delay owing manufacturing issue teva do not expect generic competition copaxone mg year however company say case generic version be launch full quarter year hurt earning cent other product azilect sale decline generic version drug be launch proair decline combine treanda bendeka revenue decline qvar decline other segment distribution other activity record revenue segment mainly gain inclusion distribution revenue anda profit declineadjust gross margin contract basis point bps quarter due addition low margin anda distribution business low margin generic medicine segment gross margin rise specialty segment research development expense increase year period selling marketing expenditure be year level adjust operate margin exclude equity compensation expense decline bps quarter outlook slashedteva slash previously issue sale earning guidance increase price erosion generic market delay generic launch greater instability venezuela market lead cut guidance revenue guidance be cut range earning be expect band much lower share expect previously teva expect continue sale erosion copaxone due increase competition management say venezuelan business be not expect contribute anything earning last quarters dividend cutteva announce cut dividend second quarter cent share cent share paid first quarter taketeva second quarter earning sale be dismal generic industry continue face significant competitive pricing pressure israel base generic drug maker also slash earning sale outlook reflect challenge environment generic business venezuela devaluation generic industry pressure be expect persist management expect lower revenue profit generic potentially major cut dividend help pay debt invest business be big disappointment also company do not provide update new chief executive officer ceo say be process be not go rush teva ceo erez vigodman have step february year teva chief financial officer eyal desheh also retire june share decline thursday hit week low share fact share have slump so far year compare industry sdecline teva carry zack rank hold see complete list today zack rank strong buy stock here teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit price consensus ep surprise teva pharmaceutical industry limit quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1370,MYL,parker hannifin corporation ph free report be schedule report first quarter fiscal result open bell nov last quarter company post eighth consecutive earning beat record positive surprise parker hannifin boast average positive surprise trail quarters let see thing be shape announcement factor considerparker hannifin continue benefit extensive distribution network sell more lucrative mro market robust distribution sale help reach smaller oem believe company strong aftermarket sale be likely raise bottom line margin fiscal first quarter apart parker hannifin revamp strategy cushion global macroeconomic uncertainty have act staple growth driver expect company diversify industrial north america segment continue solid growth trajectory come quarterly result well fact zack consensus estimate segment sale currently be peg reflect growth year year industrial international segment be also project grow year year aerospace segment company have be tepid recent time come result estimate revenue inch year year separately strategy host other consolidation simplification initiative have help parker hannifin garner significant cost saving witness margin expansion report fiscal fourth quarter company adjust segment operate margin expand basis point year year thank concerted restructure activity undertake last few year trend be likely continue soon be report quarter well parker hannifin corporation price consensus ep surprise parker hannifin corporation price consensus ep surprise parker hannifin corporation quotein addition recent clarcor buyout strengthen parker hannifin filtration product suite supplement company recur revenue growth also other bolt acquisition complete past year namely jger automobil technik gmbh jger automotive polska president engineering group limit helac corporation be also likely stoke inorganic growth fiscal first quarter positive parker hannifin diverse geographic presence be expose currency headwind apart sluggishness key natural resource market include oil gas agriculture mining construction equipment hamper company growth addition escalate price core material steel aluminium be expect erode company financial soon be report quarter moreover parker hannifin high restructure charge headwind upcoming result earning whispersour proven model do not conclusively show parker hannifin likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy least hold happen be not case here see zack esp earning esp company be currently peg be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank parker hannifin have zack rank increase predictive power esp need have positive esp be confident earning surprise be note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be company want consider model show have right combination element post earning beat quarter terex corporation tex free report earning esp zack rank be expect release quarterly number nov see complete list today zack rank stock here mylan myl free report earning esp zack rank be slate report result nov scripps network interactive inc have earning esp zack rank company be likely release earning nov wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1371,MYL,mylan myl free report be schedule report third quarter result nov market open company performance have be mixed so far have top earning estimate trail quarters miss other company deliver average negative earning surprise trail quarters last quarter company miss earning estimate let see thing be shape announcement mylan stock have increase year date compare industry decline stock get boost approval generic copaxone mg likely positive surprise proven model show mylan be likely beat estimate quarter have right combination key ingredient zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be peg zack consensus estimate be peg positive esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank mylan currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate combination zack rank positive esp make confident earning beat conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision factor consider second quarter result mylan lower revenue guidance company now expect revenue earlier projection company now project earning range previous project range guidance be lower result expect delay timing certain new key product launch ongoing challenge unite state uncertain regulatory environment have lead company defer major launch unite state include generic advair generic copaxone pricing generic be expect decline mid single digit globally high single digit erosion expect north america nevertheless newly launch product be likely perform well aid top line acquisition meda renaissance topical business continue boost top line generic segment major boost mylan receive fda approval generic version multiple sclerosis ms drug copaxone mg be first generic copaxone have be approve company be first filer also enjoy day exclusivity accord quintilesim sale copaxone mg ml dose be approximately mg ml dose be month period end july however mylan specialty segment epipen be most significant product continue be weak sale epipen auto injector be anticipate continue decline current quarter result increase competition impact authorize generic launch meanwhile company effort get advair generic approve suffer blow fda issue complete response letter anda generic advair diskus fda oncologic drug advisory committee recently unanimously recommend approval biosimilar version roche holding rhhby free report herceptin however anticipate fda goal date set biosimilar user fee act have be defer december september earning call expect investor focus performance epipen newly launch drug progress biosimilar pipeline mylan price ep surprise mylan price ep surprise mylan quotestock considerhere be health care stock want consider model show have right combination element post earning beat quarter inc agen free report have earning esp zack rank company be schedule release third quarter result nov see complete list today zack rank stock here acadium pharmaceutical inc acad free report have earning esp currently carry zack rank company be expect release third quarter result nov wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1372,MYL,teva pharmaceutical industry ltd teva free report be report third quarter earning nov market open last quarter company deliver negative earning surprise generic drug maker share have lose so far year industry witness decrease teva earning have surpass expectation only last quarters meet same miss expectation remain result average negative surprise let see thing be shape announcement factor considera challenge environment generic business continue deterioration venezuela have be hurt teva sale generic industry be face significant competitive pricing pressure have be affect company generic revenue increase fda generic drug approval ongoing customer consolidation be result additional competitive pressure industry challenge generic market be expect hurt sale third quarter well fact conference call management have say drug price erosion accelerate second half year meanwhile delay launch new generic drug increase competition other be also expect hurt segment sale meanwhile specialty segment loss exclusivity key drug copaxone azilect nuvigil hurt sale sale blockbuster multiple sclerosis ms treatment copaxone be likely erode due lower volume mg formulation be face generic competition glatopa generic version copaxone mg have be market june fact earlier month major blow teva mylan myl free report launch generic version mg formulation much earlier expect mylan also launch second generic version copaxone mg formulation once daily generic launch not hurt teva third quarter sale profit teva estimate have negative impact least cent share fourth quarter earning meanwhile low margin anda distribution business low margin generic medicine segment hurt gross margin quarter also last month teva announce appointment kre schultz president chief executive officer ceo thus end more month long search permanent ceo schultz be likely address teva first conference call expect discuss strategy help company regain lose ground earning whispersour proven model do not conclusively show teva be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand share zack consensus estimate be peg higher share uncover best stock buy sell re report earning esp filter zack rank teva have zack rank strong sell caution stock zack rank sell go earning announcement especially company be see negative estimate revision stock considersome stock biotech pharma sector have positive earning esp favorable zack rank be inc agen free report schedule release result nov have earning esp zack rank see complete list today zack rank stock here clovis oncology inc clvs free report schedule release result nov have earning esp zack rank zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1373,MYL,expect flowserve corporation fls free report beat earning third quarter company be schedule release result nov close bell company miss earning last report quarter overall flowserve have average negative surprise trail quarters marked earning beat many miss let see thing be shape announcement factor drive better expect have difficult second quarter earning miss half drag precipitous top line decline owing macroeconomic volatility foreign currency headwind company do not anticipate major turnaround adverse geopolitical environment weak end market expect factor cast shadow upcoming quarterly result well company have be witness acute weakness segment flowserve flow control division fcd witness year year decline revenue prior quarter likely be weak come result well owing part lower original equipment sale americas africa zack consensus estimate fcd segment revenue be report quarter be peg reflect dismal contraction year year likewise engineer product division be project decline year year upcoming result mar soft customer original equipment sale key end market industrial product division sale also likely be hurt low original equipment sale expect segment sale go year year flowserve corporation price consensus ep surprise flowserve corporation price consensus ep surprise flowserve corporation quotehowever company have be witness stabilization core aftermarket activity concern part service repair market return regular maintenance schedule believe company top line third quarter benefit slightly modest natural gas investment north america asia also increase bidding activity desalination space be anticipate bolster sale apart company restructure initiative past few quarters be anticipate prove conducive third quarter result currently company be pursue multus year investment plan be expect result saving initiative help company garner saving second quarter further flowserve be plan trim workforce compare level well shift manufacturing lower cost region believe saving restructure activity boost profit upcoming quarter earning whispersour proven model do not conclusively show flowserve likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy least hold happen be not case here see zack esp earning esp company be currently peg be most accurate estimate be peg cent lower zack consensus estimate cent uncover best stock buy sell re report earning esp filter zack rank flowserve have zack rank increase predictive power esp need have positive esp be confident earning surprise be note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be company want consider model show have right combination element post earning beat quarter terex corporation tex free report earning esp zack rank be expect release quarterly number nov see complete list today zack rank stock here mylan myl free report earning esp zack rank be slate report result nov scripps network interactive inc have earning esp zack rank company be likely release earning nov zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1374,MYL,gopro inc gpro free report be slate release third quarter result close bell nov company have have decent earning history have beaten estimate thrice trail quarters average positive surprise last quarter gopro trump estimate whopping let see thing be shape announcement expect gopro score earning beat be report quarter well likely positive surprise proven model show gopro have right combination key ingredient stock need have positive earning esp zack rank strong buy buy least hold happen be perfectly case here see zack esp gopro have earning esp uncover best stock buy sell re report earning esp filter zack rank company carry zack rank combine positive esp make reasonably confident earning beat conversely caution stock zack rank sell rate go earning announcement especially company be witness negative estimate revision factor considergopro hero camera be enjoy impressive market traction be likely reflect well company quarterly result hero camera be prove be particularly popular china europe also company have be book strong accessory revenue lately be anticipate boost top line quarter review well believe gopro be well poise capitalize fast grow consumer drone market karma karma success be integral part gopro return growth hero camera be likely contribute well quarter top line september gopro raise outlook third quarter emphasize track deliver profit long trail post quarterly earning red be break only once last quarters have originally project revenue quarter gross margin however gopro now anticipate revenue gross margin quarter come higher end previous guidance light several positive development company stock have have great turnaround bourse well past month have appreciate outperform industry average return gopro optimism stem company wide restructure effort include combination program cut cost comprise reduction total workforce shut entertainment division reduction office space effort undoubtedly drive earning quarter higher further gopro second quarter result have be favorably influenced significant reduction operate expense be report quarter profit also likely benefit gopro intensive cost cut restructure measure not surprisingly analyst have become increasingly bullish stock lately company estimate move north sharply past couple month zack consensus estimate narrow loss cent loss penny past day indicate positive analyst sentiment gopro inc price consensus ep surprise gopro inc price consensus ep surprise gopro inc quotestock warrant lookhere be company want consider model show have right combination element post earning beat quarter terex corporation tex free report earning esp zack rank be expect release quarterly number nov see complete list today zack rank stock here mylan myl free report earning esp zack rank be slate report result nov scripps network interactive inc have earning esp zack rank company be likely release earning nov zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1375,MYL,teva pharmaceutical industry limit teva free report announce appointment kre schultz president chief executive officer ceo thus end israeli generic maker more month long search permanent ceo share rise more pre market trading monday schultz now serve president ceo denmark lundbeck joined lundbeck company be struggle due loss patent key drug help company turn have also work chief operate officer denmark base drug giant nordisk nvo free report teva ceo erez vigodman have step february year dr yitzhak peterburg take interim ceo search permanent ceo begin teva chief financial officer eyal desheh also retire june schultz age take peterburg continue serve interim ceo teva have be face tough time be zack rank strong sell stock challenge environment generic business continue deterioration venezuela have be hurt teva sale generic industry be face significant competitive pricing pressure have be affect company top line performance increase fda generic drug approval ongoing customer consolidation have increase competitive pressure industry challenge generic market be expect continue year meanwhile delay launch new generic drug increase competition other be also hurt segment sale management expect lower revenue profit generic unit potentially due generic industry pressure teva be also face several other challenge form generic competition multiple sclerosis drug copaxone key revenue generator new competition brand product high cost base debt load generic version mg formulation copaxone be already market tevais face patent challenge mg thrice weekly formulation copaxone company mylan myl free report momenta pharmaceutical inc mnta free report be look get approval generic version mg thrice weekly formulation copaxone teva miss second quarter earning revenue lower outlook year company share be significantly follow release disappointing result august year date ytd teva have lose value compare decline industry august teva also announce cut dividend critical period teva remain be see schultz use year extensive global pharmaceutical experience help company regain lose ground see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1376,MYL,be quite few important development week eli lilly company lly free report announce be streamline operation cut workforce focus develop new medicine improve cost structure meanwhile novartis nvs free report announce ceo be step recap week most important storieslilly streamline operation cut job lilly announce restructure plan see company streamline operation so focus develop new medicine improve cost structure company be cut job most reduction expect voluntary early retirement program lilly also be close certain site move production larchwood ia animal health manufacturing facility exist plant fort dodge ia research development office bridgewater nj lilly china research development center shanghai china also shut lilly expect generate annualize saving be used improve cost structure new product launch label expansion study streamline program result company incur pre tax charge post tax charge cent share be recognize third fourth quarters cut report earning guidance adjust earning outlook remain unchanged lilly also say streamline effort now expect achieve opex revenue ratio less indicate improvement previous forecast merck buy rigontec immuno oncology focuse deal immune oncology space continue attract interest big pharma player merck mrk free report announce intention acquire rigontec deal worth include upfront payment rigontec expertise lie access retinoic acid inducible gene rig pathway be part innate immune system goal induce immediate long term tumor immunity acquisition add rigontec lead candidate rgt merck pipeline rgt be currently early stage development patient various tumor also read merck opt buy german immuno oncology biotech merck also announce european commission have expand label pd therapy keytruda treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer also read merck keytruda get eu approval bladder cancer bmy opdivo impress rcc study bristol myer squibb company bmy free report have mixed news pd immune checkpoint inhibitor opdivo company say late stage study checkmate evaluate opdivo yervoy be stop early show overall survival os benefit patient previously untreated advanced metastatic renal cell carcinoma rcc follow plan interim analysis independent datum monitoring committee dmc recommend study be stop early combination provide rcc patient new first line treatment option approval indication boost sale significantly be significant unmet need area rcc be most common type kidney cancer adult year survival rate advanced metastatic stage be second set opdivo related news be not so encourage company say partial clinical hold have be place fda opdivo base combination study multiple myeloma fda decide place study partial hold follow identification risk identify combination study evaluate merck keytruda multiple myeloma mylan face month delay herceptin biosimilar decision mylan nv myl free report partner biocon have bit longer get response fda biosimilar version roche blockbuster drug herceptin trastuzumab fda inform mylan be extend target action date month so review clarificatory information submit part application review process result regulatory body now issue response regard approval status biosimilar dec biosimilar version have receive favorable vote july fda oncologic drug advisory committee odac herceptin be approve wide range indication include breast cancer metastatic adjuvant setting novartis ceo retire replacement announce novartis ceo joseph jimenez be step position board director have appoint vasant vas global head drug development chief medical officer successor effective feb also read replace jimenez novartis ceo novartis stock have gain year date outperform rally industry belong novartis be zack rank hold stock see complete list today zack rank strong buy stock here fda issue warning letter pfizer pfizer get warning letter fda regard manufacturing facility meridian medical technology inc brentwood mo letter mention significant violation current good manufacturing practice cgmp requirement combination product company have be accuse fail thoroughly investigate several serious component product failure epipen product manufacture behalf mylan include failure associate patient death severe illness earlier year march meridian medical technology have announce voluntary recall epipen product follow receipt previously disclose report outside unite state failure activate device due potential defect supplier component cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session most major stock record gain astrazeneca azn free report rise bristol myer be last month bristol myer be merck decline see last pharma stock roundup here novartis car drug get fda nod lilly give baricitinib update next pharma world watch usual pipeline regulatory update safety effectiveness glaxosmithkline plc gsk free report shingle vaccine shingrix be review fda vaccine related biological product committee vrbpac sep more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1377,MYL,fda approve novel drug last year have give approval drug so far include august key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential recent landmark approval be novartis kymriah make first gene therapy unite state mark begin new era treatment cancer other serious life threaten disease drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month september fda follow advisory panel vote mylan herceptin biosimilar mylan nv myl free report hear fda soon approval status biosimilar version roche blockbuster drug herceptin trastuzumab company partner biocon ltd get favorable vote fda oncologic drug advisory committee odac july biosimilar herceptin be approve wide range indication include breast cancer metastatic adjuvant setting earlier year mylan have enter global settlement agreement roche genentech hoffmann la roche ltd herceptin trastuzumab mylan get global license exclude japan brazil mexico trastuzumab product mylan well be first launch biosimilar version herceptin unite state approval boost investor sentiment company have lose year date versus decline industry fda advisory panel discuss glaxo pfizer ptc therapeutic few fda advisory panel meeting be schedule month fda vaccine related biological product committee vrbpac be meeting sep discuss safety effectiveness glaxosmithkline plc gsk free report shingrix glaxo be look get live recombinant vaccine approve prevention herpes zoster shingle person be year old shingle common potentially serious condition cause last pain other complication such scarring visual impairment then sep fda odac be meeting discuss supplemental new drug application snda submit pfizer pfe free report cancer drug sutent pfizer be look expand sutent label adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney fda be expect render final decision regard label expansion jan sutent bring sale first half later month sep fda peripheral central nervous system drug advisory committee discuss ptc therapeutic ptct free report new drug application nda translarna ataluren treatment patient due nonsense mutation gene translarna be already approve outside unite state fda be expect give response regard approval status drug oct fda grant approval amgen allergan avastin biosimilar amgen amgn free report allergan be also expect decision fda biosimilar version roche cancer drug avastin bevacizumab company get favorable vote fda advisory panel odac recently chance gain approval fda action date sep look good share amgen have gain year date significantly outperform industry rally merck bristol myer seek label expansionmerck mrk free report be look expand label pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma keytruda be priority review indication response expect sep keytruda bring sale first half be key product merck portfolio be be evaluate wide range indication merck have gain year date versus growth industry bristol myer squibb company bmy free report be also look expand label pd inhibitor opdivo opdivo be priority review use patient hepatocellular carcinoma hcc prior treatment nexavar sorafenib fda be expect give response sep opdivo prioritize brand bristol myer portfolio bring sale first half bristol myer have gain year date versus growth industry fda approve plivensia johnson johnson investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor be fda review response expect sep however early august plivensia fail get support fda arthritis advisory committee safety concern be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person unite state fda be not require do so usually follow advice advisory panel consider safety concern raise panel quite likely agency ask additional information grant approval share have gain year date outperform industry rally neos therapeutic be also await decision month nt amphetamine xr liquid suspension product candidate attention deficit hyperactive disorder adhd approval sep allow company go ahead plan launch product jan zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1378,MYL,mylan myl free report japan base otsuka pharmaceutical sign license agreementto commercialize deltyba delamanid low middle income country include south africa india drug be approve treatment pulmonary multidrug resistant tuberculosis mdr tb adult deltyba be develop be currently market otsuka mylan share have underperform industry so far year company have lose industry lose period agreement otsuka grant exclusive license mylan prioritize access deltyb south africa india agreement also allow company initiate technology transfer plan enable mylan manufacture distribute deltyba additional country otsuka expand commercial presence however financial term be discuss release deltyba be study phase ii trial month combination world health organization recommend optimized background regimen obr datum study show statistically significant placebo moreover deltyba also lower mortality rate patient administer least month datum phase iii study be expect south africa india be highest burden country mdr tb tb hiv co infection be estimate more be more new case mdr tb rifampicin resistant tb country deltyba have be approve drug controller general india registration process be underway south africa deltyba be approve eu japan republic korea hong kong turkey india successful drug country other country receive approval help mylan long run however mylan be face tough year ongoing challenge uncertain regulatory environment region have lead company defer major launch country have also lower annual guidance moreover fda issue complete response letter mylan abbreviated new drug application anda generic version glaxosmithkline gsk free report advair earlier year accept sandoz anda same potential approval sandoz subsidiary novartis ag nvs free report anda hurt mylan also apr mylan receive warning letter fda manufacturing facility india mylan price consensus mylan price consensus mylan quotezack rank stock considermylan have zack rank strong sell better rank stock pharma sector be therapeutic incorporate cort free report carry zack rank buy see complete list today zack rank strong buy stock here earning estimate increase cent cent cent cent last day company deliver average earning beat trail quarters stock be so far year surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1379,MYL,share mylan myl free report have lose almost year so far thereby underperform increase register industry period here analyze factor lead mylan global pharmaceutical company have well establish generic business be know specialty pharmaceutical product note mylan have be immense pressure august company face severe criticism lawmaker consumer common person alike price increase epipen acquisition drug further mylan make headline wrongly classify epipen generic product medicaid drug rebate program imply mylan have be vastly underpay rebate medicaid drug long time have drug be classify brand company recently sign agreement department justice other relator finalize medicaid drug rebate settlement worth announce oct sale epipen continue decline due increase competition impact launch authorize generic adamis pharmaceutical admp free report recently receive fda nod symjepi generic version epipen epipen represent less global revenue less sale north america company effort get generic version glaxosmithkline plc gsk free report asthma drug advair diskus suffer blow fda issue complete response letter anda generic version company do not mention content crl such setback be likely weigh share moreover fda recently accept novartis ag nvs free report sandoz anda advair potential approval give sandoz edge mylan moreover company believe approval delay persist thereby impact business further company believe increase competition result fda focus accelerate approval third fourth fifth generic impact sale meanwhile mylan second quarter result be dismal company miss earning sale estimate due challenge north america cut annual guidance be also disappointing mylan now expect revenue earlier projection company now project earning share range previous project range guidance be lower due expect delay timing certain key new product launch be challenge company due volatility uncertainty world largest pharmaceutical market due pressure accelerate new approval company exist generic product continue consolidation customer base contribution new product launch be lowest second quarter company also see increase competition exist generic product fda approve more generic accelerate approval zack rankmylan currently carry zack rank strong sell see complete list today zack rank stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1380,MYL,investor mylan myl free report need pay close attention stock base move option market lately be august put have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move mylan share be fundamental picture company currently mylan be zack rank strong sell medical generic drug industry rank bottom zack industry rank last day analyst have increase earning estimate current quarter have drop estimate net effect have take zack consensus estimate current quarter share period give way analyst feel mylan right now huge imply volatility mean trade develop often time option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here bartosiak trading netflix nflx earning option check embed video more detail
1381,MYL,mylan myl free report recently announce subsidiary mylan inc mylan specialty have sign agreement department justice doj other relator agreement finalize medicaid drug rebate settlement worth announce oct settlement resolve claim relate classification epipen auto injector epipen jr auto injector purpose medicaid drug rebate program doj want ascertain epipen product be properly classify center medicare medicaid service innovator drug applicable definition medicaid rebate statute drug be subject formula be used calculate rebate medicaid such drug note mylan have be immense pressure aug company come spotlight price increase epipen acquisition drug draw immense criticism lawmaker consumer common person alike further mylan make headline wrongly classify epipen generic product medicaid drug rebate program imply mylan have be vastly underpay rebate medicaid drug long time have drug be classify brand epipen auto injector be classify innovator drug cms mylan acquire product base longstanding written guidance federal government nevertheless settlement provide resolution potential medicaid rebate liability claim federal government well potential claim certain hospital other cover entity participate drug pricing program moreover mylan reclassify epipen auto injector purpose medicaid drug rebate program pay rebate applicable innovator product effective apr mylan stock have fall year date compare industry decline mylan second quarter result be dismal company miss earning sale estimate due challenge north america cut annual guidance be also disappointing ongoing challenge uncertain regulatory environment region have lead company defer major launch guidance include generic version glaxosmithkline inc gsk free report asthma drug advair diskusand generic copaxone meanwhile mylan biologic license application propose biosimilar version roche holding rhhby free report herceptin be currently review fda anticipate fda goal date set biosimilar user fee act be sep expect investor focus same zack rankmylan currently carry zack rank strong sell better rank stock health care sector be gilead science inc gild free report carriesa zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1382,MYL,pharmaceutical stock be limelight week merck mrk free report ceo ken frazier resign president donald trump manufacturing council sector be also news investigation be launch rise price multiple sclerosis ms drug recap week most important storiesbayer novartis teva other face ms drug price probe drug pricing be back news investigation skyrocket price ms drug be launch rep elijah cumming rep peter welch letter have be send company include biogen teva roche novartis nvs free report merck kgaa bayer sanofi request information pricing strategy ms drug letter have also raise issue shadow pricing expensive new drug be launch price exist drug be raise other company follow suit increase price match higher price accord american academy neurology study annual sale ms drug double almost meanwhile information provide national multiple sclerosis society show average wholesale price ms disease modify therapy be shot mylan pay doj settlement mylan myl free report announce agreement have be sign department justice doj relator regard medicaid drug rebate settlement move claim relate classification mylan epipen auto injector epipen jr auto injector purpose medicaid drug rebate program have be resolve epipen be list innovator drug be reclassify mylan say also enter corporate integrity agreement office inspector general department health human service also read do mylan stock surge today broader label astrazeneca merck parp inhibitor fda expand label astrazeneca azn free report merck parp inhibitor lynparza ovarian cancer new tablet formulation be also approve maintenance treatment woman platinum sensitive recurrent ovarian cancer regardless brca mutation status well use third line set brca mutate ovarian cancer approval tablet formulation provide patient convenient dose option take tablet twice daily instead capsule twice daily astrazeneca merck be zack rank hold stock see complete list today zack rank strong buy stock here pfizer get fda nod target cancer drug pfizer pfe free report gain fda approval besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less besponsa approval path include breakthrough therapy designation priority review label come black box warning hepatotoxicity not impact uptake give poor survival rate patient population eu approval besponsa come earlier year june bristol myer opdivo combination disappoint kidney cancer study bristol myer squibb bmy free report opdivo fail meet co primary endpoint late stage study evaluate pd immune checkpoint inhibitor yervoy versus sutent sunitinib intermediate poor risk patient previously untreated advanced metastatic renal cell cancer opdivo yervoy combination meet objective response rate co primary endpoint versus fail show statistical significance progression free survival third co primary endpoint overall survival be yet mature opdivo be approve second line renal cell carcinoma positive datum study have help support label expansion first line set study ongoing overall survival datum hit co primary endpoint support label expansion also read bristol myer opdivo fail kidney cancer trial checkmate bristol myer stock have lose value year date versus gain industry cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock glaxo gsk free report be lilly lose last month be merck decline see last pharma stock roundup here mylan miss perrigo top zynerba plunge study failure next pharmaceutical world watch usual pipeline regulatory update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1383,MYL,similar wise buy decision exit certain underperformer right time help maximize portfolio return selling loser be difficult share price estimate be fall be time get rid security more loss hit portfolio such stock want consider drop be mylan myl free report have witness significant price decline past week have see negative earning estimate revision current quarter current year zack rank strong sell further confirm weakness myl key reason move have be negative trend earning estimate revision full year have see estimate move past day compare upward revision trend have cause consensus estimate trend lower go share month current level also current quarter mylan have see downward estimate revision versus revision opposite direction drag consensus estimate share past day stock also have see pretty dismal trading lately share price have drop past month mylan price consensus mylan price consensus mylan quoteso not be good decision keep stock portfolio anymore least don have long time horizon be still interested health care sector instead consider better rank stock gilead science inc gild free report stock currently hold zack rank buy be better selection time see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1384,MYL,second quarter earning season be draw close most major company have report result week company endo mylan myl free report nordisk perrigo prgo free report present second quarter result recap week most important storiesa look earning result mylan second quarter result be disappointing company miss earning revenue cut outlook also read mylan miss earning sale lower view mylan have push back major product launch reflect ongoing challenge uncertain regulatory environment product launch include generic version advair copaxone escalate price erosion generic market remain major challenge meanwhile mylan get subpoena department justice doj late jul seek information relate opioid manufacture market sell company jan dec mylan have lose value year date versus decline industry perrigo second quarter result be better expect company raise outlook also read perrigo earning sale top view raise nordisk also top earning estimate raise outlook meanwhile endo top earning revenue estimate lower outlook also read endo beat earning sale guidance lower endo stock have lose value year date versus decline industry perrigo be zack rank hold stock see complete list today zack rank strong buy stock here esperion positive mid stage datum esperion espr free report share be positive top line datum study evaluate company bempedoic acid zetia ezetimibe combination lipitor versus placebo patient mid stage triplet oral therapy study meet primary endpoint greater ldl lower compare placebo company intend conduct additional study next year expect file fda approval combination first quarter zynerba plunge star fail shine zynerba see share plunge disappointing mid stage datum company experimental cannabinoid treatment zyn result double blind placebo controlled star study adult epilepsy patient focal seizure show dose zyn fail meet endpoint compare placebo focus have now shift couple more study be conduct zyn osteoarthritis top line datum expect aug fragile syndrome top line datum expect sep valeant get crl eye drop valeant vrx free report report second quarter result week also read valeant beat earning sale line trim view get complete response letter crl fda new drug application nda vyzulta latanoprostene bunod ophthalmic solution company be look gain approval use intraocular pressure lower single agent eye drop patient open angle glaucoma ocular hypertension safety efficacy concern be raise fda crl refer current good manufacturing practice cgmp inspection bausch lomb manufacturing facility tampa fl valeant be work resolve manufacturing quality issue tampa plant be work agency determine path forward cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock bristol myer bmy free report be glaxo lose last month be merck mrk free report decline see last pharma stock roundup here mixed result pfizer bristol myer announce io deal next pharma world watch usual pipeline regulatory update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1385,MYL,mylan myl free report report disappointing second quarter result earning sale miss estimate company also lower guidance share be trading due dismal result mylan stock fall year date compare industry decline company report earning share miss zack consensus estimate be report year quarter second quarter revenue miss zack consensus estimate nevertheless top line record year year growth back acquisition mylan price ep surprise mylan price ep surprise mylan quotequarter company report result segment geographic basis north america europe rest world north america segment third party net sale come due decline sale exist product result lower volume pricing more offset acquisition meda ab sterile topical focuse business renaissance acquisition holding llc sale epipen auto injector decline current quarter due increase competition impact authorize generic launch generic product experience price erosion mid single digit third party net sale europe be propel acquisition meda be partially offset lower volume exist product unfavorable foreign currency translation have impact europe rest world segment third party net sale be fuel meda acquisition moreover net sale exist product increase due higher sale retroviral franchise sale new product higher volume exist product more offset lower pricing foreign currency translation have favorable impact adjust gross margin decline year quarter due lower gross profit sale exist product north america include epipen auto injector partially offset contribution acquire business outlook loweredmylan now expect revenue earlier projection company now project earning range previous project range guidance be lower result expect delay timing certain key new product launch ongoing challenge uncertain regulatory environment region have lead company defer major launch guidance include generic advair generic copaxone pricing generic be expect decline mid single digit globally high single digit erosion expect north america takemylan second quarter result be dismal company miss earning sale estimate due challenge north america pricing continue impact result company project mid single digit price erosion globally decrease guidance be also disappointing company recently suffer few setback mylan receive complete response letter fda regard abbreviated new drug application anda generic version glaxosmithkline plc gsk free report asthma drug advair diskus positive note fda oncologic drug advisory committee recently unanimously recommend approval mylan biosimilar version roche hold ag rhhby free report breast cancer drug herceptin zack rank key pickmylan currently carry zack rank sell better rank stock health care sector be gilead science inc gild free report carriesa zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1386,MYL,straight day dow close include straight time high investor be forgive robust bull market heel successful earning season have momentum power anything then cold go everyone president trump retort new threat attack north korea fire fury world have never see market sank negative territory first time almost week likely re look mere idle rhetoric here re not regardless investor foreign policy belief background be yesterday episode be instructional market bull run be completely bullet proof nuke proof also help give insight person fed president be constantly lookout event capable unsettling steady growth ve see quite time serve convenient reminder always be pitfall lurk even seemingly strongest market eye caution always be warrant productivity labor costseconomic datum meanwhile continue muted march positive morning case productivity labor cost report more accommodative result expect preliminary farm business productivity reach growth expect unit labor cost be lower anticipate have be expect analyst revision figure rise today latest account productivity go modestly unch previous quarter read labor cost other hand balloon revision last time morning version result be more datum tracking overall inflation metric consider quarterly labor cost go early be something charge create policy be circle red marker morning earning continuezack rank buy rate wendy co wen free report top earning estimate morning cent cent share quarterly sale soar past expect restaurant comp north america grow more quarter share be trading nearly today pre market generic pharma major mylan myl free report miss expectation top bottom line morning share miss zack consensus revenue come just short have be look yesterday bell disney free report mixed fiscal earning result company beat cent share revenue slightly expect be eclipse announcement entertainment giant be end distribution agreement stream major netflix nflx free report disney plan create own stream service disney pixar film be stream own subscription service include sport content espn franchise novel approach disney shore content future term market doesn share be nearly today pre market longer term perhaps netflix amazon amzn free report other stream model be right way go company
1387,MYL,mylan myl free report be schedule report second quarter result aug market open company performance have be mixed so far have top earning estimate trail quarters miss once company have deliver average positive surprise trail quarters last quarter company deliver positive earning surprise let see thing be shape announcement note share mylan have gain year date industry dip factor consider first quarter earning call mylan state expect revenue company project earning range share newly launch product be likely perform well aid top line acquisition meda renaissance topical business be anticipate continue boost topline generic segment pricing continue impact result company project mid single digit price erosion globally year base business biosimilar pipeline continue progress well fda oncologic drug advisory committee odac recently unanimously recommend approval mylan biosimilar version roche holding ag rhhby free report breast cancer drug herceptin however mylan specialty segment epipen be most significant product continue be weak dec mylan announce launch authorize generic epipen auto injector wholesale acquisition cost epinephrine injection usp pack be more lower wac epipen pak auto injector sale epipen auto injector be anticipate continue decline current quarter result increase competition impact authorize generic launch mylan state epipen represent less global revenue less sale north america meanwhile company effort get advair generic approve suffer blow fda issue complete response letter anda generic advair diskus earning call expect investor focus performance epipen newly launch drug progress biosimilar pipeline mylan price ep surprise mylan price ep surprise mylan quoteearning whispersour proven model do not conclusively show mylan be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold likely post earning beat be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank mylan currently carry zack rank rank be favorable company negative esp make surprise prediction difficult note caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider instead model show have right combination element post earning beat quarter arena pharmaceutical inc arna free report be expect release result aug company have earning esp zack rank see complete list today zack rank stock here impax laboratory have earning esp zack rank company be expect release second quarter result aug more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1388,MYL,teva pharmaceutical industry ltd teva free report be report second quarter earning aug market open last quarter company deliver line earning generic drug maker share have lose so far year industry witness increase teva earning have surpass expectation last quarters meet same remain deliver average positive surprise let see thing be shape announcement factor considerwe believe inclusion sale actavis generic acquisition continue pull teva sale however generic segment continue see weakness segment remain pressure due pricing erosion well competitive pressure meanwhile specialty segment loss exclusivity key drug copaxone azilect nuvigil hurt sale sale blockbuster multiple sclerosis ms treatment copaxone be likely erode due increase competition glatopa generic version copaxone mg enter market jun teva be also face patent challenge mg thrice weekly formulation copaxone company mylan myl free report momenta be look get approval generic version mg thrice weekly formulation copaxone teva suffer major setback jan district court district delaware invalidate orange book patent copaxone mg teva intend appeal decision be uncertainty regard timing generic launch copaxone mg be possible certain competitor receive fda approval launch appeal decision be however generic version mg formulation have not be launch yet fda approval momenta generic version copaxone have be delay owing manufacturing issue first quarter call company have mentioned earning growth be weight second half company expect majority generic launch occur only second half imply profit second quarter not improve much weakness see first quarter nonetheless teva focus cost reduction program give profit boost april teva announce fda approval austedo sd treatment chorea associate huntington disease hd expect management update plan same teva also continue search permanent ceo remain company highest priority first quarter call chairman sol barer have say company be look top notch ceo deep broad pharmaceutical experience expect update ceo search upcoming conference call earning whispersour proven model do not conclusively show teva be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate well zack consensus estimate stand share uncover best stock buy sell re report earning esp filter zack rank teva szack rank increase predictive power esp however need have positive esp be confident earning beat sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision teva pharmaceutical industry limit price ep surprise teva pharmaceutical industry limit price ep surprise teva pharmaceutical industry limit quotestock considersome stock generic drug sector have positive earning esp favorable zack rank be mallinckrodt public limit company mnk free report be schedule release result aug company have earning esp zack rank see complete list today zack rank stock here impax laboratory inc be schedule release result aug company have earning esp zack rank more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
1389,MYL,momenta pharmaceutical inc mnta free report report loss cent share second quarter line zack consensus estimate report loss be however wider year loss cent momenta pharmaceutical inc price ep surprise momenta pharmaceutical inc price ep surprise momenta pharmaceutical inc quoterevenue quarter improve top zack consensus estimate momenta stock have rally year date compare industry rally quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be primarily due lower sale deduction second quarter well legal reimbursement second quarter collaborative research development revenue come year quarter decline revenue be mainly due termination baxalta collaboration agreement effective dec research development expense be general administrative expense increase outlook updatedmomenta now expect operate expense exclude stock base compensation net collaborative revenue range compare previous guidance guidance also include approximately capital expenditure operate expense third quarter be project momenta expect generate revenue mylan myl free report upfront payment quarterly basis jul momenta earn milestone payment sandoz glatopa mg continue be sole fda approve generic copaxone mg pipeline updatesandoz abbreviated new drug application anda mg thrice weekly formulation copaxone glatopa mg be fda review however momenta suffer setback fda issue warning letter pfizer inc pfe free report feb be sandoz contract fill finish manufacturing partner glatopa pfizer have submit comprehensive response observation cite warning letter anda approval be now contingent satisfactory resolution compliance observation state warning letter issue pfizer meanwhile momenta continue progress other pipeline candidate currently momenta biosimilar version abbvie inc abbv free report humira be be evaluate phase iii study patient suffering moderate severe chronic plaque psoriasis move ahead company plan submit candidate approval regulatory body fourth quarter also expect first commercial launch be early timeframe company complete enrolment phase study biosimilar version orencia apr collaboration mylan top line datum study be expect second half furthermore momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody jan company enter research collaboration license agreement csl potential future fc multimer program candidate be expect enter clinic momenta successfully complete phase single ascend dose study healthy volunteer multiple ascend dose portion study be initiate jan expect be complete aug datum single multiple ascend dose portion study be project second half takemomenta loss share come line estimate second quarter sale beat estimate anda approval glatopa be contingent satisfactory resolution compliance observation state warning letter issue fda result delay approval expect warning letter remain drag company share issue be solve nevertheless sale glatopa mg continue do well glatopa mg have capture approximately market addition potential approval boost investor confidence zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1390,MYL,sucampo pharmaceutical inc report adjust earning cent share second quarter beating zack consensus estimate cent report earning be also year figure cent total revenue come year quarter surpass zack consensus estimate drive higher amitiza sale japan sucampo have license supply agreement mylan myl free report marketing amitiza japan sucampo share price have decrease year date industry gain quarter detailproduct sale be year year product royalty revenue be year year sale amitiza sucampo market product report takeda pharmaceutical royalty calculation purpose be takeda hold global marketing right amitiza outside japan china pay royalty sucampo total prescription product be report mylan amitizia sale increase japan unit volume increase company operational expense ga increase year period include milestone payment cancer prevention pharmaceutical inclusion research development expense related vtesse developmentsin april company complete acquisition privately hold rare disease company vtesse inc upfront payment acquisition add late stage orphan candidate vts be be evaluate niemann pick disease type npc moreover vts be grant patent unique composition same month strengthen ip position subsequent quarter jul company file supplemental new drug application snda fda label expansion amitizia include pediatric patient year age suffering functional constipation snda be file base support datum evident efficacy age group guidance reiterate guidance full year company expect total revenue range zack consensus estimate be company expect adjust net income range adjust earning range sucampo pharmaceutical inc price consensus ep surprise sucampo pharmaceutical inc price consensus ep surprise sucampo pharmaceutical inc quotezack rank key pickssucampo carry zack rank hold stock couple better rank stock pharma sector include inc agen free report arena pharmaceutical inc arna free report stock carry zack rank buy see complete list today zack rank strong buy stock here loss estimate narrow last day company deliver positive earning surprise trail quarters average beat share price have remain flat so far year arena pharma loss share estimate narrow last day company deliver positive surprise trail quarters average beat company share be so far year company be schedule report aug more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1391,MYL,glaxosmithkline plc gsk free report report core earning cent american depositary share second quarter beat zack consensus estimate cent almost earning be however year year constant exchange rate cer drive negative impact settlement intercompany transaction quarter so far year glaxo share have gain compare unfavorably industry increase quarterly revenue be cer back strong performance business segment however revenue marginally miss zack consensus estimate growth rate mentioned be year year basis cer quarterly highlightssale be international market also sale europe register growth rate sale new pharmaceutical vaccine product be drive hiv drug tivicay triumeq respiratory drug ellipta product nucala vaccine prevent meningitis drug bexsero menveo glaxo report result segment pharmaceutical vaccine consumer healthcare pharmaceutical division register revenue growth drive hiv drug tivicay triumeq respiratory disease drug relvar breo nucala be partly offset impact recent divestment establish pharmaceutical hiv sale be growth international sale europe sale be however flat year year encourage number come back continue market share growth triumeq sale tivicay sale however sale hiv drug epzicom kivexa tumble due increase generic competition particularly affect european market respiratory sale increase back growth international market europe however respiratory sale slide portfolio continue transition newer product include relvar breo ellipta sale new respiratory product relvar breo ellipta anoro ellipta arnuity ellipta nucala offset decline seretide advair sale flixotide flovent ventolin sale decrease respectively ellipta product record surge sale drive market share gain global roll continue immuno inflammation drug include benlysta rise quarter new grouping establish pharmaceutical include previous establish product cardiovascular metabolic urology cvmu other pharma product establish pharmaceutical sale be quarter however sale be flat consumer healthcare segment due slowdown market condition sale be hurt disposal nigeria beverage business challenge condition emerge market particularly india weaker allergy performance however power brand particularly pain relief oral health category see strong performance quarter sale vaccine segment be geographically be europe be international market be sale benefit continue uptake meningitis vaccine bexsero globally menveo international market segment also experience strong performance establish vaccine drive higher demand boostrix hepatitis vaccine particularly company expect face generic competition advair affect top line however be uncertainty regard timing launch generic version drug generic version advair expect be launch company expect core earning growth cer lower project previously additionally second quarter company decide invest priority review voucher accelerate fda review drug regimen hiv investment decision other accelerate launch cost related hiv drug lead lower profit guidance remind investor mylan myl free report effort bring generic version advair market suffer blow fda issue complete response letter abbreviated new drug application anda advair april thereby delay entry generic hikma pharmaceutical plc generic version advair be also deny approval fda generic version advair be therefore not likely be approve year glaxo expect approval shingrix europe close triple fourth quarter hence product generate significant sale figure only long term outlookglaxo expect adjust ep growth be range mid high single digit period company plan stop development pre clinical clinical programme instead shift pipeline focus respiratory hiv infectious disease therapeutic area company already enjoy strong presence also company make investment potentially fast grow therapeutic area oncology immuno inflammation cost reduction initiative lead additional annual cost saving glaxosmithkline plc price consensus ep plc price consensus ep surprise glaxosmithkline plc quotezack rank key picksglaxo currently carry zack rank hold better rank stock healthcare sector include enzo inc exelixis inc exel free report stock sport zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate inched cent cent last day company have deliver positive earning surprise trail quarters average beat exelixis share have soar so far year enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1392,MYL,glaxosmithkline plc gsk free report be schedule report second quarter result jul market open last quarter company deliver line earning glaxo share be year so far underperform increase witness zack classify large cap pharma industry glaxo performance have be pretty good so far company earning beating expectation thrice trail quarters meeting estimate remain quarter overall company have deliver average positive earning surprise let see thing be shape quarter factor considerall business segment pharmaceutical vaccine consumer healthcare be expect do well be report quarter glaxo pharmaceutical segment be expect be drive strong sale new hiv product tivicay triumeq sale newly launch respiratory drug ellipta product nucala be expect offset decline seretide advair avodart many glaxo key drug lovaza avodart be face decline sale due generic competition importantly pricing dynamic competitive pressure be hurt sale top selling drug advair generic competition be hurt advair sale europe first quarter call company have mentioned lot uncertainty surround timing advair generic launch however mylan myl free report effort bring generic version advair market suffer blow fda issue complete response letter abbreviated new drug application anda apr thereby delay entry generic hikma pharmaceutical generic version advair be also deny approval fda generic version advair be therefore not likely be approve year vaccine segment continue benefit uptake meningitis vaccine bexsero menveo acquire novartis importantly growth consumer healthcare segment have slow first quarter conference call management have mentioned impact general sale tax continue slowdown nutrition category india challenge economic condition other international market nigerian beverage business divestment be expect hurt consumer healthcare segment sale year factor impact second quarter result however cost saving restructure continue efficiency be likely boost operate profit earning whispersour proven model do not conclusively show glaxo be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand cent zack consensus estimate be peg higher cent uncover best stock buy sell re report earning esp filter zack rank glaxo zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quotestock considera couple stock large cap pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug top pick ride hottest tech trend zack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
1393,MYL,mylan myl free report partner biocon ltd announce fda oncologic drug advisory committee odac unanimously recommend approval roche rhhby free report breast cancer drug herceptin trastuzumab fact fda odac vote favor biosimilar candidate have be develop treat positive breast cancer be more aggressive form disease notably share mylan inched follow news release however company have outperformed zack categorize medical generic drug industry year so far stock gain industry decline meanwhile datum present odac include result show propose biosimilar trastuzumab be highly similar herceptin line fda assessment provide pre meeting briefing document odac be clinically meaningful difference mylan biosimilar candidate herceptin term safety purity potency biosimilar trastuzumab be also review regulatory authority australia canada europe several emerge market be good news mylan be blow roche herceptin be key drug last week biosimilar roche be put review odac amgen amgn free report partner allergan plc agn free report announce supplemental biologic license application sbla candidate abp biosimilar roche cancer drug avastin also be review odac herceptin avastin be key drug roche biosimiar version drug once approve hurt sale drug mylan price consensus mylan price consensus mylan quotezack rankmylan currently sport zack rank strong buy see complete list today zack rank stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1394,MYL,be busy week fda oncologic drug advisory committee odac review several experimental treatment week include novartis nvs free report car cell drug meanwhile french pharma giant sanofi sny free report announce be acquire vaccine company recap week most important storiesfda panel support novartis car drug novartis get huge boost fda advisory panel voting unanimously favor company experimental car cell therapy ctl novartis be look get treatment approve pediatric young adult relapse refractory cell acute lymphoblastic leukemia positive vote be major milestone company become first launch car cell therapy fda follow advisory panel advice ctl be currently priority review advisory panel issue positive recommendation believe chance gain approval be high read more novartis car therapy drug recommend fda panel so far novartis have outperformed zack categorize large cap pharmaceutical industry share gain industry be fda nod psoriasis treatment jnj free report tremfya gain fda approval treatment moderate severe plaque psoriasis make drug first only biologic approve selectively block only il cytokine play key role plaque psoriasis psoriasis market be pretty crowd tremfya demonstrated superior result skin clearance compare humira head head analysis week tremfya be currently late stage study treatment active psoriatic arthritis phase iii program evaluate efficacy compare cosentyx treatment moderate severe plaque psoriasis mar pdufa date pfizer xeljanz label expansion pfizer pfe free report snda xeljanz have be accept review fda response expect mar timely approval make xeljanz first oral janus kinase jak inhibitor be available person live moderately severely active ulcerative colitis uc pfizer also get favorable vote fda advisory panel acute myeloid leukemia aml drug mylotarg newly diagnosed patient final decision fda be sep mylotarg be initially approve be subsequently withdraw market late stage study fail show clinical benefit moreover higher rate fatality result treatment related toxicity be observed mylotarg arm priority review lilly advanced breast cancer drug lilly lly free report get priority review fda cdk inhibitor abemaciclib company be look get abemaciclib approve monotherapy combination therapy fulvestrant patient advanced breast cancer give priority review status lilly get response fda first quarter currently approve cdk inhibitor include pfizer ibrance novartis kisqali read more lilly breast cancer drug get priority review status fda lilly also enter settlement agreement generic player settle patent infringement lawsuit related ciali tadalafil unit dose patent settlement agreement patent be previously set expire apr now end sep ciali be approve treatment erectile dysfunction ed frustrate urinary symptom benign prostatic hyperplasia bph ciali sale be lilly say adcirca tadalafil patent remain protected nov pediatric exclusivity be grant adcirca be approve pulmonary arterial hypertension read more lilly settle patent litigation ciali generic firm sanofi buy vaccine company sanofi fail effort acquire medivation actelion announce be acquire protein science base privately hold vaccine biotech company include upfront payment achievement certain milestone acquisition sanofi be look expand flu portfolio addition egg base vaccine protein science flublok quadrivalent influenza vaccine qiv be approve fda oct be only recombinant protein base flu vaccine approve agency acquisition be schedule close third quarter sanofi be zack rank buy stock see complete list today zack rank strong buy stock here mylan herceptin biosimilar get favorable panel vote mylan myl free report get boost biosimilar version herceptin trastuzumab get favorable recommendation fda advisory panel panel vote support eligible indication reference product include breast cancer metastatic adjuvant setting biosimilar version have be develop collaboration biocon cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock astrazeneca azn free report be lilly gain almost last month astrazeneca be bristol myer be see last pharma stock roundup here mrk keytruda mm combo study clinical hold bayer revise outlook next pharma world watch second quarter earning result company be report jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1395,MYL,healthcare sector be spotlight again due exorbitant drug pricing president donald trump tweet monday criticize pharmaceutical giant pfizer inc pfe free report recent price increase several prescription drug last week new york base company announce increase list price several drug be second time year pfizer have increase price medicine pfizer raise price medicine average be agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include january hike pfizer defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio reduce price drug pfizer announcement price hike come only few week trump claim pharma company soon take massive price cut voluntarily however have be sign such price cut pfizer face criticism price hike be concern price hike company soon trigger market wide increase drug price other pharma bigwig merck mrk free report other latest tweet trump warn administration act response pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas pricing controversy linger issue healthcare industry have always be spotlight high drug price sector previously wall street favorite be hit hard political rhetoric increase medium public focus high price drug drug pricing controversy have grab headline september several company be criticize overpricing drug include mylan myl free report increase price epipen valeant pharmaceutical international inc vrx free report strategy acquire company selling drug higher price trump election campaign have pledge take step lower prescription drug price ensure affordability high cost drug however concrete policy change have be announce decrease drug price trump take office industry have be constantly warn trump keep price drug affordable be probably not do anything part president take several step direction push faster generic cheaper copycat version brand drug approval be already do also ask discount rebate be disclose put limitation promotion advertisement drug mandate medicare negotiate drug price manufacturer be high time drug company take step provide relief consumer keep cost medicine affordable then drug pricing controversy remain overhang space pfizer share do take dip trump tweet close day green pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1396,MYL,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put mylan myl free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front mylan have trail month pe ratio see chart level actually compare pretty favorably market large pe compare focus stock long term pe trend current level put mylan current pe ratio slightly midpoint be past year further stock pe also compare favorably industry trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point mylan have forward pe ratio price relative year earning so be fair say slightly more value oriented path be ahead mylan stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now mylan have ratio be substantially lower average come right now also see chart be somewhat high stock particular past few year anything suggest level undervalue trading least compare historical norm broad value outlookin aggregate mylan currently have value style score putt top stock cover look make myl solid choice value investor other key metric make pretty clear too example peg ratio mylan be just level be slightly lower industry average peg ratio be modify pe ratio take account stock earning growth rate additionally cf ratio great indicator value come be way better industry average clearly myl be solid choice value front multiple angle stock overall mylan be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give odp vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be disappointing current quarter have see estimate go higher past day lower full year estimate have see upward downward revision same time period have have noticeable impact consensus estimate current quarter consensus estimate have dip past month full year estimate have slip see consensus estimate trend recent price action stock chart mylan price consensus mylan price consensus mylan somewhat bearish trend be stock have just zack rank hold be look line performance company term bottom linemylan be inspire choice value investor be hard beat incredible lineup statistic front however sluggish industry rank bottom more industry zack rank be hard get too excited company overall fact past year sector have clearly underperform broader market see so value investor want estimate analyst sentiment broader factor turn favorable name first once happen stock be compelling pick today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1397,MYL,share adamis pharmaceutical admp free report surge company announce enter exclusive distribution agreement symjepi epinephrine swiss pharma giant novartis nvs free report generic arm sandoz term agreementper agreement sandoz own commercial right symjepi unite state exchange upfront fee potential performance base milestone payment company share profit equally note symjepi injection mg be approve fda use emergency treatment acute allergic reaction include anaphylaxis sandoz also get commercial right symjepi injection mg approval product be fda review now other hand adamis retain right commercialize product territory outside unite state sandoz however get first right negotiation such territory adamis also have option develop symject injection platform additional product candidate include naloxone product candidate be develop treat opioid overdose adamis gain adamis get novartis strong commercial partner give latter dominant position pharmaceutical market moreover financial term agreement be favorable adamis get upfront fee milestone payment remind investor symjepi compete mylan myl free report epipen adamis have be lookout commercial partner long earlier allergan agn free report have terminate license agreement commercialize product be then not approve fda hence agreement novartis bode well adamis news boost investor sentiment well adamis stock gain year so far outperform industry growth other hand addition symjepi further expand sandoz exist portfolio give market potential epinephrine zack rankadamis currently carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1398,MYL,mylan myl free report india base lupin limit have enter partnership commercialize biosimilar amgen amgn free report blockbuster drug enbrel partnership agreement mylan commercialize lupin propose biosimilar europe australia new latin america africa most market asia note enbrel be approve treat certain autoimmune disease include rheumatoid arthritis psoriatic arthritis plaque psoriasis ankylose spondylitis accord brand sale approximately month end dec lupin successfully complete phase iii trial feb company have file product european medicine agency plan file product other jurisdiction assume approval biosimilar have great market potential give sale agreement lupin receive front payment company be entitle commercial milestone together equal share net profit product mylan have widest portfolio generic biosimilar addition biosimilar enbrel further boost company portfolio mylan biosimilar portfolio get boost recent fda approval fulphila biosimilar neulasta company have earlier win fda approval ogivri biosimilar roche rhhby free report herceptin other hand agreement mylan bode well lupin give former significant expertise global infrastructure mylan stock have lose year so far compare industry gain stock take hit earlier month company announce fda not approve abbreviated new drug application generic version glaxosmithkline gsk free report asthma drug advair diskus yet again mylan have receive major boost fda approval generic version copaxone mg company have more submission plan however generic business unite state continue experience pricing pressure volatility market be expect continue yet new approval position mylan better year ahead help combat decline epipen sale be also face supply constraint issue zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1399,MYL,dr reddy laboratory ltd rdy free report mylan myl free report announce fda have approve first generic version suboxone buprenorphine naloxone sublingual film tongue film treatment opioid addiction company sell generic version drug fda approval be aim make treatment available more person buprenorphine naloxone be used treat adult opioid dependence addiction buprenorphine help suppress withdrawal symptom cause discontinuation opioid drug naloxone reverse block effect opioid suboxone brand have sale approximately mat most recent month end april accord im health share dr reddy have decrease year date compare industry growth last month indivior plc enter settlement agreement par pharmaceutical inc par pharmaceutical company inc endo international plc collectively par intelgenx technology corp resolve patent litigation related suboxone sublingual film litigation be pending district court district delaware result par submission abbreviated new drug application anda fda seek approval market generic version suboxone film settlement permit par begin selling generic version suboxone film jan earlier certain circumstance note dr reddy enjoy strong position generic market mar dr reddy have generic filing abbreviated new drug application anda new drug application be pending fda approval dr reddy laboratory ltd price dr reddy laboratory ltd price dr reddy laboratory ltd quote zack rank stock considerdr reddy sha zack rank hold better rank stock same space be illumina inc ilmn free report aeglea biotherapeutic inc agle free report illumina sport zack rank strong buy aeglea carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1400,MYL,glaxosmithkline plc gsk free report hiv company viiv healthcare announce late stage study testing drug hiv regimen dolutegravir tivicay lamivudine epivir meet primary endpoint phase iii study gemini gemini evaluate drug regimen treatment nave have not receive prior antiviral therapy hiv infected adult compare drug regimen dolutegravir tenofovir alafenamide fumarate emtricitabine study demonstrated dolutegravir lamivudine regimen be inferior standard drug regimen hiv control mean drug hiv regimen control hiv treatment nave patient effectively drug regimen share glaxo be almost thursday response positive news year so far glaxo share have gain industry decline share glaxo also receive boost week mylan myl free report application get approval generic version glaxo blockbuster respiratory drug advair be reject second time fda full result study be present future medical meeting regulatory application get drug regimen dolutegravir lamivudine approve be expect be file later year glaxo have several phase iii study ongoing evaluate drug regimen hiv treatment study conduct global research center include approximately hiv infected man woman drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen thereby reduce long term toxicity concern juluca be glaxo first only approve drug regimen gain approval eu last month unite state november last year generate sale first quarter glaxo have develop juluca partnership jnj free report juluca combine approve hiv drug glaxo tivicay dolutegravir mg edurant rilpivirine mg single once daily pill treatment virologically suppress hiv infection viiv healthcare be hiv company majorly own glaxo pfizer pfe free report japanese pharma company shinogi have minor stake viiv healthcare glaxo currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1401,MYL,etsy inc etsy free report share jump company announce now expect revenue grow year year previous forecast increase royal caribbean cruise ltd rcl free report soar announce have acquire stake luxury cruise line silversea cruise billionmylan myl free report share plummet fda refuse approve abbreviated new drug application generic version glaxosmithkline plc gsk free report asthma drug advair diskusshare twitter inc twtr free report surge company reveal update social networking platform make easier user find follow big event news
1402,MYL,share mylan myl free report be company announce fda not approve abbreviated new drug application generic version glaxosmithkline gsk free report asthma drug advair diskus yet again agency find minor deficiency application be relay company complete response letter crl be issue june news come disappointment mylan last year fda have issue crl well probable approval have boost mylan generic portfolio immensely give potential market same crl also put question mark mylan guidance company be expect update same mylan stock have gain last month compare industry gain challenge thing be look mylan recent approval be expect help company combat persistent decline epipen sale mylan biosimilar portfolio get boost recent fda approval fulphila biosimilar neulasta company have earlier win fda approval ogivri biosimilar herceptin earlier mylan receive major boost fda approval generic version teva teva free report copaxone mg be first filer also enjoy day exclusivity company have more submission plan hence approval generic advair have further propel company broad portfolio biosimilar generic meanwhile mylan be not only company anda have be reject fda earlier swiss pharma giant novartis nvs free report generic arm sandoz also get crl fda generic version advair sandoz be process address issue identify crl do not expect launch generic end hikma pharmaceutical also receive crl fda generic version advair other hand delay approval generic version advair bode well glaxo concurrent first quarter result glaxo state expect advair sale assume mid year introduction substitutable generic competitor advair unite state zack rankmylan carry zack rank hold see complete list today zack rank stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1403,MYL,have be month last earning report mylan myl free report share have add time frame recent positive trend continue lead next earning release be myl due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst mylan earning lag weak north america salesmylan report disappointing result first quarter earning sale miss estimate adjust earning share miss zack consensus estimate be year quarter first quarter revenue miss zack consensus estimate be prior year period quarter company post result segment geographic basis namely north america europe rest world north america segment third party net sale come due decrease sale brand product include epipen auto injector impact loss exclusivity olmesartan olmesartan hctz prior year divestiture certain contract manufacturing asset sale be adversely impact due implementation new accounting standard lower volume lesser extent pricing other exist product partially offset new product introduction third party net sale europe be be propel new product introduction region combine volume expansion offset impact pricing exist product favorable foreign currency translation positively impact sale rest world segment third party net sale be drive new product increase volume retroviral franchise higher sale emerge market adjust gross margin be year quarter quarter mylan repurchase ordinary share complete previously authorize share repurchase program outlook reiteratedmylan expect revenue zack consensus estimate stand mylan anticipate adjust ep zack consensus estimate be peg have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower mylan price consensus mylan price consensus mylan quotevgm scoresat time myl have nice growth score grade same score momentum front stock be allocate grade value side putt top quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable value investor look growth momentum outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift interestingly myl have zack rank hold expect line return stock next few month
1404,MYL,palo alto network inc panw free report share decline company narrow project fiscal gaap earning share compare earlier range share starbucks corporation sbux free report fall company announce executive chairman howard schultz be step effective june mylan myl free report share jump company india biocon receive approval food drug administration fulphila biosimilar drug neulastashare hd supply holding inc hds free report rise company report first quarter fiscal earning share beating zack consensus estimate
1405,MYL,allergan plc agn free report issue statement response letter public shareholder appaloosa senator investment group company express disappointment recently announce strategic plan divest woman health infectious disease unit activist investor tepper appaloosa dougla silverman senator investment group have request split brent saunder responsibility be currently chairman well chief executive officer ceo suggest recruit new chairman ceo be not company replacement additional board member change management critical operate unit be view company need fresh idea believe change be require drive return else share price continue decline statement company state board management be open input shareholder consider same make decision be focuse build world class company drive return shareholder earning call hold allergan management discuss several strategic plan include divestment share buyback company recently conclude strategic review announce focus lead therapeutic area medical aesthetic cns eye care gi divest unit mentioned january company cut job part restructure process moreover allergan also mentioned board have be refreshed addition member last month meanwhile shareholder have reject proposal splitting role brent appointment independent chairman annual general meeting hold so far year allergan share price have decline compare industry decline note allergan record strong earning first quarter also announce successful result clinical study however share be decline several key product be face loss exclusivity have unfavorable impact top line restasis major revenue contributor be face stiff competition launch shire plc shpg free report dry eye disease drug xiidra last year sale have decline more first quarter generic version drug also be launch mid meanwhile synergy pharmaceutical inc sgyp free report trulance be approve chronic idiopathic constipation last year be expect increase competition linzess several company be look bring generic version drug market moreover january mylan myl free report launch generic version estrace vaginal cream see sale erosion more first quarter company estimate product lose exclusivity be worth expect significant decline revenue product allergan plc price allergan plc price allergan plc quoteallergan currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1406,MYL,mylan myl free report partner biocon announce fda have approve fulphila biosimilar amgen amgn free report neulasta news come significant boost mylan give potential market fulphilium accord neulasta generate sale month end mar biosimilar have be approve reduce duration febrile neutropenia fever other sign infection low count neutrophil type white blood cell patient treat chemotherapy certain type cancer notably be first fda approve biosimilar neulasta company plan launch biosimilar come week approval broaden mylan biosimilar portfolio fda approval be base comprehensive package analytical nonclinical clinical datum confirm biosimilar be highly similar brand drug datum demonstrated be clinically meaningful difference biosimilar product neulasta term safety purity potency company have earlier win fda approval ogivri biosimilar herceptin biosimilar be also approve additional country mylan biocon be collaborate develop biologic insulin product mylan own right product unite state canada japan australia new european union european free trade association country biocon have co exclusive right mylan product rest world march mylan biocon announce co develop biosimilar insulin glargine semglee have obtain approval european commission ec follow positive recommendation committee medicinal product human use chmp european medicine agency note mylan have widest portfolio generic biosimilar company have portfolio bioismilar insulin analog product mylan stock have gain last month compare industry decline share be trading news mylan effort develop biosimilar portfolio be impressive mylan also have partnership momenta pharmaceutical mnta free report development biosimilar company plan initiate patient clinical trial propose biosimilar regeneron pharmaceutical regn free report eylea first half trial be randomize double blind active control multicenter study patient diabetic macular edema compare safety efficacy immunogenicity reference drug eylea vascular endothelial growth factor vegf inhibitor have be approve treatment neovascular wet age related macular degeneration macular edema follow retinal vein occlusion diabetic macular edema diabetic retinopathy patient diabetic macular edema volatility unite state market be expect continue yet new approval position mylan better year ahead help combat decline epipen sale zack rankmylan carry zack rank hold see complete list today zack rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1407,MYL,decline sharply share teva pharmaceutical industry limit teva free report have picked pace year so far stock have rise industry decline go teva favor israel base generic drug maker have be face significant challenge include accelerate generic competition blockbuster multiple sclerosis drug copaxone new competition brand product pricing erosion generic business massive debt load more mylan myl free report earlier expect launch first generic version mg strength copaxone october last year be major setback teva same month mylan also launch second generic version mg formulation copaxone first generic version mg formulation have be market momenta pharmaceutical inc mnta free report sandoz novartis nvs free report generic arm entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation glatopa be launch sandoz february year much earlier schedule launch april however teva have undertake strategic restructure initiative revive growth company divest core asset last year mainly woman health business cut significant debt load also have new organizational structure place be close plant cut generic portfolio eliminate low value project aim cut global workforce more next year part restructure plan reveal december teva be progress well re structuring activity still expect save almost end initiative financial position also seem more stable be regularly pay debt earlier month teva announce first quarter result beating expectation earning sale also raise full year outlook metricsthe stock also get impetus recently warren buffett berkshire hathaway reveal have double investment company first quarter berkshire say own teva american depositary receipt adrs end march adrs end earning estimate increase respective past day teva currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1408,MYL,cambridge base momenta pharmaceutical inc mnta free report be currently face challenge business condition operate area complex generic biosimilar novel therapeutic company market glatopa generic version teva teva free report multiple sclerosis ms drug copaxone mg collaboration novartis nvs free report sandoz glatopa be first substitutable generic drug approve treatment relapse form multiple sclerosis rrm offer major relief investor fda finally approve sandoz abbreviated new drug application glatopa mg february initial setback however mylan myl free report win fda approval generic version teva pharmaceutical copaxone mg earlier momenta notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company already have upper hand market make difficult momenta gain market share sandoz be still early phase launch mylan launch generic equivalent once daily copaxone mg ml time weekly copaxone mg ml october result market contractual profit share revenue glatopa mg ml have be reduce accelerate conversion patient once daily mg ml glatiramer acetate injection time weekly mg ml glatiramer acetate injection due lower pricing market end teva time weekly copaxone mg ml mylan time weekly generic equivalent product account approximately overall glatiramer acetate injection market mg ml mg ml base volume prescribe progress biosimilar pipeline have be encourage momenta suffer setback company partner mylan announce propose biosimilar orencia do not meet primary pharmacokinetic end point phase study compare pharmacokinetic safety immunogenicity orencia normal healthy volunteer biologic license application bla momenta biosimilar version humira be also ready be file fda however filing bla be dependent outcome company ongoing strategic review note give recent setback momenta initiate strategic review ongoing operation goal reduce expenditure biosimilar portfolio free additional capital fully fund novel autoimmune portfolio company do not have runway develop broad portfolio create bar revenue stream glatopa excessive dilution investor hence momenta be explore few option expect complete strategic review end second quarter momenta pharmaceutical inc price consensus ep surprise momenta pharmaceutical inc price consensus ep surprise momenta pharmaceutical inc autoimmune portfolio hold promise momenta stock have gain past month industry decline zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1409,MYL,share teva pharmaceutical industry limit teva free report shot hour trading tuesday be reveal warren buffett berkshire hathaway inc brk have double investment company first say own teva american depositary receipt adrs end march adrs end change be reflect regulatory filing berkshire tuesday attract buffett teva big question now be lead buffett increase stake israel base generic drugmaker have be face significant challenge include accelerate generic competition blockbuster multiple sclerosis drug copaxone new competition brand product pricing erosion generic business massive debt load more mylan myl free report earlier expect launch first generic version mg strength copaxone october be major setback teva same month mylan also launch second generic version mg formulation copaxone first generic version mg formulation have be market momenta pharmaceutical inc mnta free report sandoz novartis nvs free report generic arm entry generic version mg formulation entry second generic version mg formulation have be rapid erosion sale copaxone moreover second generic version mg formulation glatopa be launch sandoz february year much earlier schedule launch april however teva have undertake strategic restructure initiative revive growth company divest core asset last year mainly woman health business cut significant debt load also have new organizational structure place be close plant cut generic portfolio eliminate low value project aim cut global workforce more next year part restructure plan reveal december last year teva be progress well re structuring activity still expect save almost end initiative financial position also seem more stable be regularly pay debt earlier month teva announce first quarter result beating expectation earning sale also raise full year outlook metricsnumber favor tevaafter decline sharply teva share have also picked year stock have rise year so far industry decline earning estimate increase respective past day stock also trade attractive valuation evident favorable ratio compare generic industry median forward month past year be be discount stock high same time frame stock also trade discount generic industry show stock have potential grow further similarly median level trail month price sale ratio teva be past year discount industry teva currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1410,MYL,mylan myl free report report disappointing result first quarter earning sale miss estimate mylan price consensus mylan price consensus mylan quoteadjusted earning cent share miss zack consensus estimate cent be cent year quarter first quarter revenue miss zack consensus estimate be prior year period mylan stock have lose last month compare industry decline quarter company post result segment geographic basis namely north america europe rest world north america segment third party net sale come due decrease sale brand product include epipen auto injector impact loss exclusivity olmesartan olmesartan hctz prior year divestiture certain contract manufacturing asset sale be adversely impact due implementation new accounting standard lower volume lesser extent pricing other exist product partially offset new product introduction third party net sale europe be be propel new product introduction region combine volume expansion offset impact pricing exist product favorable foreign currency translation positively impact sale rest world segment third party net sale be drive new product increase volume retroviral franchise higher sale emerge market adjust gross margin be year quarter quarter mylan repurchase ordinary share complete previously authorize share repurchase program outlook reiteratedmylan expect revenue zack consensus estimate stand mylan anticipate adjust ep zack consensus estimate be peg takemylan first quarter result be dismal challenge north america persist generic business unite state continue experience pricing pressure loss exclusivity olmesartan product also impact sale nevertheless thing be likely look long run mylan have already win fda approval generic version teva pharmaceutical teva free report copaxone mg notably be first generic copaxone have be approve mylan be first applicant submit substantially complete anda glatiramer acetate injection mg ml contain paragraph iv certification company other first filer be eligible day generic drug exclusivity company also receive fda approval biosimilar version roche holding rhhby free report herceptin volatility market be expect persist yet approval position mylan better year ahead help combat decline epipen sale company have more submission plan launch generic version estrace cream be also underway key anticipate approval also include biosimilar version neulasta target action date june company expect launch biosimilar second half assume approval ema have also accept application biosimilar mylan partner momenta mnta free report initiate patient clinical trial propose biosimilar ophthalmology drug eylea first half zack rankmylan carry zack rank hold see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1411,MYL,theravance biopharma tbph free report report first quarter loss share narrower zack consensus estimate loss year loss total revenue quarter surge year year upside mainly be attribute amortization upfront fee related global development agreement janssen subsidiary johnson johnson jnj free report td moreover top line surpass zack consensus estimate theravance share be follow earning release however share have underperform industry year time stock have lose compare industry decrease quarterly detailsvibativ generate revenue first quarter year period revenue collaboration be compare year earlier quarter research development expense be year period selling general administrative expense rise increase expense be due higher employee related cost stock base compensation pipeline other updatesin february theravance enter global collaboration agreement janssen jointly develop commercialize pan janus kinase inhibitor td treatment inflammatory intestinal disease phase ii study phase iib iii study be likely be initiate second half evaluate td crohn disease ulcerative colitis respectively january theravance partner mylan myl free report announce new drug application nda pipeline candidate revefenacin td have be accept fda treatment adult chronic obstructive pulmonary disease response regulatory body be expect nov company be prepare commercial launch drug potential approval company collaboration partner alfasigma velusetrag td opted acquire right candidate opt decision global right develop manufacture commercialize velusetrag be transfer alfasigma upfront fee future milestone payment royalty theravance have decide not pursue further development velusetrag part pipeline strategy outlook continue expect operate loss exclude cash share base compensation range theravance biopharma inc price consensus ep surprise theravance biopharma inc price consensus ep surprise theravance biopharma inc quotezack rank key picktheravance currently carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank strong buy stock here ligand earning share estimate moved remain stable respectively last day company pull positive earning surprise last quarters average beat company stock be so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1412,MYL,new economic datum have be release today pre market inflation gauge metric producer price index ppi hit tape result be more tepid expect month april estimate march read strip volatile food energy price number reach year year ppi sister survey consumer price index cpi due tomorrow ahead open bell metric be illustrative regard far fast inflation be seep economy march number be bitter hotter expect market analyst suspect be precipice rampant inflation today number mute notion time tend see picture more clearly now expectation fed need act more aggressively raise interest rate be not be ignited again look tomorrow cpi number complete picture boee lose iran deal president trump announce end obama era nuclear proliferation deal iran remove agreement still support other member germany france china russia unite kingdom european union whole report morning world biggest aircraft manufacturer boee ba free report be not good boee stand lose contract produce new plane irani airline company mostly iran air company have day sever agreement iran likely also be subject renew sanction impose reportedly be penalty fail do so have yet be determine france base airbus also be affected accord report aircraft part producer general electric ge free report earning activity stay heavythough most marquee name have already report earning calendar amount company report remain very high today market close expect result firm st century fox foxa free report roku roku free report beauty free report ahead bell have already see result follow anheuser busch inbev bud free report post mixed earning report morning cent share miss zack consensus cent penny year quarter sale surpass expect revenue beverage giant main brand group budweiser corona stella artois rise nearly year year more bud earning click here generic drug maker mylan myl free report miss expectation top bottom line putt cent share miss cent revenue slightly zack consensus lower sale total featured product such epi pen be cite partially responsible miss more myl earning click here
1413,MYL,wednesday new economic datum have be release today pre market inflation gauge metric producer price index ppi hit tape result be more tepid expect month april estimate march read strip volatile food energy price number reach year year ppi sister survey consumer price index cpi due tomorrow ahead open bell metric be illustrative regard far fast inflation be seep economy march number be bitter hotter expect market analyst suspect be precipice rampant inflation today number mute notion time tend see picture more clearly now expectation fed need act more aggressively raise interest rate be not be ignited again look tomorrow cpi number complete picture boee lose iran deal president trump announce end obama era nuclear proliferation deal iran remove agreement still support other member germany france china russia unite kingdom european union whole report morning world biggest aircraft manufacturer boee ba free report be not good boee stand lose contract produce new plane irani airline company mostly iran air company have day sever agreement iran likely also be subject renew sanction impose reportedly be penalty fail do so have yet be determine france base airbus also be affected accord report aircraft part producer general electric ge free report earning activity stay heavythough most marquee name have already report earning calendar amount company report remain very high today market close expect result firm st century fox foxa free report roku roku free report beauty free report ahead bell have already see result follow anheuser busch inbev bud free report post mixed earning report morning cent share miss zack consensus cent penny year quarter sale surpass expect revenue beverage giant main brand group budweiser corona stella artois rise nearly year year more bud earning click here generic drug maker mylan myl free report miss expectation top bottom line putt cent share miss cent revenue slightly zack consensus lower sale total featured product such epi pen be cite partially responsible miss more myl earning click here mark vickerysenior editorquestion comment article author click here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1414,MYL,mylan myl free report be global pharmaceutical company well establish generic business well presence specialty pharmaceutical company business model include development manufacturing marketing brand generic drug well active pharmaceutical ingredient apis north america europe rest world notably mylan have world largest api operation mylan have largest product portfolio generic pharmaceutical company challenge thing be look mylan company get major boost fda approval generic version copaxone mg volatility market be expect persist yet approval position mylan better year ahead help combat decline epipen sale company have more submission plan company performance have be mixed so far have top earning estimate miss other trail quarters company report average negative earning surprise say time frame currently mylan have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning mylan miss earning consensus call ep company report ep revenue revenue too miss expectation mylan post revenue compare consensus estimate mylan price consensus ep surprise mylan price consensus ep surprise mylan quotekey stat challenge north america continue impact performance primarily due combine impact loss exclusivity olmesartan product lower sale brand product include epipen auto injector divestiture certain contract manufacturing asset impact adoption new accounting standard pre market trading share be trading pre market trading check back later full mylan earning report later hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
